NZ626751B2 - Aryl dihydropyridinones and piperidinones as mgat2 inhibitors - Google Patents
Aryl dihydropyridinones and piperidinones as mgat2 inhibitors Download PDFInfo
- Publication number
- NZ626751B2 NZ626751B2 NZ626751A NZ62675112A NZ626751B2 NZ 626751 B2 NZ626751 B2 NZ 626751B2 NZ 626751 A NZ626751 A NZ 626751A NZ 62675112 A NZ62675112 A NZ 62675112A NZ 626751 B2 NZ626751 B2 NZ 626751B2
- Authority
- NZ
- New Zealand
- Prior art keywords
- isomer
- alkyl
- rac
- independently selected
- group
- Prior art date
Links
- 230000002401 inhibitory effect Effects 0.000 title claims abstract description 41
- 239000003112 inhibitor Substances 0.000 title claims abstract description 36
- XUWHAWMETYGRKB-UHFFFAOYSA-N 2-Piperidinone Chemical class O=C1CCCCN1 XUWHAWMETYGRKB-UHFFFAOYSA-N 0.000 title abstract description 4
- 125000003118 aryl group Chemical group 0.000 title description 11
- 150000001875 compounds Chemical class 0.000 claims abstract description 240
- 239000003814 drug Substances 0.000 claims abstract description 48
- 206010012601 Diabetes mellitus Diseases 0.000 claims abstract description 24
- 208000008589 Obesity Diseases 0.000 claims abstract description 17
- 235000020824 obesity Nutrition 0.000 claims abstract description 17
- 206010058108 Dyslipidaemia Diseases 0.000 claims abstract description 14
- 206010061227 Lipid metabolism disease Diseases 0.000 claims abstract description 14
- 125000000217 alkyl group Chemical group 0.000 claims description 238
- -1 2-C alkoxy-pyridinyl Chemical group 0.000 claims description 229
- 239000000203 mixture Substances 0.000 claims description 113
- 239000011780 sodium chloride Substances 0.000 claims description 92
- 229910052799 carbon Inorganic materials 0.000 claims description 91
- 125000003545 alkoxy group Chemical group 0.000 claims description 77
- 125000005843 halogen group Chemical group 0.000 claims description 67
- 125000001188 haloalkyl group Chemical group 0.000 claims description 66
- 150000003839 salts Chemical class 0.000 claims description 66
- 125000004432 carbon atoms Chemical group C* 0.000 claims description 63
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 61
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 60
- 229910052739 hydrogen Inorganic materials 0.000 claims description 53
- 125000004438 haloalkoxy group Chemical group 0.000 claims description 50
- 239000012453 solvate Substances 0.000 claims description 43
- 125000000623 heterocyclic group Chemical group 0.000 claims description 42
- 239000003795 chemical substances by application Substances 0.000 claims description 40
- 201000010099 disease Diseases 0.000 claims description 38
- 229910052760 oxygen Inorganic materials 0.000 claims description 34
- 229910052731 fluorine Inorganic materials 0.000 claims description 30
- 125000001072 heteroaryl group Chemical group 0.000 claims description 28
- 125000005842 heteroatoms Chemical group 0.000 claims description 28
- 125000003373 pyrazinyl group Chemical group 0.000 claims description 28
- 229910052717 sulfur Inorganic materials 0.000 claims description 28
- 229910052757 nitrogen Inorganic materials 0.000 claims description 24
- 239000008194 pharmaceutical composition Substances 0.000 claims description 21
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 21
- 125000004076 pyridyl group Chemical group 0.000 claims description 20
- 230000000051 modifying Effects 0.000 claims description 19
- 239000003472 antidiabetic agent Substances 0.000 claims description 18
- 229910052801 chlorine Inorganic materials 0.000 claims description 18
- 125000000392 cycloalkenyl group Chemical group 0.000 claims description 17
- 125000002883 imidazolyl group Chemical group 0.000 claims description 17
- 125000002971 oxazolyl group Chemical group 0.000 claims description 17
- 125000004008 6 membered carbocyclic group Chemical group 0.000 claims description 16
- 125000006367 bivalent amino carbonyl group Chemical group [H]N([*:1])C([*:2])=O 0.000 claims description 16
- 229920000728 polyester Polymers 0.000 claims description 16
- 125000003226 pyrazolyl group Chemical group 0.000 claims description 16
- 125000003831 tetrazolyl group Chemical group 0.000 claims description 16
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 15
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 15
- 125000000842 isoxazolyl group Chemical group 0.000 claims description 14
- 125000001424 substituent group Chemical group 0.000 claims description 14
- 239000003937 drug carrier Substances 0.000 claims description 13
- 125000002757 morpholinyl group Chemical group 0.000 claims description 13
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 12
- 239000001257 hydrogen Substances 0.000 claims description 12
- 125000000335 thiazolyl group Chemical group 0.000 claims description 12
- 102000007330 LDL Lipoproteins Human genes 0.000 claims description 11
- 108010007622 LDL Lipoproteins Proteins 0.000 claims description 11
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 11
- 238000004519 manufacturing process Methods 0.000 claims description 11
- 238000002560 therapeutic procedure Methods 0.000 claims description 11
- 108060003412 GRP Proteins 0.000 claims description 10
- 102000015779 HDL Lipoproteins Human genes 0.000 claims description 10
- 208000008338 Non-alcoholic Fatty Liver Disease Diseases 0.000 claims description 10
- 108009000135 Nonalcoholic fatty liver disease Proteins 0.000 claims description 10
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 10
- 125000001715 oxadiazolyl group Chemical group 0.000 claims description 10
- 125000001425 triazolyl group Chemical group 0.000 claims description 10
- 208000003067 Myocardial Ischemia Diseases 0.000 claims description 9
- 125000003342 alkenyl group Chemical group 0.000 claims description 9
- 125000004435 hydrogen atoms Chemical class [H]* 0.000 claims description 9
- 206010020772 Hypertension Diseases 0.000 claims description 8
- 208000001145 Metabolic Syndrome Diseases 0.000 claims description 8
- 125000004430 oxygen atoms Chemical group O* 0.000 claims description 8
- 125000000304 alkynyl group Chemical group 0.000 claims description 7
- 201000001421 hyperglycemia Diseases 0.000 claims description 7
- 125000001037 p-tolyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])[H] 0.000 claims description 7
- 125000006569 (C5-C6) heterocyclic group Chemical group 0.000 claims description 6
- KQGBKOKXOUMLOT-UHFFFAOYSA-N FC(F)(F)N1C(C=CCC1)C(=O)N Chemical compound FC(F)(F)N1C(C=CCC1)C(=O)N KQGBKOKXOUMLOT-UHFFFAOYSA-N 0.000 claims description 6
- 208000004104 Gestational Diabetes Diseases 0.000 claims description 6
- 206010022489 Insulin resistance Diseases 0.000 claims description 6
- 206010053219 Non-alcoholic steatohepatitis Diseases 0.000 claims description 6
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 claims description 6
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 claims description 6
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 6
- 125000000714 pyrimidinyl group Chemical group 0.000 claims description 6
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims description 5
- 206010003210 Arteriosclerosis Diseases 0.000 claims description 5
- 208000010412 Glaucoma Diseases 0.000 claims description 5
- 208000002705 Glucose Intolerance Diseases 0.000 claims description 5
- 208000009576 Hypercholesterolemia Diseases 0.000 claims description 5
- 206010060378 Hyperinsulinaemia Diseases 0.000 claims description 5
- 206010062060 Hyperlipidaemia Diseases 0.000 claims description 5
- 208000006575 Hypertriglyceridemia Diseases 0.000 claims description 5
- 208000001083 Kidney Disease Diseases 0.000 claims description 5
- 206010029149 Nephropathy Diseases 0.000 claims description 5
- 206010029151 Nephropathy Diseases 0.000 claims description 5
- 206010029331 Neuropathy peripheral Diseases 0.000 claims description 5
- 206010038932 Retinopathy Diseases 0.000 claims description 5
- 206010038923 Retinopathy Diseases 0.000 claims description 5
- 208000006011 Stroke Diseases 0.000 claims description 5
- 201000001320 atherosclerosis Diseases 0.000 claims description 5
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 5
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 claims description 5
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 5
- 230000003451 hyperinsulinaemic Effects 0.000 claims description 5
- 201000008980 hyperinsulinism Diseases 0.000 claims description 5
- 150000002632 lipids Chemical class 0.000 claims description 5
- 201000001119 neuropathy Diseases 0.000 claims description 5
- 230000003405 preventing Effects 0.000 claims description 5
- 125000004182 2-chlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(*)C([H])=C1[H] 0.000 claims description 4
- 102100016749 SLC5A2 Human genes 0.000 claims description 4
- 101710040674 SLC5A2 Proteins 0.000 claims description 4
- 230000002159 abnormal effect Effects 0.000 claims description 4
- 125000004414 alkyl thio group Chemical group 0.000 claims description 4
- 239000003524 antilipemic agent Substances 0.000 claims description 4
- 239000002830 appetite depressant Substances 0.000 claims description 4
- 230000003111 delayed Effects 0.000 claims description 4
- 230000004217 heart function Effects 0.000 claims description 4
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 4
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 claims description 4
- 230000029663 wound healing Effects 0.000 claims description 4
- 230000001708 anti-dyslipidemic Effects 0.000 claims description 3
- 239000000883 anti-obesity agent Substances 0.000 claims description 3
- 229910052794 bromium Inorganic materials 0.000 claims description 3
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 claims description 3
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 claims description 2
- 229920000089 Cyclic olefin copolymer Polymers 0.000 claims description 2
- 102100004109 HEY1 Human genes 0.000 claims description 2
- 108010081348 HRT1 protein Hairy Proteins 0.000 claims description 2
- 230000000879 anti-atherosclerotic Effects 0.000 claims description 2
- 230000001346 anti-hypertriglyceridemic Effects 0.000 claims description 2
- 230000002253 anti-ischaemic Effects 0.000 claims description 2
- 230000003063 anti-neuropathic Effects 0.000 claims description 2
- 230000002769 anti-restenotic Effects 0.000 claims description 2
- 239000003529 anticholesteremic agent Substances 0.000 claims description 2
- 239000002220 antihypertensive agent Substances 0.000 claims description 2
- 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 claims description 2
- 125000004995 haloalkylthio group Chemical group 0.000 claims description 2
- 125000004458 methylaminocarbonyl group Chemical group [H]N(C(*)=O)C([H])([H])[H] 0.000 claims description 2
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 claims description 2
- 125000001183 hydrocarbyl group Chemical group 0.000 claims 3
- VFGLIMYZMXZWIQ-UHFFFAOYSA-N FC(F)(F)C1N(CCCC1)C(=O)N Chemical compound FC(F)(F)C1N(CCCC1)C(=O)N VFGLIMYZMXZWIQ-UHFFFAOYSA-N 0.000 claims 1
- XNVPUGWFJCHIHA-UHFFFAOYSA-N FC(F)(F)N1C(C=CCC1)=O Chemical compound FC(F)(F)N1C(C=CCC1)=O XNVPUGWFJCHIHA-UHFFFAOYSA-N 0.000 claims 1
- 239000003603 dipeptidyl peptidase IV inhibitor Substances 0.000 claims 1
- 230000035876 healing Effects 0.000 claims 1
- 230000000069 prophylaxis Effects 0.000 abstract description 26
- 108010092861 EC 2.3.1.22 Proteins 0.000 abstract description 4
- AEMPUAWUDAMJBV-QFIPXVFZSA-N (2S)-4-(4-methylphenyl)-5-(2H-tetrazol-5-yl)-2-[4-(4,4,4-trifluorobutoxy)phenyl]-2-(trifluoromethyl)-1,3-dihydropyridin-6-one Chemical compound C1=CC(C)=CC=C1C(C[C@](NC1=O)(C=2C=CC(OCCCC(F)(F)F)=CC=2)C(F)(F)F)=C1C1=NN=NN1 AEMPUAWUDAMJBV-QFIPXVFZSA-N 0.000 abstract 2
- FBBPRPJENPWDPL-LJAQVGFWSA-N (2S)-N-(4-methoxyphenyl)-4-(4-methylphenyl)-6-oxo-2-[4-(4,4,4-trifluorobutoxy)phenyl]-2-(trifluoromethyl)-1,3-dihydropyridine-5-carboxamide Chemical compound C1=CC(OC)=CC=C1NC(=O)C1=C(C=2C=CC(C)=CC=2)C[C@@](C(F)(F)F)(C=2C=CC(OCCCC(F)(F)F)=CC=2)NC1=O FBBPRPJENPWDPL-LJAQVGFWSA-N 0.000 abstract 2
- WEZGTBDFZRBLRD-DEOSSOPVSA-N N-[(2S)-4-(4-methylphenyl)-6-oxo-2-[4-(4,4,4-trifluorobutoxy)phenyl]-2-(trifluoromethyl)-1,3-dihydropyridin-5-yl]-2-methylsulfonylacetamide Chemical compound C1=CC(C)=CC=C1C1=C(NC(=O)CS(C)(=O)=O)C(=O)N[C@](C(F)(F)F)(C=2C=CC(OCCCC(F)(F)F)=CC=2)C1 WEZGTBDFZRBLRD-DEOSSOPVSA-N 0.000 abstract 2
- XEKOWRVHYACXOJ-UHFFFAOYSA-N acetic acid ethyl ester Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 211
- 239000000543 intermediate Substances 0.000 description 209
- 238000006243 chemical reaction Methods 0.000 description 137
- OKKJLVBELUTLKV-UHFFFAOYSA-N methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 126
- 235000019439 ethyl acetate Nutrition 0.000 description 105
- 239000000460 chlorine Substances 0.000 description 104
- WYURNTSHIVDZCO-UHFFFAOYSA-N tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 102
- 239000000243 solution Substances 0.000 description 100
- 239000002904 solvent Substances 0.000 description 93
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 89
- 239000000047 product Substances 0.000 description 71
- DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 64
- FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 54
- 239000007787 solid Substances 0.000 description 51
- 238000010898 silica gel chromatography Methods 0.000 description 49
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 49
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 49
- 239000008079 hexane Substances 0.000 description 45
- AFABGHUZZDYHJO-UHFFFAOYSA-N 2-Methylpentane Chemical class CCCC(C)C AFABGHUZZDYHJO-UHFFFAOYSA-N 0.000 description 44
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 44
- 239000011541 reaction mixture Substances 0.000 description 41
- 239000000741 silica gel Substances 0.000 description 38
- 229910002027 silica gel Inorganic materials 0.000 description 38
- 239000003921 oil Substances 0.000 description 37
- 235000019198 oils Nutrition 0.000 description 37
- JUJWROOIHBZHMG-UHFFFAOYSA-N pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 36
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 33
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium on carbon Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 31
- 239000002585 base Substances 0.000 description 30
- RTZKZFJDLAIYFH-UHFFFAOYSA-N diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 28
- KFZMGEQAYNKOFK-UHFFFAOYSA-N iso-propanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 28
- 238000004166 bioassay Methods 0.000 description 26
- VEXZGXHMUGYJMC-UHFFFAOYSA-N HCl Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 24
- 238000002953 preparative HPLC Methods 0.000 description 23
- WEVYAHXRMPXWCK-UHFFFAOYSA-N acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 22
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 22
- 238000000034 method Methods 0.000 description 22
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 20
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 20
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Inorganic materials [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 20
- 239000002253 acid Substances 0.000 description 19
- 150000001408 amides Chemical class 0.000 description 19
- 150000001412 amines Chemical class 0.000 description 19
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 18
- 239000012043 crude product Substances 0.000 description 18
- YMWUJEATGCHHMB-UHFFFAOYSA-N methylene dichloride Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 17
- 239000012044 organic layer Substances 0.000 description 17
- UIIMBOGNXHQVGW-UHFFFAOYSA-M NaHCO3 Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 16
- CTSLXHKWHWQRSH-UHFFFAOYSA-N Oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 16
- XKRFYHLGVUSROY-UHFFFAOYSA-N argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 16
- 150000002576 ketones Chemical class 0.000 description 16
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N Triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 14
- 239000012267 brine Substances 0.000 description 14
- 239000003153 chemical reaction reagent Substances 0.000 description 14
- 238000002347 injection Methods 0.000 description 14
- 239000007924 injection Substances 0.000 description 14
- 239000004480 active ingredient Substances 0.000 description 13
- 239000012071 phase Substances 0.000 description 13
- 238000003786 synthesis reaction Methods 0.000 description 13
- ODUCDPQEXGNKDN-UHFFFAOYSA-N Nitroxyl Chemical compound O=N ODUCDPQEXGNKDN-UHFFFAOYSA-N 0.000 description 12
- 150000002148 esters Chemical class 0.000 description 12
- BDAGIHXWWSANSR-UHFFFAOYSA-N formic acid Chemical compound OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 12
- 241000282414 Homo sapiens Species 0.000 description 11
- VEXZGXHMUGYJMC-UHFFFAOYSA-M chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 11
- 239000000706 filtrate Substances 0.000 description 11
- 239000010410 layer Substances 0.000 description 11
- 239000000651 prodrug Substances 0.000 description 11
- 229940002612 prodrugs Drugs 0.000 description 11
- 238000010992 reflux Methods 0.000 description 11
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 10
- 102000004877 Insulin Human genes 0.000 description 10
- 108090001061 Insulin Proteins 0.000 description 10
- 101710017815 MOGAT2 Proteins 0.000 description 10
- 102100012600 MOGAT2 Human genes 0.000 description 10
- 229940079593 drugs Drugs 0.000 description 10
- 150000002430 hydrocarbons Chemical group 0.000 description 10
- UFHFLCQGNIYNRP-UHFFFAOYSA-N hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 10
- 238000007363 ring formation reaction Methods 0.000 description 10
- 239000000126 substance Substances 0.000 description 10
- IJJJSNBMFDDFBC-UHFFFAOYSA-N 2-cyanoethyl acetate Chemical compound CC(=O)OCCC#N IJJJSNBMFDDFBC-UHFFFAOYSA-N 0.000 description 9
- 125000004429 atoms Chemical group 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- 150000004795 grignard reagents Chemical class 0.000 description 9
- 150000002466 imines Chemical class 0.000 description 9
- 239000012074 organic phase Substances 0.000 description 9
- NQRYJNQNLNOLGT-UHFFFAOYSA-N piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 9
- 238000003756 stirring Methods 0.000 description 9
- XJHCXCQVJFPJIK-UHFFFAOYSA-M Caesium fluoride Chemical compound [F-].[Cs+] XJHCXCQVJFPJIK-UHFFFAOYSA-M 0.000 description 8
- 101700062901 DPP Proteins 0.000 description 8
- 102000016622 Dipeptidyl Peptidase 4 Human genes 0.000 description 8
- 241000220324 Pyrus Species 0.000 description 8
- 235000014443 Pyrus communis Nutrition 0.000 description 8
- 229910052786 argon Inorganic materials 0.000 description 8
- 230000015572 biosynthetic process Effects 0.000 description 8
- 239000002552 dosage form Substances 0.000 description 8
- 238000004128 high performance liquid chromatography Methods 0.000 description 8
- 125000002950 monocyclic group Chemical group 0.000 description 8
- 238000000746 purification Methods 0.000 description 8
- BZKBCQXYZZXSCO-UHFFFAOYSA-N sodium hydride Inorganic materials [H-].[Na+] BZKBCQXYZZXSCO-UHFFFAOYSA-N 0.000 description 8
- 150000003626 triacylglycerols Chemical class 0.000 description 8
- 150000004798 β-ketoamides Chemical class 0.000 description 8
- 239000007818 Grignard reagent Substances 0.000 description 7
- ZMANZCXQSJIPKH-UHFFFAOYSA-N N,N-Diethylethanamine Substances CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 7
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 7
- 238000006664 bond formation reaction Methods 0.000 description 7
- 238000004296 chiral HPLC Methods 0.000 description 7
- 239000012230 colorless oil Substances 0.000 description 7
- 230000001808 coupling Effects 0.000 description 7
- 238000010168 coupling process Methods 0.000 description 7
- 238000005859 coupling reaction Methods 0.000 description 7
- 239000000284 extract Substances 0.000 description 7
- 238000001914 filtration Methods 0.000 description 7
- WMFOQBRAJBCJND-UHFFFAOYSA-M lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 7
- 239000000463 material Substances 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- 239000002841 Lewis acid Substances 0.000 description 6
- 241000124008 Mammalia Species 0.000 description 6
- 210000004379 Membranes Anatomy 0.000 description 6
- QOSSAOTZNIDXMA-UHFFFAOYSA-N N,N′-Dicyclohexylcarbodiimide Substances C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 6
- PQDJYEQOELDLCP-UHFFFAOYSA-N Trimethylsilane Chemical compound C[SiH](C)C PQDJYEQOELDLCP-UHFFFAOYSA-N 0.000 description 6
- 238000007792 addition Methods 0.000 description 6
- 239000000556 agonist Substances 0.000 description 6
- 239000000010 aprotic solvent Substances 0.000 description 6
- 239000003054 catalyst Substances 0.000 description 6
- HEDRZPFGACZZDS-MICDWDOJSA-N cdcl3 Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 6
- 238000006460 hydrolysis reaction Methods 0.000 description 6
- 150000007517 lewis acids Chemical class 0.000 description 6
- 239000012528 membrane Substances 0.000 description 6
- 230000002265 prevention Effects 0.000 description 6
- 230000001603 reducing Effects 0.000 description 6
- 230000002194 synthesizing Effects 0.000 description 6
- 125000001544 thienyl group Chemical group 0.000 description 6
- 102100007851 DGAT1 Human genes 0.000 description 5
- 101700003156 DGAT2 Proteins 0.000 description 5
- 101710042131 GCG Proteins 0.000 description 5
- 102100003818 GCG Human genes 0.000 description 5
- 108010041872 Islet amyloid polypeptide Proteins 0.000 description 5
- 102000036849 Islet amyloid polypeptide Human genes 0.000 description 5
- 101700019872 MGAT1 Proteins 0.000 description 5
- 102100019046 MGAT1 Human genes 0.000 description 5
- MWKJTNBSKNUMFN-UHFFFAOYSA-N Trifluoromethyltrimethylsilane Chemical compound C[Si](C)(C)C(F)(F)F MWKJTNBSKNUMFN-UHFFFAOYSA-N 0.000 description 5
- 101700078733 ZGLP1 Proteins 0.000 description 5
- 230000002378 acidificating Effects 0.000 description 5
- 239000012298 atmosphere Substances 0.000 description 5
- 125000002618 bicyclic heterocycle group Chemical group 0.000 description 5
- OKTJSMMVPCPJKN-UHFFFAOYSA-N carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 5
- 238000004587 chromatography analysis Methods 0.000 description 5
- 108060000942 fbpB Proteins 0.000 description 5
- 125000002541 furyl group Chemical group 0.000 description 5
- 230000001976 improved Effects 0.000 description 5
- 125000001041 indolyl group Chemical group 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 239000011777 magnesium Substances 0.000 description 5
- 150000002829 nitrogen Chemical group 0.000 description 5
- 241000894007 species Species 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- 239000010936 titanium Substances 0.000 description 5
- 238000000844 transformation Methods 0.000 description 5
- 230000001131 transforming Effects 0.000 description 5
- 125000004306 triazinyl group Chemical group 0.000 description 5
- SYOKIDBDQMKNDQ-HHUWHTLVSA-N (2S)-1-[2-[[(5S,7R)-3-hydroxy-1-adamantyl]amino]acetyl]pyrrolidine-2-carbonitrile Chemical compound C([C@@H]1C[C@H](C2)CC(C1)(C1)O)C21NCC(=O)N1CCC[C@H]1C#N SYOKIDBDQMKNDQ-HHUWHTLVSA-N 0.000 description 4
- PAAZPARNPHGIKF-UHFFFAOYSA-N 1,2-Dibromoethane Chemical compound BrCCBr PAAZPARNPHGIKF-UHFFFAOYSA-N 0.000 description 4
- JVVRCYWZTJLJSG-UHFFFAOYSA-N 4-Dimethylaminophenol Chemical compound CN(C)C1=CC=C(O)C=C1 JVVRCYWZTJLJSG-UHFFFAOYSA-N 0.000 description 4
- RGHHSNMVTDWUBI-UHFFFAOYSA-N 4-Hydroxybenzaldehyde Chemical compound OC1=CC=C(C=O)C=C1 RGHHSNMVTDWUBI-UHFFFAOYSA-N 0.000 description 4
- ZSBOMTDTBDDKMP-OAHLLOKOSA-N Alogliptin Chemical compound C=1C=CC=C(C#N)C=1CN1C(=O)N(C)C(=O)C=C1N1CCC[C@@H](N)C1 ZSBOMTDTBDDKMP-OAHLLOKOSA-N 0.000 description 4
- QGJUIPDUBHWZPV-YQBUGCKMSA-N DB07465 Chemical compound C([C@@H](C1)C2)[C@@H](C3)C[C@@]1(O)C[C@]23[C@H](N)C(=O)N1[C@H](C#N)C[C@@H]2C[C@@H]21 QGJUIPDUBHWZPV-YQBUGCKMSA-N 0.000 description 4
- FXHOOIRPVKKKFG-UHFFFAOYSA-N DMA Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 4
- NKLCNNUWBJBICK-UHFFFAOYSA-N Dess–Martin periodinane Chemical compound C1=CC=C2I(OC(=O)C)(OC(C)=O)(OC(C)=O)OC(=O)C2=C1 NKLCNNUWBJBICK-UHFFFAOYSA-N 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- HSZCZNFXUDYRKD-UHFFFAOYSA-M Lithium iodide Chemical compound [Li+].[I-] HSZCZNFXUDYRKD-UHFFFAOYSA-M 0.000 description 4
- NHQDETIJWKXCTC-UHFFFAOYSA-N Meta-Chloroperoxybenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 4
- KXKVLQRXCPHEJC-UHFFFAOYSA-N Methyl acetate Natural products COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 description 4
- KRKPYFLIYNGWTE-UHFFFAOYSA-N N,O-Dimethylhydroxylamine Chemical compound CNOC KRKPYFLIYNGWTE-UHFFFAOYSA-N 0.000 description 4
- 108010016731 PPAR gamma Proteins 0.000 description 4
- NRKVKVQDUCJPIZ-MKAGXXMWSA-N Pramlintide acetate Chemical compound C([C@@H](C(=O)NCC(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CS)NC(=O)[C@@H](N)CCCCN)[C@@H](C)O)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 NRKVKVQDUCJPIZ-MKAGXXMWSA-N 0.000 description 4
- 229960004937 Saxagliptin Drugs 0.000 description 4
- TXRPHPUGYLSHCX-UHFFFAOYSA-N Selectfluor Chemical compound F[B-](F)(F)F.F[B-](F)(F)F.C1C[N+]2(CCl)CC[N+]1(F)CC2 TXRPHPUGYLSHCX-UHFFFAOYSA-N 0.000 description 4
- MFFMDFFZMYYVKS-SECBINFHSA-N Sitagliptin Chemical compound C([C@H](CC(=O)N1CC=2N(C(=NN=2)C(F)(F)F)CC1)N)C1=CC(F)=C(F)C=C1F MFFMDFFZMYYVKS-SECBINFHSA-N 0.000 description 4
- DRUIESSIVFYOMK-UHFFFAOYSA-N Trichloroacetonitrile Chemical compound ClC(Cl)(Cl)C#N DRUIESSIVFYOMK-UHFFFAOYSA-N 0.000 description 4
- 125000001931 aliphatic group Chemical group 0.000 description 4
- 125000002947 alkylene group Chemical group 0.000 description 4
- 229960001667 alogliptin Drugs 0.000 description 4
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 4
- 125000002527 bicyclic carbocyclic group Chemical group 0.000 description 4
- 125000002619 bicyclic group Chemical group 0.000 description 4
- OKKJLVBELUTLKV-MZCSYVLQSA-N cd3od Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 4
- LKYXEULZVGJVTG-UHFFFAOYSA-N chloromethane Chemical compound Cl[CH] LKYXEULZVGJVTG-UHFFFAOYSA-N 0.000 description 4
- 230000000875 corresponding Effects 0.000 description 4
- 235000013367 dietary fats Nutrition 0.000 description 4
- 235000014113 dietary fatty acids Nutrition 0.000 description 4
- RQBKGJOQACIQDG-UHFFFAOYSA-N difluoro(triphenyl)silanuide;tetrabutylazanium Chemical compound CCCC[N+](CCCC)(CCCC)CCCC.C=1C=CC=CC=1[Si-](F)(C=1C=CC=CC=1)(F)C1=CC=CC=C1 RQBKGJOQACIQDG-UHFFFAOYSA-N 0.000 description 4
- 210000001842 enterocyte Anatomy 0.000 description 4
- 239000000194 fatty acid Substances 0.000 description 4
- 150000004665 fatty acids Chemical class 0.000 description 4
- KRHYYFGTRYWZRS-UHFFFAOYSA-M fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 4
- 235000019253 formic acid Nutrition 0.000 description 4
- 150000004820 halides Chemical class 0.000 description 4
- OAKJQQAXSVQMHS-UHFFFAOYSA-N hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 4
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 4
- 125000002632 imidazolidinyl group Chemical group 0.000 description 4
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 description 4
- GLXDVVHUTZTUQK-UHFFFAOYSA-M lithium;hydroxide;hydrate Chemical compound [Li+].O.[OH-] GLXDVVHUTZTUQK-UHFFFAOYSA-M 0.000 description 4
- FYYHWMGAXLPEAU-UHFFFAOYSA-N magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 4
- IUYHWZFSGMZEOG-UHFFFAOYSA-M magnesium;propane;chloride Chemical compound [Mg+2].[Cl-].C[CH-]C IUYHWZFSGMZEOG-UHFFFAOYSA-M 0.000 description 4
- 238000004949 mass spectrometry Methods 0.000 description 4
- 125000001624 naphthyl group Chemical group 0.000 description 4
- 125000004433 nitrogen atoms Chemical group N* 0.000 description 4
- 239000006186 oral dosage form Substances 0.000 description 4
- 125000002524 organometallic group Chemical group 0.000 description 4
- 125000000160 oxazolidinyl group Chemical group 0.000 description 4
- 229910052763 palladium Inorganic materials 0.000 description 4
- 230000037361 pathway Effects 0.000 description 4
- 229920003023 plastic Polymers 0.000 description 4
- KWYUFKZDYYNOTN-UHFFFAOYSA-M potassium hydroxide Inorganic materials [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 4
- 229960003611 pramlintide Drugs 0.000 description 4
- 108010029667 pramlintide Proteins 0.000 description 4
- 125000000168 pyrrolyl group Chemical group 0.000 description 4
- 230000002829 reduced Effects 0.000 description 4
- 108010033693 saxagliptin Proteins 0.000 description 4
- 238000000926 separation method Methods 0.000 description 4
- 229960004034 sitagliptin Drugs 0.000 description 4
- WQDUMFSSJAZKTM-UHFFFAOYSA-N sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 4
- 125000004434 sulfur atoms Chemical group 0.000 description 4
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 4
- 230000001225 therapeutic Effects 0.000 description 4
- YXFVVABEGXRONW-UHFFFAOYSA-N toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 4
- 229960001254 vildagliptin Drugs 0.000 description 4
- MNFORVFSTILPAW-UHFFFAOYSA-N Β-Lactam Chemical compound O=C1CCN1 MNFORVFSTILPAW-UHFFFAOYSA-N 0.000 description 4
- 125000005955 1H-indazolyl group Chemical group 0.000 description 3
- GEQZTCMVWVDEDF-UHFFFAOYSA-N 2-cyanoacetyl chloride Chemical compound ClC(=O)CC#N GEQZTCMVWVDEDF-UHFFFAOYSA-N 0.000 description 3
- XSRCFERAMLNCDQ-UHFFFAOYSA-N 2-methylpropane-1-sulfinamide Chemical compound CC(C)CS(N)=O XSRCFERAMLNCDQ-UHFFFAOYSA-N 0.000 description 3
- UPWGQKDVAURUGE-KTKRTIGZSA-N 2-oleoylglycerol Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC(CO)CO UPWGQKDVAURUGE-KTKRTIGZSA-N 0.000 description 3
- WGQKYBSKWIADBV-UHFFFAOYSA-N Benzylamine Chemical compound NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 description 3
- 210000004369 Blood Anatomy 0.000 description 3
- 229910014264 BrF Inorganic materials 0.000 description 3
- 229920002676 Complementary DNA Polymers 0.000 description 3
- MLIREBYILWEBDM-UHFFFAOYSA-N Cyanoacetic acid Chemical compound OC(=O)CC#N MLIREBYILWEBDM-UHFFFAOYSA-N 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N D-Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- VVWRJUBEIPHGQF-KTKRTIGZSA-N Diisopropyl azodicarboxylate Chemical compound CC(C)OC(=O)\N=N/C(=O)OC(C)C VVWRJUBEIPHGQF-KTKRTIGZSA-N 0.000 description 3
- 101700077246 EHMT1 Proteins 0.000 description 3
- 229940088598 Enzyme Drugs 0.000 description 3
- 235000004694 Eucalyptus leucoxylon Nutrition 0.000 description 3
- 240000000437 Eucalyptus leucoxylon Species 0.000 description 3
- 101710004768 GER5 Proteins 0.000 description 3
- 101710004110 GLP Proteins 0.000 description 3
- 210000001035 Gastrointestinal Tract Anatomy 0.000 description 3
- 101700022962 HSP12 Proteins 0.000 description 3
- YNESATAKKCNGOF-UHFFFAOYSA-N Lithium bis(trimethylsilyl)amide Chemical compound [Li+].C[Si](C)(C)[N-][Si](C)(C)C YNESATAKKCNGOF-UHFFFAOYSA-N 0.000 description 3
- ZADPBFCGQRWHPN-UHFFFAOYSA-N OBO Chemical compound OBO ZADPBFCGQRWHPN-UHFFFAOYSA-N 0.000 description 3
- 101710042151 Os01g0681900 Proteins 0.000 description 3
- 101710039481 Os03g0179100 Proteins 0.000 description 3
- SCVFZCLFOSHCOH-UHFFFAOYSA-M Potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 3
- JGDQQHLRHVADDG-UHFFFAOYSA-N Potassium bifluoride Chemical compound [K+].[F-]F JGDQQHLRHVADDG-UHFFFAOYSA-N 0.000 description 3
- QDRKDTQENPPHOJ-UHFFFAOYSA-N Sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 description 3
- ZRJNGFJIBZKXTP-UHFFFAOYSA-M [Br-].CC1=CC=C([Mg+])C=C1 Chemical compound [Br-].CC1=CC=C([Mg+])C=C1 ZRJNGFJIBZKXTP-UHFFFAOYSA-M 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 239000012190 activator Substances 0.000 description 3
- 125000006242 amine protecting group Chemical group 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 125000005605 benzo group Chemical group 0.000 description 3
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- CPELXLSAUQHCOX-UHFFFAOYSA-M bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- KXDHJXZQYSOELW-UHFFFAOYSA-M carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 3
- 230000003197 catalytic Effects 0.000 description 3
- 210000004027 cells Anatomy 0.000 description 3
- 150000001805 chlorine compounds Chemical class 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 125000004093 cyano group Chemical group *C#N 0.000 description 3
- NLUNLVTVUDIHFE-UHFFFAOYSA-N cyclooctylcyclooctane Chemical compound C1CCCCCCC1C1CCCCCCC1 NLUNLVTVUDIHFE-UHFFFAOYSA-N 0.000 description 3
- 230000003247 decreasing Effects 0.000 description 3
- LCGLNKUTAGEVQW-UHFFFAOYSA-N dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 3
- 239000012458 free base Substances 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 230000004153 glucose metabolism Effects 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 230000001965 increased Effects 0.000 description 3
- 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 description 3
- 239000003999 initiator Substances 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 230000000968 intestinal Effects 0.000 description 3
- 229910052740 iodine Inorganic materials 0.000 description 3
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 3
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 3
- 230000000670 limiting Effects 0.000 description 3
- 229910052749 magnesium Inorganic materials 0.000 description 3
- 229910052751 metal Inorganic materials 0.000 description 3
- 239000002184 metal Substances 0.000 description 3
- CSNNHWWHGAXBCP-UHFFFAOYSA-L mgso4 Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 3
- 150000007522 mineralic acids Chemical class 0.000 description 3
- 230000003000 nontoxic Effects 0.000 description 3
- 231100000252 nontoxic Toxicity 0.000 description 3
- 239000000123 paper Substances 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- RLOWWWKZYUNIDI-UHFFFAOYSA-N phosphinic chloride Chemical compound ClP=O RLOWWWKZYUNIDI-UHFFFAOYSA-N 0.000 description 3
- ABLZXFCXXLZCGV-UHFFFAOYSA-N phosphorous acid Chemical compound OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 description 3
- 125000004193 piperazinyl group Chemical group 0.000 description 3
- 125000003386 piperidinyl group Chemical group 0.000 description 3
- 239000004033 plastic Substances 0.000 description 3
- 125000003367 polycyclic group Polymers 0.000 description 3
- 201000010065 polycystic ovary syndrome Diseases 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 238000001556 precipitation Methods 0.000 description 3
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 3
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 3
- 210000000813 small intestine Anatomy 0.000 description 3
- NINIDFKCEFEMDL-UHFFFAOYSA-N sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 3
- 230000002459 sustained Effects 0.000 description 3
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 3
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 3
- 125000004525 thiadiazinyl group Chemical group S1NN=C(C=C1)* 0.000 description 3
- 125000001113 thiadiazolyl group Chemical group 0.000 description 3
- CYPYTURSJDMMMP-WVCUSYJESA-N (1E,4E)-1,5-diphenylpenta-1,4-dien-3-one;palladium Chemical compound [Pd].[Pd].C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1 CYPYTURSJDMMMP-WVCUSYJESA-N 0.000 description 2
- XUFXOAAUWZOOIT-WVJZLWNXSA-N (2S,3R,4R,5S,6R)-5-[(2R,3R,4R,5S,6R)-5-[(2R,3R,4S,5S,6R)-3,4-dihydroxy-6-methyl-5-[[(1S,4R,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)cyclohex-2-en-1-yl]amino]oxan-2-yl]oxy-3,4-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-(hydroxymethyl)oxane-2,3,4-triol Chemical compound O([C@H]1O[C@H](CO)[C@H]([C@@H]([C@H]1O)O)O[C@H]1O[C@@H]([C@H]([C@H](O)[C@H]1O)N[C@@H]1[C@@H]([C@@H](O)[C@H](O)C(CO)=C1)O)C)[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O XUFXOAAUWZOOIT-WVJZLWNXSA-N 0.000 description 2
- 125000004514 1,2,4-thiadiazolyl group Chemical group 0.000 description 2
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 2
- GNKZMNRKLCTJAY-UHFFFAOYSA-N 1-(4-methylphenyl)ethanone Chemical compound CC(=O)C1=CC=C(C)C=C1 GNKZMNRKLCTJAY-UHFFFAOYSA-N 0.000 description 2
- GQIRIWDEZSKOCN-UHFFFAOYSA-N 1-chloro-N,N,2-trimethylprop-1-en-1-amine Chemical compound CN(C)C(Cl)=C(C)C GQIRIWDEZSKOCN-UHFFFAOYSA-N 0.000 description 2
- DTHNMHAUYICORS-KTKZVXAJSA-N 107444-51-9 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 description 2
- 238000005160 1H NMR spectroscopy Methods 0.000 description 2
- 125000004206 2,2,2-trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 description 2
- VUKAUDKDFVSVFT-UHFFFAOYSA-N 2-[6-[4,5-bis(2-hydroxypropoxy)-2-(2-hydroxypropoxymethyl)-6-methoxyoxan-3-yl]oxy-4,5-dimethoxy-2-(methoxymethyl)oxan-3-yl]oxy-6-(hydroxymethyl)-5-methoxyoxane-3,4-diol Chemical compound COC1C(OC)C(OC2C(C(O)C(OC)C(CO)O2)O)C(COC)OC1OC1C(COCC(C)O)OC(OC)C(OCC(C)O)C1OCC(C)O VUKAUDKDFVSVFT-UHFFFAOYSA-N 0.000 description 2
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 2
- YEDUAINPPJYDJZ-UHFFFAOYSA-N 2-hydroxybenzothiazole Chemical compound C1=CC=C2SC(O)=NC2=C1 YEDUAINPPJYDJZ-UHFFFAOYSA-N 0.000 description 2
- VKRFUGHXKNNIJO-UHFFFAOYSA-N 4,4,4-trifluorobutan-1-ol Chemical compound OCCCC(F)(F)F VKRFUGHXKNNIJO-UHFFFAOYSA-N 0.000 description 2
- JTEGQNOMFQHVDC-NKWVEPMBSA-N 4-amino-1-[(2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]-1,2-dihydropyrimidin-2-one Chemical compound O=C1N=C(N)C=CN1[C@H]1O[C@@H](CO)SC1 JTEGQNOMFQHVDC-NKWVEPMBSA-N 0.000 description 2
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 2
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-dimethylaminopyridine Substances CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 2
- 102000006902 5-HT2C Serotonin Receptor Human genes 0.000 description 2
- 108010072553 5-HT2C Serotonin Receptor Proteins 0.000 description 2
- 101700062069 AWAT1 Proteins 0.000 description 2
- 102100018926 AWAT1 Human genes 0.000 description 2
- DAYKLWSKQJBGCS-NRFANRHFSA-N Aleglitazar Chemical compound C1=2C=CSC=2C(C[C@H](OC)C(O)=O)=CC=C1OCCC(=C(O1)C)N=C1C1=CC=CC=C1 DAYKLWSKQJBGCS-NRFANRHFSA-N 0.000 description 2
- 229950010157 Aleglitazar Drugs 0.000 description 2
- VSCWAEJMTAWNJL-UHFFFAOYSA-K Aluminium chloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 description 2
- XXEPPPIWZFICOJ-UHFFFAOYSA-N Amfepramone Chemical compound CCN(CC)C(C)C(=O)C1=CC=CC=C1 XXEPPPIWZFICOJ-UHFFFAOYSA-N 0.000 description 2
- 239000005695 Ammonium acetate Substances 0.000 description 2
- 206010007554 Cardiac failure Diseases 0.000 description 2
- 208000008787 Cardiovascular Disease Diseases 0.000 description 2
- MVCQKIKWYUURMU-UHFFFAOYSA-N Cetilistat Chemical compound C1=C(C)C=C2C(=O)OC(OCCCCCCCCCCCCCCCC)=NC2=C1 MVCQKIKWYUURMU-UHFFFAOYSA-N 0.000 description 2
- 229950002397 Cetilistat Drugs 0.000 description 2
- 108010004103 Chylomicrons Proteins 0.000 description 2
- JVHXJTBJCFBINQ-ADAARDCZSA-N Dapagliflozin Chemical compound C1=CC(OCC)=CC=C1CC1=CC([C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)=CC=C1Cl JVHXJTBJCFBINQ-ADAARDCZSA-N 0.000 description 2
- UAOMVDZJSHZZME-UHFFFAOYSA-N Diisopropylamine Chemical compound CC(C)NC(C)C UAOMVDZJSHZZME-UHFFFAOYSA-N 0.000 description 2
- 102000019622 EC 2.7.1.2 Human genes 0.000 description 2
- 108010021582 EC 2.7.1.2 Proteins 0.000 description 2
- 108010011459 Exenatide Proteins 0.000 description 2
- HTQBXNHDCUEHJF-XWLPCZSASA-N Exendin-4 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 HTQBXNHDCUEHJF-XWLPCZSASA-N 0.000 description 2
- 102100009019 FFAR1 Human genes 0.000 description 2
- 229960004580 GLIBENCLAMIDE Drugs 0.000 description 2
- 102100004504 GPR119 Human genes 0.000 description 2
- 101710030426 GPR119 Proteins 0.000 description 2
- 101700071595 GRZ1 Proteins 0.000 description 2
- ZNNLBTZKUZBEKO-UHFFFAOYSA-N Glibenclamide Chemical compound COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZNNLBTZKUZBEKO-UHFFFAOYSA-N 0.000 description 2
- WIGIZIANZCJQQY-RUCARUNLSA-N Glimepiride Chemical compound O=C1C(CC)=C(C)CN1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)N[C@@H]2CC[C@@H](C)CC2)C=C1 WIGIZIANZCJQQY-RUCARUNLSA-N 0.000 description 2
- 229960001381 Glipizide Drugs 0.000 description 2
- ZJJXGWJIGJFDTL-UHFFFAOYSA-N Glipizide Chemical compound C1=NC(C)=CN=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZJJXGWJIGJFDTL-UHFFFAOYSA-N 0.000 description 2
- 102000007446 Glucagon-Like Peptide-1 Receptor Human genes 0.000 description 2
- 108010086246 Glucagon-Like Peptide-1 Receptor Proteins 0.000 description 2
- 108010090776 Glucagon-like peptide 1(7-37) Proteins 0.000 description 2
- 102400000324 Glucagon-like peptide 1(7-37) Human genes 0.000 description 2
- 102000004366 Glucosidases Human genes 0.000 description 2
- 108010056771 Glucosidases Proteins 0.000 description 2
- 229940014653 Glyburide Drugs 0.000 description 2
- UHUSDOQQWJGJQS-UHFFFAOYSA-N Glycerol 1,2-dioctadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(CO)OC(=O)CCCCCCCCCCCCCCCCC UHUSDOQQWJGJQS-UHFFFAOYSA-N 0.000 description 2
- 229910004373 HOAc Inorganic materials 0.000 description 2
- 206010019280 Heart failure Diseases 0.000 description 2
- 102000004286 Hydroxymethylglutaryl CoA Reductases Human genes 0.000 description 2
- 108090000895 Hydroxymethylglutaryl CoA Reductases Proteins 0.000 description 2
- MDXYQVPFSHFPHS-CVYXXLPWSA-N IRP peptide Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)NC(=O)CNC(=O)[C@H](CCCNC(N)=N)NC(=O)CNC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CC=1C2=CC=CC=C2NC=1)C(C)C)NC(=O)[C@H](CCC(=O)OC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(=O)OC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)NC(=O)[C@@H](N)CCCCN)C1=CC=CC=C1 MDXYQVPFSHFPHS-CVYXXLPWSA-N 0.000 description 2
- 210000000936 Intestines Anatomy 0.000 description 2
- LTXREWYXXSTFRX-QGZVFWFLSA-N Linagliptin Chemical compound N=1C=2N(C)C(=O)N(CC=3N=C4C=CC=CC4=C(C)N=3)C(=O)C=2N(CC#CC)C=1N1CCC[C@@H](N)C1 LTXREWYXXSTFRX-QGZVFWFLSA-N 0.000 description 2
- 229960002397 Linagliptin Drugs 0.000 description 2
- 108010019598 Liraglutide Proteins 0.000 description 2
- 229940040692 Lithium Hydroxide Monohydrate Drugs 0.000 description 2
- 210000004185 Liver Anatomy 0.000 description 2
- XTTZERNUQAFMOF-QMMMGPOBSA-N Lorcaserin Chemical compound C[C@H]1CNCCC2=CC=C(Cl)C=C12 XTTZERNUQAFMOF-QMMMGPOBSA-N 0.000 description 2
- 210000002751 Lymph Anatomy 0.000 description 2
- 102100009276 MCHR1 Human genes 0.000 description 2
- 101700067919 MCHR1 Proteins 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 229960003105 Metformin Drugs 0.000 description 2
- FUSUHKVFWTUUBE-UHFFFAOYSA-N Methyl vinyl ketone Chemical compound CC(=O)C=C FUSUHKVFWTUUBE-UHFFFAOYSA-N 0.000 description 2
- IBAQFPQHRJAVAV-ULAWRXDQSA-N Miglitol Chemical compound OCCN1C[C@H](O)[C@@H](O)[C@H](O)[C@H]1CO IBAQFPQHRJAVAV-ULAWRXDQSA-N 0.000 description 2
- PXZWGQLGAKCNKD-DPNMSELWSA-N MolPort-023-276-326 Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O)[C@@H](C)O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 PXZWGQLGAKCNKD-DPNMSELWSA-N 0.000 description 2
- IRLWJILLXJGJTD-UHFFFAOYSA-N Muraglitazar Chemical compound C1=CC(OC)=CC=C1OC(=O)N(CC(O)=O)CC(C=C1)=CC=C1OCCC1=C(C)OC(C=2C=CC=CC=2)=N1 IRLWJILLXJGJTD-UHFFFAOYSA-N 0.000 description 2
- 229950001135 Muraglitazar Drugs 0.000 description 2
- 150000001204 N-oxides Chemical class 0.000 description 2
- DQCKKXVULJGBQN-XFWGSAIBSA-N Naltrexone Chemical compound N1([C@@H]2CC3=CC=C(C=4O[C@@H]5[C@](C3=4)([C@]2(CCC5=O)O)CC1)O)CC1CC1 DQCKKXVULJGBQN-XFWGSAIBSA-N 0.000 description 2
- 229960003086 Naltrexone Drugs 0.000 description 2
- 102000030004 Neuropeptide Y2 receptor Human genes 0.000 description 2
- 108010089579 Neuropeptide Y2 receptor Proteins 0.000 description 2
- 102000020213 Neuropeptide Y5 receptor Human genes 0.000 description 2
- 108010046593 Neuropeptide Y5 receptor Proteins 0.000 description 2
- 235000019502 Orange oil Nutrition 0.000 description 2
- AHLBNYSZXLDEJQ-FWEHEUNISA-N Orlistat Chemical compound CCCCCCCCCCC[C@H](OC(=O)[C@H](CC(C)C)NC=O)C[C@@H]1OC(=O)[C@H]1CCCCCC AHLBNYSZXLDEJQ-FWEHEUNISA-N 0.000 description 2
- 206010033307 Overweight Diseases 0.000 description 2
- 102400000319 Oxyntomodulin Human genes 0.000 description 2
- 101800001388 Oxyntomodulin Proteins 0.000 description 2
- 101700000651 PCSK9 Proteins 0.000 description 2
- 102100005352 PCSK9 Human genes 0.000 description 2
- 102000024367 PPAR alpha Human genes 0.000 description 2
- 108010028924 PPAR alpha Proteins 0.000 description 2
- 102000000536 PPAR gamma Human genes 0.000 description 2
- YJVFFLUZDVXJQI-UHFFFAOYSA-L Palladium(II) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 2
- 229940116369 Pancreatic lipase Drugs 0.000 description 2
- 102000019280 Pancreatic lipase Human genes 0.000 description 2
- 108050006759 Pancreatic lipase Proteins 0.000 description 2
- 102000012132 Peroxisome proliferator-activated receptor gamma Human genes 0.000 description 2
- MFOCDFTXLCYLKU-CMPLNLGQSA-N Phendimetrazine Chemical compound O1CCN(C)[C@@H](C)[C@@H]1C1=CC=CC=C1 MFOCDFTXLCYLKU-CMPLNLGQSA-N 0.000 description 2
- 229960000436 Phendimetrazine Drugs 0.000 description 2
- 229960003243 Phenformin Drugs 0.000 description 2
- ICFJFFQQTFMIBG-UHFFFAOYSA-N Phenformin Chemical compound NC(=N)NC(=N)NCCC1=CC=CC=C1 ICFJFFQQTFMIBG-UHFFFAOYSA-N 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Natural products OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 229960003562 Phentermine Drugs 0.000 description 2
- DHHVAGZRUROJKS-UHFFFAOYSA-N Phentermine Chemical compound CC(C)(N)CC1=CC=CC=C1 DHHVAGZRUROJKS-UHFFFAOYSA-N 0.000 description 2
- XHXFXVLFKHQFAL-UHFFFAOYSA-N Phosphoryl chloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 2
- 229960005095 Pioglitazone Drugs 0.000 description 2
- HYAFETHFCAUJAY-UHFFFAOYSA-N Pioglitazone Chemical compound N1=CC(CC)=CC=C1CCOC(C=C1)=CC=C1CC1C(=O)NC(=O)S1 HYAFETHFCAUJAY-UHFFFAOYSA-N 0.000 description 2
- 239000004743 Polypropylene Substances 0.000 description 2
- 239000004793 Polystyrene Substances 0.000 description 2
- IUBQJLUDMLPAGT-UHFFFAOYSA-N Potassium bis(trimethylsilyl)amide Chemical compound C[Si](C)(C)N([K])[Si](C)(C)C IUBQJLUDMLPAGT-UHFFFAOYSA-N 0.000 description 2
- YASAKCUCGLMORW-UHFFFAOYSA-N Rosiglitazone Chemical compound C=1C=CC=NC=1N(C)CCOC(C=C1)=CC=C1CC1SC(=O)NC1=O YASAKCUCGLMORW-UHFFFAOYSA-N 0.000 description 2
- UNAANXDKBXWMLN-UHFFFAOYSA-N Sibutramine Chemical compound C=1C=C(Cl)C=CC=1C1(C(N(C)C)CC(C)C)CCC1 UNAANXDKBXWMLN-UHFFFAOYSA-N 0.000 description 2
- WRIKHQLVHPKCJU-UHFFFAOYSA-N Sodium bis(trimethylsilyl)amide Chemical compound C[Si](C)(C)N([Na])[Si](C)(C)C WRIKHQLVHPKCJU-UHFFFAOYSA-N 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L Sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- 229940090121 Sulfonylureas for blood glucose lowering Drugs 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 239000005864 Sulphur Substances 0.000 description 2
- 101700024355 TBAT Proteins 0.000 description 2
- CXGTZJYQWSUFET-IBGZPJMESA-N Tesaglitazar Chemical compound C1=CC(C[C@H](OCC)C(O)=O)=CC=C1OCCC1=CC=C(OS(C)(=O)=O)C=C1 CXGTZJYQWSUFET-IBGZPJMESA-N 0.000 description 2
- 229950004704 Tesaglitazar Drugs 0.000 description 2
- VDZOOKBUILJEDG-UHFFFAOYSA-M Tetrabutylammonium hydroxide Chemical compound [OH-].CCCC[N+](CCCC)(CCCC)CCCC VDZOOKBUILJEDG-UHFFFAOYSA-M 0.000 description 2
- CXWXQJXEFPUFDZ-UHFFFAOYSA-N Tetralin Chemical compound C1=CC=C2CCCCC2=C1 CXWXQJXEFPUFDZ-UHFFFAOYSA-N 0.000 description 2
- JMXKSZRRTHPKDL-UHFFFAOYSA-N Titanium ethoxide Chemical compound [Ti+4].CC[O-].CC[O-].CC[O-].CC[O-] JMXKSZRRTHPKDL-UHFFFAOYSA-N 0.000 description 2
- KJADKKWYZYXHBB-XBWDGYHZSA-N Topiramic acid Chemical compound C1O[C@@]2(COS(N)(=O)=O)OC(C)(C)O[C@H]2[C@@H]2OC(C)(C)O[C@@H]21 KJADKKWYZYXHBB-XBWDGYHZSA-N 0.000 description 2
- QAEDZJGFFMLHHQ-UHFFFAOYSA-N Trifluoroacetic anhydride Chemical compound FC(F)(F)C(=O)OC(=O)C(F)(F)F QAEDZJGFFMLHHQ-UHFFFAOYSA-N 0.000 description 2
- FIQMHBFVRAXMOP-UHFFFAOYSA-N Triphenylphosphine oxide Chemical compound C=1C=CC=CC=1P(C=1C=CC=CC=1)(=O)C1=CC=CC=C1 FIQMHBFVRAXMOP-UHFFFAOYSA-N 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K Tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- 101700086325 WRN Proteins 0.000 description 2
- 229960002632 acarbose Drugs 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 230000003213 activating Effects 0.000 description 2
- 238000005917 acylation reaction Methods 0.000 description 2
- 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 description 2
- 150000001299 aldehydes Chemical class 0.000 description 2
- 150000001336 alkenes Chemical class 0.000 description 2
- 125000004450 alkenylene group Chemical group 0.000 description 2
- 125000004419 alkynylene group Chemical group 0.000 description 2
- USFZMSVCRYTOJT-UHFFFAOYSA-N ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 2
- 235000019257 ammonium acetate Nutrition 0.000 description 2
- 229940043376 ammonium acetate Drugs 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 150000001502 aryl halides Chemical class 0.000 description 2
- 150000004792 aryl magnesium halides Chemical class 0.000 description 2
- 235000020127 ayran Nutrition 0.000 description 2
- 125000004604 benzisothiazolyl group Chemical group S1N=C(C2=C1C=CC=C2)* 0.000 description 2
- 125000004603 benzisoxazolyl group Chemical group O1N=C(C2=C1C=CC=C2)* 0.000 description 2
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 2
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 2
- 125000004935 benzoxazolinyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 2
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 2
- 125000005512 benztetrazolyl group Chemical group 0.000 description 2
- 229940058933 biguanide antimalarials Drugs 0.000 description 2
- 229940090145 biguanide blood glucose lower drugs Drugs 0.000 description 2
- 150000004283 biguanides Chemical class 0.000 description 2
- 229940090129 blood glucose lowering drugs Thiazolidinediones Drugs 0.000 description 2
- 125000001246 bromo group Chemical group Br* 0.000 description 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 229960001713 canagliflozin Drugs 0.000 description 2
- VHOFTEAWFCUTOS-TUGBYPPCSA-N canagliflozin hydrate Chemical compound O.CC1=CC=C([C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)C=C1CC(S1)=CC=C1C1=CC=C(F)C=C1.CC1=CC=C([C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)C=C1CC(S1)=CC=C1C1=CC=C(F)C=C1 VHOFTEAWFCUTOS-TUGBYPPCSA-N 0.000 description 2
- 125000000609 carbazolyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3NC12)* 0.000 description 2
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 2
- 239000011111 cardboard Substances 0.000 description 2
- 230000024881 catalytic activity Effects 0.000 description 2
- 239000007795 chemical reaction product Substances 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 230000001906 cholesterol absorption Effects 0.000 description 2
- 239000003354 cholesterol ester transfer protein inhibitor Substances 0.000 description 2
- 125000003016 chromanyl group Chemical group O1C(CCC2=CC=CC=C12)* 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 238000006880 cross-coupling reaction Methods 0.000 description 2
- 238000010192 crystallographic characterization Methods 0.000 description 2
- 125000004122 cyclic group Chemical group 0.000 description 2
- 125000001047 cyclobutenyl group Chemical group C1(=CCC1)* 0.000 description 2
- 125000001162 cycloheptenyl group Chemical group C1(=CCCCCC1)* 0.000 description 2
- 229960003834 dapagliflozin Drugs 0.000 description 2
- 238000010511 deprotection reaction Methods 0.000 description 2
- 238000004807 desolvation Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 229960004890 diethylpropion Drugs 0.000 description 2
- 238000007876 drug discovery Methods 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N edta Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 230000002708 enhancing Effects 0.000 description 2
- 229960001519 exenatide Drugs 0.000 description 2
- 125000001153 fluoro group Chemical group F* 0.000 description 2
- 239000006260 foam Substances 0.000 description 2
- 238000005755 formation reaction Methods 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- 230000002068 genetic Effects 0.000 description 2
- 229960004346 glimepiride Drugs 0.000 description 2
- 108010063245 glucagon-like peptide 1 (7-36)amide Proteins 0.000 description 2
- 239000003292 glue Substances 0.000 description 2
- 230000002641 glycemic Effects 0.000 description 2
- 229910052736 halogen Inorganic materials 0.000 description 2
- 150000002367 halogens Chemical class 0.000 description 2
- 235000009200 high fat diet Nutrition 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxyl anion Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 2
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- 230000001639 hypophagic Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 239000002198 insoluble material Substances 0.000 description 2
- 239000011630 iodine Substances 0.000 description 2
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 125000004936 isatinoyl group Chemical group N1(C(=O)C(=O)C2=CC=CC=C12)C(=O)* 0.000 description 2
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 2
- 125000001786 isothiazolyl group Chemical group 0.000 description 2
- YSDQQAXHVYUZIW-QCIJIYAXSA-N liraglutide Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCNC(=O)CC[C@H](NC(=O)CCCCCCCCCCCCCCC)C(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=C(O)C=C1 YSDQQAXHVYUZIW-QCIJIYAXSA-N 0.000 description 2
- 229960002701 liraglutide Drugs 0.000 description 2
- 229960005060 lorcaserin Drugs 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 2
- 235000019341 magnesium sulphate Nutrition 0.000 description 2
- LROBJRRFCPYLIT-UHFFFAOYSA-M magnesium;ethyne;bromide Chemical compound [Mg+2].[Br-].[C-]#C LROBJRRFCPYLIT-UHFFFAOYSA-M 0.000 description 2
- OFOBLEOULBTSOW-UHFFFAOYSA-N malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 2
- 230000002503 metabolic Effects 0.000 description 2
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 2
- 229960001110 miglitol Drugs 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N n-butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- MZRVEZGGRBJDDB-UHFFFAOYSA-N n-butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 2
- SJRJJKPEHAURKC-UHFFFAOYSA-N n-methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 2
- 108010002245 neuropeptide Y4 receptor Proteins 0.000 description 2
- 102000020217 neuropeptide Y4 receptor Human genes 0.000 description 2
- 239000012457 nonaqueous media Substances 0.000 description 2
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 2
- 125000004930 octahydroisoquinolinyl group Chemical group C1(NCCC2CCCC=C12)* 0.000 description 2
- 239000010502 orange oil Substances 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 229960001243 orlistat Drugs 0.000 description 2
- 235000020825 overweight Nutrition 0.000 description 2
- 125000004095 oxindolyl group Chemical group N1(C(CC2=CC=CC=C12)=O)* 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- LXNAVEXFUKBNMK-UHFFFAOYSA-N palladium(II) acetate Substances [Pd].CC(O)=O.CC(O)=O LXNAVEXFUKBNMK-UHFFFAOYSA-N 0.000 description 2
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 2
- 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 description 2
- 125000001557 phthalyl group Chemical group C(=O)(O)C1=C(C(=O)*)C=CC=C1 0.000 description 2
- 230000003449 preventive Effects 0.000 description 2
- 101700002674 proA1 Proteins 0.000 description 2
- WPDCHTSXOPUOII-UHFFFAOYSA-N propan-2-yl 4-[5-methoxy-6-[(2-methyl-6-methylsulfonylpyridin-3-yl)amino]pyrimidin-4-yl]oxypiperidine-1-carboxylate Chemical compound N1=CN=C(OC2CCN(CC2)C(=O)OC(C)C)C(OC)=C1NC1=CC=C(S(C)(=O)=O)N=C1C WPDCHTSXOPUOII-UHFFFAOYSA-N 0.000 description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 125000006239 protecting group Chemical group 0.000 description 2
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 2
- 125000002098 pyridazinyl group Chemical group 0.000 description 2
- 239000002464 receptor antagonist Substances 0.000 description 2
- 239000003638 reducing agent Substances 0.000 description 2
- 230000001105 regulatory Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000004007 reversed phase HPLC Methods 0.000 description 2
- 229960004586 rosiglitazone Drugs 0.000 description 2
- 239000012488 sample solution Substances 0.000 description 2
- 230000000580 secretagogue Effects 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 231100000489 sensitizer Toxicity 0.000 description 2
- 229960004425 sibutramine Drugs 0.000 description 2
- LIVNPJMFVYWSIS-UHFFFAOYSA-N silicon monoxide Inorganic materials [Si-]#[O+] LIVNPJMFVYWSIS-UHFFFAOYSA-N 0.000 description 2
- 238000001877 single-ion monitoring Methods 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L sodium carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 229910052938 sodium sulfate Inorganic materials 0.000 description 2
- 235000011152 sodium sulphate Nutrition 0.000 description 2
- 150000003413 spiro compounds Chemical class 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 238000010189 synthetic method Methods 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- NHGXDBSUJJNIRV-UHFFFAOYSA-M tetrabutylammonium chloride Chemical compound [Cl-].CCCC[N+](CCCC)(CCCC)CCCC NHGXDBSUJJNIRV-UHFFFAOYSA-M 0.000 description 2
- 125000003039 tetrahydroisoquinolinyl group Chemical group C1(NCCC2=CC=CC=C12)* 0.000 description 2
- 125000001712 tetrahydronaphthyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 description 2
- 125000000147 tetrahydroquinolinyl group Chemical group N1(CCCC2=CC=CC=C12)* 0.000 description 2
- 150000001467 thiazolidinediones Chemical class 0.000 description 2
- 210000001519 tissues Anatomy 0.000 description 2
- RTAQQCXQSZGOHL-UHFFFAOYSA-N titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 2
- 229910052719 titanium Inorganic materials 0.000 description 2
- 229960004394 topiramate Drugs 0.000 description 2
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 238000010792 warming Methods 0.000 description 2
- 239000003643 water by type Substances 0.000 description 2
- 238000010626 work up procedure Methods 0.000 description 2
- BIWQNIMLAISTBV-UHFFFAOYSA-N (4-methylphenyl)boronic acid Chemical compound CC1=CC=C(B(O)O)C=C1 BIWQNIMLAISTBV-UHFFFAOYSA-N 0.000 description 1
- JOGKWALAFPNFPR-VURMDHGXSA-N (4Z)-cycloocta-1,4-diene Chemical group [CH]1CC\C=C/CC=C1 JOGKWALAFPNFPR-VURMDHGXSA-N 0.000 description 1
- GKYDQFHHCDAUDA-UHFFFAOYSA-N (6-ethoxypyridin-2-yl)boronic acid Chemical compound CCOC1=CC=CC(B(O)O)=N1 GKYDQFHHCDAUDA-UHFFFAOYSA-N 0.000 description 1
- UWTUEMKLYAGTNQ-OWOJBTEDSA-N (E)-1,2-dibromoethene Chemical compound Br\C=C\Br UWTUEMKLYAGTNQ-OWOJBTEDSA-N 0.000 description 1
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-Bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 1
- 125000004605 1,2,3,4-tetrahydroisoquinolinyl group Chemical group C1(NCCC2=CC=CC=C12)* 0.000 description 1
- 125000004607 1,2,3,4-tetrahydroquinolinyl group Chemical group N1(CCCC2=CC=CC=C12)* 0.000 description 1
- 125000004502 1,2,3-oxadiazolyl group Chemical group 0.000 description 1
- 125000004511 1,2,3-thiadiazolyl group Chemical group 0.000 description 1
- 125000001399 1,2,3-triazolyl group Chemical group N1N=NC(=C1)* 0.000 description 1
- 125000004504 1,2,4-oxadiazolyl group Chemical group 0.000 description 1
- 125000001376 1,2,4-triazolyl group Chemical group N1N=C(N=C1)* 0.000 description 1
- 125000004506 1,2,5-oxadiazolyl group Chemical group 0.000 description 1
- 125000004517 1,2,5-thiadiazolyl group Chemical group 0.000 description 1
- 125000001781 1,3,4-oxadiazolyl group Chemical group 0.000 description 1
- 125000004520 1,3,4-thiadiazolyl group Chemical group 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N 1,4-Butanediol, dimethanesulfonate Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- MGUNASSHKYQWCZ-UHFFFAOYSA-N 1,5-diphenylpenta-1,4-dien-3-one;palladium Chemical compound [Pd].C=1C=CC=CC=1C=CC(=O)C=CC1=CC=CC=C1.C=1C=CC=CC=1C=CC(=O)C=CC1=CC=CC=C1.C=1C=CC=CC=1C=CC(=O)C=CC1=CC=CC=C1 MGUNASSHKYQWCZ-UHFFFAOYSA-N 0.000 description 1
- PDJLFESXPVLVMR-UHFFFAOYSA-N 1-(3-bromo-4-methylphenyl)ethanone Chemical compound CC(=O)C1=CC=C(C)C(Br)=C1 PDJLFESXPVLVMR-UHFFFAOYSA-N 0.000 description 1
- IHGSAQHSAGRWNI-UHFFFAOYSA-N 1-(4-bromophenyl)-2,2,2-trifluoroethanone Chemical compound FC(F)(F)C(=O)C1=CC=C(Br)C=C1 IHGSAQHSAGRWNI-UHFFFAOYSA-N 0.000 description 1
- YYLCJWIQUFHYMY-UHFFFAOYSA-N 1-(4-butoxyphenyl)ethanone Chemical compound CCCCOC1=CC=C(C(C)=O)C=C1 YYLCJWIQUFHYMY-UHFFFAOYSA-N 0.000 description 1
- QKVVOTNTWBPZSG-UHFFFAOYSA-N 1-[1-(benzylamino)-2,2,2-trifluoro-1-[4-(4,4,4-trifluorobutoxy)phenyl]ethyl]cyclopropane-1-carboxylic acid Chemical compound C=1C=CC=CC=1CNC(C(F)(F)F)(C=1C=CC(OCCCC(F)(F)F)=CC=1)C1(C(=O)O)CC1 QKVVOTNTWBPZSG-UHFFFAOYSA-N 0.000 description 1
- NACDWFXPFSCTPL-UHFFFAOYSA-N 1-aminooctan-2-one Chemical compound CCCCCCC(=O)CN NACDWFXPFSCTPL-UHFFFAOYSA-N 0.000 description 1
- ZBTMRBYMKUEVEU-UHFFFAOYSA-N 1-bromo-4-methylbenzene Chemical compound CC1=CC=C(Br)C=C1 ZBTMRBYMKUEVEU-UHFFFAOYSA-N 0.000 description 1
- 125000006432 1-methyl cyclopropyl group Chemical group [H]C([H])([H])C1(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000006017 1-propenyl group Chemical group 0.000 description 1
- 125000000453 2,2,2-trichloroethyl group Chemical group [H]C([H])(*)C(Cl)(Cl)Cl 0.000 description 1
- YZNZZRXZPJKXLG-UHFFFAOYSA-N 2,2,2-trifluoro-1-[4-(4,4,4-trifluorobutoxy)phenyl]ethanol Chemical compound FC(F)(F)C(O)C1=CC=C(OCCCC(F)(F)F)C=C1 YZNZZRXZPJKXLG-UHFFFAOYSA-N 0.000 description 1
- JIUOWTGXIVGXCW-UHFFFAOYSA-N 2,2,2-trifluoro-1-[4-(4,4,4-trifluorobutoxy)phenyl]ethanone Chemical compound FC(F)(F)CCCOC1=CC=C(C(=O)C(F)(F)F)C=C1 JIUOWTGXIVGXCW-UHFFFAOYSA-N 0.000 description 1
- PHYLLWIRJLKLGJ-UHFFFAOYSA-N 2,2,2-trifluoro-1-[4-(6,6,6-trifluorohexoxy)phenyl]ethanone Chemical compound FC(F)(F)CCCCCOC1=CC=C(C(=O)C(F)(F)F)C=C1 PHYLLWIRJLKLGJ-UHFFFAOYSA-N 0.000 description 1
- BCJUMGSHTLYECD-UHFFFAOYSA-N 2,2,2-trifluoro-1-piperidin-1-ylethanone Chemical compound FC(F)(F)C(=O)N1CCCCC1 BCJUMGSHTLYECD-UHFFFAOYSA-N 0.000 description 1
- DTLXIIQKQXADNF-UHFFFAOYSA-N 2,2-difluoro-1-piperidin-1-yl-3-[4-(4,4,4-trifluorobutoxy)phenyl]propane-1,3-dione Chemical compound C1=CC(OCCCC(F)(F)F)=CC=C1C(=O)C(F)(F)C(=O)N1CCCCC1 DTLXIIQKQXADNF-UHFFFAOYSA-N 0.000 description 1
- FITNPEDFWSPOMU-UHFFFAOYSA-N 2,3-dihydrotriazolo[4,5-b]pyridin-5-one Chemical compound OC1=CC=C2NN=NC2=N1 FITNPEDFWSPOMU-UHFFFAOYSA-N 0.000 description 1
- BVDRUCCQKHGCRX-UHFFFAOYSA-N 2,3-dihydroxypropyl formate Chemical compound OCC(O)COC=O BVDRUCCQKHGCRX-UHFFFAOYSA-N 0.000 description 1
- IAQANEMMNGDBSC-LJAQVGFWSA-N 2-(1,3-dioxoisoindol-2-yl)-N-[(2S)-1,1,1-trifluoro-4-(4-methylphenyl)-4-oxo-2-[4-(4,4,4-trifluorobutoxy)phenyl]butan-2-yl]acetamide Chemical compound C1=CC(C)=CC=C1C(=O)C[C@@](C(F)(F)F)(C=1C=CC(OCCCC(F)(F)F)=CC=1)NC(=O)CN1C(=O)C2=CC=CC=C2C1=O IAQANEMMNGDBSC-LJAQVGFWSA-N 0.000 description 1
- WQINSVOOIJDOLJ-UHFFFAOYSA-N 2-(1,3-dioxoisoindol-2-yl)acetic acid Chemical compound C1=CC=C2C(=O)N(CC(=O)O)C(=O)C2=C1 WQINSVOOIJDOLJ-UHFFFAOYSA-N 0.000 description 1
- ZYHXBGMQUWRUBE-UHFFFAOYSA-N 2-(tetrazol-2-yl)acetic acid Chemical compound OC(=O)CN1N=CN=N1 ZYHXBGMQUWRUBE-UHFFFAOYSA-N 0.000 description 1
- CATSNJVOTSVZJV-UHFFFAOYSA-N 2-Heptanone Chemical compound CCCCCC(C)=O CATSNJVOTSVZJV-UHFFFAOYSA-N 0.000 description 1
- BZCALJIHZVNMGJ-HSZRJFAPSA-N 2-[(3S)-6-[[3-[2,6-dimethyl-4-(3-methylsulfonylpropoxy)phenyl]phenyl]methoxy]-2,3-dihydro-1-benzofuran-3-yl]acetic acid Chemical compound CC1=CC(OCCCS(C)(=O)=O)=CC(C)=C1C1=CC=CC(COC=2C=C3OC[C@@H](CC(O)=O)C3=CC=2)=C1 BZCALJIHZVNMGJ-HSZRJFAPSA-N 0.000 description 1
- PTIFVLOBVCIMKL-UHFFFAOYSA-N 2-[3-[1-(4-chlorophenyl)cyclopropyl]-[1,2,4]triazolo[4,3-a]pyridin-8-yl]propan-2-ol Chemical compound N=1N=C2C(C(C)(O)C)=CC=CN2C=1C1(C=2C=CC(Cl)=CC=2)CC1 PTIFVLOBVCIMKL-UHFFFAOYSA-N 0.000 description 1
- 125000005273 2-acetoxybenzoic acid group Chemical group 0.000 description 1
- 125000004974 2-butenyl group Chemical group C(C=CC)* 0.000 description 1
- HACXYXBQBYZDLL-UHFFFAOYSA-N 2-cyano-N-[2,2,2-trifluoro-1-[1-(4-methoxybenzoyl)cyclopropyl]-1-[4-(4,4,4-trifluorobutoxy)phenyl]ethyl]acetamide Chemical compound C1=CC(OC)=CC=C1C(=O)C1(C(NC(=O)CC#N)(C=2C=CC(OCCCC(F)(F)F)=CC=2)C(F)(F)F)CC1 HACXYXBQBYZDLL-UHFFFAOYSA-N 0.000 description 1
- XNINAOUGJUYOQX-UHFFFAOYSA-M 2-cyanobutanoate Chemical compound CCC(C#N)C([O-])=O XNINAOUGJUYOQX-UHFFFAOYSA-M 0.000 description 1
- 125000006040 2-hexenyl group Chemical group 0.000 description 1
- 125000006022 2-methyl-2-propenyl group Chemical group 0.000 description 1
- GPZXFICWCMCQPF-UHFFFAOYSA-N 2-methylbenzoyl chloride Chemical compound CC1=CC=CC=C1C(Cl)=O GPZXFICWCMCQPF-UHFFFAOYSA-N 0.000 description 1
- CESUXLKAADQNTB-SSDOTTSWSA-N 2-methylpropane-2-sulfinamide Chemical compound CC(C)(C)[S@](N)=O CESUXLKAADQNTB-SSDOTTSWSA-N 0.000 description 1
- 125000006024 2-pentenyl group Chemical group 0.000 description 1
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- 125000004975 3-butenyl group Chemical group C(CC=C)* 0.000 description 1
- 125000006041 3-hexenyl group Chemical group 0.000 description 1
- CFLAHQSWDKNWPW-UHFFFAOYSA-M 3-oxo-3-phenylmethoxypropanoate Chemical compound [O-]C(=O)CC(=O)OCC1=CC=CC=C1 CFLAHQSWDKNWPW-UHFFFAOYSA-M 0.000 description 1
- LAXWLCVPJLBABV-UHFFFAOYSA-N 4,4,4-trifluorobutan-1-amine Chemical compound NCCCC(F)(F)F LAXWLCVPJLBABV-UHFFFAOYSA-N 0.000 description 1
- CJSATUYAABUQSB-UHFFFAOYSA-N 4-(4,4,4-trifluorobutoxy)benzaldehyde Chemical compound FC(F)(F)CCCOC1=CC=C(C=O)C=C1 CJSATUYAABUQSB-UHFFFAOYSA-N 0.000 description 1
- WUMARFNARLFOGR-UHFFFAOYSA-N 4-(6,6,6-trifluorohexoxy)benzaldehyde Chemical compound FC(F)(F)CCCCCOC1=CC=C(C=O)C=C1 WUMARFNARLFOGR-UHFFFAOYSA-N 0.000 description 1
- XUJFOSLZQITUOI-UHFFFAOYSA-N 4-(trifluoromethoxy)aniline Chemical compound NC1=CC=C(OC(F)(F)F)C=C1 XUJFOSLZQITUOI-UHFFFAOYSA-N 0.000 description 1
- YBAZINRZQSAIAY-UHFFFAOYSA-N 4-aminobenzonitrile Chemical compound NC1=CC=C(C#N)C=C1 YBAZINRZQSAIAY-UHFFFAOYSA-N 0.000 description 1
- DBCAQXHNJOFNGC-UHFFFAOYSA-N 4-bromo-1,1,1-trifluorobutane Chemical compound FC(F)(F)CCCBr DBCAQXHNJOFNGC-UHFFFAOYSA-N 0.000 description 1
- GZFGOTFRPZRKDS-UHFFFAOYSA-N 4-bromophenol Chemical compound OC1=CC=C(Br)C=C1 GZFGOTFRPZRKDS-UHFFFAOYSA-N 0.000 description 1
- 125000006042 4-hexenyl group Chemical group 0.000 description 1
- VZVPZGGGUJONKU-UHFFFAOYSA-N 4-iodo-1-(5,5,5-trifluoropentyl)pyrazole Chemical compound FC(F)(F)CCCCN1C=C(I)C=N1 VZVPZGGGUJONKU-UHFFFAOYSA-N 0.000 description 1
- LLNQWPTUJJYTTE-UHFFFAOYSA-N 4-iodopyrazole Chemical compound IC=1C=NNC=1 LLNQWPTUJJYTTE-UHFFFAOYSA-N 0.000 description 1
- 125000004217 4-methoxybenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1OC([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000005986 4-piperidonyl group Chemical group 0.000 description 1
- 125000002471 4H-quinolizinyl group Chemical group C=1(C=CCN2C=CC=CC12)* 0.000 description 1
- 125000004608 5,6,7,8-tetrahydroquinolinyl group Chemical group N1=C(C=CC=2CCCCC12)* 0.000 description 1
- BEQKYEJRVRVZNZ-UHFFFAOYSA-N 5-bromo-1,1,1-trifluoropentane Chemical compound FC(F)(F)CCCCBr BEQKYEJRVRVZNZ-UHFFFAOYSA-N 0.000 description 1
- 125000006043 5-hexenyl group Chemical group 0.000 description 1
- 125000006163 5-membered heteroaryl group Chemical group 0.000 description 1
- CNJBUMYNBDASSP-UHFFFAOYSA-N 6-bromo-1,1,1-trifluorohexane Chemical compound FC(F)(F)CCCCCBr CNJBUMYNBDASSP-UHFFFAOYSA-N 0.000 description 1
- 229940116904 ANTIINFLAMMATORY THERAPEUTIC RADIOPHARMACEUTICALS Drugs 0.000 description 1
- 101700018994 ARYL Proteins 0.000 description 1
- 208000004476 Acute Coronary Syndrome Diseases 0.000 description 1
- 102000019632 Acyl transferases Human genes 0.000 description 1
- 108091022082 Acyl transferases Proteins 0.000 description 1
- 210000000577 Adipose Tissue Anatomy 0.000 description 1
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonium chloride Substances [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 1
- 206010002383 Angina pectoris Diseases 0.000 description 1
- BNBQRQQYDMDJAH-UHFFFAOYSA-N Benzodioxan Chemical compound C1=CC=C2OCCOC2=C1 BNBQRQQYDMDJAH-UHFFFAOYSA-N 0.000 description 1
- AGEZXYOZHKGVCM-UHFFFAOYSA-N Benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 1
- WTEOIRVLGSZEPR-UHFFFAOYSA-N Boron trifluoride Chemical class FB(F)F WTEOIRVLGSZEPR-UHFFFAOYSA-N 0.000 description 1
- QJPJQTDYNZXKQF-UHFFFAOYSA-N Bromoanisole Chemical compound COC1=CC=C(Br)C=C1 QJPJQTDYNZXKQF-UHFFFAOYSA-N 0.000 description 1
- FAJZRHQSUSEYLE-UHFFFAOYSA-L C([O-])([O-])=O.[Ag+].C(C)(=O)O.[Ag+] Chemical compound C([O-])([O-])=O.[Ag+].C(C)(=O)O.[Ag+] FAJZRHQSUSEYLE-UHFFFAOYSA-L 0.000 description 1
- YOMWYEITAAOYEC-LRYVRFSDSA-N CC[C@H](C)S(=O)N Chemical compound CC[C@H](C)S(=O)N YOMWYEITAAOYEC-LRYVRFSDSA-N 0.000 description 1
- 125000006414 CCl Chemical group ClC* 0.000 description 1
- FJDQFPXHSGXQBY-UHFFFAOYSA-L Caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 1
- MIOPJNTWMNEORI-UHFFFAOYSA-N Camphorsulfonic acid Chemical class C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 230000037250 Clearance Effects 0.000 description 1
- CETRZFQIITUQQL-UHFFFAOYSA-N DMSO dimethylsulfoxide Chemical compound CS(C)=O.CS(C)=O CETRZFQIITUQQL-UHFFFAOYSA-N 0.000 description 1
- NNBZCPXTIHJBJL-UHFFFAOYSA-N Decalin Chemical compound C1CCCC2CCCCC21 NNBZCPXTIHJBJL-UHFFFAOYSA-N 0.000 description 1
- XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical compound C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 1
- OJCSPXHYDFONPU-UHFFFAOYSA-N EtOAc EtOAc Chemical compound CCOC(C)=O.CCOC(C)=O OJCSPXHYDFONPU-UHFFFAOYSA-N 0.000 description 1
- HVTICUPFWKNHNG-UHFFFAOYSA-N Ethyl iodide Chemical compound CCI HVTICUPFWKNHNG-UHFFFAOYSA-N 0.000 description 1
- RDTNMPNQLTWWOT-UHFFFAOYSA-N F[B-](F)(F)F.F[B-](F)(F)F.C1CC2CC[NH+]1[NH2+]C2 Chemical compound F[B-](F)(F)F.F[B-](F)(F)F.C1CC2CC[NH+]1[NH2+]C2 RDTNMPNQLTWWOT-UHFFFAOYSA-N 0.000 description 1
- 241000272184 Falconiformes Species 0.000 description 1
- 210000002468 Fat Body Anatomy 0.000 description 1
- IRXSLJNXXZKURP-UHFFFAOYSA-N Fluorenylmethyloxycarbonyl chloride Chemical compound C1=CC=C2C(COC(=O)Cl)C3=CC=CC=C3C2=C1 IRXSLJNXXZKURP-UHFFFAOYSA-N 0.000 description 1
- AWUCVROLDVIAJX-UHFFFAOYSA-N Glycerol 3-phosphate Chemical compound OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N HEPES Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 230000036499 Half live Effects 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 229940088597 Hormone Drugs 0.000 description 1
- 206010020993 Hypoglycaemia Diseases 0.000 description 1
- SYJRVVFAAIUVDH-UHFFFAOYSA-N IPA isopropanol Chemical compound CC(C)O.CC(C)O SYJRVVFAAIUVDH-UHFFFAOYSA-N 0.000 description 1
- 206010022562 Intermittent claudication Diseases 0.000 description 1
- GUBGYTABKSRVRQ-UUNJERMWSA-N Lactose Natural products O([C@@H]1[C@H](O)[C@H](O)[C@H](O)O[C@@H]1CO)[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1 GUBGYTABKSRVRQ-UUNJERMWSA-N 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- COTNUBDHGSIOTA-UHFFFAOYSA-N MeOH methanol Chemical compound OC.OC COTNUBDHGSIOTA-UHFFFAOYSA-N 0.000 description 1
- XZTYGFHCIAKPGJ-UHFFFAOYSA-N Meclofenoxate Chemical compound CN(C)CCOC(=O)COC1=CC=C(Cl)C=C1 XZTYGFHCIAKPGJ-UHFFFAOYSA-N 0.000 description 1
- LWJROJCJINYWOX-UHFFFAOYSA-L Mercury(II) chloride Chemical compound Cl[Hg]Cl LWJROJCJINYWOX-UHFFFAOYSA-L 0.000 description 1
- 208000008466 Metabolic Disease Diseases 0.000 description 1
- 230000036740 Metabolism Effects 0.000 description 1
- 210000002027 Muscle, Skeletal Anatomy 0.000 description 1
- 208000010125 Myocardial Infarction Diseases 0.000 description 1
- PEECTLLHENGOKU-UHFFFAOYSA-N N,N-dimethylpyridin-4-amine Chemical compound CN(C)C1=CC=NC=C1.CN(C)C1=CC=NC=C1 PEECTLLHENGOKU-UHFFFAOYSA-N 0.000 description 1
- BAPROVDXKNPHAM-UHFFFAOYSA-N N-(2-aminoethyl)-3-(3,5-ditert-butyl-4-hydroxyphenyl)propanamide Chemical compound CC(C)(C)C1=CC(CCC(=O)NCCN)=CC(C(C)(C)C)=C1O BAPROVDXKNPHAM-UHFFFAOYSA-N 0.000 description 1
- GSCCALZHGUWNJW-UHFFFAOYSA-N N-cyclohexyl-N-methylcyclohexanamine Chemical compound C1CCCCC1N(C)C1CCCCC1 GSCCALZHGUWNJW-UHFFFAOYSA-N 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 239000007832 Na2SO4 Substances 0.000 description 1
- RGHXWDVNBYKJQH-UHFFFAOYSA-N Nitroacetic acid Chemical compound OC(=O)C[N+]([O-])=O RGHXWDVNBYKJQH-UHFFFAOYSA-N 0.000 description 1
- 229940074726 OPHTHALMOLOGIC ANTIINFLAMMATORY AGENTS Drugs 0.000 description 1
- 230000035536 Oral bioavailability Effects 0.000 description 1
- BHAAPTBBJKJZER-UHFFFAOYSA-N P-Anisidine Chemical compound COC1=CC=C(N)C=C1 BHAAPTBBJKJZER-UHFFFAOYSA-N 0.000 description 1
- 101710043771 PDCL Proteins 0.000 description 1
- 229910019213 POCl3 Inorganic materials 0.000 description 1
- 229940049954 Penicillin Drugs 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 208000005764 Peripheral Arterial Disease Diseases 0.000 description 1
- 206010062585 Peripheral arterial occlusive disease Diseases 0.000 description 1
- 206010034636 Peripheral vascular disease Diseases 0.000 description 1
- NHKJPPKXDNZFBJ-UHFFFAOYSA-N Phenyllithium Chemical compound [Li]C1=CC=CC=C1 NHKJPPKXDNZFBJ-UHFFFAOYSA-N 0.000 description 1
- 229960005235 Piperonyl Butoxide Drugs 0.000 description 1
- 108010039918 Polylysine Proteins 0.000 description 1
- 101700026766 RAC2 Proteins 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-N Salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 1
- 210000002784 Stomach Anatomy 0.000 description 1
- WROMPOXWARCANT-UHFFFAOYSA-N TFA trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F WROMPOXWARCANT-UHFFFAOYSA-N 0.000 description 1
- YMBCJWGVCUEGHA-UHFFFAOYSA-M Tetraethylammonium chloride Chemical compound [Cl-].CC[N+](CC)(CC)CC YMBCJWGVCUEGHA-UHFFFAOYSA-M 0.000 description 1
- CZDYPVPMEAXLPK-UHFFFAOYSA-N Tetramethylsilane Chemical compound C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 description 1
- OGIDPMRJRNCKJF-UHFFFAOYSA-N TiO Inorganic materials [Ti]=O OGIDPMRJRNCKJF-UHFFFAOYSA-N 0.000 description 1
- AXZWODMDQAVCJE-UHFFFAOYSA-L Tin(II) chloride Chemical compound [Cl-].[Cl-].[Sn+2] AXZWODMDQAVCJE-UHFFFAOYSA-L 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- CGUAWVQGHRPFMH-UHFFFAOYSA-N [1-[1-(benzylamino)-2,2,2-trifluoro-1-[4-(4,4,4-trifluorobutoxy)phenyl]ethyl]cyclopropyl]-(4-methoxyphenyl)methanone Chemical compound C1=CC(OC)=CC=C1C(=O)C1(C(NCC=2C=CC=CC=2)(C=2C=CC(OCCCC(F)(F)F)=CC=2)C(F)(F)F)CC1 CGUAWVQGHRPFMH-UHFFFAOYSA-N 0.000 description 1
- JJOQGJKCVHXUFP-UHFFFAOYSA-N [1-[1-amino-2,2,2-trifluoro-1-[4-(4,4,4-trifluorobutoxy)phenyl]ethyl]cyclopropyl]-(4-methoxyphenyl)methanone Chemical compound C1=CC(OC)=CC=C1C(=O)C1(C(N)(C=2C=CC(OCCCC(F)(F)F)=CC=2)C(F)(F)F)CC1 JJOQGJKCVHXUFP-UHFFFAOYSA-N 0.000 description 1
- HPJVYDQTEHKVHG-UHFFFAOYSA-M [C-]#N.[K+].C([O-])(O)=O.[K+] Chemical compound [C-]#N.[K+].C([O-])(O)=O.[K+] HPJVYDQTEHKVHG-UHFFFAOYSA-M 0.000 description 1
- DUVKJGRTGPRRGL-UHFFFAOYSA-N [O-]B[O-] Chemical class [O-]B[O-] DUVKJGRTGPRRGL-UHFFFAOYSA-N 0.000 description 1
- 201000010272 acanthosis nigricans Diseases 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 125000000641 acridinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3C=C12)* 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 125000005076 adamantyloxycarbonyl group Chemical group C12(CC3CC(CC(C1)C3)C2)OC(=O)* 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000240 adjuvant Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000001058 adult Effects 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 125000006177 alkyl benzyl group Chemical group 0.000 description 1
- 150000001350 alkyl halides Chemical class 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- 230000000172 allergic Effects 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 239000000908 ammonium hydroxide Substances 0.000 description 1
- 125000002178 anthracenyl group Chemical group C1(=CC=CC2=CC3=CC=CC=C3C=C12)* 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000003178 anti-diabetic Effects 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000002946 anti-pancreatic Effects 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 125000006615 aromatic heterocyclic group Chemical group 0.000 description 1
- 150000001499 aryl bromides Chemical class 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 239000005441 aurora Substances 0.000 description 1
- 125000002393 azetidinyl group Chemical group 0.000 description 1
- 125000004931 azocinyl group Chemical group N1=C(C=CC=CC=C1)* 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 125000004618 benzofuryl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 125000003354 benzotriazolyl group Chemical group N1N=NC2=C1C=CC=C2* 0.000 description 1
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 1
- 229960000626 benzylpenicillin Drugs 0.000 description 1
- 230000027455 binding Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000000975 bioactive Effects 0.000 description 1
- 235000010290 biphenyl Nutrition 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 150000001642 boronic acid derivatives Chemical class 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 125000000480 butynyl group Chemical group [*]C#CC([H])([H])C([H])([H])[H] 0.000 description 1
- 125000002837 carbocyclic group Chemical group 0.000 description 1
- 125000004452 carbocyclyl group Chemical group 0.000 description 1
- 125000004623 carbolinyl group Chemical group 0.000 description 1
- 235000011089 carbon dioxide Nutrition 0.000 description 1
- CURLTUGMZLYLDI-UHFFFAOYSA-N carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 150000001735 carboxylic acids Chemical group 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 150000001780 cephalosporins Chemical class 0.000 description 1
- 125000003636 chemical group Chemical group 0.000 description 1
- 239000007810 chemical reaction solvent Substances 0.000 description 1
- 239000012320 chlorinating reagent Substances 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- IFMWVBVPVXRZHE-UHFFFAOYSA-M chlorotitanium(3+);propan-2-olate Chemical compound [Cl-].[Ti+4].CC(C)[O-].CC(C)[O-].CC(C)[O-] IFMWVBVPVXRZHE-UHFFFAOYSA-M 0.000 description 1
- 125000004230 chromenyl group Chemical group O1C(C=CC2=CC=CC=C12)* 0.000 description 1
- 125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 description 1
- 230000035512 clearance Effects 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000019771 cognition Effects 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 201000008739 coronary artery disease Diseases 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- UVCMYJYTEVWUCV-UHFFFAOYSA-N cyclononylcyclononane Chemical compound C1CCCCCCCC1C1CCCCCCCC1 UVCMYJYTEVWUCV-UHFFFAOYSA-N 0.000 description 1
- 125000000522 cyclooctenyl group Chemical group C1(=CCCCCCC1)* 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000004856 decahydroquinolinyl group Chemical group N1(CCCC2CCCCC12)* 0.000 description 1
- 239000012024 dehydrating agents Substances 0.000 description 1
- 230000001419 dependent Effects 0.000 description 1
- 229910052805 deuterium Inorganic materials 0.000 description 1
- YZCKVEUIGOORGS-OUBTZVSYSA-N deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 1
- 230000001079 digestive Effects 0.000 description 1
- 229940043279 diisopropylamine Drugs 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- XTHFKEDIFFGKHM-UHFFFAOYSA-N dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 1
- ROSDSFDQCJNGOL-UHFFFAOYSA-N dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 1
- UXGNZZKBCMGWAZ-UHFFFAOYSA-N dimethylformamide DMF Chemical compound CN(C)C=O.CN(C)C=O UXGNZZKBCMGWAZ-UHFFFAOYSA-N 0.000 description 1
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical group C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 1
- LZWLLMFYVGUUAL-UHFFFAOYSA-N ditert-butyl(cyclopenta-1,3-dien-1-yl)phosphanium;dichloropalladium;iron(2+) Chemical compound [Cl-].[Cl-].[Fe+2].[Pd+2].CC(C)(C)[PH+](C(C)(C)C)C1=CC=C[CH-]1.CC(C)(C)[PH+](C(C)(C)C)C1=CC=C[CH-]1 LZWLLMFYVGUUAL-UHFFFAOYSA-N 0.000 description 1
- SACNIGZYDTUHKB-UHFFFAOYSA-N ditert-butyl-[2-[2,4,6-tri(propan-2-yl)phenyl]phenyl]phosphane Chemical compound CC(C)C1=CC(C(C)C)=CC(C(C)C)=C1C1=CC=CC=C1P(C(C)(C)C)C(C)(C)C SACNIGZYDTUHKB-UHFFFAOYSA-N 0.000 description 1
- 238000009510 drug design Methods 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 125000005610 enamide group Chemical group 0.000 description 1
- 238000004146 energy storage Methods 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 238000010931 ester hydrolysis Methods 0.000 description 1
- OTMSDBZUPAUEDD-UHFFFAOYSA-N ethane Chemical compound CC OTMSDBZUPAUEDD-UHFFFAOYSA-N 0.000 description 1
- OCLXJTCGWSSVOE-UHFFFAOYSA-N ethanol EtOH Chemical compound CCO.CCO OCLXJTCGWSSVOE-UHFFFAOYSA-N 0.000 description 1
- HHFAWKCIHAUFRX-UHFFFAOYSA-N ethoxide Chemical class CC[O-] HHFAWKCIHAUFRX-UHFFFAOYSA-N 0.000 description 1
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 description 1
- CCYFHICOPGZKBR-VAWYXSNFSA-N ethyl (E)-3-[4-(4,4,4-trifluorobutoxy)phenyl]but-2-enoate Chemical compound CCOC(=O)\C=C(/C)C1=CC=C(OCCCC(F)(F)F)C=C1 CCYFHICOPGZKBR-VAWYXSNFSA-N 0.000 description 1
- ZFDIRQKJPRINOQ-HWKANZROSA-N ethyl (E)-but-2-enoate Chemical compound CCOC(=O)\C=C\C ZFDIRQKJPRINOQ-HWKANZROSA-N 0.000 description 1
- XXRCUYVCPSWGCC-UHFFFAOYSA-N ethyl 2-oxopropanoate Chemical compound CCOC(=O)C(C)=O XXRCUYVCPSWGCC-UHFFFAOYSA-N 0.000 description 1
- OIQULCHHLQEWPS-UHFFFAOYSA-N ethyl 3-chloro-2-oxopropanoate Chemical compound CCOC(=O)C(=O)CCl OIQULCHHLQEWPS-UHFFFAOYSA-N 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000002360 explosive Substances 0.000 description 1
- 235000020828 fasting Nutrition 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000012065 filter cake Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 description 1
- 238000003682 fluorination reaction Methods 0.000 description 1
- 125000003709 fluoroalkyl group Chemical group 0.000 description 1
- 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
- 238000001640 fractional crystallisation Methods 0.000 description 1
- 125000003838 furazanyl group Chemical group 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000003629 gastrointestinal hormone Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 238000007446 glucose tolerance test Methods 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000002440 hepatic Effects 0.000 description 1
- 125000006343 heptafluoro propyl group Chemical group 0.000 description 1
- UCVODTZQZHMTPN-UHFFFAOYSA-N heptanoyl chloride Chemical compound CCCCCCC(Cl)=O UCVODTZQZHMTPN-UHFFFAOYSA-N 0.000 description 1
- AETGYOWKOXPRCB-UHFFFAOYSA-N heptylhydrazine Chemical compound CCCCCCCNN AETGYOWKOXPRCB-UHFFFAOYSA-N 0.000 description 1
- 125000005980 hexynyl group Chemical group 0.000 description 1
- 238000004896 high resolution mass spectrometry Methods 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 150000002429 hydrazines Chemical class 0.000 description 1
- 150000003840 hydrochlorides Chemical class 0.000 description 1
- 150000004680 hydrogen peroxides Chemical class 0.000 description 1
- USZLCYNVCCDPLQ-UHFFFAOYSA-N hydron;N-methoxymethanamine;chloride Chemical compound Cl.CNOC USZLCYNVCCDPLQ-UHFFFAOYSA-N 0.000 description 1
- UWYVPFMHMJIBHE-OWOJBTEDSA-N hydroxymaleic acid group Chemical group O/C(/C(=O)O)=C/C(=O)O UWYVPFMHMJIBHE-OWOJBTEDSA-N 0.000 description 1
- 230000000910 hyperinsulinemic Effects 0.000 description 1
- 230000002218 hypoglycaemic Effects 0.000 description 1
- 125000002636 imidazolinyl group Chemical group 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 239000000859 incretin Substances 0.000 description 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000004926 indolenyl group Chemical group 0.000 description 1
- 125000003406 indolizinyl group Chemical group C=1(C=CN2C=CC=CC12)* 0.000 description 1
- 239000012442 inert solvent Substances 0.000 description 1
- 200000000018 inflammatory disease Diseases 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- 125000001977 isobenzofuranyl group Chemical group C=1(OC=C2C=CC=CC12)* 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000003384 isochromanyl group Chemical group C1(OCCC2=CC=CC=C12)* 0.000 description 1
- 125000005438 isoindazolyl group Chemical group 0.000 description 1
- 125000004594 isoindolinyl group Chemical group C1(NCC2=CC=CC=C12)* 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000003253 isopropoxy group Chemical group [H]C([H])([H])C([H])(O*)C([H])([H])[H] 0.000 description 1
- 125000005956 isoquinolyl group Chemical group 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- LVKCSZQWLOVUGB-UHFFFAOYSA-M magnesium;propane;bromide Chemical compound [Mg+2].[Br-].C[CH-]C LVKCSZQWLOVUGB-UHFFFAOYSA-M 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 229960002523 mercuric chloride Drugs 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000035786 metabolism Effects 0.000 description 1
- NBTOZLQBSIZIKS-UHFFFAOYSA-N methoxide Chemical class [O-]C NBTOZLQBSIZIKS-UHFFFAOYSA-N 0.000 description 1
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 description 1
- IKMSUJQFXGRCAK-UHFFFAOYSA-N methyl 1-[1-(benzylamino)-2,2,2-trifluoro-1-[4-(4,4,4-trifluorobutoxy)phenyl]ethyl]cyclopropane-1-carboxylate Chemical compound C=1C=CC=CC=1CNC(C(F)(F)F)(C=1C=CC(OCCCC(F)(F)F)=CC=1)C1(C(=O)OC)CC1 IKMSUJQFXGRCAK-UHFFFAOYSA-N 0.000 description 1
- IKXLXDZWVIYKSG-UHFFFAOYSA-N methyl 1-[4-(4,4,4-trifluorobutoxy)benzoyl]cyclopropane-1-carboxylate Chemical compound C=1C=C(OCCCC(F)(F)F)C=CC=1C(=O)C1(C(=O)OC)CC1 IKXLXDZWVIYKSG-UHFFFAOYSA-N 0.000 description 1
- PCRCLYBCNAMQNS-UHFFFAOYSA-N methyl 1-[N-benzyl-C-[4-(4,4,4-trifluorobutoxy)phenyl]carbonimidoyl]cyclopropane-1-carboxylate Chemical compound C=1C=CC=CC=1CN=C(C=1C=CC(OCCCC(F)(F)F)=CC=1)C1(C(=O)OC)CC1 PCRCLYBCNAMQNS-UHFFFAOYSA-N 0.000 description 1
- WVNLFGKYZQVBOV-UHFFFAOYSA-N methyl 2,2-difluoro-3-oxo-3-[4-(4,4,4-trifluorobutoxy)phenyl]propanoate Chemical compound COC(=O)C(F)(F)C(=O)C1=CC=C(OCCCC(F)(F)F)C=C1 WVNLFGKYZQVBOV-UHFFFAOYSA-N 0.000 description 1
- SUCCFVIDDHJCNY-UHFFFAOYSA-N methyl 3-(4-hydroxyphenyl)-2-oxopropanoate Chemical compound COC(=O)C(=O)CC1=CC=C(O)C=C1 SUCCFVIDDHJCNY-UHFFFAOYSA-N 0.000 description 1
- 150000004702 methyl esters Chemical class 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- QDHHCQZDFGDHMP-UHFFFAOYSA-N monochloramine Chemical compound ClN QDHHCQZDFGDHMP-UHFFFAOYSA-N 0.000 description 1
- YNAVUWVOSKDBBP-UHFFFAOYSA-N morpholine Chemical group C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 1
- 229940113083 morpholine Drugs 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000003506 n-propoxy group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])O* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L na2so4 Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- 239000006070 nanosuspension Substances 0.000 description 1
- 125000004593 naphthyridinyl group Chemical group N1=C(C=CC2=CC=CN=C12)* 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 230000001264 neutralization Effects 0.000 description 1
- 150000002825 nitriles Chemical group 0.000 description 1
- 239000002664 nootropic agent Substances 0.000 description 1
- 125000002868 norbornyl group Chemical group C12(CCC(CC1)C2)* 0.000 description 1
- 238000005016 nuclear Overhauser enhanced spectroscopy Methods 0.000 description 1
- 239000012038 nucleophile Substances 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- XDUHQPOXLUAVEE-BPMMELMSSA-N oleoyl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)CCCCCCC\C=C/CCCCCCCC)O[C@H]1N1C2=NC=NC(N)=C2N=C1 XDUHQPOXLUAVEE-BPMMELMSSA-N 0.000 description 1
- 230000003287 optical Effects 0.000 description 1
- 230000036220 oral bioavailability Effects 0.000 description 1
- 239000007935 oral tablet Substances 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 125000001979 organolithium group Chemical group 0.000 description 1
- 125000003431 oxalo group Chemical group 0.000 description 1
- 150000002916 oxazoles Chemical class 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 125000004043 oxo group Chemical group O=* 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N oxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000036961 partial Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 125000006340 pentafluoro ethyl group Chemical group FC(F)(F)C(F)(F)* 0.000 description 1
- 125000002255 pentenyl group Chemical group C(=CCCC)* 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 125000005981 pentynyl group Chemical group 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 230000002093 peripheral Effects 0.000 description 1
- 239000000546 pharmaceutic aid Substances 0.000 description 1
- 239000008024 pharmaceutical diluent Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000003285 pharmacodynamic Effects 0.000 description 1
- 230000000275 pharmacokinetic Effects 0.000 description 1
- 125000004934 phenanthridinyl group Chemical group C1(=CC=CC2=NC=C3C=CC=CC3=C12)* 0.000 description 1
- 125000004625 phenanthrolinyl group Chemical group N1=C(C=CC2=CC=C3C=CC=NC3=C12)* 0.000 description 1
- 125000001791 phenazinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3N=C12)* 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- 125000001484 phenothiazinyl group Chemical group C1(=CC=CC=2SC3=CC=CC=C3NC12)* 0.000 description 1
- 125000005954 phenoxathiinyl group Chemical group 0.000 description 1
- 125000001644 phenoxazinyl group Chemical group C1(=CC=CC=2OC3=CC=CC=C3NC12)* 0.000 description 1
- LCPDWSOZIOUXRV-UHFFFAOYSA-N phenoxyacetic acid Chemical compound OC(=O)COC1=CC=CC=C1 LCPDWSOZIOUXRV-UHFFFAOYSA-N 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 229910000073 phosphorus hydride Inorganic materials 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 125000004928 piperidonyl group Chemical group 0.000 description 1
- 125000004591 piperonyl group Chemical group C(C1=CC=2OCOC2C=C1)* 0.000 description 1
- 125000005575 polycyclic aromatic hydrocarbon group Chemical group 0.000 description 1
- 229920000656 polylysine Polymers 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 235000011056 potassium acetate Nutrition 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 239000008057 potassium phosphate buffer Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000001737 promoting Effects 0.000 description 1
- OGHBATFHNDZKSO-UHFFFAOYSA-N propan-2-olate Chemical class CC(C)[O-] OGHBATFHNDZKSO-UHFFFAOYSA-N 0.000 description 1
- VVWRJUBEIPHGQF-UHFFFAOYSA-N propan-2-yl N-propan-2-yloxycarbonyliminocarbamate Chemical compound CC(C)OC(=O)N=NC(=O)OC(C)C VVWRJUBEIPHGQF-UHFFFAOYSA-N 0.000 description 1
- 125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 125000001042 pteridinyl group Chemical group N1=C(N=CC2=NC=CN=C12)* 0.000 description 1
- 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 description 1
- 125000003072 pyrazolidinyl group Chemical group 0.000 description 1
- 125000002755 pyrazolinyl group Chemical group 0.000 description 1
- 125000000246 pyrimidin-2-yl group Chemical group [H]C1=NC(*)=NC([H])=C1[H] 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 125000001422 pyrrolinyl group Chemical group 0.000 description 1
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000000171 quenching Effects 0.000 description 1
- 125000005493 quinolyl group Chemical group 0.000 description 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
- 125000004621 quinuclidinyl group Chemical group N12C(CC(CC1)CC2)* 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000004805 robotic Methods 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000008299 semisolid dosage form Substances 0.000 description 1
- 231100000486 side effect Toxicity 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017550 sodium carbonate Nutrition 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- WGRULTCAYDOGQK-UHFFFAOYSA-M sodium;sodium;hydroxide Chemical compound [OH-].[Na].[Na+] WGRULTCAYDOGQK-UHFFFAOYSA-M 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 238000007614 solvation Methods 0.000 description 1
- 239000011877 solvent mixture Substances 0.000 description 1
- 230000003595 spectral Effects 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000010922 spray-dried dispersion Methods 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 235000011150 stannous chloride Nutrition 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 125000000547 substituted alkyl group Chemical group 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 238000004808 supercritical fluid chromatography Methods 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 201000010874 syndrome Diseases 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- DZLFLBLQUQXARW-UHFFFAOYSA-N tetrabutylammonium Chemical compound CCCC[N+](CCCC)(CCCC)CCCC DZLFLBLQUQXARW-UHFFFAOYSA-N 0.000 description 1
- ODGCEQLVLXJUCC-UHFFFAOYSA-N tetrafluoroborate Chemical compound F[B-](F)(F)F ODGCEQLVLXJUCC-UHFFFAOYSA-N 0.000 description 1
- WHRNULOCNSKMGB-UHFFFAOYSA-N tetrahydrofuran THF Chemical compound C1CCOC1.C1CCOC1 WHRNULOCNSKMGB-UHFFFAOYSA-N 0.000 description 1
- 125000004627 thianthrenyl group Chemical group C1(=CC=CC=2SC3=CC=CC=C3SC12)* 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
- 125000005309 thioalkoxy group Chemical group 0.000 description 1
- 125000005403 thiohaloalkoxy group Chemical group 0.000 description 1
- 150000003573 thiols Chemical class 0.000 description 1
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 1
- 229910001929 titanium oxide Inorganic materials 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 238000006478 transmetalation reaction Methods 0.000 description 1
- 125000003866 trichloromethyl group Chemical group ClC(Cl)(Cl)* 0.000 description 1
- IMNIMPAHZVJRPE-UHFFFAOYSA-N triethylene diamine Substances C1CN2CCN1CC2 IMNIMPAHZVJRPE-UHFFFAOYSA-N 0.000 description 1
- 125000002827 triflate group Chemical group FC(S(=O)(=O)O*)(F)F 0.000 description 1
- 125000004044 trifluoroacetyl group Chemical group FC(C(=O)*)(F)F 0.000 description 1
- CMSYDJVRTHCWFP-UHFFFAOYSA-N triphenylphosphane;hydrobromide Chemical compound Br.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 CMSYDJVRTHCWFP-UHFFFAOYSA-N 0.000 description 1
- RIOQSEWOXXDEQQ-UHFFFAOYSA-O triphenylphosphanium Chemical compound C1=CC=CC=C1[PH+](C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-O 0.000 description 1
- 235000019798 tripotassium phosphate Nutrition 0.000 description 1
- 229910052722 tritium Inorganic materials 0.000 description 1
- YZCKVEUIGOORGS-NJFSPNSNSA-N tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
- 241000701447 unidentified baculovirus Species 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 125000001834 xanthenyl group Chemical group C1=CC=CC=2OC3=CC=CC=C3C(C12)* 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D211/84—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
- C07D211/86—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D211/84—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
- C07D211/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/20—Spiro-condensed ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/38—Phosphonic acids RP(=O)(OH)2; Thiophosphonic acids, i.e. RP(=X)(XH)2 (X = S, Se)
- C07F9/40—Esters thereof
- C07F9/4003—Esters thereof the acid moiety containing a substituent or a structure which is considered as characteristic
- C07F9/4006—Esters of acyclic acids which can have further substituents on alkyl
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/535—Organo-phosphoranes
- C07F9/5352—Phosphoranes containing the structure P=C-
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
- C07F9/576—Six-membered rings
- C07F9/59—Hydrogenated pyridine rings
Abstract
Disclosed are dihydropyridinone and piperidinone compounds of formula (I), wherein the substituents are as defined in the specification. The compounds are monoacylglycerol acyltransferase type 2 (MGAT2) inhibitors which may be used as medicaments for the treatment or prophylaxis of diabetes, obesity, and dyslipidemia. Example of a compound of formula (I) are: (S)-3-(1H-tetrazol-5-yl)-4-(p-tolyl)-6-(4-(4,4,4-trifluorobutoxy)phenyl)-6-(trifluoromethyl)-5,6-dihydropyridin-2(1H)-one (S)-N-(4-methoxyphenyl)-2-oxo-4-(p-tolyl)-6-(4-(4,4,4-trifluorobutoxy)phenyl)-6-(trifluoromethyl)-1,2,5,6-tetrahydropyridine-3-carboxamide (S)-2-(methylsulfonyl)-N-(2-oxo-4-(p-tolyl)-6-(4-(4,4,4-trifluorobutoxy)phenyl)-6-(trifluoromethyl)-1,2,5,6-tetrahydropyridin-3-yl)acetamide , and dyslipidemia. Example of a compound of formula (I) are: (S)-3-(1H-tetrazol-5-yl)-4-(p-tolyl)-6-(4-(4,4,4-trifluorobutoxy)phenyl)-6-(trifluoromethyl)-5,6-dihydropyridin-2(1H)-one (S)-N-(4-methoxyphenyl)-2-oxo-4-(p-tolyl)-6-(4-(4,4,4-trifluorobutoxy)phenyl)-6-(trifluoromethyl)-1,2,5,6-tetrahydropyridine-3-carboxamide (S)-2-(methylsulfonyl)-N-(2-oxo-4-(p-tolyl)-6-(4-(4,4,4-trifluorobutoxy)phenyl)-6-(trifluoromethyl)-1,2,5,6-tetrahydropyridin-3-yl)acetamide
Description
-PCT
ARYL DIHYDROPYRIDINONES AND PIPERIDINONES AS MGAT2 INHIBITORS
CROSS-REFERENCE TO RELATED APPLICATIONS
This application claims the priority benefit of U.S. Provisional Application
No. 61/566,039 filed December 2, 2011 and the priority benefit of U.S. Non-Provisional
Application No. 13/688,584 filed November 29, 2012, both of which are incorporated
fully herein by reference.
FIELD OF THE INVENTION
[0002] The present invention provides novel aryl dihydropyridinone and piperidinone
compounds, and their analogues thereof, which are MGAT2 inhibitors, compositions
containing them, and methods of using them, for example, for the treatment or
prophylaxis of diabetes, obesity, dyslipidemia and related conditions.
BACKGROUND OF THE INVENTION
The prevalence of obesity and diabetes is increasing at an alarming rate.
According to WHO, in 2008, 70% of the U.S. adult population was overweight, and
among them 33% were obese. Parallel to the explosive number of people becoming
overweight and obese, in 2008, it was estimated that 12.3% of the U.S. population had
elevated blood glucose [http://www.who.int/diabetes/facts/en/]. The obesity/diabetes
epidemic is not unique to the U.S. According to WHO (Fact Sheet No. 312, September
2012), 347 million people worldwide have diabetes. Treating obesity and improving
glycemic control effectively and safely remain major challenges for modern medicine.
Monoacylglycerol acyltransferase 2 (MGAT2) has emerged as an attractive
target for the treatment of obesity and type II diabetes [Yen, C.L. et al., Nat. Med.,
(4):442-446 (2009)]. MGAT2 is highly and selectively expressed in the small intestine
where it exerts a pivotal role in the monoacylglycerol-pathway for the absorption of
dietary fat. When dietary fat is ingested, pancreatic lipase digests triglycerides into free
fatty acids and 2-monoacylglycerol, which are absorbed by intestinal epithelial
enterocytes. Once inside enterocytes, free fatty acids and 2-monoacylglycerol are used as
building blocks to resynthesize triglycerides by two sequential acylation steps; first by
MGAT and then by DGAT enzyme reactions. Triglycerides are then incorporated into
11841-PCT
chylomicrons and secreted into lymph to be utilized as an energy supply for the body.
MGAT2 knockout mice exhibit a healthy metabolic phenotype and show resistance to
high-fat diet induced obesity, improvement in insulin sensitivity and decreased fat
accumulation in liver and adipose tissue. In addition, genetic deletion of MGAT2
produces mice with increased levels of GLP1 [Yen, C.L. et al., Nat. Med., 15(4):442-446
(2009)]. Taken together, these data show that MGAT2 inhibitors hold promise to treat
metabolic disorders such as obesity, type II diabetes and dyslipidemia.
SUMMARY OF THE INVENTION
[0005] The present invention provides aryl dihydropyridinone and piperidinone
compounds, and their analogues thereof, which are useful as MGAT2 inhibitors,
including stereoisomers, tautomers, pharmaceutically acceptable salts, or solvates thereof.
The present invention also provides processes and intermediates for making
the compounds of the present invention or stereoisomers, tautomers, pharmaceutically
acceptable salts, or solvates thereof.
The present invention also provides pharmaceutical compositions comprising
a pharmaceutically acceptable carrier and at least one of the compounds of the present
invention or stereoisomers, tautomers, pharmaceutically acceptable salts, or solvates
thereof.
[0008] The compounds of the invention may be used in the treatment and/or
prophylaxis of multiple diseases or disorders associated with MGAT2, such as diabetes,
obesity, dyslipidemia and related conditions, such as microvascular and macrovascular
complications associated with diabetes, cardiovascular diseases, Metabolic Syndrome and
its component conditions, disorders of glucose and lipid metabolism and other maladies.
[0009] The compounds of the invention may be used in therapy.
The compounds of the invention may be used for the manufacture of a
medicament for the treatment and/or prophylaxis of multiple diseases or disorders
associated with MGAT2.
The compounds of the invention can be used alone, in combination with other
compounds of the present invention, or in combination with one or more other agent(s).
Other features and advantages of the invention will be apparent from the
following detailed description and claims.
11841-PCT
DETAILED DESCRIPTION OF THE INVENTION
I. COMPOUNDS OF THE INVENTION
In a first aspect, the present invention provides, inter alia, a compound of
Formula (I):
12 14
or a stereoisomer, a tautomer, a pharmaceutically acceptable salt, or a solvate thereof,
wherein:
designates a single or double bond;
x and y can be both a single bond; when x is a double bond, then y is a single
4 16 5
bond and R and R are absent; when y is a double bond, then x is a single bond and R
and R are absent;
R is independently selected from the group consisting of: -CONH(C alkyl),
4-18
-CONHC haloalkyl, -CONH(CH ) Ph, -CONHCH COC alkyl,
2-8 2 1-8 2 2-8
-(CH ) -(C carbocycle substituted with 0-2 R and 0-2 R ), -(CH ) -(5- to
2 m 3-10 2 m
6-membered heteroaryl comprising: carbon atoms and 1-4 heteroatoms selected from N,
e b g
NR , O and S; wherein said heteroaryl is substituted with 0-1 R and 0-2 R ), and a C
1-12
hydrocarbon chain substituted with 0-3 R ; wherein said hydrocarbon chain may be
straight or branched, saturated or unsaturated;
R is independently selected from the group consisting of: C alkyl,
C cycloalkyl, and C haloalkyl;
3-4 1-4
R is independently selected from the group consisting of: H, F, Cl, C alkyl and
11841-PCT
R and R are independently selected from the group consisting of: H, F, Cl, and
C alkyl;
when x is a single bond, R and R may be combined with the carbon atom to
which they are attached to form a 3- to 6-membered carbocycle;
R is independently selected from the group consisting of: H, halo, C alkyl,
NO , R , -(CH ) -(X) -(CH ) R , NH , -CONH(C alkyl), -NHCOX SO R ,
2 2 n t 2 m 2 1-6 1 2
j j j
-NHCOCH PO(OEt) , -NHCOCOR , -NHCOCH(OH)R , -NHCOCH COR ,
2 2 2
j f j
-NHCONHR , and -OCONR R ;
X is independently selected from the group consisting of: O, S, NH, CONH, and
NHCO;
X is independently C hydrocarbon chain optionally substituted with C alkyl
1 1-4 1-4
or C cycloalkyl;
when y is a single bond, R and R may be combined with the carbon atom to
which they are attached to form a 3- to 6-membered carbocycle;
11 12 13 14 15
R , R , R , R and R are independently selected from the group consisting
of: H, halo, C alkyl substituted with 0-2 R , C alkoxy, C haloalkyl,
1-4 1-4 1-4
f j j j
C haloalkoxy, -(CH ) -C cycloalkyl, CN, NR R , OR , SR , NHCO (C alkyl),
1-4 2 m 3-6 2 1-4
NHSO (C alkyl), and a 4- to 6-membered heterocycle comprising: carbon atoms and
2 1-4
1-4 heteroatoms selected from N, NR , O, and S;
11 12
alternatively, R and R , together with the carbon atoms to which they are
attached, combine to form a 5 to 6-membered carbocyclic ring or a 5 to 6-membered
heterocyclic ring comprising: carbon atoms and 1-3 heteroatoms selected from N, NR ,
O, and S;
12 13
alternatively, R and R , together with the carbon atoms to which they are
attached, combine to form a 5 to 6-membered carbocyclic ring or a 5 to 6-membered
heterocyclic ring comprising: carbon atoms and 1-3 heteroatoms selected from N, NR ,
O, and S;
R is independently selected from the group consisting of: H and C alkyl;
11841-PCT
R is, at each occurrence, independently selected from the group consisting of:
halo, OH, C alkoxy, C haloalkyl, C haloalkoxy, N(C alkyl) ,
1-6 1-6 1-6 1-4 2
-(CH ) -(X) -(CH ) R , and -(CH ) -(CH O) -(CH ) R ;
2 n t 2 m 2 n 2 m 2 n
R is, at each occurrence, independently selected from the group consisting of:
halo, OH, C alkyl, C alkoxy, C haloalkyl, C haloalkoxy, C alkylthio,
1-10 1-10 1-10 1-10 1-10
C haloalkyltho, N(C alkyl) , -CONH(CH ) H, -O(CH ) O(C alkyl), R ,
1-10 1-4 2 2 4-20 2 s 1-6
-(CH ) -(X) -(CH ) R , and -(CH ) -(CH O) -(CH ) R ;
2 n t 2 m 2 n 2 m 2 n
R is, at each occurrence, independently selected from the group consisting of:
C cycloalkyl substituted with 0-2 R , C cycloalkenyl substituted with 0-2 R ,
3-6 3-6
-(CH ) -(phenyl substituted with 0-3 R ), and a 5- to 6-membered heterocycle
comprising: carbon atoms and 1-4 heteroatoms selected from N, NR , O, and S; wherein
said heterocycle is substituted with 0-2 R ;
R is, at each occurrence, independently selected from the group consisting of:
halo, OH, CN, NO , C alkyl, C alkoxy, C haloalkyl, C haloalkoxy, tetrazolyl,
2 1-4 1-4 1-4 1-4
OBn and phenyl substituted with 0-2 R ;
R is, at each occurrence, independently selected from the group consisting of: H,
C alkyl, C haloalkyl, benzyl optionally substituted with C alkoxy, CO(C alkyl)
1-8 1-8 1-4 1-4
and COBn;
R is, at each occurrence, independently selected from the group consisting of: H
and C alkyl;
g h i
R , R and R are, at each occurrence, independently selected from the group
consisting of: halo, C alkyl, C alkoxy, C haloalkyl, and C haloalkoxy;
1-4 1-4 1-4 1-4
R is, at each occurrence, independently selected from the group consisting of:
C alkyl, C cycloalkyl and phenyl;
1-4 3-4
n, at each occurrence, is independently 0 or 1;
m, at each occurrence, is independently 0, 1, 2, 3, or 4;
s, at each occurrence, is independently 1, 2, or 3; and
t, at each occurrence, is independently 0 or 1;
provided that the following compound is excluded:
11841-PCT
Me H
In a second aspect, the present invention includes a compound of Formula (I),
or a stereoisomer, a tautomer, a pharmaceutically acceptable salt, or a solvate thereof,
within the scope of the first aspect, wherein:
R is independently selected from the group consisting of: -CONHC alkyl,
4-18
-CONH(CH ) Ph, C alkyl substituted with 0-2 R , C alkenyl substituted with
2 1-8 1-12 1-12
a a b
0-2 R , C alkynyl substituted with 0-2 R , -(CH ) -(phenyl substituted with 0-1 R
1-12 2 m
and 0-2 R ), -(CH ) -(C cycloalkyl substituted with 0-1 R ), and
2 m 3-6
-(CH ) -(5- to 6-membered heteroaryl substituted with 0-1 R and 0-2 R ), wherein said
heteroaryl is selected from: pyridyl, oxazolyl, thiazolyl and .
In a third aspect, the present invention includes a compound of Formula (I), or
a stereoisomer, a tautomer, a pharmaceutically acceptable salt, or a solvate thereof,
within the scope of the first or second aspect, wherein:
11 15
R and R are independently selected from the group consisting of: H,
C alkyl and halo;
12 14
R and R are independently selected from the group consisting of: H, halo,
C alkyl and C alkoxy; and
1-4 1-4
R is independently selected from the group consisting of: H, halo, C alkyl
substituted with 0-1 R , C alkoxy, C haloalkyl, C haloalkoxy,
1-4 1-4 1-4
f j j
-(CH ) -C cycloalkyl, CN, NR R , SR , NHCO (C alkyl), NHSO (C alkyl), and
2 m 3-4 2 1-4 2 1-4
a 4- to 6-membered heterocycle comprising: carbon atoms and 1-4 heteroatoms selected
from N, NR , O, and S.
In a fourth aspect, the present invention provides a compound of Formula (II):
11841-PCT
(II)
or a stereoisomer, a tautomer, a pharmaceutically acceptable salt, or a solvate thereof;
within the scope of any of the above aspects.
[0017] In a fifth aspect, the present invention includes a compound of Formula (I) or
(II), or a stereoisomer, a tautomer, a pharmaceutically acceptable salt, or a solvate
thereof, within the scope of any of the above aspects, wherein:
R is independently selected from the group consisting of: C alkyl,
C cycloalkyl, -CONHC alkyl, -CONHC haloalkyl, -CONH(CH ) Ph,
3-6 4-18 2-8 2 1-8
-(CH ) -(phenyl substituted with 1 R and 0-2 R ), and a 5- to 6-membered heteroaryl
substituted with 0-1 R and 0-2 R , wherein said heteroaryl is selected from: pyridyl,
oxazolyl, thiazolyl and ;
R is independently selected from the group consisting of: C alkyl and
C haloalkyl;
R is independently selected from the group consisting of: H and F;
R is independently selected from the group consisting of: H and F;
R is independently selected from the group consisting of: NH ,
-CONH(C alkyl), R , -(CH ) -(X) -(CH ) R , -NHCO(CH )SO (C alkyl),
1-6 2 n t 2 m 2 2 1-4
-NHCOCH PO(OEt) , -NHCOCO(C alkyl), -NHCOCH(OH)(C alkyl),
2 2 1-4 1-4
-NHCOCH CO(C alkyl), -NHCONH(C alkyl), and -OCONH(C alkyl);
2 1-4 1-4 1-4
11 15
R and R are independently selected from the group consisting of: H,
C alkyl and halo;
11841-PCT
12 14
R and R are independently selected from the group consisting of: H, halo,
C alkyl and C alkoxy;
1-4 1-4
R is independently selected from the group consisting of: H, halo, C alkyl
substituted with 0-1 C alkoxy, C alkoxy, C haloalkyl, C haloalkoxy,
1-4 1-4 1-4 1-4
-(CH ) -C cycloalkyl, CN, N(C alkyl) , NHCO (C alkyl), NHSO (C alkyl),
2 m 3-4 1-4 2 2 1-4 2 1-4
pyrazolyl, and morpholinyl;
12 13
alternatively, R and R , together with the carbon atoms to which they are
attached, combine to form a 5 to 6-membered carbocyclic ring or a 5 to 6-membered
heterocyclic ring comprising: carbon atoms and 1-3 heteroatoms selected from N, NR ,
O, and S;
R is, at each occurrence, independently selected from the group consisting of:
halo, OH, C alkyl, C alkoxy, C haloalkyl, C haloalkoxy,
1-8 1-8 1-8 1-10
-O(CH ) O(C alkyl), N(C alkyl) , -CONH(CH ) H,
2 s 1-6 1-4 2 2 6-20
-(CH ) (C cycloalkyl), -(CH ) (C cycloalkenyl), -O(CH ) (C cycloalkyl),
2 m 3-6 2 m 4-6 2 m 3-6
4-C alkoxy-Ph, -O(CH ) Ph, morpholinyl, pyridyl, 2-C alkoxy-pyridinyl,
1-4 2 m 1-4
pyrimidinyl, pyrazinyl, and -O-pyrimidinyl;
R is, at each occurrence, independently selected from the group consisting of:
halo, C alkyl, C alkoxy, C haloalkyl, and C haloalkoxy;
1-4 1-4 1-4 1-4
m, at each occurrence, is independently 0, 1, 2 or 3; and
s, at each occurrence, is independently 1, 2, or 3.
In a sixth aspect, the present invention includes a compound of Formula (I) or
(II), or a stereoisomer, a tautomer, a pharmaceutically acceptable salt, or a solvate
thereof, within the scope of any of the above aspects, wherein:
R is independently selected from the group consisting of: C alkyl,
-CONHC alkyl, -CONH(CH ) Ph, and ;
4-18 2 1-8
R is independently selected from the group consisting of: NH ,
11841-PCT
-CONH(C alkyl), -NHCOCH PO(OEt) , -NHCO(CH )SO (C alkyl), R , OR ,
1-6 2 2 2 2 1-4
-CONHR , and -NHCOR ;
R is independently selected from the group consisting of: H, halo, C alkyl
and C alkoxy;
R is independently selected from the group consisting of: H, halo, C alkyl
substituted with 0-1 C alkoxy, C alkoxy, C haloalkyl, C haloalkoxy,
1-4 1-4 1-4 1-4
-(CH ) -C cycloalkyl, CN, N(C alkyl) , NHCO (C alkyl), NHSO (C alkyl),
2 m 3-4 1-4 2 2 1-4 2 1-4
pyrazolyl, and morpholinyl;
12 13
alternatively, R and R , together with the carbon atoms to which they are
attached, combine to form a 5 to 6-membered carbocyclic ring or a 5 to 6-membered
saturated heterocyclic ring comprising: carbon atoms and 1-2 oxygen atoms;
R is independently selected from the group consisting of: H and C alkoxy;
R is, at each occurrence, independently selected from the group consisting of:
halo, C alkyl, C alkoxy, C haloalkyl, C haloalkoxy, -O(CH ) O(C alkyl),
1-6 1-6 1-6 1-10 2 s 1-6
-CONH(CH ) H, -(CH ) (C cycloalkyl), -(CH ) (C cycloalkenyl),
2 6-20 2 m 3-6 2 m 4-6
-O(CH ) (C cycloalkyl), phenoxy, benzoxy, morpholinyl, 2-C alkoxy-pyridinyl,
2 m 3-6 1-4
pyrimidinyl, pyrazinyl and -O-pyrimidinyl; and
R is, at each occurrence, independently selected from the group consisting of:
C cycloalkyl substituted with 0-2 R , -(CH ) -(phenyl substituted with 0-3 R ), and a
3-6 2 m
heteroaryl selected from: oxazolyl, isoxazolyl, thiazolyl, pyrazolyl, imidazolyl,
oxadiazolyl, triazolyl, tetrazolyl, pyridyl, and pyrazinyl; wherein said heteroaryl is
substituted with 0-2 R .
In a seventh aspect, the present invention includes a compound of Formula (I)
or (II), or a stereoisomer, a tautomer, a pharmaceutically acceptable salt, or a solvate
thereof, within the scope of any of the above aspects, wherein:
R is ;
11841-PCT
R is independently selected from the group consisting of: NH ,
-CONH(C alkyl), OPh, -CONH(C cycloalkyl), -CONHPh, -CONH-(2-halo-Ph),
1-4 3-6
-CONH-(3-halo-Ph), -CONH-(4-halo-Ph), -CONH-(4-C alkyl-Ph), -CONH(4-OH-Ph),
-CONH-(3-C alkoxy-Ph), -CONH-(4-C alkoxy-Ph), -CONH-(4-C haloalkyl-Ph),
1-4 1-4 1-4
-CONH-(4-C haloalkoxy-Ph), -CONH-(4-CN-Ph), -CONH-(4-tetrazolyl-Ph),
-CONH-(3-haloC alkyl-Ph), -CONH-(3-haloC alkoxy-Ph), -CONH(CH ) Ph,
1-4 1-4 2 2
-CONH(4-(4-C alkoxy-Ph)-thiazolyl),
-CONH(1-C alkyl-pyrazolyl), -CONH(5-C alkoxy-pyridyl),
1-4 1-4
-CONH(6-C alkoxy-pyridyl), -CONH(5-C alkoxy-pyrazinyl),
1-4 1-4
-CONH(6-C alkoxy-pyridazinyl), -NHCO(CH )SO (C alkyl), -NHCOPh,
1-4 2 2 1-4
-NHCO(2-C alkyl-Ph), -NHCO(3-C alkyl-Ph), -NHCO(4-C alkyl-Ph),
1-4 1-4 1-4
-NHCO(2-halo-Ph), -NHCO(3-halo-Ph), -NHCO(2-C haloalkyl-Ph),
-NHCO(2-C haloalkoxy-Ph), -NHCO(2-halohalo-Ph), -NHCO(2-halohalo-Ph),
-NHCO(oxazolyl), -NHCO(isoxazolyl), -NHCO(3-C alkyl-isoxazolyl),
-NHCO(4-C alkyl-isoxazolyl), -NHCO(3-C alkoxy-isoxazolyl),
1-4 1-4
-NHCO(4-C alkoxy-isoxazolyl), -NHCO(3-halo-isoxazolyl),
-NHCO(3-OBn-isoxazolyl), -NHCO(3-(2-halo-Ph)-isoxazolyl),
-NHCO(3-(3-halo-Ph)-isoxazolyl), -NHCO(5-C alkyl-1H-pyrazolyl), imidazolyl,
-NHCO(5-C alkyl-1,3,4-oxadiazolyl), -NHCO(1-C alkyl-1,2,3-triazolyl),
1-4 1-4
-NHCO(6-C alkoxy-pyridyl), -NHCO(pyrazinyl), -NHCO(6-halo-pyridazinyl),
-C haloalkyl-1,3,4-oxadiazolyl, 3-NO -1H-1,2,4-triazolyl, tetrazolyl and
1-4 2
-C alkyl-tetrazolyl;
R is independently selected from the group consisting of: halo, C alkyl,
C alkoxy, C haloalkyl, C haloalkoxy, -CONH(CH ) H, C cycloalkyl,
1-6 1-6 1-8 2 6-20 3-6
C cycloalkenyl, -O(CH ) (C cycloalkyl), phenoxy, benzoxy, pyrimidinyl, pyrazinyl
4-6 2 m 3-6
and -O-pyrimidinyl; and
R is independently selected from the group consisting of: halo and C alkyl.
11841-PCT
In an eighth aspect, the present invention includes a compound of Formula (I)
or (II), or a stereoisomer, a tautomer, a pharmaceutically acceptable salt, or a solvate
thereof, within the scope of any of the above aspects, wherein:
R is independently selected from the group consisting of: CF and Me;
R is independently selected from the group consisting of: H and F;
R is independently selected from the group consisting of: H and F;
R is independently selected from the group consisting of: NH , -CONHMe, OPh,
-CONH(cyclopropyl), -CONH(cyclobutyl), -CONH(cyclopentyl),
-CONH(cyclohexyl), -CONHPh, -CONH(4-F-Ph), -CONH(2-Cl-Ph),
-CONH(4-Cl-Ph), -CONH(4-Me-Ph), -CONH(4-OH-Ph), -CONH(3-OMe-Ph),
-CONH(4-OMe-Ph), -CONH(4-CF -Ph), -CONH(4-OCF -Ph),
-CONH(1-Me-pyrazolyl), -CONH(4-(1H-tetrazolyl)-Ph),
-CONH(4-(2H-tetrazolyl)-Ph), -CONH(3-FMe-Ph), -CONH(3-FOMe-Ph),
-CONH(CH ) Ph, -CONH(5-OMe-pyridyl), -CONH(6-OMe-pyridyl),
-CONH(5-OMe-pyrazinyl), -CONH(6-OMe-pyridazinyl), -NHCO(CH )SO Me,
-NHCOPh, -NHCO(2-Me-Ph), -NHCO(3-Me-Ph), -NHCO(4-Me-Ph), -NHCO(2-Cl-Ph),
-NHCO(3-Cl-Ph), -NHCO(2-ClF-Ph), -NHCO(2-ClF-Ph), -NHCO(isoxazolyl),
-NHCO(3-Me-isoxazolyl), -NHCO(4-Me-isoxazolyl),
-NHCO(3-OMe-isoxazolyl), -NHCO(3-Br-isoxazolyl),
-NHCO(3-(2-Cl-Ph)-isoxazolyl), -NHCO(3-(3-F-Ph)-isoxazolyl),
-NHCO(3-OBn-isoxazolyl), 1H-imidazolyl, -NHCO(5-Me-1,3,4-oxadiazolyl),
-NHCO(1-Me-1,2,3-triazolyl), -NHCO(6-OMe-pyridyl),
-NHCO(6-Cl-pyridazinyl), 5-CF -1,3,4-oxadiazolyl, 1H-tetrazolyl,
1H-tetrazolyl, and 2H-tetrazolyl;
11 15
R and R are independently selected from the group consisting of: H, Me, F,
and Cl;
R is independently selected from the group consisting of: H, F, Cl, Me and
OMe;
R is independently selected from the group consisting of: H, F, Cl, Br, Me,
OMe, OEt, CH OMe, CF , CH CF , OCHF , OCF , CN, N(Me) , cyclopropyl and
2 3 2 3 2 3 2
cyclopropylmethyl;
11841-PCT
12 13
alternatively, R and R , together with the carbon atoms to which they are
attached, combine to form a 5 to 6-membered carbocyclic ring or a 5 to 6-membered
saturated heterocyclic ring comprising: carbon atoms and 1-2 oxygen atoms;
R is H;
R is, at each occurrence, independently selected from the group consisting of:
n-pentyl, methoxy, n-butoxy, i-butoxy, i-pentoxy, -O(CH ) CF , -O(CH ) CF CF ,
2 1-6 3 2 1-4 2 3
-CONH(CH ) H, cyclopropyl, cyclopentenyl, cyclohexenyl,
2 6-20
-O(CH ) (cyclopentyl), phenoxy, benzoxy, pyrimidinyl, pyrazinyl and
-O-pyrimidinyl; and
R is F.
In a ninth aspect, the present invention includes a compound of Formula (I) or
(II), or a stereoisomer, a tautomer, a pharmaceutically acceptable salt, or a solvate
thereof, within the scope of any of the first, second, third, fourth, fifth and sixth apsects,
wherein:
R is ;
R is independently selected from CF and CH ;
6 c c c
R is independently selected from: R , -CONHR , -NHCOR , and
-NHCOCH SO (C alkyl);
2 2 1-4
R is independently selected from: -O(CH ) CF , -O(CH ) CF CF ,
2 1-6 3 2 1-4 2 3
-CONH(CH ) H, cyclopentenyl, cyclohexenyl, -O(CH ) (cyclopentyl),
2 6-20 2 2
phenoxy, benzoxy, pyrimidinyl, pyrazinyl and -O-pyrimidinyl;
R is, at each occurrence, independently selected from the group consisting of:
-(CH ) -(phenyl substituted with 0-3 R ), and a heteroaryl selected from: oxazolyl,
isoxazolyl, pyrazolyl, imidazolyl, oxadiazolyl, triazolyl, tetrazolyl, pyridyl, and
pyrazinyl; wherein said heteroaryl is substituted with 0-2 R ; and
11841-PCT
R is, at each occurrence, independently selected from the group consisting of:
halo, OH, CN, C alkyl, C alkoxy, C haloalkyl, C haloalkoxy, tetrazolyl and
1-4 1-4 1-4 1-4
OBn.
[0022] In another aspect, the present invention includes a compound of Formula (I) or
(II), or a stereoisomer, a tautomer, a pharmaceutically acceptable salt, or a solvate
thereof, within the scope of any of the first, second, third, fourth, fifth, sixth and ninth
apsects, wherein:
R is ;
R is independently selected from CF and CH ;
6 c c c
R is independently selected from: R , -CONHR , -NHCOR , and
-NHCOCH SO (C alkyl);
2 2 1-4
11 12 14 15
R , R , R and R are H;
R is independently selected from the group consisting of: H, C alkyl,
C haloalkyl, C alkoxy, and C haloalkoxy; and
1-4 1-4 1-4
R is independently selected from: -O(CH ) CF and -O(CH ) CF CF .
2 1-6 3 2 1-4 2 3
In another aspect, the present invention includes a compound of Formula (II),
or a stereoisomer, a tautomer, a pharmaceutically acceptable salt, or a solvate thereof,
within the scope of the fourth or fifth aspect, wherein:
R is ;
R is independently selected from CF and CH ;
R and R are H;
R is independently 5-membered nitrogen heteroaryl;
11 12 14 15
R , R , R and R are H;
R is independently selected from the group consisting of: H, C alkyl,
C haloalkyl, C alkoxy, and C haloalkoxy; and
1-4 1-4 1-4
11841-PCT
R is independently selected from: -O(CH ) CF and -O(CH ) CF CF .
2 1-6 3 2 1-4 2 3
In another aspect, the present invention includes a compound of Formula (II),
or a stereoisomer, a tautomer, a pharmaceutically acceptable salt, or a solvate thereof,
within the scope of the fourth or ffith aspect, wherein:
R is ;
R is independently selected from CF and CH ;
R and R are H;
R is independently selected from: 1H-imidazolyl, 1H-tetrazolyl,
1H-tetrazolyl, and 2H-tetrazolyl;
11 12 14 15
R , R , R and R are H;
R is independently selected from the group consisting of: H, Me, OMe, and
OCHF ; and
R is independently selected from: -O(CH ) CF and -O(CH ) CF CF .
2 1-6 3 2 1-4 2 3
Also described herein is a compound of Formula (I):
12 14
or a stereoisomer, a tautomer, a pharmaceutically acceptable salt, or a solvate thereof,
wherein:
designates a single or double bond;
x and y can be both a single bond; when x is a double bond, then y is a single
4 16 5
bond and R and R are absent; when y is a double bond, then x is a single bond and R
and R are absent;
R is independently selected from the group consisting of:
11841-PCT
-(CH ) -(C carbocycle substituted with 0-3 R ) or a C hydrocarbon chain
2 m 3-10 1-12
substituted with 0-3 R ; wherein said hydrocarbon chain may be straight or branched,
saturated or unsaturated;
R is independently selected from the group consisting of: C alkyl and
C haloalkyl;
R is independently selected from the group consisting of: H, halo, C alkyl and
R and R are independently selected from the group consisting of: H, halo and
C alkyl;
when x is a single bond, R and R may be combined with the carbon atom to
which they are attached to form a 3- to 6-membered carbocycle;
R is independently selected from the group consisting of: H, halo, C alkyl,
CN, NO , and -(CH ) -(X) -(CH ) R ;
2 2 n t 2 m
X is independently selected from the group consisting of: O, S, NH, CONH and
NHCO;
when y is a single bond, R and R may be combined with the carbon atom to
which they are attached to form a 3- to 6-membered carbocycle;
11 12 13 14 15
R , R , R , R and R are independently selected from the group consisting
of: H, halo, C alkyl, C alkoxy, C haloalkyl, C haloalkoxy, CN and a 5- to
1-4 1-4 1-4 1-4
6-membered heterocycle comprising: carbon atoms and 1-4 heteroatoms selected from N,
NR , O, and S;
R is independently selected from the group consisting of: H and C alkyl;
R is, at each occurrence, independently selected from the group consisting of:
halo, OH, C alkoxy, C haloalkyl, C haloalkoxy, N(C alkyl) ,
1-6 1-6 1-6 1-4 2
-(CH ) -(X) -(CH ) R , and -(CH ) -(CH O) -(CH ) R ;
2 n t 2 m 2 n 2 m 2 n
R is, at each occurrence, independently selected from the group consisting of:
halo, OH, C alkyl, C alkoxy, C haloalkyl, C haloalkoxy,
1-6 1-6 1-6 1-6
-(CH ) -(X) -(CH ) R , and -(CH ) -(CH O) -(CH ) R ;
2 n t 2 m 2 n 2 m 2 n
R is independently selected from the group consisting of: C cycloalkyl
substituted with 0-2 R , phenyl substituted with 0-3 R , and a 5- to 6-membered
11841-PCT
heterocycle comprising: carbon atoms and 1-4 heteroatoms selected from N, NR , O, and
S; wherein said heterocycle is substituted with 0-2 R ;
R is, at each occurrence, independently selected from the group consisting of:
halo, OH, CN, C alkyl, C alkoxy, C haloalkyl, and C haloalkoxy;
1-4 1-4 1-4 1-4
R is independently selected from the group consisting of: H, C alkyl, benzyl,
CO(C alkyl) and COBn;
R is independently selected from the group consisting of: H and C alkyl;
n, at each occurrence, is independently 0 or 1;
m, at each occurrence, is independently 0, 1, 2, 3 or 4; and
t, at each occurrence, is independently 0 or 1;
provided that the following compounds are excluded:
CN CN
Ph Ph
N O N O
Me Me Me
H H H
, , ,
MeO Br
CN CN
N O N O
Me Me
[0026] Also described herein is a compound of Formula (I), or a stereoisomer, a
tautomer, a pharmaceutically acceptable salt, or a solvate thereof, as described in
paragraph [0025], wherein:
R is independently selected from the group consisting of: C alkyl substituted
with 0-2 R , -(CH ) -(phenyl substituted with 0-3 R ), and -(CH ) -(C cycloalkyl
2 m 2 m 3-6
substituted with 0-2 R ).
11841-PCT
Also described herein is a compound of Formula (I), or a stereoisomer, a
tautomer, a pharmaceutically acceptable salt, or a solvate thereof, as described in
paragraph [0025] or [0026], wherein:
11 15
R and R are independently selected from the group consisting of: H and halo;
12 14
R and R are independently selected from the group consisting of: H,
C alkyl and C alkoxy; and
1-4 1-4
R is independently selected from the group consisting of: H, halo, C alkyl,
C alkoxy, C haloalkyl, C haloalkoxy, CN and morpholinyl.
1-4 1-4 1-4
[0028] Also described herein is a compound of Formula (II):
(II)
or a stereoisomer, a tautomer, a pharmaceutically acceptable salt, or a solvate thereof; as
described in any of paragraphs [0025] to [0027].
[0029] Also described herein is a compound of Formula (I) or (II), or a stereoisomer,
a tautomer, a pharmaceutically acceptable salt, or a solvate thereof, as described in any
of paragraphs [0025 to 0028], wherein:
R is independently selected from the group consisting of: C alkyl,
C cycloalkyl, -(CH ) Ph and ;
3-6 2 m
R is independently selected from the group consisting of: C alkyl and
C haloalkyl;
R is H;
R is H;
R is independently selected from the group consisting of: CN, NO ,
11841-PCT
-CONH(C alkyl), -CONHPh, -CONH-(3-halo-Ph), -CONH-(4-halo-Ph),
-CONH-(4-C alkyl -Ph), -CONH-(3-C alkoxy-Ph),
1-4 1-4
-CONH-(4-C alkoxy-Ph), -CONH-(4-C haloalkyl-Ph),
1-4 1-4
-CONH-(4-C haloalkoxy-Ph), -CONH-(3-haloC alkyl-Ph),
1-4 1-4
-CONH-(3-haloC alkoxy-Ph), -CONH(CH ) Ph, and 2H-tetrazolyl;
1-4 2 2
11 15
R and R are independently selected from the group consisting of: H and halo;
12 14
R and R are independently selected from the group consisting of: H,
C alkyl and C alkoxy;
1-4 1-4
R is independently selected from the group consisting of: H, halo, C alkyl,
C alkoxy, C haloalkyl, C haloalkoxy, CN and morpholinyl;
1-4 1-4 1-4
R is independently selected from the group consisting of: halo, OH, C alkyl,
C alkoxy, C haloalkyl, C haloalkoxy, -O(CH ) O(C alkyl),
1-6 1-6 1-6 2 m 1-4
N(C alkyl) , -O(CH ) (C cycloalkyl), 4-C alkoxy-Ph, -O(CH ) Ph,
1-4 2 2 m 3-6 1-4 2 m
pyridinyl, 2-C alkoxy-pyridinyl, pyrimidinyl, pyrazinyl and
-O-pyrimidinyl; and
m, at each occurrence, is independently 0, 1, 2 or 3.
Also described herein is a compound of Formula (I) or (II), or a stereoisomer,
a tautomer, a pharmaceutically acceptable salt, or a solvate thereof, as described in any
of paragraphs [0025] to [0029], wherein:
R is independently selected from the group consisting of: C alkyl and
R is independently selected from the group consisting of: CN,
-CONH(C alkyl), -CONHPh, -CONH-(3-halo-Ph), -CONH-(4-halo-Ph),
-CONH-(4-C alkyl -Ph), -CONH-(3-C alkoxy-Ph),
1-4 1-4
-CONH-(4-C alkoxy-Ph), -CONH-(4-C haloalkyl-Ph),
1-4 1-4
-CONH-(4-C haloalkoxy-Ph), -CONH-(3-haloC alkoxy-Ph), -CONH(CH ) Ph,
1-4 1-4 2 2
and 2H-tetrazolyl;
11841-PCT
R is independently selected from the group consisting of: H, C alkyl and
C alkoxy;
R is independently selected from the group consisting of: H and C alkoxy;
R is independently selected from the group consisting of: H, halo, C alkyl,
C alkoxy, C haloalkyl, C haloalkoxy and CN;
1-4 1-4 1-4
R is independently selected from the group consisting of: C alkyl,
C alkoxy, C haloalkyl, C haloalkoxy, -O(CH ) O(C alkyl),
1-6 1-6 1-6 2 m 1-4
-O(CH ) (C cycloalkyl), phenoxy, benzoxy, 2-C alkoxy-pyridinyl,
2 m 3-6 1-4
pyrimidinyl, pyrazinyl and -O-pyrimidinyl; and
m, at each occurrence, is independently 0, 1, 2 or 3;
provided that the following compounds are excluded:
Me OMe
Me MeO
CN CN
N O N O
Me H Me H
In a tenth aspect, the present invention includes a compound of Formula (I) or
(II), or a stereoisomer, a tautomer, a pharmaceutically acceptable salt, or a solvate
thereof, within the scope of the ninth aspect, wherein:
R is ;
R is independently selected from the group consisting of: -CONHPh,
-CONH-(4-halo-Ph), -CONH-(4-C alkyl -Ph), -CONH-(3-C alkoxy-Ph),
1-4 1-4
-CONH-(4-C alkoxy-Ph), -CONH-(4-C haloalkyl-Ph),
1-4 1-4
-CONH-(4-C haloalkoxy-Ph), -CONH-(3-haloC alkoxy-Ph), -CONH(CH ) Ph,
1-4 1-4 2 2
and 2H-tetrazolyl; and
11841-PCT
R is independently selected from the group consisting of: C alkyl,
C alkoxy, C haloalkyl, C haloalkoxy, -O(CH ) (C cycloalkyl), phenoxy,
1-6 1-6 1-6 2 m 3-6
benzoxy, pyrimidinyl, pyrazinyl and -O-pyrimidinyl.
[0032] In an eleventh aspect, the present invention includes a compound of Formula
(I) or (II), or a stereoisomer, a tautomer, a pharmaceutically acceptable salt, or a solvate
thereof, within the scope of the ninth aspect, wherein:
R is independently selected from the group consisting of: CF and Me;
R is independently selected from the group consisting of: -CONHPh,
-CONH-(4-F-Ph), -CONH-(4-Cl-Ph), -CONH-(4-Me-Ph), -CONH-(3-OMe-Ph),
-CONH-(4-OMe-Ph), -CONH-(4-CF -Ph), -CONH-(4-OCF -Ph),
-CONH-(3-FOMe-Ph), -CONH(CH ) Ph, and 2H-tetrazolyl;
11 15
R and R are independently selected from the group consisting of: H and F;
R is independently selected from the group consisting of: H, Me and OMe;
R is independently selected from the group consisting of: H, F, Cl, Me, OMe,
OEt, CF , OCHF , OCF and CN;
3 2 3
R is H; and
R is independently selected from the group consisting of: n-pentyl, methoxy,
n-butoxy, i-butoxy, -O(CH ) CF , -O(CH ) (cyclopentyl), phenoxy, benzoxy,
2 1-3 3 2 2
pyrimidinyl, pyrazinyl and -O-pyrimidinyl.
In a further aspect the present invention provides a compound selected from
the exemplified examples or a stereoisomer, a tautomer, a pharmaceutically acceptable
salt, or a solvate thereof.
[0034] In another aspect, the present invention provides a compound selected from
any subset list of compounds or a single compound from the exemplified examples within
the scope of any of the above aspects.
In another aspect, the present disclosure provides a compound selected from:
(S)(1H-tetrazolyl)(p-tolyl)(4-(4,4,4-trifluorobutoxy)phenyl)
(trifluoromethyl)-5,6-dihydropyridin-2(1H)-one,
11841-PCT
(S)-N-(4-methoxyphenyl)oxo(p-tolyl)(4-(4,4,4-trifluorobutoxy)phenyl)-
6-(trifluoromethyl)-1,2,5,6-tetrahydropyridinecarboxamide,
(S)(2H-tetrazolyl)(p-tolyl)(4-((6,6,6-trifluorohexyl)oxy)phenyl)
(trifluoromethyl)-5,6-dihydropyridin-2(1H)-one,
(S)oxo(p-tolyl)(4-(4,4,4-trifluorobutoxy)phenyl)-N-(4-
(trifluoromethoxy)phenyl)(trifluoromethyl)-1,2,5,6-tetrahydropyridinecarboxamide,
(S)-N-(6-methoxypyridinyl)oxo(p-tolyl)(4-(4,4,4-
trifluorobutoxy)phenyl)(trifluoromethyl)-1,2,5,6-tetrahydropyridinecarboxamide,
(S)-N-cyclopropyloxo(p-tolyl)(4-(4,4,4-trifluorobutoxy)phenyl)
(trifluoromethyl)-1,2,5,6-tetrahydropyridinecarboxamide,
(S)-N-(4-hydroxyphenyl)oxo(p-tolyl)(4-(4,4,4-trifluorobutoxy)phenyl)
(trifluoromethyl)-1,2,5,6-tetrahydropyridinecarboxamide,
(S)(4-(difluoromethoxy)phenyl)(1H-tetrazolyl)(4-(4,4,4-
trifluorobutoxy)phenyl)(trifluoromethyl)-5,6-dihydropyridin-2(1H)-one,
(S)methyl-N-(2-oxo(p-tolyl)(4-(4,4,4-trifluorobutoxy)phenyl)
(trifluoromethyl)-1,2,5,6-tetrahydropyridinyl)isoxazolecarboxamide,
(S)methyl-N-(2-oxo(p-tolyl)(4-(4,4,4-trifluorobutoxy)phenyl)
(trifluoromethyl)-1,2,5,6-tetrahydropyridinyl)-1,3,4-oxadiazolecarboxamide,
N -heptyl-N -(4-methoxyphenyl)methyloxo(p-tolyl)-1,2,3,6-
tetrahydropyridine-2,5-dicarboxamide,
(S)(1H-tetrazolyl)(p-tolyl)(4-((6,6,6-trifluorohexyl)oxy)phenyl)
(trifluoromethyl)-5,6-dihydropyridin-2(1H)-one,
(S)(5,6,7,8-tetrahydronaphthalenyl)(1H-tetrazolyl)(4-(4,4,4-
trifluorobutoxy)phenyl)(trifluoromethyl)-5,6-dihydropyridin-2(1H)-one,
(S)(methylsulfonyl)-N-(2-oxo(p-tolyl)(4-(4,4,4-trifluorobutoxy)phenyl)-
6-(trifluoromethyl)-1,2,5,6-tetrahydropyridinyl)acetamide,
(S)(1H-tetrazolyl)(4-(4,4,4-trifluorobutoxy)phenyl)(4-(2,2,2-
trifluoroethyl)phenyl)(trifluoromethyl)-5,6-dihydropyridin-2(1H)-one, and
(S)-N-(5-methoxypyrazinyl)oxo(p-tolyl)(4-(4,4,4-
trifluorobutoxy)phenyl)(trifluoromethyl)-1,2,5,6-tetrahydropyridinecarboxamide;
or a pharmaceutically acceptable salt thereof.
11841-PCT
In another embodiment, R is independently -CONH(C alkyl),
4-18
-CONHC haloalkyl, or -CONH(CH ) Ph.
2-8 2 1-8
In another embodiment, R is -(CH ) -(C carbocycle substituted with 0-2
2 m 3-10
R and 0-2 R ), or -(CH ) -(5- to 6-membered heteroaryl comprising: carbon atoms and
1-4 heteroatoms selected from N, NR , O and S; wherein said heteroaryl is substituted
with 0-1 R and 0-2 R ).
In another embodiment, R is -(CH ) -(C carbocycle substituted with 0-2
2 m 3-10
R and 0-2 R ).
In another embodiment, R is -(CH ) -(phenyl substituted with 0-2 R and
0-2 R ).
In another embodiment, R is -(CH ) -(5- to 6-membered heteroaryl
comprising: carbon atoms and 1-4 heteroatoms selected from N, NR , O and S; wherein
said heteroaryl is substituted with 0-1 R and 0-2 R ).
In another embodiment, R is a C hydrocarbon chain substituted with 0-3
1-12
R ; wherein said hydrocarbon chain may be straight or branched, saturated or
unsaturated.
In another embodiment, R is independently: C alkyl, C cycloalkyl,
1-6 3-6
-CONHC alkyl, -CONHC haloalkyl, -CONH(CH ) Ph, -(CH ) -(phenyl
4-18 2-8 2 1-8 2 m
substituted with 1 R and 0-2 R ), or a 5- to 6-membered heteroaryl substituted with 0-1
R and 0-2 R , wherein said heteroaryl is selected from: pyridyl, oxazolyl, thiazolyl and
In another embodiment, R is independently: C alkyl, -CONHC alkyl,
1-6 4-18
-CONH(CH ) Ph, or .
2 1-8
In another embodiment, R is .
11841-PCT
In another embodiment, R is independently .
In another embodiment, R is independently C alkyl or C haloalkyl.
1-4 1-4
In another embodiment, R is C alkyl.
[0048] In another embodiment, R is C haloalkyl.
In another embodiment, R is independently CF or Me.
In another embodiment, R is CF .
In another embodiment, R is Me.
[0052] In another embodiment, R is independently H or F.
In another embodiment, R is H.
In another embodiment, R is F.
In another embodiment, R is independently H or F.
[0056] In another embodiment, R is H.
In another embodiment, R is F.
In another embodiment, R is independently H or F.
In another embodiment, R is H.
[0060] In another embodiment, R is F.
In another embodiment, R is independently C alkyl, R , or
-(CH ) -(X) -(CH ) R .
2 n t 2 m
In another embodiment, R is independently -CONH(C alkyl),
j j j j j
-NHCOX SO R , -NHCOCOR , -NHCOCH(OH)R , -NHCOCH COR , -NHCONHR , or
1 2 2
-OCONR R .
In another embodiment, R is independently NH , -CONH(C alkyl),
2 1-6
11841-PCT
R , -(CH ) -(X) -(CH ) R , -NHCO(CH )SO (C alkyl), -NHCOCO(C alkyl),
2 n t 2 m 2 2 1-4 1-4
-NHCOCH(OH)(C alkyl), -NHCOCH CO(C alkyl), -NHCONH(C alkyl), or
1-4 2 1-4 1-4
-OCONH(C alkyl).
In another embodiment, R is independently NH , -CONH(C alkyl),
2 1-6
c c c c
-NHCO(CH )SO (C alkyl), R , OR , -CONHR , or -NHCOR .
2 2 1-4
In another embodiment, R is independently NH , -CONH(C alkyl),
2 1-6
c c c c
-NHCO(CH )SO (C alkyl), R , OR , -CONHR , or -NHCOR .
2 2 1-4
6 c c c
In another embodiment, R is independently R , -CONHR , -NHCOR , or -
NHCOCH SO (C alkyl).
2 2 1-4
[0067] In another embodiment, R is independently 5-membered nitrogen heteroaryl.
In another embodiment, R is independently: 1H-imidazolyl,
1H-tetrazolyl, 1H-tetrazolyl, or 2H-tetrazolyl.
In another embodiment, R is independently H, C alkyl or halo.
[0070] In another embodiment, R is independently H, Me, F, or Cl.
In another embodiment, R is H.
In another embodiment, R is C alkyl.
In another embodiment, R is Me.
In another embodiment, R is halo.
[0075] In another embodiment, R is independently F or Cl.
In another embodiment, R is independently H, halo, C alkyl or
C alkoxy.
In another embodiment, R is independently H, F, Cl, Me and OMe.
[0078] In another embodiment, R is H.
In another embodiment, R is C alkyl.
In another embodiment, R is Me.
In another embodiment, R is C alkoxy.
In another embodiment, R is OMe.
11841-PCT
In another embodiment, R is halo.
In another embodiment, R is independently F or Cl.
In another embodiment, R is independently: H, halo, C alkyl substituted
with 0-1 R , C alkoxy, C haloalkyl, C haloalkoxy, C cycloalkyl, CN, NR R ,
1-4 1-4 1-4 3-4
SR , NHCO (C alkyl), NHSO (C alkyl), or a 4- to 6-membered heterocycle
2 1-4 2 1-4
comprising: carbon atoms and 1-4 heteroatoms selected from N, NR , O, and S.
In another embodiment, R is independently: H, halo, C alkyl substituted
with 0-1 C alkoxy, C alkoxy, C haloalkyl, C haloalkoxy, CN, C cycloalkyl,
1-4 1-4 1-4 1-4 3-4
N(C alkyl) , NHCO (C alkyl), NHSO (C alkyl), pyrazolyl, or morpholinyl.
1-4 2 2 1-4 2 1-4
In another embodiment, R is independently: H, halo, C alkyl substituted
with 0-1 C alkoxy, C alkoxy, C haloalkyl, C haloalkoxy, CN or
1-4 1-4 1-4 1-4
C cycloalkyl.
In another embodiment, R is independently: NR R , NHCO (C alkyl),
2 1-4
NHSO (C alkyl), or a 4- to 6-membered heterocycle comprising: carbon atoms and 1-4
2 1-4
heteroatoms selected from N, NR , O, and S.
In another embodiment, R is independently H, halo, C alkyl or
C alkoxy.
[0090] In another embodiment, R is independently H, F, Cl, Me and OMe.
In another embodiment, R is H.
In another embodiment, R is C alkyl.
In another embodiment, R is Me.
In another embodiment, R is C alkoxy.
[0095] In another embodiment, R is OMe.
In another embodiment, R is halo.
In another embodiment, R is independently F or Cl.
In another embodiment, R is independently H, C alkyl or halo.
11841-PCT
In another embodiment, R is independently H, Me, F, or Cl.
In another embodiment, R is H.
In another embodiment, R is C alkyl.
In another embodiment, R is Me.
[00103] In another embodiment, R is halo.
In another embodiment, R is independently F or Cl.
In another embodiment, R is H.
In another embodiment, R is C alkyl.
In another embodiment, X is independently O, S, or NH.
In another embodiment, X is independently O or S.
In another embodiment, X is O.
In another embodiment, X is independently CONH or NHCO.
[00111] In another embodiment, X is CONH.
In another embodiment, X is NHCO.
In another embodiment, R is, at each occurrence, independently: C alkyl,
1-10
C alkoxy, C haloalkyl, C haloalkoxy, C alkylthio, C haloalkyltho,
1-10 1-10 1-10 1-10 1-10
-CONH(CH ) H, -O(CH ) O(C alkyl), R , -(CH ) -(X) -(CH ) R , or
2 4-20 2 s 1-6 2 n t 2 m
-(CH ) -(CH O) -(CH ) R .
2 n 2 m 2 n
In another embodiment, R is, at each occurrence, independently: halo, OH,
C alkyl, C alkoxy, C haloalkyl, C haloalkoxy, -O(CH ) O(C alkyl),
1-8 1-8 1-8 1-10 2 s 1-6
N(C alkyl) , -CONH(CH ) H, -(CH ) (C cycloalkyl),
1-4 2 2 6-20 2 m 3-6
-(CH ) (C cycloalkenyl), -O(CH ) (C cycloalkyl), 4-C alkoxy-Ph,
2 m 4-6 2 m 3-6 1-4
-O(CH ) Ph, morpholinyl, pyridyl, 2-C alkoxy-pyridinyl, pyrimidinyl, pyrazinyl,
2 m 1-4
or -O-pyrimidinyl.
In another embodiment, R is, at each occurrence, independently: halo,
C alkyl, C alkoxy, C haloalkyl, C haloalkoxy, -O(CH ) O(C alkyl),
1-6 1-6 1-6 1-10 2 s 1-6
-CONH(CH ) H, -(CH ) (C cycloalkyl), -(CH ) (C cycloalkenyl),
2 6-20 2 m 3-6 2 m 4-6
11841-PCT
-O(CH ) (C cycloalkyl), phenoxy, benzoxy, morpholinyl, 2-C alkoxy-pyridinyl,
2 m 3-6 1-4
pyrimidinyl, pyrazinyl or -O-pyrimidinyl.
In another embodiment, R is, at each occurrence, independently: halo,
C alkyl, C alkoxy, C haloalkyl, C haloalkoxy, -CONH(CH ) H,
1-6 1-6 1-6 1-8 2 6-20
C cycloalkyl, C cycloalkenyl, -O(CH ) (C cycloalkyl), phenoxy, benzoxy,
3-6 4-6 2 m 3-6
pyrimidinyl, pyrazinyl and -O-pyrimidinyl.
In another embodiment, R is, at each occurrence, independently:
-O(CH ) CF and -O(CH ) CF CF .
2 1-6 3 2 1-4 2 3
[00118] In another embodiment, R is, at each occurrence, independently:
C cycloalkyl substituted with 0-2 R , C cycloalkenyl substituted with 0-2 R , or
3-6 3-6
-(CH ) -(phenyl substituted with 0-3 R ).
In another embodiment, R is, at each occurrence, independently:
C cycloalkyl substituted with 0-2 R or C cycloalkenyl substituted with 0-2 R .
3-6 3-6
[00120] In another embodiment, R is, at each occurrence, independently
-(CH ) -(phenyl substituted with 0-3 R ),.
In another embodiment, R is, at each occurrence, independently
C cycloalkyl substituted with 0-2 R .
In another embodiment, R is, at each occurrence, independently
C cycloalkenyl substituted with 0-2 R .
In another embodiment, R is, at each occurrence, independently a 5- to
6-membered heterocycle comprising: carbon atoms and 1-4 heteroatoms selected from N,
NR , O, and S; wherein said heterocycle is substituted with 0-2 R .
In another embodiment, R is, at each occurrence, independently
-(CH ) -(phenyl substituted with 0-3 R ), or a heteroaryl selected from: oxazolyl,
isoxazolyl, pyrazolyl, imidazolyl, oxadiazolyl, triazolyl, tetrazolyl, pyridyl, and
pyrazinyl; wherein said heteroaryl is substituted with 0-2 R .
In another embodiment, R is, at each occurrence, independently a heteroaryl
selected from: oxazolyl, isoxazolyl, pyrazolyl, imidazolyl, oxadiazolyl, triazolyl,
tetrazolyl, pyridyl, and pyrazinyl; wherein said heteroaryl is substituted with 0-2 R .
11841-PCT
In another embodiment, the compounds of the present invention have
hMGAT2 IC values ≤ 10 µM, using the MGAT2 SPA assay.
In another embodiment, the compounds of the present invention have
hMGAT2 IC values ≤ 5 µM, using the MGAT2 SPA assay.
In another embodiment, the compounds of the present invention have
hMGAT2 IC values ≤ 1 µM, using the MGAT2 SPA assay.
In another embodiment, the compounds of the present invention have
hMGAT2 IC values ≤ 0.5 µM, using the MGAT2 SPA assay.
In another embodiment, the compounds of the present invention have
hMGAT2 IC values ≤ 10 µM, using the MGAT2 LCMS assay.
In another embodiment, the compounds of the present invention have
hMGAT2 IC values ≤ 5 µM, using the MGAT2 LCMS assay.
[00132] In another embodiment, the compounds of the present invention have
hMGAT2 IC values ≤ 2.5 µM, using the MGAT2 LCMS assay.
In another embodiment, the compounds of the present invention have
hMGAT2 IC values ≤ 1 µM, using the MGAT2 LCMS assay.
In another embodiment, the compounds of the present invention have
hMGAT2 IC values ≤ 0.5 µM, using the MGAT2 LCMS assay.
In another embodiment, the compounds of the present invention have
hMGAT2 IC values ≤ 0.1 µM, using the MGAT2 LCMS assay.
II. OTHER EMBODIMENTS OF THE INVENTION
In another embodiment, the present invention provides a composition
comprising at least one of the compounds of the present invention or a stereoisomer, a
tautomer, a pharmaceutically acceptable salt, or a solvate thereof.
In another embodiment, the present invention provides a pharmaceutical
composition comprising a pharmaceutically acceptable carrier and at least one of the
11841-PCT
compounds of the present invention or a stereoisomer, a tautomer, a pharmaceutically
acceptable salt, or a solvate thereof.
In another embodiment, the present invention provides a pharmaceutical
composition, comprising: a pharmaceutically acceptable carrier and a therapeutically
effective amount of at least one of the compounds of the present invention or a
stereoisomer, a tautomer, a pharmaceutically acceptable salt, or a solvate thereof.
In another embodiment, the present invention provides a process for making a
compound of the present invention or a stereoisomer, a tautomer, a pharmaceutically
acceptable salt, or a solvate thereof.
[00140] In another embodiment, the present invention provides an intermediate for
making a compound of the present invention or a stereoisomer, a tautomer, a
pharmaceutically acceptable salt, or a solvate thereof.
In another embodiment, the present invention provides a pharmaceutical
composition further comprising additional therapeutic agent(s). In a preferred
embodiment, the present invention provides pharmaceutical composition, wherein the
additional therapeutic agent is, for example, a dipeptidyl peptidase-IV (DPP4) inhibitor
(for example a member selected from saxagliptin, sitagliptin, vildagliptin and alogliptin).
Also described herein is a method for the treatment and/or prophylaxis of
multiple diseases or disorders associated with MGAT2, comprising administering to a
patient in need of such treatment and/or prophylaxis a therapeutically effective amount of
at least one of the compounds of the present invention, alone, or, optionally, in
combination with another compound of the present invention and/or at least one other
type of therapeutic agent.
Examples of diseases or disorders associated with the activity of the MGAT2
that can be prevented, modulated, or treated according to the present invention include,
but are not limited to, diabetes, hyperglycemia, impaired glucose tolerance, gestational
diabetes, insulin resistance, hyperinsulinemia, nonalcoholic fatty liver disease (NAFLD)
including nonalcoholic steatohepatitis (NASH), retinopathy, neuropathy, nephropathy,
delayed wound healing, atherosclerosis and its sequelae, abnormal heart function,
myocardial ischemia, stroke, Metabolic Syndrome, hypertension, obesity, dyslipidemia,
dyslipidemia, hyperlipidemia, hypertriglyceridemia, hypercholesterolemia, low high-
11841-PCT
density lipoprotein (HDL), high low-density lipoprotein (LDL), non-cardiac ischemia,
lipid disorders, and glaucoma.
Also described herein is a method for the treatment and/or prophylaxis of
diabetes, hyperglycemia, gestational diabetes, obesity, dyslipidemia, and hypertension,
comprising administering to a patient in need of such treatment and/or prophylaxis a
therapeutically effective amount of at least one of the compounds of the present
invention, alone, or, optionally, in combination with another compound of the present
invention and/or at least one other type of therapeutic agent.
Also described herein is a method for the treatment and/or prophylaxis of
diabetes, comprising administering to a patient in need of such treatment and/or
prophylaxis a therapeutically effective amount of at least one of the compounds of the
present invention, alone, or, optionally, in combination with another compound of the
present invention and/or at least one other type of therapeutic agent.
Also described herein is a method for the treatment and/or prophylaxis of
hyperglycemia, comprising administering to a patient in need of such treatment and/or
prophylaxis a therapeutically effective amount of at least one of the compounds of the
present invention, alone, or, optionally, in combination with another compound of the
present invention and/or at least one other type of therapeutic agent.
Also described herein is a method for the treatment and/or prophylaxis of
obesity, comprising administering to a patient in need of such treatment and/or
prophylaxis a therapeutically effective amount of at least one of the compounds of the
present invention, alone, or, optionally, in combination with another compound of the
present invention and/or at least one other type of therapeutic agent.
Also described herein is a method for the treatment and/or prophylaxis of
dyslipidemia, comprising administering to a patient in need of such treatment and/or
prophylaxis a therapeutically effective amount of at least one of the compounds of the
present invention, alone, or, optionally, in combination with another compound of the
present invention and/or at least one other type of therapeutic agent.
Also described herein is a method for the treatment and/or prophylaxis of
hypertension, comprising administering to a patient in need of such treatment and/or
prophylaxis a therapeutically effective amount of at least one of the compounds of the
11841-PCT
present invention, alone, or, optionally, in combination with another compound of the
present invention and/or at least one other type of therapeutic agent.
In another embodiment, the present invention provides a compound of the
present invention for use in therapy.
[00151] In another embodiment, the present invention provides a compound of the
present invention for use in therapy for the treatment and/or prophylaxis of multiple
diseases or disorders associated with MGAT2.
In another embodiment, the present invention also provides the use of a
compound of the present invention for the manufacture of a medicament for the treatment
and/or prophylaxis of multiple diseases or disorders associated with MGAT2, wherein the
diseases and disorders are selected from diabetes, hyperglycemia, impaired glucose
tolerance, gestational diabetes, insulin resistance, hyperinsulinemia, nonalcoholic fatty
liver disease (NAFLD), retinopathy, neuropathy, nephropathy, delayed wound healing,
atherosclerosis and its sequelae, abnormal heart function, myocardial ischemia, stroke,
Metabolic Syndrome, hypertension, obesity, dyslipidemia, hyperlipidemia,
hypertriglyceridemia, hypercholesterolemia, low high-density lipoprotein (HDL), high
low-density lipoprotein (LDL), non-cardiac ischemia, lipid disorders, or glaucoma.
Also described herein is a method for the treatment and/or prophylaxis of
multiple diseases or disorders associated with MGAT2, comprising: administering to a
patient in need thereof a therapeutically effective amount of a first and second therapeutic
agent, wherein the first therapeutic agent is a compound of the present invention.
Preferably, the second therapeutic agent, for example, dipeptidyl peptidase-IV (DPP4)
inhibitor (for example a member selected from saxagliptin, sitagliptin, vildagliptin,
linagliptin and alogliptin).
[00154] In another embodiment, the present invention provides a combined
preparation of a compound of the present invention and additional therapeutic agent(s) for
simultaneous, separate or sequential use in therapy.
In another embodiment, the present invention provides a combined
preparation of a compound of the present invention and additional therapeutic agent(s) for
simultaneous, separate or sequential use in the treatment and/or prophylaxis of multiple
diseases or disorders associated with MGAT2.
11841-PCT
Where desired, the compound of the present invention may be used in
combination with one or more other types of antidiabetic agents and/or one or more other
types of therapeutic agents which may be administered orally in the same dosage form, in
a separate oral dosage form or by injection. The other type of antidiabetic agent that may
be optionally employed in combination with the MGAT2 inhibitor of the present
invention may be one, two, three or more antidiabetic agents or antihyperglycemic agents
which may be administered orally in the same dosage form, in a separate oral dosage
form, or by injection to produce an additional pharmacological benefit.
The antidiabetic agents used in the combination with the MGAT2 inhibitor of
the present invention include, but are not limited to, insulin secretagogues or insulin
sensitizers, other MGAT2 inhibitors, or other antidiabetic agents. These agents include,
but are not limited to, dipeptidyl peptidase IV (DP4) inhibitors (for example, sitagliptin,
saxagliptin, alogliptin, linagliptin and vildagliptin), biguanides (for example, metformin
and phenformin), sulfonyl ureas (for example, glyburide, glimepiride and glipizide),
glucosidase inhibitors (for example, acarbose, miglitol), PPARγ agonists such as
thiazolidinediones (for example, rosiglitazone and pioglitazone), PPAR α/γ dual agonists
(for example, muraglitazar, tesaglitazar and aleglitazar), glucokinase activators, GPR40
receptor modulators (e.g. TAK-875), GPR119 receptor modulators (for example,
MBX-2952, PSN821, and APD597), sodium-glucose transporter-2 (SGLT2) inhibitors
(for example, dapagliflozin, canagliflozin and remagliflozin), 11b-HSD-1 inhibitors (for
example MK-0736, BI35585, BMS-823778, and LY2523199), amylin analogs such as
pramlintide, and/or insulin.
The MGAT2 inhibitor of the present invention may also be optionally
employed in combination with one or more hypophagic and/or weight-loss agents such as
diethylpropion, phendimetrazine, phentermine, orlistat, sibutramine, lorcaserin,
pramlintide, topiramate, MCHR1 receptor antagonists, oxyntomodulin, naltrexone,
Amylin peptide, NPY Y5 receptor modulators, NPY Y2 receptor modulators, NPY Y4
receptor modulators, cetilistat, 5HT2c receptor modulators, and the like. The compounds
of the present invention may also be employed in combination with an agonist of the
glucagon-like peptide-1 receptor (GLP-1 R), such as exenatide, liraglutide, GPR-1(1-36)
amide, GLP-1(7-36) amide, GLP-1(7-37), which may be administered via injection,
intranasal, or by transdermal or buccal devices.
11841-PCT
The MGAT2 inhibitor of the present invention may also be optionally
employed in combination with one or more other types of therapeutic agents, such as
DGAT inhibitors, LDL lowering drugs such as statins (inhibitors of HMG CoA
reductase) or inhibitors of cholesterol absorption, modulators of PCSK9, drugs that
increase HDL such as CETP inhibitors.
The present invention may be embodied in other specific forms without
departing from the spirit or essential attributes thereof. This invention encompasses all
combinations of preferred aspects of the invention noted herein. It is understood that any
and all embodiments of the present invention may be taken in conjunction with any other
embodiment or embodiments to describe additional embodiments. It is also understood
that each individual element of the embodiments is its own independent embodiment.
Furthermore, any element of an embodiment is meant to be combined with any and all
other elements from any embodiment to describe an additional embodiment.
III. CHEMISTRY
Throughout the specification and the appended claims, a given chemical
formula or name shall encompass all stereo and optical isomers and racemates thereof
where such isomers exist. Unless otherwise indicated, all chiral (enantiomeric and
diastereomeric) and racemic forms are within the scope of the invention. Many
geometric isomers of C=C double bonds, C=N double bonds, ring systems, and the like
can also be present in the compounds, and all such stable isomers are contemplated in the
present invention. Cis- and trans- (or E- and Z-) geometric isomers of the compounds of
the present invention are described and may be isolated as a mixture of isomers or as
separated isomeric forms. The present compounds can be isolated in optically active or
racemic forms. Optically active forms may be prepared by resolution of racemic forms or
by synthesis from optically active starting materials. All processes used to prepare
compounds of the present invention and intermediates made therein are considered to be
part of the present invention. When enantiomeric or diastereomeric products are
prepared, they may be separated by conventional methods, for example, by
chromatography or fractional crystallization. Depending on the process conditions the
end products of the present invention are obtained either in free (neutral) or salt form.
Both the free form and the salts of these end products are within the scope of the
11841-PCT
invention. If so desired, one form of a compound may be converted into another form. A
free base or acid may be converted into a salt; a salt may be converted into the free
compound or another salt; a mixture of isomeric compounds of the present invention may
be separated into the individual isomers. Compounds of the present invention, free form
and salts thereof, may exist in multiple tautomeric forms, in which hydrogen atoms are
transposed to other parts of the molecules and the chemical bonds between the atoms of
the molecules are consequently rearranged. It should be understood that all tautomeric
forms, insofar as they may exist, are included within the invention.
As used herein, the term “alkyl” or “alkylene” is intended to include both
branched and straight-chain saturated aliphatic hydrocarbon groups having the specified
number of carbon atoms. For examples, “C to C alkyl” or “C alkyl” (or alkylene),
1 12 1-12
is intended to include C , C , C , C , C , C , C , C , C , C , C and C alkyl groups;
1 2 3 4 5 6 7 8 9 10 11 12
“C to C alkyl” or “C alkyl” (or alkylene), is intended to include C , C , C , C , C ,
4 18 4-18 4 5 6 7 8
C , C , C , C , C , C , C , C , C , and C alkyl groups. Additionally, for
9 10 11 12 13 14 15 16 17 18
example, “C to C alkyl” or “C alkyl” denotes alkyl having 1 to 6 carbon atoms.
1 6 1-6
Alkyl group can be unsubstituted or substituted with at least one hydrogen being replaced
by another chemical group. Example alkyl groups include, but are not limited to, methyl
(Me), ethyl (Et), propyl (e.g., n-propyl and isopropyl), butyl (e.g., n-butyl, isobutyl, t-
butyl), and pentyl (e.g., n-pentyl, isopentyl, neopentyl). When “C alkyl” or “C
alkylene” is used, it is intended to denote a direct bond.
Alkenyl” or “alkenylene” is intended to include hydrocarbon chains of either
straight or branched configuration having the specified number of carbon atoms and one
or more, preferably one to two, carbon-carbon double bonds that may occur in any stable
point along the chain. For example, “C to C alkenyl” or “C alkenyl” (or alkenylene),
2 6 2-6
is intended to include C , C , C , C , and C alkenyl groups. Examples of alkenyl
2 3 4 5 6
include, but are not limited to, ethenyl, 1-propenyl, 2-propenyl, 2-butenyl, 3-butenyl, 2-
pentenyl, 3, pentenyl, 4-pentenyl, 2-hexenyl, 3-hexenyl, 4-hexenyl, 5-hexenyl, 2-methyl-
2-propenyl, and 4-methylpentenyl.
“Alkynyl” or “alkynylene” is intended to include hydrocarbon chains of either
straight or branched configuration having one or more, preferably one to three,
carbon-carbon triple bonds that may occur in any stable point along the chain. For
example, “C to C alkynyl” or “C alkynyl” (or alkynylene), is intended to include C ,
2 6 2-6 2
11841-PCT
C , C , C , and C alkynyl groups; such as ethynyl, propynyl, butynyl, pentynyl, and
3 4 5 6
hexynyl.
When the term “hydrocarbon chain” is used, it is intended to include “alkyl”,
“alkenyl” and “alkynyl”, unless otherwise specified.
[00166] The term "alkoxy" or "alkyloxy" refers to an -O-alkyl group. For example,
"C to C alkoxy" or "C alkoxy" (or alkyloxy), is intended to include C , C , C , C ,
1 6 1-6 1 2 3 4
C , and C alkoxy groups. Example alkoxy groups include, but are not limited to,
methoxy, ethoxy, propoxy (e.g., n-propoxy and isopropoxy), and t-butoxy. Similarly,
"alkylthio" or "thioalkoxy" represents an alkyl group as defined above with the indicated
number of carbon atoms attached through a sulphur bridge; for example methyl-S- and
ethyl-S-.
"Halo" or "halogen" includes fluoro, chloro, bromo, and iodo. "Haloalkyl" is
intended to include both branched and straight-chain saturated aliphatic hydrocarbon
groups having the specified number of carbon atoms, substituted with 1 or more
halogens. Examples of haloalkyl include, but are not limited to, fluoromethyl,
difluoromethyl, trifluoromethyl, trichloromethyl, pentafluoroethyl, pentachloroethyl,
2,2,2-trifluoroethyl, heptafluoropropyl, and heptachloropropyl. Examples of haloalkyl
also include "fluoroalkyl" that is intended to include both branched and straight-chain
saturated aliphatic hydrocarbon groups having the specified number of carbon atoms,
substituted with 1 or more fluorine atoms.
"Haloalkoxy" or "haloalkyloxy" represents a haloalkyl group as defined above
with the indicated number of carbon atoms attached through an oxygen bridge. For
example, "C haloalkoxy", is intended to include C , C , C , C , C , and C haloalkoxy
1-6 1 2 3 4 5 6
groups. Examples of haloalkoxy include, but are not limited to, trifluoromethoxy,
2,2,2-trifluoroethoxy, and pentafluorothoxy. Similarly, "haloalkylthio" or
"thiohaloalkoxy" represents a haloalkyl group as defined above with the indicated number
of carbon atoms attached through a sulphur bridge; for example trifluoromethyl-S-, and
pentafluoroethyl-S-.
The term "cycloalkyl" refers to cyclized alkyl groups, including mono-, bi- or
poly-cyclic ring systems. For example, "C to C cycloalkyl" or "C cycloalkyl" is
3 6 3-6
intended to include C , C , C , and C cycloalkyl groups. Example cycloalkyl groups
3 4 5 6
include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and
11841-PCT
norbornyl. Branched cycloalkyl groups such as 1-methylcyclopropyl and
2-methylcyclopropyl are included in the definition of "cycloalkyl". The term
"cycloalkenyl" refers to cyclized alkenyl groups. C cycloalkenyl is intended to include
C , C , and C cycloalkenyl groups. Example cycloalkenyl groups include, but are not
4 5 6
limited to, cyclobutenyl, cyclopentenyl, and cyclohexenyl.
As used herein, “carbocycle,” “carbocyclyl,” or “carbocyclic residue” is
intended to mean any stable 3-, 4-, 5-, 6-, 7-, or 8-membered monocyclic or bicyclic or 7-,
8-, 9-, 10-, 11-, 12-, or 13-membered bicyclic or tricyclic ring, any of which may be
saturated, partially unsaturated, unsaturated or aromatic. Examples of such carbocycles
include, but are not limited to, cyclopropyl, cyclobutyl, cyclobutenyl, cyclopentyl,
cyclopentenyl, cyclohexyl, cycloheptenyl, cycloheptyl, cycloheptenyl, adamantyl,
cyclooctyl, cyclooctenyl, cyclooctadienyl, [3.3.0]bicyclooctane, [4.3.0]bicyclononane,
[4.4.0]bicyclodecane (decalin), [2.2.2]bicyclooctane, fluorenyl, phenyl, naphthyl, indanyl,
adamantyl, anthracenyl, and tetrahydronaphthyl (tetralin). As shown above, bridged rings
are also included in the definition of carbocycle (e.g., [2.2.2]bicyclooctane). Preferred
carbocycles, unless otherwise specified, are cyclopropyl, cyclobutyl, cyclopentyl,
cyclohexyl, phenyl, indanyl, and tetrahydronaphthyl. When the term “carbocycle” is
used, it is intended to include “aryl.” A bridged ring occurs when one or more, preferably
one to three, carbon atoms link two non-adjacent carbon atoms. Preferred bridges are one
or two carbon atoms. It is noted that a bridge always converts a monocyclic ring into a
tricyclic ring. When a ring is bridged, the substituents recited for the ring may also be
present on the bridge.
As used herein, the term “bicyclic carbocycle” or “bicyclic carbocyclic group”
is intended to mean a stable 9- or 10-membered carbocyclic ring system that contains two
fused rings and consists of carbon atoms. Of the two fused rings, one ring is a benzo ring
fused to a second ring; and the second ring is a 5- or 6-membered carbon ring which is
saturated, partially unsaturated, or unsaturated. The bicyclic carbocyclic group may be
attached to its pendant group at any carbon atom which results in a stable structure. The
bicyclic carbocyclic group described herein may be substituted on any carbon if the
resulting compound is stable. Examples of a bicyclic carbocyclic group are, but not
limited to, naphthyl, 1,2-dihydronaphthyl, 1,2,3,4-tetrahydronaphthyl, and indanyl.
11841-PCT
“Aryl” groups refer to monocyclic or bicyclic aromatic hydrocarbons,
including, for example, phenyl, and naphthyl. Aryl moieties are well known and
described, for example, in Hawley’s Condensed Chemical Dictionary (15 ed.), R.J.
Lewis, ed., J. Wiley & Sons, Inc., New York, 2007. “C aryl” refers to phenyl and
6-10
naphthyl.
The term "benzyl," as used herein, refers to a methyl group on which one of
the hydrogen atoms is replaced by a phenyl group.
As used herein, the term "heterocycle," "heterocyclyl," or "heterocyclic group"
is intended to mean a stable 3-, 4-, 5-, 6-, or 7-membered monocyclic or bicyclic or 7-, 8-,
9-, 10-, 11-, 12-, 13-, or 14-membered polycyclic heterocyclic ring that is saturated,
partially unsaturated, or fully unsaturated, and that contains carbon atoms and 1, 2, 3 or 4
heteroatoms independently selected from the group consisting of N, O and S; and
including any polycyclic group in which any of the above-defined heterocyclic rings is
fused to a benzene ring. The nitrogen and sulfur heteroatoms may optionally be oxidized
(i.e., N→O and S(O) , wherein p is 0, 1 or 2). The nitrogen atom may be substituted or
unsubstituted (i.e., N or NR wherein R is H or another substituent, if defined). The
heterocyclic ring may be attached to its pendant group at any heteroatom or carbon atom
that results in a stable structure. The heterocyclic rings described herein may be
substituted on carbon or on a nitrogen atom if the resulting compound is stable. A
nitrogen in the heterocycle may optionally be quaternized. It is preferred that when the
total number of S and O atoms in the heterocycle exceeds 1, then these heteroatoms are
not adjacent to one another. It is preferred that the total number of S and O atoms in the
heterocycle is not more than 1. When the term "heterocycle" is used, it is intended to
include heteroaryl.
[00175] Examples of heterocycles include, but are not limited to, acridinyl, azetidinyl,
azocinyl, benzimidazolyl, benzofuranyl, benzothiofuranyl, benzothiophenyl,
benzoxazolyl, benzoxazolinyl, benzthiazolyl, benztriazolyl, benztetrazolyl,
benzisoxazolyl, benzisothiazolyl, benzimidazolinyl, carbazolyl, 4aH-carbazolyl,
carbolinyl, chromanyl, chromenyl, cinnolinyl, decahydroquinolinyl,
2H,6H-1,5,2-dithiazinyl, dihydrofuro[2,3-b]tetrahydrofuran, furanyl, furazanyl,
imidazolidinyl, imidazolinyl, imidazolyl, 1H-indazolyl, imidazolopyridinyl, indolenyl,
indolinyl, indolizinyl, indolyl, 3H-indolyl, isatinoyl, isobenzofuranyl, isochromanyl,
11841-PCT
isoindazolyl, isoindolinyl, isoindolyl, isoquinolinyl, isothiazolyl, isothiazolopyridinyl,
isoxazolyl, isoxazolopyridinyl, methylenedioxyphenyl, morpholinyl, naphthyridinyl,
octahydroisoquinolinyl, oxadiazolyl, 1,2,3-oxadiazolyl, 1,2,4-oxadiazolyl,
1,2,5-oxadiazolyl, 1,3,4-oxadiazolyl, oxazolidinyl, oxazolyl, oxazolopyridinyl,
oxazolidinylperimidinyl, oxindolyl, pyrimidinyl, phenanthridinyl, phenanthrolinyl,
phenazinyl, phenothiazinyl, phenoxathiinyl, phenoxazinyl, phthalazinyl, piperazinyl,
piperidinyl, piperidonyl, 4-piperidonyl, piperonyl, pteridinyl, purinyl, pyranyl, pyrazinyl,
pyrazolidinyl, pyrazolinyl, pyrazolopyridinyl, pyrazolyl, pyridazinyl, pyridooxazolyl,
pyridoimidazolyl, pyridothiazolyl, pyridinyl, pyrimidinyl, pyrrolidinyl, pyrrolinyl,
2-pyrrolidonyl, 2H-pyrrolyl, pyrrolyl, quinazolinyl, quinolinyl, 4H-quinolizinyl,
quinoxalinyl, quinuclidinyl, tetrazolyl, tetrahydrofuranyl, tetrahydroisoquinolinyl,
tetrahydroquinolinyl, 6H-1,2,5-thiadiazinyl, 1,2,3-thiadiazolyl, 1,2,4-thiadiazolyl,
1,2,5-thiadiazolyl, 1,3,4-thiadiazolyl, thianthrenyl, thiazolyl, thienyl, thiazolopyridinyl,
thienothiazolyl, thienooxazolyl, thienoimidazolyl, thiophenyl, triazinyl, 1,2,3-triazolyl,
1,2,4-triazolyl, 1,2,5-triazolyl, 1,3,4-triazolyl, and xanthenyl. Also included are fused
ring and spiro compounds containing, for example, the above heterocycles.
Examples of 5- to 10-membered heterocycles include, but are not limited to,
pyridinyl, furanyl, thienyl, pyrrolyl, pyrazolyl, pyrazinyl, piperazinyl, piperidinyl,
imidazolyl, imidazolidinyl, indolyl, tetrazolyl, isoxazolyl, morpholinyl, oxazolyl,
oxadiazolyl, oxazolidinyl, tetrahydrofuranyl, thiadiazinyl, thiadiazolyl, thiazolyl,
triazinyl, triazolyl, benzimidazolyl, 1H-indazolyl, benzofuranyl, benzothiofuranyl,
benztetrazolyl, benzotriazolyl, benzisoxazolyl, benzoxazolyl, oxindolyl, benzoxazolinyl,
benzthiazolyl, benzisothiazolyl, isatinoyl, isoquinolinyl, octahydroisoquinolinyl,
tetrahydroisoquinolinyl, tetrahydroquinolinyl, isoxazolopyridinyl, quinazolinyl,
quinolinyl, isothiazolopyridinyl, thiazolopyridinyl, oxazolopyridinyl, imidazolopyridinyl,
and pyrazolopyridinyl.
Examples of 5- to 6-membered heterocycles include, but are not limited to,
pyridinyl, furanyl, thienyl, pyrrolyl, pyrazolyl, pyrazinyl, piperazinyl, piperidinyl,
imidazolyl, imidazolidinyl, indolyl, tetrazolyl, isoxazolyl, morpholinyl, oxazolyl,
oxadiazolyl, oxazolidinyl, tetrahydrofuranyl, thiadiazinyl, thiadiazolyl, thiazolyl,
triazinyl, and triazolyl. Also included are fused ring and spiro compounds containing, for
example, the above heterocycles.
11841-PCT
As used herein, the term "bicyclic heterocycle" or "bicyclic heterocyclic
group" is intended to mean a stable 9- or 10-membered heterocyclic ring system which
contains two fused rings and consists of carbon atoms and 1, 2, 3, or 4 heteroatoms
independently selected from the group consisting of N, O and S. Of the two fused rings,
one ring is a 5- or 6-membered monocyclic aromatic ring comprising a 5-membered
heteroaryl ring, a 6-membered heteroaryl ring or a benzo ring, each fused to a second
ring. The second ring is a 5- or 6-membered monocyclic ring which is saturated, partially
unsaturated, or unsaturated, and comprises a 5-membered heterocycle, a 6-membered
heterocycle or a carbocycle (provided the first ring is not benzo when the second ring is a
carbocycle).
The bicyclic heterocyclic group may be attached to its pendant group at any
heteroatom or carbon atom which results in a stable structure. The bicyclic heterocyclic
group described herein may be substituted on carbon or on a nitrogen atom if the
resulting compound is stable. It is preferred that when the total number of S and O atoms
in the heterocycle exceeds 1, then these heteroatoms are not adjacent to one another. It is
preferred that the total number of S and O atoms in the heterocycle is not more than 1.
Examples of a bicyclic heterocyclic group are, but not limited to, quinolinyl,
isoquinolinyl, phthalazinyl, quinazolinyl, indolyl, isoindolyl, indolinyl, 1H-indazolyl,
benzimidazolyl, 1,2,3,4-tetrahydroquinolinyl, 1,2,3,4-tetrahydroisoquinolinyl,
5,6,7,8-tetrahydro-quinolinyl, 2,3-dihydro-benzofuranyl, chromanyl,
1,2,3,4-tetrahydro-quinoxalinyl, and 1,2,3,4-tetrahydro-quinazolinyl.
As used herein, the term "aromatic heterocyclic group" or "heteroaryl" is
intended to mean stable monocyclic and polycyclic aromatic hydrocarbons that include at
least one heteroatom ring member such as sulfur, oxygen, or nitrogen. Heteroaryl groups
include, without limitation, pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, triazinyl, furyl,
quinolyl, isoquinolyl, thienyl, imidazolyl, thiazolyl, indolyl, pyrroyl, oxazolyl,
benzofuryl, benzothienyl, benzthiazolyl, isoxazolyl, pyrazolyl, triazolyl, tetrazolyl,
indazolyl, 1,2,4-thiadiazolyl, isothiazolyl, purinyl, carbazolyl, benzimidazolyl, indolinyl,
benzodioxolanyl, and benzodioxane. Heteroaryl groups are substituted or unsubstituted.
The nitrogen atom is substituted or unsubstituted (i.e., N or NR wherein R is H or another
substituent, if defined). The nitrogen and sulfur heteroatoms may optionally be oxidized
(i.e., N→O and S(O) , wherein p is 0, 1 or 2).
11841-PCT
Examples of 5- to 6-membered heteroaryls include, but are not limited to,
pyridinyl, furanyl, thienyl, pyrrolyl, pyrazolyl, pyrazinyl, imidazolyl, imidazolidinyl,
tetrazolyl, isoxazolyl, oxazolyl, oxadiazolyl, oxazolidinyl, thiadiazinyl, thiadiazolyl,
thiazolyl, triazinyl, and triazolyl.
[00183] Bridged rings are also included in the definition of heterocycle. A bridged
ring occurs when one or more, preferably one to three, atoms (i.e., C, O, N, or S) link two
non-adjacent carbon or nitrogen atoms. Examples of bridged rings include, but are not
limited to, one carbon atom, two carbon atoms, one nitrogen atom, two nitrogen atoms,
and a carbon-nitrogen group. It is noted that a bridge always converts a monocyclic ring
into a tricyclic ring. When a ring is bridged, the substituents recited for the ring may also
be present on the bridge.
The term "counter ion" is used to represent a negatively charged species such
as chloride, bromide, hydroxide, acetate, and sulfate or a positively charged species such
as sodium (Na+), potassium (K+), ammonium (R NH + where n=0-4 and m=0-4) and
the like.
When a dotted ring is used within a ring structure, this indicates that the ring
structure may be saturated, partially saturated or unsaturated.
As used herein, the term "amine protecting group" means any group known in
the art of organic synthesis for the protection of amine groups which is stable to an ester
reducing agent, a disubstituted hydrazine, R4-M and R7-M, a nucleophile, a hydrazine
reducing agent, an activator, a strong base, a hindered amine base and a cyclizing agent.
Such amine protecting groups fitting these criteria include those listed in Wuts, P. G. M.
and Greene, T.W. Protecting Groups in Organic Synthesis, 4th Edition, Wiley (2007) and
The Peptides: Analysis, Synthesis, Biology, Vol. 3, Academic Press, New York (1981),
the disclosure of which is hereby incorporated by reference. Examples of amine
protecting groups include, but are not limited to, the following: (1) acyl types such as
formyl, trifluoroacetyl, phthalyl, and p-toluenesulfonyl; (2) aromatic carbamate types
such as benzyloxycarbonyl (Cbz) and substituted benzyloxycarbonyls,
1-(p-biphenyl)methylethoxycarbonyl, and 9-fluorenylmethyloxycarbonyl (Fmoc); (3)
aliphatic carbamate types such as tert-butyloxycarbonyl (Boc), ethoxycarbonyl,
diisopropylmethoxycarbonyl, and allyloxycarbonyl; (4) cyclic alkyl carbamate types such
as cyclopentyloxycarbonyl and adamantyloxycarbonyl; (5) alkyl types such as
11841-PCT
triphenylmethyl and benzyl; (6) trialkylsilane such as trimethylsilane; (7) thiol containing
types such as phenylthiocarbonyl and dithiasuccinoyl; and (8) alkyl types such as
triphenylmethyl, methyl, and benzyl; and substituted alkyl types such as
2,2,2-trichloroethyl, 2-phenylethyl, and t-butyl; and trialkylsilane types such as
trimethylsilane.
As referred to herein, the term "substituted" means that at least one hydrogen
atom is replaced with a non-hydrogen group, provided that normal valencies are
maintained and that the substitution results in a stable compound. Ring double bonds, as
used herein, are double bonds that are formed between two adjacent ring atoms (e.g.,
C=C, C=N, or N=N).
In cases wherein there are nitrogen atoms (e.g., amines) on compounds of the
present invention, these may be converted to N-oxides by treatment with an oxidizing
agent (e.g., mCPBA and/or hydrogen peroxides) to afford other compounds of this
invention. Thus, shown and claimed nitrogen atoms are considered to cover both the
shown nitrogen and its N-oxide (N→O) derivative.
When any variable occurs more than one time in any constituent or formula
for a compound, its definition at each occurrence is independent of its definition at every
other occurrence. Thus, for example, if a group is shown to be substituted with 0-3 R,
then said group may optionally be substituted with up to three R groups, and at each
occurrence R is selected independently from the definition of R.
When a bond to a substituent is shown to cross a bond connecting two atoms
in a ring, then such substituent may be bonded to any atom on the ring. When a
substituent is listed without indicating the atom in which such substituent is bonded to the
rest of the compound of a given formula, then such substituent may be bonded via any
atom in such substituent.
Combinations of substituents and/or variables are permissible only if such
combinations result in stable compounds.
The phrase "pharmaceutically acceptable" is employed herein to refer to those
compounds, materials, compositions, and/or dosage forms that are, within the scope of
sound medical judgment, suitable for use in contact with the tissues of human beings and
animals without excessive toxicity, irritation, allergic response, and/or other problem or
complication, commensurate with a reasonable benefit/risk ratio.
11841-PCT
As used herein, "pharmaceutically acceptable salts" refer to derivatives of the
disclosed compounds wherein the parent compound is modified by making acid or base
salts thereof. Examples of pharmaceutically acceptable salts include, but are not limited
to, mineral or organic acid salts of basic groups such as amines; and alkali or organic salts
of acidic groups such as carboxylic acids. The pharmaceutically acceptable salts include
the conventional non-toxic salts or the quaternary ammonium salts of the parent
compound formed, for example, from non-toxic inorganic or organic acids. For example,
such conventional non-toxic salts include those derived from inorganic acids such as
hydrochloric, hydrobromic, sulfuric, sulfamic, phosphoric, and nitric; and the salts
prepared from organic acids such as acetic, propionic, succinic, glycolic, stearic, lactic,
malic, tartaric, citric, ascorbic, pamoic, maleic, hydroxymaleic, phenylacetic, glutamic,
benzoic, salicylic, sulfanilic, 2-acetoxybenzoic, fumaric, toluenesulfonic,
methanesulfonic, ethane disulfonic, oxalic, and isethionic, and the like.
The pharmaceutically acceptable salts of the present invention can be
synthesized from the parent compound that contains a basic or acidic moiety by
conventional chemical methods. Generally, such salts can be prepared by reacting the
free acid or base forms of these compounds with a stoichiometric amount of the
appropriate base or acid in water or in an organic solvent, or in a mixture of the two;
generally, nonaqueous media like ether, ethyl acetate, ethanol, isopropanol, or acetonitrile
are preferred. Lists of suitable salts are found in Remington: The Science and Practice of
Pharmacy, 22 Edition, Allen, L. V. Jr., Ed.; Pharmaceutical Press, London, UK (2012),
the disclosure of which is hereby incorporated by reference.
In addition, compounds of formula I may have prodrug forms. Any
compound that will be converted in vivo to provide the bioactive agent (i.e., a compound
of formula I) is a prodrug as described herein. Various forms of prodrugs are well known
in the art. For examples of such prodrug derivatives, see:
a) Bundgaard, H., ed., Design of Prodrugs, Elsevier (1985), and Widder, K.
et al., eds., Methods in Enzymology, 112:309-396, Academic Press (1985);
b) Bundgaard, H., Chapter 5, "Design and Application of Prodrugs," A
Textbook of Drug Design and Development, pp. 113-191, Krosgaard-Larsen, P. et al.,
eds., Harwood Academic Publishers (1991);
c) Bundgaard, H., Adv. Drug Deliv. Rev., 8:1-38 (1992);
11841-PCT
d) Bundgaard, H. et al., J. Pharm. Sci., 77:285 (1988);
e) Kakeya, N. et al., Chem. Pharm. Bull., 32:692 (1984); and
f) Rautio, J (Editor). Prodrugs and Targeted Delivery (Methods and
Principles in Medicinal Chemistry), Vol 47, Wiley-VCH, 2011.
Compounds containing a carboxy group can form physiologically
hydrolyzable esters that serve as prodrugs by being hydrolyzed in the body to yield
formula I compounds per se. Such prodrugs are preferably administered orally since
hydrolysis in many instances occurs principally under the influence of the digestive
enzymes. Parenteral administration may be used where the ester per se is active, or in
those instances where hydrolysis occurs in the blood. Examples of physiologically
hydrolyzable esters of compounds of formula I include C alkyl, C alkylbenzyl,
1-6 1-6
4-methoxybenzyl, indanyl, phthalyl, methoxymethyl, C alkanoyloxy-C alkyl (e.g.,
1-6 1-6
acetoxymethyl, pivaloyloxymethyl or propionyloxymethyl),
C alkoxycarbonyloxy-C alkyl (e.g., methoxycarbonyl-oxymethyl or
1-6 1-6
ethoxycarbonyloxymethyl, glycyloxymethyl, phenylglycyloxymethyl,
(5-methyloxo-1,3-dioxolenyl)-methyl), and other well known physiologically
hydrolyzable esters used, for example, in the penicillin and cephalosporin arts. Such
esters may be prepared by conventional techniques known in the art.
[00197] Preparation of prodrugs is well known in the art and described in, for example,
King, F.D., ed., Medicinal Chemistry: Principles and Practice, The Royal Society of
Chemistry, Cambridge, UK (2 edition, reproduced, 2006); Testa, B. et al., Hydrolysis in
Drug and Prodrug Metabolism. Chemistry, Biochemistry and Enzymology, VCHA and
Wiley-VCH, Zurich, Switzerland (2003); Wermuth, C.G., ed., The Practice of Medicinal
Chemistry, 3 edition, Academic Press, San Diego, CA (2008).
The present invention is intended to include all isotopes of atoms occurring in
the present compounds. Isotopes include those atoms having the same atomic number but
different mass numbers. By way of general example and without limitation, isotopes of
13 14
hydrogen include deuterium and tritium. Isotopes of carbon include C and C.
Isotopically-labeled compounds of the invention can generally be prepared by
conventional techniques known to those skilled in the art or by processes analogous to
11841-PCT
those described herein, using an appropriate isotopically-labeled reagent in place of the
non-labeled reagent otherwise employed.
The term "solvate" means a physical association of a compound of this
invention with one or more solvent molecules, whether organic or inorganic. This
physical association includes hydrogen bonding. In certain instances the solvate will be
capable of isolation, for example when one or more solvent molecules are incorporated in
the crystal lattice of the crystalline solid. The solvent molecules in the solvate may be
present in a regular arrangement and/or a non-ordered arrangement. The solvate may
comprise either a stoichiometric or nonstoichiometric amount of the solvent molecules.
"Solvate" encompasses both solution-phase and isolable solvates. Exemplary solvates
include, but are not limited to, hydrates, ethanolates, methanolates, and isopropanolates.
Methods of solvation are generally known in the art.
Abbreviations as used herein, are defined as follows: "1 x" for once, "2 x" for
twice, "3 x" for thrice, "°C" for degrees Celsius, "eq" for equivalent or equivalents, "g"
for gram or grams, "mg" for milligram or milligrams, "L" for liter or liters, "mL" for
milliliter or milliliters, "μL" for microliter or microliters, "N" for normal, "M" for molar,
"mmol" for millimole or millimoles, "min" for minute or min, "h" for hour or h, "rt" for
room temperature, "RT" for retention time, "atm" for atmosphere, "psi" for pounds per
square inch, "conc." for concentrate, "aq" for "aqueous", "sat" or "sat'd " for saturated,
"MW" for molecular weight, "mp" for melting point, "MS" or "Mass Spec" for mass
spectrometry, "ESI" for electrospray ionization mass spectroscopy, "HR" for high
resolution, "HRMS" for high resolution mass spectrometry, "LCMS" for liquid
chromatography mass spectrometry, "HPLC" for high pressure liquid chromatography,
"RP HPLC" for reverse phase HPLC, "TLC" or "tlc" for thin layer chromatography,
"NMR" for nuclear magnetic resonance spectroscopy, "nOe" for nuclear Overhauser
effect spectroscopy, " H" for proton, "δ" for delta, "s" for singlet, "d" for doublet, "t" for
triplet, "q" for quartet, "m" for multiplet, "br" for broad, "Hz" for hertz, and "α", "β", "R",
"S", "E", "Z" and "ee" are stereochemical designations familiar to one skilled in the art.
Me methyl
Et ethyl
Pr propyl
11841-PCT
i-Pr isopropyl
Bu butyl
i-Bu isobutyl
t-Bu tert-butyl
Ph phenyl
Bn benzyl
Hex hexanes
MeOH methanol
EtOH ethanol
i-PrOH or IPA isopropanol
AcOH or HOAc acetic acid
Ag CO silver carbonate
silver acetate
AgOAc
CDCl deutero-chloroform
CHCl chloroform
cDNA complimentary DNA
DCC N,N′-dicyclohexylcarbodiimide
DIAD diisopropyl azodicarboxylate
DMA dimethylamine
DME dimethylether
DMF dimethyl formamide
DMSO dimethyl sulfoxide
DMAP 4-dimethylaminopyridine
EDTA ethylenediaminetetraacetic acid
EtOAc ethyl acetate
Et O diethyl ether
AlCl aluminum chloride
Boc tert-butyloxycarbonyl
CH Cl dichloromethane
CH CN or ACN acetonitrile
Cs CO cesium carbonate
11841-PCT
HCl hydrochloric acid
H SO sulfuric acid
K CO potassium carbonate
potassium cyanide
mCPBA or m-CPBA meta-chloroperbenzoic acid
Pd/C palladium on carbon
PhSO Cl benzenesulfonyl chloride
diisopropylethylamine
i-Pr NEt
PS polystyrene
SFC Supercritical Fluid Chromatography
SiO silica oxide
SnCl tin(II) chloride
TBAT tetrabutylammonium triphenydifluorosilicate
TEA triethylamine
TFA trifluoroacetic acid
THF tetrahydrofuran
KOAc potassium acetate
MgSO magnesium sulfate
NaCl sodium chloride
NaH sodium hydride
NaHCO sodium bicarbonate
NaOH sodium hydroxide
Na SO sodium sulfite
Na SO sodium sulfate
NH ammonia
NH Cl ammonium chloride
NH OH ammonium hydroxide
LG leaving group
Pd dba tris(dibenzylideneacetone)dipalladium(0)
selectFluor N-fluoro-N′-methyl-triethylenediamine
bis(tetrafluoroborate)
11841-PCT
The compounds of the present invention can be prepared in a number of ways
known to one skilled in the art of organic synthesis. The compounds of the present
invention can be synthesized using the methods described below, together with synthetic
methods known in the art of synthetic organic chemistry, or by variations thereon as
appreciated by those skilled in the art. Preferred methods include, but are not limited to,
those described below. The reactions are performed in a solvent or solvent mixture
appropriate to the reagents and materials employed and suitable for the transformations
being effected. It will be understood by those skilled in the art of organic synthesis that
the functionality present on the molecule should be consistent with the transformations
proposed. This will sometimes require a judgment to modify the order of the synthetic
steps or to select one particular process scheme over another in order to obtain a desired
compound of the invention.
The novel compounds of this invention may be prepared using the reactions
and techniques described in this section. Also, in the description of the synthetic methods
described below, it is to be understood that all proposed reaction conditions, including
choice of solvent, reaction atmosphere, reaction temperature, duration of the experiment
and workup procedures, are chosen to be the conditions standard for that reaction, which
should be readily recognized by one skilled in the art. Restrictions to the substituents that
are compatible with the reaction conditions will be readily apparent to one skilled in the
art and alternate methods must then be used.
SYNTHESIS
The compounds of Formula (I) may be prepared by the exemplary processes
described in the following schemes and working examples, as well as relevant published
literature procedures that are used by one skilled in the art. Exemplary reagents and
procedures for these reactions appear hereinafter and in the working examples.
Protection and de-protection in the processes below may be carried out by procedures
generally known in the art (see, for example, Wuts, P. G. M. and Greene, T.W. Protecting
Groups in Organic Synthesis, 4th Edition, Wiley (2007)). General methods of organic
synthesis and functional group transformations are found in: Trost, B.M. and Fleming, I.,
eds., Comprehensive Organic Synthesis: Selectivity, Strategy & Efficiency in Modern
Organic Chemistry, Pergamon Press, New York, NY (1991); Smith, M. B. and March, J.,
11841-PCT
March’s Advanced Organic Chemistry: Reactions, Mechanisms, and Structure. 6th
Edition, Wiley & Sons, New York, NY (2007); Katritzky, A.R. and Taylor, R. J. K., eds.,
Comprehensive Organic Functional Groups Transformations II, 2nd Edition, Elsevier
Science Inc., Tarrytown, NY (2004); Larock, R.C., Comprehensive Organic
Transformations, VCH Publishers, Inc., New York, NY (1999), and references therein.
3 4 6
For example, compounds of Formula (II), where R = R = H and R = CN,
can be made according to Scheme 1. Ketones 1 and 2 and 2-cyanoethyl acetate (3) are
heated to between 80 °C and 110 °C with ammonium acetate in a solvent such as DMF or
DMSO. Ketones 1 and 2 may be different or the same.
Scheme 1
Alternatively, compounds of Formula (II), where R = R = H, may be made
according to Scheme 2. α-Bromoketone 4 is combined with triphenylphosphine in a
solvent such as THF, CH Cl or 1,4-dioxane at temperatures between room temperature
and reflux. The intermediate triphenylphosphonium bromide is treated with base, such as
NaOH, in a solvent such as methanol and water to form the phosphorous ylide 5. The
phosphorous ylide 5 is heated to 80 °C with ketone 2 in a suitable solvent such as THF or
DMSO to give α,β-unsat'd ketone 6, which may exist as a mixture of E/Z isomers.
Microwave irradiation may be employed to shorten the reaction time. α,β-Unsat'd ketone
6 is treated with concentrated aq NH OH in a solvent such as DMSO in a sealed vessel to
provide amine 7. Alternatively, alkene 6 may be treated with NH in a solvent such as
DMSO or DMSO and methanol in a sealed vessel to provide amine 7. Amine 7 is couple
with carboxylic acid 8 using a variety of amide bond forming reactions. For example,
carboxylic acid 8 may be converted to the corresponding acid chloride using oxalyl
11841-PCT
chloride in a solvent such as CH Cl and catalytic DMF. Alternatively, when R is an
amide or a heterocycle, the carboxylic acid 8 may be activated using triphenylphosphine
and trichloroacetonitrile in a suitable solvent such as CH Cl . The acid chlorides thus
formed are combined with amine 7 in a suitable solvent such as CH Cl or CH Cl and
2 2 2 2
DMF in the presence of a base, preferably pyridine. When R is CF , cyclization of
amide 9 to a compound of Formula (I) typically occurs during the work-up procedure for
amide 9; for example, when an EtOAc solution of amide 9 is washed with sat'd aq
NaHCO . When cyclization does not occur under these conditions, cyclization may be
affected by stirring amide 9 in the presence of a weak base such as piperidine in a suitable
solvent such as EtOH at a temperature between room temperature and reflux.
11841-PCT
Scheme 2
An alternate synthesis to α,β-unsaturated ketone 6, where R is
-(CH ) - (phenyl substituted with 0-3 R ) and m = 0, is shown in Scheme 3. Aryl
bromide 10 and α,β-unsat'd ester 11 are coupled using palladium (II) acetate,
tetrabutylammonium chloride and dicyclohexylamine in DMA at 110 °C. α,β-Unsat'd
ester 12 is combined with O,N-dimethylhydroxyl-amine 13 in the presence of a strong
base such as iso-propylmagnesium bromide in an aprotic solvent such as THF.
α,β-Unsat'd amide 14 is combined with aryl magnesium halide 15 to provide α,β-unsat'd
ketone 6. The identity of the halide in the aryl magnesium halide is dependent upon
availability of the aryl halide used to make the Grignard reagent; typically the halide is
chloride or bromide.
11841-PCT
Scheme 3
Pd(OAc)
Et NCl
O dicylcohexylmethylamine
DMA O
H CH
11 12 13
2 15
R R O R
R O 12 14
iPrMgBr R R R
R N CH
11 15
11 13
3 R R
R CH
14 15 6
[00207] Non-commercial α,α,α-trifluoroketones 2, where R = CF , may be made
from the corresponding aldehyde 16 as shown in Scheme 4. Aldehyde 16 is reacted with
trimethyl-(trifluoromethyl)silane in the presence of a fluoride source, for example cesium
fluoride, using a suitable solvent such dimethoxyethane at room temperature. Other
fluoride sources, such as potassium hydrogen fluoride or tetrabutylammonium
difluorotriphenylsilicate, and other solvents, such as THF or acetonitrile and methanol,
may also be employed. Trifluoromethyl alcohol 17 is oxidized using, for example,
Dess-Martin periodinane in a suitable solvent such as CH Cl .
Scheme 4
OH O
(CH ) SiCF oxidize
3 3 3
1 2 1 2
R R R R
16 17: R = CF
2: R = CF
Ketones of formula 2 may be made according to Scheme 5. For example, aryl
halide 18, where X = bromine and the aryl group is a suitable chemical moiety to form a
Grignard reagent, is combined with magnesium metal in the presence of an initiator such
as iodine in a suitable solvent such as THF. Other alkyl halides having a chemical moiety
suitable for formation of Grignard reagents, other halides such as chlorine or iodine, other
11841-PCT
solvents such as diethyl ether or 1,4-dioxane, and other initiators such as
1,2-dibromoethene, may be employed as determined by one skilled in the art. Grignard
reagent 19 is combined with amide 20 in a suitable solvent such as THF to provide ketone
2. Other solvents such as 1,4-dioxane or diethyl ether may be employed as determined
by one skilled in the art.
Scheme 5
solvent
R MgX +
18 19
2
3 4 1
[00209] Compounds of Formula 23 having R = R = H, R = -(CH ) -(phenyl
b b c
substituted with 0-3 R ) where m = 0, and at least one R = -(CH ) -(X) -(CH ) -R
2 n t 2 m
where n = m = t = 0, or n = m = 0 and t = 1 when X = O or NH, and R is a suitable
chemical moiety to participate in palladium cross coupling reactions, may be made
according to Scheme 6. Compound 21 is heated with boronic acid 22, where R = H, in
the presence of a palladium catalyst and base using a suitable solvent such as 1,4-dioxane,
toluene, DMF with or without water. Boronic acid 22 may be substituted with alternative
boronic acid analogs such as boronate esters, trifluoroborates, and others known to those
skilled in the art. Palladium catalyst commonly employed include, but are not restricted
to, Pd(PPh ) and PdCl (dppf). Other palladium catalyst known to those skilled in the art
3 4 2
may be employed. Bases commonly employed include, but are not restricted to, K PO
and K CO . Other bases known to those skilled in the art may also be employed. When n
= m = 0 and t = 1 when X = O or NH, biarylethers or biarylamines such as 23 can be
obtained from 21 when G = OH. Alternatively, biaryl ethers and amines can also be
obtained from 21, when G = boronic acid or equivalent, via metal-catalyzed coupling
with suitable phenols or amines.
11841-PCT
Scheme 6
13 13
12 14 12 14
R R R R
11 15 11 15
R R R R
Pd catalyzed
6 coupling 6
R -B(OR)
N O 22 N O
G = Cl, Br, I, OMs, OTs, OTf, OH, NH
3 4 1
Compounds of Formula 27 having R = R = H, R = -(CH ) -(phenyl
b b c
substituted with 0-3 R ) where m = 0, and at least one R = -(CH ) -(X) -(CH ) -R
2 n t 2 m
where n = 0, t = 1, m = 1-4 and X = O, may be made according to Scheme 7. Bromide 24
is treated with tris(dibenzylideneacetone)palladium (0) in the presence of
bis(1,1-dimethylethyl)[2′,4′,6′-tris(1-methylethyl)[1,1′-biphenyl]yl]- phosphine
(t-butyl-Xphos) using 1,4-dioxane and water as solvent and KOH as base. Phenol 25 and
alcohol 26 were stirred in the presence of triphenylphosphine and DIAD in a suitable
solvent such as CH Cl .
11841-PCT
Scheme 7
Carboxylic acid 8, where R = CONHR , may be made according to Scheme
8. The mono-ester of malonic acid 28, where PG = benzyl group, and amine 29 are
coupled together using standard amide bond forming conditions. For example, treatment
of carboxylic acid 28 with oxalyl chloride in CH Cl and DMF provides the acid
chloride. The acid chloride is then combined with amine 29 in the presence of pyridine in
a suitable solvent such as CH Cl . Other amide bond forming reaction known to those
skilled in the art may be employed. The benzyl group is removed using a combination of
hydrogen gas and 10% palladium on carbon in a suitable solvent such as methanol or
methanol and EtOAc. Other PG moieties and methods for their removal known to those
skilled in the art may be employed.
11841-PCT
Scheme 8
1. amide coupling
2. deprotection
NH -R R
O OH
28 29
8: R = CONHR
Compounds of Formula (I), where R and R are combined with the carbon
atom to which they are attached to form a 3-6 membered carbocycle, or R = R = F, may
be made according to Scheme 9. For example, to synthesize compounds for Formula (I)
where R and R are combined with the carbon atom to which they are attached to form a
3-membered ring (i.e., cyclopropyl), β-ketoester 30 is stirred at room temperature with
1,2-dibromoethane in the presence of a base, for example K CO , in a suitable solvent
such as DMF to provide the cyclopropyl β-ketoester 31. Cyclopropyl β-ketoester 31 is
stirred with a suitable amine, such as benzyl amine, in the presence of a suitable Lewis
acid, such as TiCl , in a solvent such as CH Cl starting at 0 °C then warming to room
4 2 2
temperature. Other amines, Lewis acids, solvents and temperatures may be used as
determined by those skilled in the art. The use of benzylamine provides imine 32, where
PG = benzyl. Imine 32 is alkylated with, for example, trimethyl(trifluoromethyl)silane in
the presence of a fluoride source such as potassium hydrogen fluoride and TFA, using
acetonitrile and DMF. Other fluoride sources, such as tetrabutylammonium
difluorotriphenylsilicate or cesium fluoride, other acids such as HOAc or HCl, and other
solvents may be employed as determined by those skilled in the art. Use of
trimethyl(trifluoromethyl)silane provides amino ester 33, where R = CF . Ester
hydrolysis of amino ester 33 was done in the presence of lithium iodide in refluxing
pyridine to provide amino acid 34. Use of other hydrolysis conditions known to those
skilled in the art may be employed. Cyclization of amino acid 34 to β-lactam 35 was
affected by activating the carboxylic acid of amino acid 34 with oxalyl chloride in a
suitable solvent such as CH Cl containing catalytic DMF. The cyclization occurred
spontaneously at room temperature to provide β-lactam 35. Other methods for activating
the carboxylic acid may be employed as determined by those skilled in the art. β-Lactam
is arylated using an organometallic reagent. Organometallic reagents may include,
for example, Grignard reagents or organolithium reagents, formed from a suitably
11841-PCT
substituted phenyl ring containing a halide atom able to react with either elemental
magnesium to form a Grignard reagent or with an alkyl lithium reagent to form an phenyl
lithium reagent via transmetallation. Exact conditions required to form these phenyl
organometallic species must determined by those skilled in the art. A suitable aprotic
solvent is used, for example, THF. Other suitable solvents may be employed as
determined by those skilled in the art. The reaction is carried out between room
temperature and reflux depending upon the identity of the organometallic reagent
employed and the substitution pattern on β-lactam 35. The β-amino ketone 37 thus
formed is deprotected using hydrogen gas and 10% palladium on carbon in a suitable
solvent such as methanol containing 4.4% formic acid to provide β-amino ketone 38.
Other conditions to remove the benzyl group may be employed as determined by those
skilled in the art. β-Amino ketone 38 is acylated with carboxylic acid 8 using conditions
described in Scheme 2 to give the β-keto amide 39. Stirring β-keto amide 39 with a base
such as sodium ethoxide in a suitable solvent such as ethanol at room temperature
provides compounds having Formula (I).
11841-PCT
Scheme 9
Compounds of Formula (I), where y is a single bond and R = F may be made
according to Scheme 10. This synthesis is exemplified for a compound of Formula (I)
where R = CN. Thus, a compound of Formula (I), where x is a single bond and R =
CN, was heated to 80 °C in the presence of a fluorinating reagent,
1-fluorohydroxy-1,4-diazoniabicyclo[2,2,2]octane bis(tetrafluoroborate), in a suitable
solvent such as DMF in the presence of a base such as Na CO to provide compounds of
Formula (I), where y is a single bond, R = F and R = CN. Other fluorinating reagents,
solvents and bases may be employed as determined by one skilled in the art.
11841-PCT
Scheme 10
12 14
12 14
11 15
fluorination 11 15
1 N O
(I): x = single bond
(I): y = single bond
R = F
Compounds of Formula (I), where x and y are both single bonds and R = H,
can be made according to Scheme 11. Reduction of compounds of Formula (I), where x
equals a single bond and y equals a double bond, is carried out using a suitable catalyst
such as palladium on carbon under an atmosphere of hydrogen gas at suitable pressure,
such as 50 psi, to effect reduction of the double bond y to a single bond. Suitable
solvents include, but are not restricted to, methanol.
Scheme 11
Compounds of Formula (II), single enantiomer, where R = R =H, can be
made according to Scheme 12. Ketone 2 was stirred with 2-methylpropanesulfinamide
in the presence of a suitable Lewis acid, such as Ti(OEt) , in a solvent such as THF at
refluxed tempereature provides imine 40. Other Lewis acids, solvents and temperatures
may be used as determined by those skilled in the art. Imine 40 is alkylated with ketone 1
11841-PCT
in the presence of a base, such as LiHMDS, KHMDS, NaHMDS, or LDA in an aprotic
solvent such as THF or ether at a temperature ranging from -78 °C to ambient to provide
β-amino ketone 41 as a mixture of two diastereomers, which can be separated by silica
gel chromatography to give the desired isomer 42. Other metal enolates (such as titanium
enolate), solvents, and temperatures may be used as determined by those skilled in the art
(T. P. Tang, J. A Ellman, J. Org. Chem. 1999, 64, 12-13, J. Org. Chem. 2002, 67, 7819-
7832). Preferably, chiral S- or Rmethylpropanesulfinamide can be optionally used
to generate each of the optically pure enantiomers of imine 40 that can allow for chiral
induction to prepare diastereomerically enriched ketone 42. In these cases, the product
mixture can be further purified by silica gel chromatography to obtain desired products
with diaseteromeric excess of >97%. β-amino ketone 42 thus formed is deprotected
using HCl in a suitable solvent such as MeOH to provide β-amino ketone 43. Other
conditions to remove the t-butylsulfinyl group may be employed as determined by those
skilled in the art. β-Amino ketone 43 is acylated with carboxylic acid 8 using conditions
described in Scheme 2 to give the β-keto amide 44. Stirring β-keto amide 44 with a base
such as sodium ethoxide in a suitable solvent such as ethanol at room temperature
provides compounds having Formula (II).
11841-PCT
Scheme 12
13
14 NH O R
imine S
2 12
N 1 R R
S formation
NH 1
1 2 2
1 2 alkylation
13
NH O R
NH O R
diastereomer separated by
2 12 R
silica gel chromatography
R R deprotection 6
13
13
enriched diastereomer
12 14
amide
11 15
NH O R
coupling R R
cyclization
13
R R N O
(I): R = R = H
Alternatively, compounds of Formula (II), where R = R =H, may be made
according to Scheme 13. Ketone 2 can be reacted with 2-methylpropanesulfinamide in
the presence of a suitable Lewis acid, such as Ti(OEt) , in a solvent such as THF at a
temperature ranging from ambient to reflux to provide imine 45. Other Lewis acids,
solvents and temperatures may be used as determined by those skilled in the art. Imine
45 is alkylated with the enolate of an ester in a suitable aprotic solvent such as THF or
ether starting at -78 °C then warming to 0 °C or room temperature to provide protected β-
amino ketone 46 as a mixture of two diastereomers, which can be separated by silica gel
chromatography to give each individual chiral compound. The generation of the ester
enolate is achieved by treating the ester, such as methyl acetate, with a suitable base such
as LHMDS, KHMDS, NaHMDS, or LDA in an aprotic solvent such as THF or ether at a
temperature ranging from -78 °C to ambient. Other metal enolates (such as titanium
enolate), solvents, and temperatures may be used as determined by those skilled in the art
(T. P. Tang, J. A Ellman, J. Org. Chem. 1999, 64, 12-13, J. Org. Chem. 2002, 67, 7819-
11841-PCT
7832). Preferably, chiral S- or Rmethylpropanesulfinamide can be optionally used
to generate each of the optically pure enantiomers of imine 45 that can allow for chiral
induction to prepare diastereomerically enriched ester 46. In these cases, the product
mixture can be further purified by silica gel chromatography to obtain desired products
with diaseteromeric excess of >97%. The tert-butyl sulfinyl group of 46 is removed
using acids such as HCl and TFA in a suitable solvent such as MeOH or dioxane to
generate amino ester 47. Other conditions to remove the t-butylsulfinyl group may be
employed as determined by those skilled in the art. β-Amino ketone 47 is acylated with
carboxylic acid 8 using conditions described in Scheme 2 to give the β-keto amide 48.
Stirring β-keto amide 48 with a base such as sodium ethoxide in a suitable solvent such as
ethanol at room temperature to 80 C provides cyclic enol 49. Other conditions can also
by used to effect the cyclization as determined by those skilled in the art. Compound 49,
when treated with stoichiometric amount of a chlorinating agent, such as POCl , at
elevated temperature in an inert solvent such as toluene, is converted to mono-chloride
50. Chloride 50 can then react with various boronic reagents through a Suzuki-type of
cross coupling reaction to generate compounds of Formula (II). The choices of boronic
reagents, catalysts, ligands, bases, solvents and temperatures are well documented in the
literature and can be selected appropriately by those skilled in the art.
11841-PCT
Scheme 13
3 4 1
Compounds of Formula (II), where R = R =H and R = CONHC alkyl or
4-18
CONH(CH ) Ph can be made according to Scheme 14. The phosphorous ylide 5 is
2 1-8
heated, using microwave irradiation, to 150 °C with α-ketoester 52 in a suitable solvent
such as THF or DMSO to give α,β-unsat'd ketone 53. α,β-Unsat'd ketone 53 is treated
with concentrated aq NH OH in a solvent such as DMSO in a sealed vessel to provide
amine 54. Alternatively, alkene 53 may be treated with NH in a solvent such as DMSO
or DMSO and methanol in a sealed vessel to provide amine 54. Amine 54 is couple with
carboxylic acid 8 using a variety of amide bond forming reactions. For example,
carboxylic acid 8 may be converted to the corresponding acid chloride using oxalyl
chloride in a solvent such as CH Cl and catalytic DMF. Alternatively, the carboxylic
acid 8 may be activated using 1-chloro-N,N,2-trimethylprop-enamine in a suitable
solvent such as CH Cl . The acid chlorides thus formed are combined with amine 54 in a
suitable solvent such as CH Cl or CH Cl and DMF in the presence of a base,
2 2 2 2
preferably pyridine. Other amide bond forming reaction known to those skilled in the art
may be employed. Cyclization of amide 55 and susequent hydrolysis to a the carboxylic
acid 56 typically occurs by stirring amide 55 in the presence of a weak base such as
11841-PCT
piperidine in a suitable solvent such as EtOH at a temperature between room temperature
and reflux or a base such as litium hydroxide in a suitable solvent such as THF and water
at room temperature. Alternatively, when R is a nitrile, cyclization of amide 55 typically
occurs by stirring amide 55 in the presence of a base such as lithium hydroxide in a
suitable solvent such as THF and water at room temperature. Hydrolysis is then carried
out under acidic conditions using a strong acid such as HCl in a suitable solvent such as
acetic acid at temperatures between room temperature and 50 C. Carboxylic acid 56 and
an amine are coupled together using standard amide bond forming conditions. For
example, treatment of carboxylic acid 56 and an amine with HOBt, EDC and DIEA in the
presence of pyridine in a suitable solvent such as DCM at room temperature provides
compounds having Formula (II). Other amide bond forming reaction known to those
skilled in the art may be employed.
Scheme 14
11841-PCT
Compounds of formula 60 having R = alkyl and R = cyano can be
synthesized by coupling acid 56 with N, O-dimethylhydroxylamine using typical amide
bond forming reactions. For example, carboxylic acid 56 is coupled to N, O-
dimethylhydroxylamine using EDC in the presence of base, preferably N-
methylmopholine, in a suitable solvent, such as CH Cl , to provide the Weinreb amide
57. Other amide forming reactions known to those skilled in the art may also be
employed. The intermediate Weinreb amide 57 is reacted with ethynylmagnesium
bromide in an aprotic solvent such as THF at 0-35 C to provide the acylacetylide
intermediate 58. Compounds of formula 60 are obtained when acylacetylide intermediate
58 is reacted with hydrazine 59 in the presence of a base such as TEA in a suitable
solvent such as EtOH.
Scheme 15
Compounds of formula 63 having R = alkyl and R = cyano can be
synthesized by first coupling acid 56 with β−ketoamine 61 using typical amide bond
forming reactions. For example, carboxylic acid 56 is coupled to α−ketoamine 61 using
EDC and HOBt in the presence of base, preferably DIEA, in a suitable solvent, such as
CH Cl , to provide β-ketoamide 62. Other amide forming reactions known to those
skilled in the art may also be employed. 5-Alkyl substituted oxazole 63 is then obtained
11841-PCT
via the dehydrative cyclization of β-ketoamide 62 using a dehydrating agent, preferably
POCl3, in the presence of a suitable base, such as DIEA, in a suitable solvent such as
dichloroethane at a temperature of 80-120 C.
Scheme 16
IV. BIOLOGY
In mammals, there are two triglyceride synthesis pathways: glycerol
phosphate pathway and monoacylglycerol pathway. The former is mainly responsible for
energy storage in the peripheral tissues such as fat, liver, skeletal muscle; the latter is
essential for the dietary fat absorption which takes place in the small intestine. When
dietary fat is ingested, pancreatic lipase digests triglycerides into free fatty acids and 2-
monoacylglycerol, which are absorbed by intestinal epithelial enterocytes. Once inside
enterocytes, free fatty acids and 2-monoacylglycerol are used as building blocks to
resynthesize triglycerides by two sequential acylation steps; first by MGAT and then by
DGAT enzyme reactions. Triglycerides are then incorporated into chylomicrons and
secreted into lymph to be utilized as an energy supply for the body.
Monoacylglycerol acyltransferase 2 (MGAT2) is a membrane bound
acyltransferase that belongs to diacylglycerol acyltransferase 2 (DGAT2) gene family. It
11841-PCT
is highly and selectively expressed in the small intestine. Genetic deletion of MGAT2 in
mice decreased the rate of absorption for the orally ingested triglycerides, indicating that
MGAT2 plays an important role for the intestinal MGAT/DGAT pathway [Yen, C.L. et
al, Nat. Med., 15(4):442-446 (2009); Okawa, M. et al., Biochem. Biophys. Res. Commun.,
390(3):377-381 (2009)]. When chronically challenged with a high fat diet, in contrast to
wild type mice that became obese, MGAT2 knockout mice resisted the impact of high-fat
feeding and demonstrated with a lower body weight, less adiposity, and less hepatic fat
accumulation. In contrast to hyperinsulinemic wild type mice after high-fat challenge,
MGAT2 deletion normalizes the insulin level and decreased fasting glucose. In the
glucose tolerance test, they also had an improved glucose excursion. Consistent with their
improved glycemic profile, MGAT2 knockout mice also had an increased level of GLP1,
an incretin gut hormone that profoundly impacts glucose metabolism[Yen, C.L. et al.,
Nat. Med., 15(4):442-446 (2009)]. Taken together, it is expected that inhibition of
MGAT2 through pharmacological intervention would provide the same benefit as
demonstrated in the knock-out mice, e.g., resistance to weight gain, or conversely,
reduction in fat body mass. In addition, MGAT2 inhibition would lead to an improved
insulin sensitivity and glucose metabolism which either leads to a decrease in the
incidence of Type II diabetes, or a treatment of diabetic condition.
It is also desirable and preferable to find compounds with advantageous and
improved characteristics compared with known anti-diabetic agents, in one or more of the
following categories that are given as examples, and are not intended to be limiting: (a)
pharmacokinetic properties, including oral bioavailability, half life, and clearance; (b)
pharmaceutical properties; (c) dosage requirements; (d) factors that decrease blood drug
concentration peak-to-trough characteristics; (e) factors that increase the concentration of
active drug at the receptor; (f) factors that decrease the liability for clinical drug-drug
interactions; (g) factors that decrease the potential for adverse side-effects, including
selectivity versus other biological targets; and (h) improved therapeutic index with less
propensity for hypoglycemia.
As used herein, the term "patient" encompasses all mammalian species.
[00224] As used herein, the term "subject" refers to any human or non-human
organism that could potentially benefit from treatment with a MGAT2 inhibitor.
Exemplary subjects include human beings of any age with risk factors for metabolic
11841-PCT
disease. Common risk factors include, but are not limited to, age, sex, weight, family
history, or signs of insulin resistance such as acanthosis nigricans, hypertension,
dyslipidemia, or polycystic ovary syndrome (PCOS).
As used herein, "treating" or "treatment" cover the treatment of a disease-state
in a mammal, particularly in a human, and include: (a) inhibiting the disease-state, i.e.,
arresting it development; and/or (b) relieving the disease-state, i.e., causing regression of
the disease state.
As used herein, "prophylaxis" or "prevention" cover the preventive treatment
of a subclinical disease-state in a mammal, particularly in a human, aimed at reducing the
probability of the occurrence of a clinical disease-state. Patients are selected for
preventative therapy based on factors that are known to increase risk of suffering a
clinical disease state compared to the general population. "Prophylaxis" therapies can be
divided into (a) primary prevention and (b) secondary prevention. Primary prevention is
defined as treatment in a subject that has not yet presented with a clinical disease state,
whereas secondary prevention is defined as preventing a second occurrence of the same
or similar clinical disease state.
As used herein, "risk reduction" covers therapies that lower the incidence of
development of a clinical disease state. As such, primary and secondary prevention
therapies are examples of risk reduction.
[00228] "Therapeutically effective amount" is intended to include an amount of a
compound of the present invention that is effective when administered alone or in
combination to inhibit MGAT2 and/or to prevent or treat the disorders listed herein.
When applied to a combination, the term refers to combined amounts of the active
ingredients that result in the preventive or therapeutic effect, whether administered in
combination, serially, or simultaneously.
A. ASSAY METHODS
MGAT SPA Assay
MGAT2 enzyme was assayed using membranes isolated from Sf9 cells
expressing the recombinant human MGAT2 cDNA with 2-monooleoylglycerol and [ H]-
oleoyl-CoA as substrates as described by Seethala et al. [Anal. Biochem., 383(2):144-150
(Dec. 15, 2008)]. Briefly, the assays were conducted in 384-well plates in a total volume
11841-PCT
of 30 µL at 25 °C. In each assay, 200 ng of recombinant human MGAT2 membrane was
incubated with 10 μM of 2-monooleoylglycerol and 15 μM of [ H]-oleoyl-CoA in 100
mM potassium phosphate (pH 7.4) for 20 min with various concentrations of compounds
delivered in DMSO. The assay was terminated by the addition of 20 μl of Stopping
Solution (7.5 mg/ml Yittrium Oxide Polylysine beads, 3.3 mg/ml Fraction V BSA and
200 μM Mercuric chloride in 50 mM HEPES, pH 7.4). The signal was measured 1 h
after quenching the reaction using LEADSEEKER for 5 minutes. To calculate the
degree of inhibition, the zero level of enzyme activity (blank) was defined by the above
assay procedure using membrane form Sf9 cell uninfected with baculovirus (Naive) and
the 100% level of MGAT2 enzyme activity was defined by human MGAT2 assay with
the vehicle DMSO. The IC s of inhibitors were determined by logistic 4 parameter
equation in XL-fit.
MGAT LCMS Assay
[00230] The MGAT enzyme reactions were performed in CORNING Falcon 96-well
Polypropylene plates, in a total volume of 60 µL of 50 mM Potassium Phosphate buffer
pH 7.4, containing a final concentration of 100 µM 2-oleoylglycerol, 15 µM oleoyl-
Coenzyme A and 0.0013 µg/µL Human or Mouse MGAT-2 or 0.0026 µg/µL Rat
recombinant MGAT-2 membranes expressed in Sf9 cells. Assay plates were run through
a fully automated robotics system and shaken for 5 seconds every minute for a total 10
minutes. The reactions were then quenched with 120 µL of ice cold methanol containing
1 µg/mL 1,2-distearoyl-rac-glycerol as the internal standard. Plates were shaken for 2
minutes and spun down to remove protein precipitation. After the spin, samples were
transferred to LC/MS compatible PCR plates. For LC/MS analysis, a ThermoFisher
Surveyor pump, utilizing a Waters Symmetry C8, 50 x 2.1 mm column, was used for the
chromatography of enzyme products. The buffer system consists of 0.1% formic acid in
water with a mobile phase consisting 0.1% formic acid in methanol. The shallow
gradient is 90-100% mobile phase in 0.2 min with a total run time of 2.3 min. The first
0.5 minutes of each injection was diverted to waste to eliminate the presence of
Phosphate buffer in the enzymatic reaction. The column was run at 0.6 mL/min and a
temperature of 65 °C. Mass spectrometry analysis of the samples was performed on a
ThermoFisher Quantum Triple quad utilizing APCI (+) as the mode of ionization. Data
11841-PCT
was acquired in Single Ion Monitoring (SIM) mode analyzing Diolein =m/z 603.6
(PRODUCT) and 1,2- distearoyl-rac-glycerol (IS)= m/z 607.6. The ratio of Diolein to
internal standard (Peak Area Ratio) is utilized to calculate IC values.
[00231] The exemplified Examples disclosed below were tested in the MGAT2 in
vitro assays described above and were found having MGAT2 inhibitory activity. Table 1
below lists human MGAT2 IC values measured for the following examples. “NT”
denotes “Not tested”.
Table 1
Example
h-MGAT2 IC (nM)
SPA Assay LCMS Assay
1 651 2049
2 85 5
2-1 35 8
2-2 1400 261
3 1804 NT
4 5871 NT
309 21
6 15 7
6-1 1435 NT
6-2 14 2
7 818 NT
8 NT 7
9 33330 121
2716 138
11 48 13
12 NT 374
13 3333 35
14 NT 2050
-1 3306 12
11841-PCT
-2 33330 431
-3 33330 756
-4 33330 2049
16-1 25 7
16-2 8430 416
17 1931 NT
18 5762 NT
19 2905 NT
3456 NT
21 913 NT
22 801 NT
23 1292 NT
24 1731 NT
4569 NT
26 6428 NT
27 2519 NT
28 564 NT
29 7602 NT
774 NT
31 1510 NT
32 9956 NT
33 167 12
34 656 126
5199 13
36 396 57
37 263 15
38 2143 NT
39 401 20
40 2546 164
41 170 15
42 403 77
43 5387 60
11841-PCT
44 1458 NT
45 569 NT
46 871 NT
47 756 NT
48 226 7
49 127 64
50 242 95
51 63 13
52 477 99
53 111 3
54 258 20
55 846 20
56 6550 NA
57 412 16
58 275 29
59 53 4
60 441 12
61 709 NT
62 156 24
63 116 28
64 761 280
65 96 3
66 731 265
67 1935 253
68 7523 1282
69 9230 983
70 3404 NA
71 2931 1917
72 3519 214
73 684 15
74 2476 697
75 873 209
11841-PCT
76 5073 370
77 89 27
78 151 4
79 1856 45
80 310 5
81 55 4
82 133 2
83 89 1
84 115 2
85 1465 7
86 201 1
87 NT 1215
88 28 5
89 731 20
90 815 18
91 916 2
92 NT 136
93 37 30
94 32 4
95 95 43
96 NT 1431
97 NT 1199
98 154 69
99 NT 795
100 NT 1575
101 379 108
102 NT 1088
103 NT 645
104 NT 103
105 672 24
106 NT 552
107 NT 93
11841-PCT
108 NT 189
109 NT 39
110 11 5
111 9 7
112 1297 204
113 158 8
114 NT 704
115 NT 40
116 48 4
117 22 18
118 32 4
119 94 21
120 58 6
121 231 20
122 14 1
123 743 5
124 4264 55
125 NT 282
126 1874 33
127 655 10
128 NT 328
129 NT 222
130 20 1
131 NT 1050
132 NT 163
133 1518 127
134 NT 168
135 NT 778
136 NT 328
137 NT 252
138 NT 5799
140 NT 356
11841-PCT
141 NT 459
142 93 10
143 156 4
144 175 16
145 130 25
146 397 25
147 91 14
148 102 9
149 53 6
150 11 3
151 NT 5115
152 NT 252
153 NT 247
154 34 8
155 NT 484
156 NT 254
157 168 84
158 302 75
159 NT 16710
160 NT 5401
161 NT 1261
162 NT 214
163 1176 47
164 NT 162
165 60 8
166 237 102
167 8 2
168 NT 113
169 NT 421
170 NT 210
171 724 57
172 16 3
11841-PCT
173 43 63
174 237 60
175 NT 264
176 NT 3
177 NT 399
178 47 78
179 24 2
180 36 30
181 NT 2049
182 NT 2049
183 NT 50
184 NT 76
185 NT 121
186 NT 229
187 NT 4
188 NT 1524
189 NT 1159
190 NT 155
191 NT 797
192 NT 433
193 NT 46
194 NT 6
195 NT 33
196 NT 826
197 NT 178
198 NT 16
199 NT 16
200 NT 37
201 NT 24
202 NT 89
203 NT 59
204 NT 41
11841-PCT
205 NT 13
206 NT 78
207 NT 11
208 NT 30
209 NT 37
210 NT 2
211 NT 97
212 NT 416
213 NT 1096
214 NT 12
215 NT 11
216 NT 440
217 NT 118
218 NT 166
219 NT 172
220 NT 13
221 NT 152
222 NT 733
223 NT 112
224 NT 414
225 NT 889
226 NT 206
227 NT 63
228 NT 7
229 NT 25
230 NT 1532
231 NT 34
232 NT 6
233 NT 639
234 NT 40
235 NT 22
236 NT 489
11841-PCT
237 NT 130
238 NT 7
239 NT 15
240 NT 7
242 NT 44
243 NT 14
244 NT 61
245 NT 46
246 NT 36
247 NT 51
248 NT 8
249 NT 185
250 NT 243
251 NT 3
252 NT 7
253 NT 411
254 NT 170
255 NT 702
256 NT 22
257 NT 421
258 NT 1147
259 NT 15
260 NT 56
261 NT 1222
262 NT 96
263 NT 103
264 NT 46
265 NT 40
266 NT 10
267 NT 796
268 NT 8
269 NT 171
11841-PCT
270 NT 407
271 NT 12
272 NT 112
273 21 10
274 NT 1
275 NT 2
276 NT 2
277 NT 2
278 NT 2
279 NT 2
280 NT 2
281 NT 3
282 NT 3
283 NT 3
284 NT 4
285 NT 4
286 NT 4
287 NT 13
288 NT 19
289 NT 19
290 NT 56
291 NT 178
292 NT 304
293 NT 7
294 NT 84
295 NT 183
296 NT 2
297 NT 639
298 NT 2
299 NT 11
300 NT 11
301 NT 19
11841-PCT
302 NT 105
303 NT 28
304 NT 6
305 NT 94
306 NT 3
307 NT 3
308 NT 61
309 NT 1
310 NT 4
311 NT 3
312 NT 21
313 NT 4
314 NT 109
The compounds of the present invention possess activity as inhibitors of
MGAT2, and, therefore, may be used in the treatment of diseases associated with
MGAT2 activity. Via modulation of MGAT2, the compounds of the present invention
may preferably be employed to modulate, either enhance or decrease the
production/secretion of insulin and/or gut hormones, such as GLP1, GIP, CCK, PYY, PP,
Amylin.
Accordingly, the compounds of the present invention can be administered to
mammals, preferably humans, for the treatment of a variety of conditions and disorders,
including, but not limited to, treating, preventing, or slowing the progression of diabetes
and related conditions, microvascular complications associated with diabetes,
macrovascular complications associated with diabetes, cardiovascular diseases, Metabolic
Syndrome and its component conditions, inflammatory diseases and other maladies.
Consequently, it is believed that the compounds of the present invention may be used in
preventing, inhibiting, or treating diabetes, hyperglycemia, impaired glucose tolerance,
gestational diabetes, insulin resistance, hyperinsulinemia, retinopathy, neuropathy,
nephropathy, wound healing, atherosclerosis and its sequelae (acute coronary syndrome,
myocardial infarction, angina pectoris, peripheral vascular disease, intermittent
claudication, myocardial ischemia, stroke, heart failure), Metabolic Syndrome,
11841-PCT
hypertension, obesity, dyslipidemia, hyperlipidemia, hypertriglyceridemia,
hypercholesterolemia, low HDL, high LDL, lipid disorders, PCOS, and glaucoma.
Metabolic Syndrome or "Syndrome X" is described in Ford et al., J. Am. Med.
Assoc., 287:356-359 (2002) and Arbeeny et al., Curr. Med. Chem. - Imm., Endoc. &
Metab. Agents, 1:1-24 (2001).
V. PHARMACEUTICAL COMPOSITIONS, FORMULATIONS AND
COMBINATIONS
The compounds of this invention can be administered for any of the uses
described herein by any suitable means, for example, orally, such as tablets, capsules
(each of which includes sustained release or timed release formulations), pills, powders,
granules, elixirs, tinctures, suspensions (including nanosuspensions, microsuspensions,
spray-dried dispersions), syrups, and emulsions; sublingually; bucally; parenterally, such
as by subcutaneous, intravenous, intramuscular, or intrasternal injection, or infusion
techniques (e.g., as sterile injectable aqueous or non-aqueous solutions or suspensions);
nasally, including administration to the nasal membranes, such as by inhalation spray;
topically, such as in the form of a cream or ointment; or rectally such as in the form of
suppositories. They can be administered alone, but generally will be administered with a
pharmaceutical carrier selected on the basis of the chosen route of administration and
standard pharmaceutical practice.
The term "pharmaceutical composition" means a composition comprising a
compound of the invention in combination with at least one additional pharmaceutically
acceptable carrier. A "pharmaceutically acceptable carrier" refers to media generally
accepted in the art for the delivery of biologically active agents to animals, in particular,
mammals, including, i.e., adjuvant, excipient or vehicle, such as diluents, preserving
agents, fillers, flow regulating agents, disintegrating agents, wetting agents, emulsifying
agents, suspending agents, sweetening agents, flavoring agents, perfuming agents,
antibacterial agents, antifungal agents, lubricating agents and dispensing agents,
depending on the nature of the mode of administration and dosage forms.
[00237] Pharmaceutically acceptable carriers are formulated according to a number of
factors well within the purview of those of ordinary skill in the art. These include,
without limitation: the type and nature of the active agent being formulated; the subject to
11841-PCT
which the agent-containing composition is to be administered; the intended route of
administration of the composition; and the therapeutic indication being targeted.
Pharmaceutically acceptable carriers include both aqueous and non-aqueous liquid media,
as well as a variety of solid and semi-solid dosage forms. Such carriers can include a
number of different ingredients and additives in addition to the active agent, such
additional ingredients being included in the formulation for a variety of reasons, e.g.,
stabilization of the active agent, binders, etc., well known to those of ordinary skill in the
art. Descriptions of suitable pharmaceutically acceptable carriers, and factors involved in
their selection, are found in a variety of readily available sources such as, for example,
Allen, L. V. Jr. et al. Remington: The Science and Practice of Pharmacy (2 Volumes),
22nd Edition (2012), Pharmaceutical Press.
The dosage regimen for the compounds of the present invention will, of
course, vary depending upon known factors, such as the pharmacodynamic characteristics
of the particular agent and its mode and route of administration; the species, age, sex,
health, medical condition, and weight of the recipient; the nature and extent of the
symptoms; the kind of concurrent treatment; the frequency of treatment; the route of
administration, the renal and hepatic function of the patient, and the effect desired.
By way of general guidance, the daily oral dosage of each active ingredient,
when used for the indicated effects, will range between about 0.001 to about 5000 mg per
day, preferably between about 0.01 to about 1000 mg per day, and most preferably
between about 0.1 to about 250 mg per day. Intravenously, the most preferred doses will
range from about 0.01 to about 10 mg/kg/minute during a constant rate infusion.
Compounds of this invention may be administered in a single daily dose, or the total daily
dosage may be administered in divided doses of two, three, or four times daily.
[00240] The compounds are typically administered in admixture with suitable
pharmaceutical diluents, excipients, or carriers (collectively referred to herein as
pharmaceutical carriers) suitably selected with respect to the intended form of
administration, e.g., oral tablets, capsules, elixirs, and syrups, and consistent with
conventional pharmaceutical practices.
[00241] Dosage forms (pharmaceutical compositions) suitable for administration may
contain from about 1 milligram to about 2000 milligrams of active ingredient per dosage
unit. In these pharmaceutical compositions the active ingredient will ordinarily be
11841-PCT
present in an amount of about 0.1-95% by weight based on the total weight of the
composition.
A typical capsule for oral administration contains at least one of the
compounds of the present invention (250 mg), lactose (75 mg), and magnesium stearate
(15 mg). The mixture is passed through a 60 mesh sieve and packed into a No. l gelatin
capsule.
A typical injectable preparation is produced by aseptically placing at least one
of the compounds of the present invention (250 mg) into a vial, aseptically freeze-drying
and sealing. For use, the contents of the vial are mixed with 2 mL of physiological saline,
to produce an injectable preparation.
The present invention includes within its scope pharmaceutical compositions
comprising, as an active ingredient, a therapeutically effective amount of at least one of
the compounds of the present invention, alone or in combination with a pharmaceutical
carrier. Optionally, compounds of the present invention can be used alone, in
combination with other compounds of the invention, or in combination with one or more
other therapeutic agent(s), e.g., an antidiabetic agent or other pharmaceutically active
material.
The compounds of the present invention may be employed in combination
with other MGAT2 inhibitors or one or more other suitable therapeutic agents useful in
the treatment of the aforementioned disorders including: anti-diabetic agents, anti-
hyperglycemic agents, anti-hyperinsulinemic agents, anti-retinopathic agents, anti-
neuropathic agents, anti-nephropathic agents, anti-atherosclerotic agents, anti-ischemic
agents, anti-hypertensive agents, anti-obesity agents, anti-dyslipidemic agents, anti-
dyslipidemic agents, anti-hyperlipidemic agents, anti-hypertriglyceridemic agents, anti-
hypercholesterolemic agents, anti-restenotic agents, anti-pancreatic agents, lipid lowering
agents, anorectic agents, memory enhancing agents, anti-dementia agents, or cognition
promoting agents, appetite suppressants, treatments for heart failure, treatments for
peripheral arterial disease and anti-inflammatory agents.
Where desired, the compound of the present invention may be used in
combination with one or more other types of antidiabetic agents and/or one or more other
types of therapeutic agents which may be administered orally in the same dosage form, in
a separate oral dosage form or by injection. The other type of antidiabetic agent that may
11841-PCT
be optionally employed in combination with the MGAT2 inhibitor of the present
invention may be one, two, three or more antidiabetic agents or antihyperglycemic agents
which may be administered orally in the same dosage form, in a separate oral dosage
form, or by injection to produce an additional pharmacological benefit.
[00247] The antidiabetic agents used in the combination with the compound of the
present invention include, but are not limited to, insulin secretagogues or insulin
sensitizers, other MGAT2 inhibitors, or other antidiabetic agents. These agents include,
but are not limited to, dipeptidyl peptidase IV (DP4) inhibitors (for example, sitagliptin,
saxagliptin, alogliptin, vildagliptin and the like), biguanides (for example, metformin,
phenformin and the like), sulfonyl ureas (for example, glyburide, glimepiride, glipizide
and the like), glucosidase inhibitors (for example, acarbose, miglitol, and the like),
PPARγ agonists such as thiazolidinediones (for example, rosiglitazone, pioglitazone, and
the like), PPAR α/γ dual agonists (for example, muraglitazar, tesaglitazar, aleglitazar, and
the like), glucokinase activators (as described in Fyfe, M.C.T. et al., Drugs of the Future,
34(8):641-653 (2009) and incorporated herein by reference), GPR40 receptor modulators,
GPR119 receptor modulators (MBX-2952, PSN821, APD597 and the like), SGLT2
inhibitors (dapagliflozin, canagliflozin, remagliflozin and the like), amylin analogs such
as pramlintide, and/or insulin. Reviews of current and emerging therapies for the
treatment of diabetes can be found in: Mohler, M.L. et al., Medicinal Research Reviews,
29(1):125-195 (2009), and Mizuno, C.S. et al., Current Medicinal Chemistry, 15:61-74
(2008).
The compounds of the present invention may also be optionally employed in
combination with agents for treating complication of diabetes. These agents include PKC
inhibitors and/or AGE inhibitors.
[00249] The compounds of the present invention may also be optionally employed in
combination with one or more hypophagic agents such as diethylpropion,
phendimetrazine, phentermine, orlistat, sibutramine, lorcaserin, pramlintide, topiramate,
MCHR1 receptor antagonists, oxyntomodulin, naltrexone, Amylin peptide, NPY Y5
receptor modulators, NPY Y2 receptor modulators, NPY Y4 receptor modulators,
cetilistat, 5HT2c receptor modulators, and the like. The compound of structure I may
also be employed in combination with an agonist of the glucagon-like peptide-1 receptor
(GLP-1 R), such as exenatide, liraglutide, GPR-1(1-36) amide, GLP-1(7-36) amide,
11841-PCT
GLP-1(7-37) (as disclosed in U.S. Patent No. 5,614,492 to Habener, the disclosure of
which is incorporated herein by reference), which may be administered via injection,
intranasal, or by transdermal or buccal devices. Reviews of current and emerging
therapies for the treatment of obesity can be found in: Melnikova, I. et al., Nature
Reviews Drug Discovery, 5:369-370 (2006); Jones, D., Nature Reviews: Drug Discovery,
8:833-834 (2009); Obici, S., Endocrinology, 150(6):2512-2517 (2009); and Elangbam,
C.S., Vet. Pathol., 46(1):10-24 (2009).
The compounds of the present invention may also be optionally employed in
combination with one or more other types of therapeutic agents, such as DGAT
inhibitors, LDL lowering drugs such as statins (inhibitors of HMG CoA reductase) or
inhibitors of cholesterol absorption, modulators of PCSK9, drugs increase HDL such as
CETP inhibitors.
The above other therapeutic agents, when employed in combination with the
compounds of the present invention may be used, for example, in those amounts
indicated in the Physicians' Desk Reference, as in the patents set out above, or as
otherwise determined by one of ordinary skill in the art.
Particularly when provided as a single dosage unit, the potential exists for a
chemical interaction between the combined active ingredients. For this reason, when the
compound of the present invention and a second therapeutic agent are combined in a
single dosage unit they are formulated such that although the active ingredients are
combined in a single dosage unit, the physical contact between the active ingredients is
minimized (that is, reduced). For example, one active ingredient may be enteric coated.
By enteric coating one of the active ingredients, it is possible not only to minimize the
contact between the combined active ingredients, but also, it is possible to control the
release of one of these components in the gastrointestinal tract such that one of these
components is not released in the stomach but rather is released in the intestines. One of
the active ingredients may also be coated with a material that affects a sustained-release
throughout the gastrointestinal tract and also serves to minimize physical contact between
the combined active ingredients. Furthermore, the sustained-released component can be
additionally enteric coated such that the release of this component occurs only in the
intestine. Still another approach would involve the formulation of a combination product
in which the one component is coated with a sustained and/or enteric release polymer,
11841-PCT
and the other component is also coated with a polymer such as a low viscosity grade of
hydroxypropyl methylcellulose (HPMC) or other appropriate materials as known in the
art, in order to further separate the active components. The polymer coating serves to
form an additional barrier to interaction with the other component.
[00253] These as well as other ways of minimizing contact between the components of
combination products of the present invention, whether administered in a single dosage
form or administered in separate forms but at the same time by the same manner, will be
readily apparent to those skilled in the art, once armed with the present disclosure.
The compounds of the present invention can be administered alone or in
combination with one or more additional therapeutic agents. By "administered in
combination" or "combination therapy" it is meant that the compound of the present
invention and one or more additional therapeutic agents are administered concurrently to
the mammal being treated. When administered in combination, each component may be
administered at the same time or sequentially in any order at different points in time.
Thus, each component may be administered separately but sufficiently closely in time so
as to provide the desired therapeutic effect.
The compounds of the present invention are also useful as standard or
reference compounds, for example as a quality standard or control, in tests or assays
involving the MGAT2 enzyme. Such compounds may be provided in a commercial kit,
for example, for use in pharmaceutical research involving MGAT2 or anti-diabetic
activity. For example, a compound of the present invention could be used as a reference
in an assay to compare its known activity to a compound with an unknown activity. This
would ensure the experimentor that the assay was being performed properly and provide
a basis for comparison, especially if the test compound was a derivative of the reference
compound. When developing new assays or protocols, compounds according to the
present invention could be used to test their effectiveness.
The compounds of the present invention may also be used in diagnostic assays
involving MGAT2.
The present invention also encompasses an article of manufacture. As used
herein, article of manufacture is intended to include, but not be limited to, kits and
packages. The article of manufacture of the present invention, comprises: (a) a first
container; (b) a pharmaceutical composition located within the first container, wherein
11841-PCT
the composition, comprises: a first therapeutic agent, comprising: a compound of the
present invention or a pharmaceutically acceptable salt form thereof; and, (c) a package
insert stating that the pharmaceutical composition can be used for the treatment and/or
prophylaxis of multiple diseases or disorders associated with MGAT2 (as defined
previously). In another embodiment, the package insert states that the pharmaceutical
composition can be used in combination (as defined previously) with a second therapeutic
agent for the treatment and/or prophylaxis of multiple diseases or disorders associated
with MGAT2. The article of manufacture can further comprise: (d) a second container,
wherein components (a) and (b) are located within the second container and component
(c) is located within or outside of the second container. Located within the first and
second containers means that the respective container holds the item within its
boundaries.
The first container is a receptacle used to hold a pharmaceutical composition.
This container can be for manufacturing, storing, shipping, and/or individual/bulk selling.
First container is intended to cover a bottle, jar, vial, flask, syringe, tube (e.g., for a cream
preparation), or any other container used to manufacture, hold, store, or distribute a
pharmaceutical product.
The second container is one used to hold the first container and, optionally,
the package insert. Examples of the second container include, but are not limited to,
boxes (e.g., cardboard or plastic), crates, cartons, bags (e.g., paper or plastic bags),
pouches, and sacks. The package insert can be physically attached to the outside of the
first container via tape, glue, staple, or another method of attachment, or it can rest inside
the second container without any physical means of attachment to the first container.
Alternatively, the package insert is located on the outside of the second container. When
located on the outside of the second container, it is preferable that the package insert is
physically attached via tape, glue, staple, or another method of attachment. Alternatively,
it can be adjacent to or touching the outside of the second container without being
physically attached.
The package insert is a label, tag, marker, etc. that recites information relating
to the pharmaceutical composition located within the first container. The information
recited will usually be determined by the regulatory agency governing the area in which
the article of manufacture is to be sold (e.g., the United States Food and Drug
11841-PCT
Administration). Preferably, the package insert specifically recites the indications for
which the pharmaceutical composition has been approved. The package insert may be
made of any material on which a person can read information contained therein or
thereon. Preferably, the package insert is a printable material (e.g., paper, plastic,
cardboard, foil, adhesive-backed paper or plastic, etc.) on which the desired information
has been formed (e.g., printed or applied).
Other features of the invention will become apparent in the course of the
following descriptions of exemplary embodiments that are given for illustration of the
invention and are not intended to be limiting thereof.
VI. EXAMPLES
The following Examples are offered as illustrative, as a partial scope and
particular embodiments of the invention and are not meant to be limiting of the scope of
the invention. In the following Examples, the compounds of Examples 1, 3-5, 7, 14-15,
17-20, 22-37, 39, 40, 42-47, 53, 63-69, 71-81, 89, 91, 107-109, 138, 144-147, 160, 177,
184, 215-227, 230, 256-264 and 269 are reference examples. The compounds of the other
Examples illustrate the presently claimed invention. Abbreviations and chemical symbols
have their usual and customary meanings unless otherwise indicated. Unless otherwise
indicated, the compounds described herein have been prepared, isolated and characterized
using the schemes and other methods disclosed herein or may be prepared using the
same.
HPLC/MS, PREPARATORY/ANALYTICAL HPLC, AND CHIRAL SEPARATION
METHODS EMPLOYED IN CHARACTERIZATION OR PURIFICATION OF
EXAMPLES
Analytical HPLC/MS (unless otherwise noted) was performed on Shimadzu
SCL-10A liquid chromatographs and Waters MICROMASS ZQ Mass Spectrometers
(Desolvation Gas: Nitrogen; Desolvation Temp. 250 °C; Ion Source Temp: 120 °C;
Positive Electrospray conditions) using the following methods:
Linear Gradient of 0% to100% solvent B over 2 min, with 1 minute hold at 100% B,
Linear Gradient of 0% to100% solvent B over 4 min, with 1 minute hold at 100% B;
11841-PCT
UV visualization at 220 nm;
Column: PHENOMENEX Luna C18 (2) 30mm × 4.6 mm; 5μ particle (heated to
Temp. 40 °C);
Flow rate: 1.0 mL/min (2 min gradient) or 0.8 ml/min (4 min gradient);
Solvent A: 10% ACN, 90% water, 0.1% TFA; or, 10% MeOH, 90% water, 0.1% TFA
Solvent B: 90% ACN, 10% water, 0.1% TFA; or, 90% MeOH, 10% water, 0.1%
TFA.
[00264] Preparatory HPLC (unless otherwise noted) was performed on a Shimadzu
SCL-10A liquid chromatograph with a linear gradient of 20-100% Solvent B over 10 to
min, with either a 2 to 5 min hold at 100% Solvent B as determined by on skilled in
the art;
UV visualization at 220 nm;
Column: PHENOMENEX Luna Axia 5μ C18 30 × 100 mm;
Flow rate: 20 mL/min;
Solvent A: 10% ACN, 90% water, 0.1% TFA; or 10% MeOH, 90% water, 0.1% TFA;
Solvent B: 90% ACN, 10% water, 0.1% TFA; or 90% MeOH, 10% water, 0.1% TFA.
Preparatory chiral SFC chromatography (unless otherwise noted) was
performed on a Berger Multigram II SFC chromatograph using one of the following
methods:
Preparative chiral SFC method A:
Column: CHIRALCEL OD-H, 30 × 250mm ID, 5 μ
Flow rate: 90 mL/min, 100 bar BP, 40 °C
Mobile Phase: 15% Methanol /85% CO
Detector Wavelength: 254 nm
Injection Vol and Sample Solution: 0.5 mL of 4.65 g in 35 mL Methanol (133
mg/mL)
Preparative chiral SFC method B:
Instrument: Berger SFC MGII (HPW-2501)
11841-PCT
Column: CHIRALPAK IA 25 × 3 cm ID, 5 µm
Flow rate: 85.0 mL/min
Mobile Phase: 85/15/0.1,CO /IPA/DEA, 150 bar
Detector Wavelength: 225 nm (Lamda max)
Sample Prep and Inj. Volume: 300 µL of ~13 mg / 0.5 mL IPA (~26 mg/mL)
Preparative chiral SFC method C
Column: CHIRALPAK IA 25 × 3 cm ID, 5 µm
Flow rate: 90 mL/min
Mobile Phase: 85/15/0.1,CO /MeOH/DEA, 150 bar
Detector Wavelength: 270 nm (Lambda max)
Sample Prep and Inj. Volume: 300 µL of ~90 mg / 2 mL MeOH (~45 mg/mL)
Preparative chiral SFC method D
Flow rate: 40 mL/min, 100 Bar, 35 °C
Mobile Phase: 20% Methanol/80% CO
Detector Wavelength: 224 nm (Lambda max)
Injection Volume: 300 µL
Sample Preparation: 10 mg dissolved in 0.5 mL MeCN (20 mg/mL);
17 mg dissolved in 0.5 mL MeCN (34 mg/mL)
[00266] Analytical chiral SFC chromatography (unless otherwise noted) was
performed on an Aurora Analytical SFC or Berger Analytical SFC using one of the
following methods:
Analytical chiral SFC method A:
Column: CHIRALCEL OD-H, 4.6 × 250mm ID, 5 μm
Flow rate: 3.0 mL/min, 100 bar BP, 35 °C.
Mobile Phase: 15% Methanol/85% CO
Detector Wavelength: 220 nm
Sample Solution: 1 mg/mL in methanol (concentrated/reconstituted)
Injection Volume: 10 μL
Analytical chiral SFC method B:
Column: CHIRALPAK IA 250 × 4.6 mm ID, 5µm
Flow rate: 2.0 mL/min
11841-PCT
Mobile Phase: 85/15/0.1, CO /IPA/DEA, 150 bar
Detector Wavelength: 225 nm (Lamda max)
Injection Volume: 10 µL
Analytical chiral SFC method C:
Column: CHIRALPAK IA 250 × 4.6 mm ID, 5 µm
Flow rate: 3.0 mL/min
Mobile Phase: 65/35/0.1, CO /MeOH/DEA, 150 bar
Detector Wavelength: 270 nm (Lambda max)
Injection Volume: 10 µL
Analytical chiral SFC method D:
Column: CHIRALCEL OD, 250 × 4.6 mm ID, 10 µm
Flow rate: 2.0 mL/min, 100 bar, 35 °C
Mobile Phase: 20% Methanol/80% CO
Detector Wavelength: 223 nm
Injection Volume: 10 µL
NMR EMPLOYED IN CHARACTERIZATION OF EXAMPLES
H NMR spectra (unless otherwise noted) were obtained with JEOL or Bruker
FOURIER transform spectrometers operating at 400 MHz or 500 MHz. H-nOe
experiments were performed in some cases for regiochemistry elucidation with a 400
MHz Bruker FOURIER Transform spectrometer.
Spectral data are reported as chemical shift (multiplicity, number of
hydrogens, coupling constants in Hz) and are reported in ppm (δ units) relative to either
an internal standard (tetramethyl silane = 0 ppm) for H NMR spectra, or are referenced
to the residual solvent peak (2.49 ppm for CD SOCD H, 3.30 ppm for CD HOD, 1.94
for CHD CN, 7.26 ppm for CHCl , 5.32 ppm for CDHCl ).
Microwave instrumentation employed in heating reactions.
BIOTAGE Initiator 2.5, maximum power 400 W, reaction volume range 0.2
- 10 mL. Reactions are run in sealed pressure vessels specially manufactured for this
instrument.
Example 1. 6-Methyloxophenylp-tolyl-1,2,5,6-tetrahydropyridinecarbonitrile
11841-PCT
A solution of heptanone (51 mg, 0.45 mmol), 1-p-tolylethanone (60 mg,
0.45 mmol), ethylcyanoacetate (51 mg, 0.45 mmol) and ammonium acetate (42 mg,
0.55 mmol) in anhydrous DMF (0.6 mL) was heated with stirring at 100 C for 16 h. The
reaction was diluted with EtOAc and washed with water. The solvent was removed in
vacuo and the product was purified by preparative HPLC (MeOH/H O/TFA) to provide
the desired product (8 mg, 6%) as a white solid. LCMS Anal. Calc'd for C H N O
19 24 2
297.41, found [M+H] 297.2. H NMR (500 MHz, CDCl ) δ 0.89 (t, J = 6.87 Hz, 3 H),
1.24 - 1.40 (m, 9 H), 1.51 - 1.71 (m, 2 H) 2.42 (s, 3 H), 2.73 - 2.97 (m, 2 H), 6.09 (s, 1 H),
7.30 (d, J = 7.70 Hz, 2 H), 7.52 (d, J = 7.70 Hz, 2 H).
Example 2. 3-(1H-Tetrazolyl)p-tolyl(4-(4,4,4-trifluorobutoxy)phenyl)
(trifluoromethyl)-5,6-dihydropyridin-2(1H)-one
Intermediate 2A. 4-(4,4,4-Trifluorobutoxy)benzaldehyde
F C O
To a solution of 4-hydroxybenzaldehyde (20 g, 164 mmol) and 4,4,4-
trifluorobutanol (25 g, 195 mmol) in anhydrous CH Cl (500 mL) at 0 °C under Ar
was added a solution of PPh (51.5 g, 196 mmol) in CH Cl (200 mL) over 15 min, and
3 2 2
11841-PCT
then DIAD (36.4 g, 180 mmol) in anhydrous CH Cl (150 mL) was added dropwise. The
mixture was stirred at 0 °C for 0.5 h. The reaction was warmed to rt and stirred for
another 3 h. The solvent was removed in vacuo and the residue was triturated with
CH Cl three times to remove insoluble solids. The combined CH Cl washings were
2 2 2 2
concentrated and the residue was purified by silica gel chromatography (330 g silica gel,
eluted with EtOAc in hexanes) to provide Intermediate 2A (27 g, 71%) as a light brown
oil. LCMS Anal. Calc'd for C H F O 232.20, found [M+H] 233.0.
11 11 3 2
Intermediate 2B. 2,2,2-Trifluoro(4-(4,4,4-trifluorobutoxy)phenyl)ethanol
F C O
To the solution of Intermediate 2A (26.7 g, 114 mmol) and
trimethyl(trifluoromethyl)silane (16.9 g, 119 mmol) in anhydrous DME (112 mL) was
added CsF (500 mg, 3.29 mmol). The reaction was stirred at rt for 16 h. To the mixture
was added 4 N aq HCl (114 mL) and the reaction was stirred at rt for 2.5 h. The reaction
was diluted with EtOAc (300 mL) and washed with water, sat'd aq NaHCO , sat'd aq
NaCl, dried over anhydrous MgSO , filtered and concentrated to provide Intermediate 2B
(42.5 g, 122%) as an oil. The crude product was used without further purification.
LCMS Anal. Calc'd for C H F O 302.21, found [M-H] 301.2.
12 12 6 2
Intermediate 2C. 2,2,2-Trifluoro(4-(4,4,4-trifluorobutoxy)phenyl)ethanone
F C O
To a solution of Intermediate 2B (115 mmol) in anhydrous CH Cl (320 mL)
was added Dess-Martin periodinane (50.2 g, 118 mmol) portionwise at 0 °C. The
reaction was stirred at 0 °C for 0.5 h then at rt for 3 h. To the reaction was added 100 mL
of sat'd aq Na CO and 250 mL of EtOAc. The reaction was stirred for another 2 h. The
insoluble material was removed by filtration. The layers were separated. The organic
layer was washed with sat'd aq Na2CO3. Additional solids that formed upon standing
overnight were removed. The organic solution was washed with sat'd aq NaCl, dried
11841-PCT
over anhydrous MgSO , filtered and concentrated to provide a dark brown liquid, which
was purified by silica gel chromatography (220 g silica gel, elute with EtOAc in hexanes
to provide Intermediate 2C (26 g, 76%) as a colorless oil.
Intermediate 2D. Triphenylphosphonium p-tolylcarbonylylide
To a refluxing solution of PPh (6.15 g, 23.47 mmol) in anhydrous THF (220
mL) under argon was added dropwise a solution of 2-bromop-tolylethanone (5 g,
23.47 mmol) in THF (60 mL). The reaction was refluxed for 2.5 h and then cooled to rt.
The precipitate was collected by filtration and rinsed with diethyl ether. The solids were
suspended in 1:1 MeOH and H O (500 mL), and then 2 N aq NaOH (55 mL) was added.
The reaction was stirred at rt for 16 h. MeOH was removed in vacuo and the aq solution
was extracted with CHCl . The combined organic extracts were washed with sat'd aq
NaCl, dried over anhydrous Na SO , filtered and concentrated to provide Intermediate 2D
(9 g, 97%) as a white solid. LCMS Anal. Calc'd for C H OP 394.44, found [M+H]
27 23
395.2.
Intermediate 2E. (Z)-4,4,4-Trifluorop-tolyl(4-(4,4,4-trifluorobutoxy)phenyl)but
enone
O CF
Intermediate 2D (5.13 g, 13 mmol) and Intermediate 2C (3.90 g, 13 mmol)
were suspended in DMSO (15 mL). The reaction was heated to 160 °C for 1000 s under
microwave conditions. The reaction was cooled to rt and diluted with EtOAc (60 mL).
The mixture was washed with water and sat'd aq NaCl, dried over anhydrous MgSO ,
filtered and concentrated. The crude product was purified by silica gel chromatography
11841-PCT
(120 g silica gel, elute with EtOAc in hexanes to provide Intermediate 2E (5.9 g, 98%) as
a light brown oil.
Intermediate 2F, isomer 1. (R)Amino-4,4,4-trifluorop-tolyl(4-(4,4,4-
trifluorobutoxy)phenyl)-butanone
O CF
Intermediate 2F, isomer 2. (S)Amino-4,4,4-trifluorop-tolyl(4-(4,4,4-
trifluorobutoxy)phenyl)-butanone
O CF
To a solution of Intermediate 2E (2.1 g, 5.04 mmol) in DMSO (50 mL) was
added 15 N aq NH OH (25 mL). The mixture was stirred in sealed pressure vessel for 2
days. The reaction was diluted with EtOAc (60 mL), washed with water and sat'd aq
NaCl, dried over anhydrous MgSO , filtered and concentrated. The residue was purified
by silica gel chromatography column (eluted with EtOAc in hexanes to provide racemic
Intermediate 2F (2.2 g, 101%) as a white solid. LCMS Anal. Calc'd for C H F NO
21 21 6 2
433.39, found [M+H] 434.2. Separation of the individual enantiomers of Intermediate 2F
was carried out using preparative chiral SFC method A: Racemic Intermediate 2F (2200
mg) provided Intermediate 2F, isomer 1 (817 mg) and Intermediate 2F, isomer 2 (790
mg). Enantiomeric purity determination of Intermediate 2F, isomer 1 and 2 was carried
out using analytical SFC method A. Intermediate 2F, isomer 1: RT = 2.2 min, 99% ee.
Intermediate 2F, isomer 2: RT = 2.8 min, 99% ee. X-ray crystal data collected for the
camphorsulfonic acid salt of Intermediate 2F, isomer 1 showed the chiral center to have
11841-PCT
the R-configuration; therefore, the chiral center for Intermediate 2F, isomer 2 has the S-
configuration.
Intermediate 2G. 2-(1H-Tetrazolyl)-N-(1,1,1-trifluorooxop-tolyl(4-(4,4,4-
trifluorobutoxy)-phenyl)butanyl)acetamide
O CF
To a solution of Intermediate 2F (789 mg, 1.82 mmol) in anhydrous THF (9
ml) at 0 °C was added DCC (1.13 g, 5.46 mmol). 2-Tetrazole acetic acid (700 mg, 5.46
mmol) was added dropwise as a suspension in anhydrous THF (8 mL). The reaction was
stirred at 0 °C for 1 h and then at rt overnight. The reaction was filtered and solids were
rinsed with THF. The filtrate was diluted with EtOAc (40 mL), washed with sat’d
Na CO and sat'd aq NaCl, dried over anhydrous MgSO , filtered and concentrated to
2 3 4
provide Intermediate 2G (1.5 g, 152%) as a reddish brown solid. Intermediate 2G was
used in the next step without further purification. LCMS Anal. Calc'd for C H F N O
24 23 6 5 3
543.46, found [M+H] 543.9.
Example 2
To a solution of Intermediate 2G (1.5 g) in EtOH (11 mL) was added
piperidine (0.33 mL). The reaction was heated to 78 °C for 16 h in a sealed vial. The
reaction was cooled to rt and the solvent was removed in vacuo. The residue was purified
by preparative HPLC (MeOH/H O/TFA). Fractions containing the product were dried in
vacuo and the product was re-dissolved in MeOH and concentrated again. The oily
brown product was re-dissolved in CH Cl (5 mL) and concentrated in vacuo to provide
Example 2 (552 mg, 57% over 2 steps) as a reddish foam. LCMS Anal. Calc'd for
C H F N O 525.45, found [M+H] 526.2. H NMR (500 MHz, CD OD) δ 7.61 (d, J =
24 21 6 5 2
9.1 Hz, 2H), 7.11 (d, J = 8.0 Hz, 2H), 7.07 - 7.01 (m, 2H), 6.90 (d, J = 8.3 Hz, 2H), 4.10
11841-PCT
(t, J = 6.1 Hz, 2H), 3.84 - 3.64 (m, 2H), 2.48 - 2.35 (m, 2H), 2.30 (s, 3H), 2.14 - 2.00 (m,
2H).
Example 2-1. (S)(1H-Tetrazolyl)p-tolyl(4-(4,4,4-trifluorobutoxy)phenyl)
(trifluoromethyl)-5,6-dihydropyridin-2(1H)-one
Separation of the individual enantiomers of Example 2 was carried out using
preparative chiral SFC method C: Racemic Example 2 (89 mg) provided Example 2-1
(21 mg). Enantiomeric purity determination of Example 2-1 was carried out using
analytical SFC method C. RT = 6.0 min, 99% ee.
Example 2-1 can be alternatively obtained from Intermediate 2F, isomer 2
using a sequence similar to one used for the conversion of Intermediate 2F to Example 2.
Example 2-2. (R)(1H-Tetrazolyl)p-tolyl(4-(4,4,4-trifluorobutoxy)phenyl)
(trifluoromethyl)-5,6-dihydropyridin-2(1H)-one
Separation of the individual enantiomers of Example 2 was carried out using
preparative chiral SFC method C: Racemic Example 2 (89 mg) provided Example 2-2
(22 mg). Enantiomeric purity determination of Example 2-2 was carried out using
analytical SFC method C. RT = 15.1 min, 99% ee.
Example 2-2 can be alternatively obtained from Intermediate 2F, isomer 1
using a sequence similar to one used for the conversion of Intermediate 2F to Example 2.
11841-PCT
Example 3. 6-(4-Bromophenyl)oxop-tolyl(trifluoromethyl)-1,2,5,6-
tetrahydropyridinecarbonitrile
Intermediate 3A. (Z)(4-Bromophenyl)-4,4,4-trifluorop-tolylbutenone
Intermediate 2D (1.84 g, 4.74 mmol) and 1-(4-bromophenyl)-2,2,2-
trifluoroethanone (1.2 g, 4.74 mmol) were dissolved in THF (8 mL) and heated to 150 °C
for 1000 s under microwave conditions. The reaction was cooled to rt and the solvent
was removed in vacuo. The residue was purified by silica gel chromatography (24 g
silica gel, elute with EtOAc in hexanes) to yield Intermediate 3A (1.51 g, 86%) as a light
brown solid. LCMS Anal. Calc'd for C H BrF O 369.18, found [M+H] 371.0.
17 12 3
Intermediate 3B. 3-Amino(4-bromophenyl)-4,4,4-trifluorop-tolylbutanone
To a solution of Intermediate 3A (1.53 g, 4.14 mmol) in DMSO (23 mL) was
added 15 N aq NH OH (10 mL). The reaction vessel was sealed and the reaction was
stirred at rt for 16 h. Additional DMSO (3 mL) and 15 N aq NH OH (1 mL) were added
11841-PCT
and the reaction was stirred at rt for 16 h. Addition of DMSO (4 mL) was repeated and
the reaction was stirred for another 16 h. The solution was concentrated in vacuo
followed by lyophilization to provide Intermediate 3B (1.8 g, 100%) as a brown oil.
LCMS Anal. Calc'd for C H BrF NO 386.21, found [M+H] 388.1.
17 15 3
Intermediate 3C. 2-Cyanoacetyl chloride
To a mixture of 2-cyanoacetic acid (893 mg, 10.5 mmol) and DMF (16 µL) in
anhydrous CH Cl (20 mL) at 0 C was added dropwise a 2 M solution of oxalyl chloride
(6 mL, 12 mmol) in CH Cl . The reaction was stirred at 0 °C for 20 min, and then
warmed to rt and stirred for 2 h. The solvent was removed in vacuo to provide
Intermediate 3C, which was used in the next reaction without purification.
Example 3
[00287] To a solution of Intermediate 3B (1.6 g, 4.1 mmol) in anhydrous CH Cl (15
mL) at 0 °C was added a solution of Intermediate 3C (1.1 g, 10.5 mmol), pyridine (0.85
mL), and DMAP (20 mg) in anhydrous CH Cl (5 mL),. The reaction was stirred at 0 °C
for 20 min, then at rt for 2.5 h. The solvent was removed in vacuo. The crude product
was dissolved in EtOAc (30 mL), washed with sat'd aq Na CO and sat'd aq NaCl, dried
over anhydrous Na SO , filtered and concentrated to yield a brown solid. The solid was
triturated with CH Cl /diethyl ether to provide Example 3 (1.27 g) as an off white solid.
The supernatant was evaporated and the residue was purified by silica gel
chromatography (eluted with EtOAc in hexanes) to provide a second batch of Example 3
(0.22 g). The combined yield was 1.49 g (80%). LCMS Anal. Calc'd for C H BrF N O
14 3 2
435.24, found [M+H] 437.0. H NMR (500 MHz, CDCl ) δ 2.42 (s, 3 H), 3.45 - 3.67 (m,
2 H), 7.30 (d, J = 7.70 Hz, 2 H), 7.39 (d, J = 8.25 Hz, 2 H), 7.45 (d, J = 7.70 Hz, 2 H),
7.60 (d, J = 8.80 Hz, 2 H).
Example 4. 6-(4-Hydroxyphenyl)oxop-tolyl(trifluoromethyl)-1,2,5,6-tetrahydro-
pyridinecarbonitrile
11841-PCT
Example 3 (1.49 g, 3.42 mmol), Pd dba (78 mg, 0.086 mmol), KOH (403
mg, 7.2 mmol) and bis(1,1-dimethylethyl)[2′,4′,6′-tris(1-methylethyl)[1,1′-biphenyl]
yl]- phosphine (73 mg, 0.17 mmol) were placed in a microwave vial. The vial was
evacuated and back filled with Ar. 1,4-Dioxane (23 mL) and water (13 mL) were added
to the vial and the reaction mixture was heated to 140 °C for 15 min under microwave
conditions. The reaction was cooled to rt, neutralized with 1 N HCl, diluted with water,
and extracted with EtOAc. The combined organic extracts were washed with water and
sat'd aq NaCl, dried over anhydrous Na SO , filtered and concentrated. The residue was
purified by silica gel chromatography to provide Example 4 (1.14 g, 85%) as a light
brown solid. LCMS Anal. Calc'd for C H F N O 372.34, found [M+H] 373.2. H
15 3 2 2
NMR (500 MHz, DMSO-d ) δ 2.30 (s, 3 H), 3.65 (q, J = 18.15 Hz, 2 H), 6.73 (d, J = 8.25
Hz, 2 H), 7.28 (d, J = 8.25 Hz, 2 H), 7.38 (d, J = 8.80 Hz, 2 H), 7.47 (d, J = 8.25 Hz, 2
H), 9.63 (s, 1 H), 9.70 (s, 1 H).
Example 5. 6-(4-Butoxyphenyl)oxop-tolyl(trifluoromethyl)-1,2,5,6-
tetrahydropyridinecarbonitrile
To a solution of Example 4 (20 mg, 0.054 mmol) and n-butanol (6 mg, 0.081
mmol) in anhydrous CH Cl (0.3 mL) under Ar was added sequentially
triphenylphosphine (21 mg, 0.081 mmol) in CH Cl (0.3 mL) and DEAD (14 mg, 0.081
mmol) in CH Cl (0.3 mL). The reaction mixture was stirred at 0 °C under argon for 20
min, then at rt for 2 h. The solvent was evaporated in vacuo and the product was purified
11841-PCT
by preparative HPLC (CH CN/H O/TFA) to provide Example 5 (5.6 mg, 24%). LCMS
Anal. Calc'd for C H F N O 428.45, found [M+H] 429.3. H NMR (500 MHz,
24 23 3 2 2
CDCl ) δ 0.98 (t, J = 7.42 Hz, 3 H), 1.41 - 1.56 (m, 2 H), 1.73 - 1.84 (m, 2 H), 2.41 (s, 3
H), 3.56 (q, J = 18.15 Hz, 2 H), 3.92-4.03 (m, 2 H), 6.94 (d, J = 8.25 Hz, 3 H), 7.29 (d, J
= 8.25 Hz, 2 H), 7.37 (d, J = 8.80 Hz, 2 H), 7.45 (d, J = 7.70 Hz, 2 H).
Example 6. N-(4-Methoxyphenyl)oxop-tolyl(4-(4,4,4-trifluorobutoxy)phenyl)
(trifluoro-methyl)-1,2,5,6-tetrahydropyridinecarboxamide
Intermediate 6A. Benzyl 3-(4-(methylamino)phenylamino)oxopropanoate
O O CH
To a solution of monobenzyl malonate (12.2 g, 63.1 mmol) and DMF (90 µL)
in anhydrous CH Cl (100 mL) at 0 °C was added 2 M oxalyl chloride (35 mL, 70 mmol)
in CH Cl . The reaction was stirred at 0 °C for 30 min, then at rt for 2.5 h. The solvent
was removed in vacuo to provide freshly prepared acid chloride. This was dissolved in
anhydrous CH Cl (50 mL) and added dropwise to a solution of 4-methoxyaniline (7.76
g, 63 mmol) in anhydrous CH Cl (50 mL) at 0 °C followed by the addition of pyridine
(5.35 mL, 66.2 mmol). The reaction was stirred at 0 °C for 0.5 h, then at rt overnight.
The reaction was washed with water and sat'd aq NaCl, dried over anhydrous MgSO ,
filtered and concentrated. The residue was triturated with EtOAc/ CH Cl to yield the
first batch of Intermediate 6A as a light brown solid (6.95 g). The supernatant was
evaporated and the residue was purified by silica gel chromatography (eluted with EtOAc
in hexanes) to provide a second batch of Intermediate 6A as a light brown solid (7.4 g).
11841-PCT
The combined yield was 14.4 g (76%). LCMS Anal. Calc'd for C H N O 298.34,
17 18 2 3
found [M+H] 300.2.
Intermediate 6B. 3-(4-Methoxyphenylamino)oxopropanoic acid
H C O O
N OH
To a solution of Intermediate 6A (14.4 g, 4.8 mmol) in 10:1 EtOAc/MeOH
(220 mL) was added 10% Pd/C (250 mg). The reaction mixture was stirred vigorously
under an atmosphere of hydrogen (40 psi) for 2 h. More 10% Pd/C (250 mg) was added
and the reaction was stirred under 50 psi hydrogen for another 1 h. Additional 10% Pd/C
(500 mg) was added and the reaction was stirred under 50 psi hydrogen for an additional
1 h. The reaction was filtered through a pad of Celite and the filtrate was concentrated
in vacuo to yield Intermediate 6B (11.1 g, 96%) as an off-white solid. LCMS Anal.
Calc'd for C10H11NO4 209.20, found [M+H] 210.1.
Intermediate 6C. N -(4-Methoxyphenyl)-N -(1,1,1-trifluorooxop-tolyl(4-(4,4,4-
trifluoro-butoxy)phenyl)-butanyl)malonamide
O CF
O CH
HN O
To triphenylphosphine (8.42 g, 32.1 mmol) in anhydrous CH Cl (70 mL) was
added Intermediate 6B (2.24 g, 10.7 mmol) in anhydrous CH Cl (30 mL) followed by
trichloroacetonitrile (1.86 g, 12.8 mmol). The mixture was stirred at rt for 3 h. The
freshly prepared acid chloride was added to a solution of Intermediate 2F (1.13 g, 2.61
mmol) in anhydrous CH Cl (20 mL), followed by the addition of pyridine (1.04 mL,
1.02 g, 12.85 mmol). The reaction was stirred at rt under argon overnight. The reaction
was cooled to 0 °C and MeOH (40 mL) was added. The reaction was stirred at 0 °C for
11841-PCT
min, then at rt for 30 min. The solvent was removed in vacuo and the crude product
was purified by silica gel chromatography (120 g silica gel, eluted with EtOAc in
hexanes). Product and triphenylphosphine oxide co-eluted. Fractions containing both
were combined and evaporated to dryness. The solids were triturated with
hexanes/EtOAc to remove most of the triphenylphosphine oxide. The product was again
purified by silica gel chromatography (40 g silica gel, eluted with EtOAc in hexanes) to
provide Intermediate 6C (1.03 g, 63%) as a brown oil. LCMS Anal. Calc'd for
C H F N O 624.57, found [M+H] 625.3.
31 30 6 2 5
Example 6
To a solution of Intermediate 6C (1.03 g, 1.65 mmol) in MeOH (10 mL) was
added piperidine (100 µL, 1.01 mmol). The reaction was stirred at 75 °C for 1 h. The
solvent was removed in vacuo and the crude product was purified by silica gel
chromatography (120 g silica gel, eluted with EtOAc in hexanes). Mixed fractions from
the first column were purified again by silica gel chromatography (40 g silica gel, eluted
with EtOAc in hexanes) to provide Example 6 (546 mg, 55%) as a off-white solid.
LCMS Anal. Calc'd for C H F N O 606.56, found [M+H] 607.3. H NMR (500 MHz,
31 28 6 2 4
CD OD) δ 1.97-2.08 (m, 2 H), 2.30 (s, 3 H), 2.32-2.44 (m, 2 H), 3.45-3.67 (m, 2 H), 3.72
(s, 3 H), 4.06 (t, J = 6.05 Hz, 2 H), 6.77 (d, J = 9.35 Hz, 2 H), 6.97 (d, J = 8.80 Hz, 2 H),
7.13-7.24 (m, 4 H), 7.28 (d, J = 8.25 Hz, 2 H), 7.52 (d, J = 8.80 Hz, 2 H).
Example 6-1. (R)-N-(4-Methoxyphenyl)oxop-tolyl(4-(4,4,4-
trifluorobutoxy)phenyl)(trifluoro-methyl)-1,2,5,6-tetrahydropyridinecarboxamide
[00294] Example 6-1 was prepared using a procedure analogous to Example 6 by
replacing Intermediate 2F with Intermediate 2F, isomer 1.
11841-PCT
Example 6-2. (S)-N-(4-Methoxyphenyl)oxop-tolyl(4-(4,4,4-
trifluorobutoxy)phenyl)(trifluoro-methyl)-1,2,5,6-tetrahydropyridinecarboxamide
Example 6-2 was prepared using a procedure analogous to Example 6 by
replacing Intermediate 2F with Intermediate 2F, isomer 2.
Example 7. 6-(4-(6-Ethoxypyridinyl)phenyl)oxop-tolyl(trifluoromethyl)-
1,2,5,6-tetrahydropyridinecarbonitrile
[00296] To a solution of Example 3 (20 mg, 0.046 mmol), 6-ethoxypyridinyl
boronic acid (11 mg, 0.07 mmol) and tetrakis(triphenylphosphine) palladium(0) (5 mg, 10
mol%) in DMF (0.6 mL) sparged with Ar was added 2 N aq K CO (46 µL, 0.096 mmol).
The vessel was sealed and the reaction heated to 80 °C for 22 h. The reaction was cooled
to rt and the product was purified twice by preparative HPLC (CH CN/H O/TFA and
CH OH/H O/TFA sequentially) to provide Example 7 (10 mg, 45%) as a light brown
solid. LCMS Anal. Calc'd for C H F N O 477.48, found [M+H] 478.3. H NMR (500
27 22 3 3 2
MHz, CD OD) δ 1.40 (t, J = 6.87 Hz, 3 H), 2.40 (s, 3 H), 3.71 - 3.88 (m, 2 H), 4.37 (q, J
= 7.15 Hz, 2 H), 6.94 (d, J = 8.25 Hz, 1 H), 7.33 (d, J = 7.70 Hz, 2 H), 7.54 (d, J = 8.25
Hz, 2 H), 7.66 - 7.78 (m, 4 H), 8.05 (dd, J = 8.80, 2.20 Hz, 1 H), 8.42 (d, J = 2.20 Hz, 1
H).
Example 8. (S)(2H-Tetrazolyl)p-tolyl(4-(6,6,6-trifluorohexyloxy)phenyl)
(trifluoromethyl)-5,6-dihydropyridin-2(1H)-one
11841-PCT
Intermediate 8A. 4-(6,6,6-Trifluorohexyloxy)benzaldehyde
[00297] To a suspension of 4-hydroxybenzaldehyde (488 mg, 4 mmol) and 6-bromo-
1,1,1-trifluorohexane (657 mg, 3 mmol) in MeCN (10 mL) was added K CO (829 mg,
6.00 mmol). The resulting mixture was reflux overnight. Insoluble material was filtered
off and rinsed with MeCN. The combined filtrate was concentrated to afford a white
solid. This white solid was partitioned between EtOAc and 1 N NaOH solution. The
organic layer was separated, washed with sat’d NH Cl, dried over MgSO , filtered and
concentrated to afford Intermediate 8A as a clear liquid. LCMS Anal. Calc’d for
C H F O 260.10, found [M+H] 261.0.
13 15 3 2
Intermediate 8B. 2,2,2-Trifluoro(4-(6,6,6-trifluorohexyloxy)phenyl)ethanone
Intermediate 8B was prepared using a procedure analogous to Intermediate 2C
except that Intermediate 2A was replaced with Intermediate 8A. H NMR (500 MHz,
CDCl ) δ 8.06 - 8.02 (m, 2 H), 6.99 - 6.97 (m, 1 H), 4.08 (t, J = 6.2 Hz, 2 H), 2.19 - 2.06
(m, 2 H), 1.92 - 1.82 (m, 2 H), 1.71 - 1.55 (m, 4 H).
Intermediate 8C. (S,E)Methyl-N-(2,2,2-trifluoro(4-(6,6,6-
trifluorohexyloxy)phenyl)ethylidene)propanesulfinamide
11841-PCT
To a solution of Intermediate 8B (717 mg, 2.184 mmol) and (S)
methylpropanesulfinamide (529 mg, 4.37 mmol) in THF (10 mL) was added
tetraethoxytitanium (1993 mg, 8.74 mmol) in THF (20 mL). The resulting mixture was
reflux for 5 h. TLC (20% EtOAc in hexane) indicated the starting ketone was completely
consumed. The solvent was evaporated to afford a yellow oil. This yellow oil was
dissolved in EtOAc and then washed with saturated NaHCO (25 mL) and a large amount
of white precipitation formed which was removed by filtering through a bed of Celite®.
The white precipitation was rinsed with EtOAc. The combined EtOAc solution was
washed again with saturated NaHCO , dried (MgSO ) and concentrated. The crude
product was purified by silica gel chromatography (40 g silica gel, eluted with EtOAc in
hexanes) to afford Intermediate 8C (620 mg, 66%).
Intermediate 8D. (S)Methyl-N-((S)-1,1,1-trifluorooxop-tolyl(4-(6,6,6-
trifluorohexyloxy)phenyl)butanyl)propanesulfinamide
To a solution of 1-(p-tolyl)ethanone (609 mg, 4.31 mmol) in THF (10 mL)
was cooled to -78 °C and to this solution was added lithium bis(trimethylsilyl)amide
(4.31 mL, 4.31 mmol). The resulting mixture was stirred at -78 °C for 20 min and then
Intermediate 8C (620 mg, 1.437 mmol) in THF (3 mL) was added dropwise. The
resulting mixture was stirred at -78 °C for 1.5 h and then at 0 °C for 1.5 h. The reaction
was quenched with NH Cl and concentrated. The crude product was purified by silica gel
chromatography (80 g silica gel, eluted with EtOAc in hexanes) to afford Intermediate 8D
11841-PCT
(482 mg, 59%) as the slower eluting diastereomer on silica gel column. LCMS Anal.
Calc’d for C H F NO S 565.21, found [M+H] 566.0.
27 33 6 3
Intermediate 8E. (S)Amino-4,4,4-trifluorop-tolyl(4-(6,6,6-
trifluorohexyloxy)phenyl)butanone
To a solution of Intermediate 8D (482 mg, 0.852 mmol) in MeOH (4 mL) was
added 4 M HCl (1 mL, 4.00 mmol) in dioxane. The resulting mixture was stirred at rt for
2 h and then concentrated. The residue was taken up in EtOAc, washed with saturated
NaHCO and brine, dried (MgSO ), filtered and concentrated to afford Intermediate (386
mg, 58%) as a colorless oil, which was used for the subsequent reaction without further
purification. LCMS Anal. Calc’d for C H F NO 461.18, found [M+H] 461.9.
23 25 6 2
Example 8
[00302] To a solution of Intermediate 8E (140 mg, 0.303 mmol) and 2-(2H-tetrazol
yl)acetic acid (117 mg, 0.910 mmol) in THF (3 mL) at 0 °C was added DCC (188 mg,
0.910 mmol). The resulting mixture was stirred overnight. The solvent was evaporated
and the crude mixture was taken up in EtOAc. The organic solution was washed with
saturated NaHCO , 1 N HCl and brine, dried (MgSO ), filtered and concentrated to afford
a brown oil. This oil was dissolved in EtOH (3 mL) and added piperidine (300 µL, 3.03
mmol). The resulting mixture was stirred at 80 °C overnight. The reaction mixture was
diluted with MeOH and purified by preparative HPLC (MeCN/H O/TFA) to yield
Example 8 (86 mg, 51%) as a solid. LCMS Anal. Calc’d for C26H25F6N5O2 553.19,
found [M+H] 554.0. H NMR (500 MHz, CDCl ) δ 7.46 (d, J = 8.8 Hz, 2 H), 7.19 (d, J
= 8.0 Hz, 3 H), 7.02 - 6.93 (m, 4 H), 3.99 (t, J = 6.3 Hz, 2 H), 3.68 - 3.56 (m, 2 H), 2.39
(s, 3 H), 2.19 - 2.07 (m, 2 H), 1.89 - 1.79 (m, 2 H), 1.71 - 1.63 (m, 2 H), 1.62 - 1.53 (m, 2
11841-PCT
Example 9. 3-(2-Ethyl-2H-tetrazolyl)p-tolyl(4-(4,4,4-trifluorobutoxy)phenyl)
(trifluoromethyl)-5,6-dihydropyridin-2(1H)-one
To Example 2 (30 mg, 0.057 mmol) in anhydrous CH Cl (0.6 mL) was added
iodoethane (9 mg, 0.057 mmol) and triethylamine (24 µL, 0.17 mmol). The reaction was
heated to 120 °C for 10 min under microwave conditions. The solvent was evaporated in
vacuo and the residue was purified by preparative HPLC (CH CN/H O/TFA) to provide
Example 9 (2.3 mg, 7%) as a light brown solid. LCMS Anal. Calc'd for C H F N O
26 25 6 5 2
553.50, found [M+H] 554.3. H NMR (500 MHz, CDCl3) δ 1.51 (t, J = 7.42 Hz, 2 H),
1.98 - 2.13 (m, 2 H), 2.21 - 2.39 (m, 5 H), 3.51 (d, J = 17.60 Hz, 1 H), 3.72 (d, J = 17.60
Hz, 1 H), 4.04 (t, J = 6.05 Hz, 2 H), 4.56 (q, J = 7.52 Hz, 2 H) 6.87 (d, J = 8.25 Hz, 2 H),
6.95 (d, J = 8.80 Hz, 2 H), 7.02 (d, J = 8.25 Hz, 2 H), 7.46 (d, J = 8.80 Hz, 2 H), 7.93 (s,
1 H).
Example 10. 4-p-Tolyl(4-(4,4,4-trifluorobutoxy)phenyl)(trifluoromethyl)(5-
(trifluoromethyl)-1,3,4-oxadiazolyl)-5,6-dihydropyridin-2(1H)-one
To Example 2 (29 mg, 0.055 mmol) in anhydrous CH Cl (0.3 mL) was added
a solution of trifluoroacetic anhydride (23.2 mg, 0.11 mmol) in anhydrous CH Cl (0.2
mL) dropwise. The mixture was stirred at rt for 4 h and then concentrated. The residue
was purified by preparative HPLC to provide Example 10 (19 mg, 58%) as a white solid.
LCMS Anal. Calc'd for C H F N O 593.44, found [M+H] 594.2. H NMR (500 MHz,
26 20 9 3 3
11841-PCT
CD OD) δ 1.97 - 2.11 (m, 2 H), 2.31 (s, 3 H), 2.34 - 2.44 (m, 2 H), 3.64 - 3.88 (m, 2 H),
4.08 (t, J = 6.05 Hz, 2 H), 6.98 (d, J = 8.25 Hz, 2 H), 7.03 (d, J = 8.80 Hz, 2 H), 7.16 (d, J
= 8.25 Hz, 2 H), 7.57 (d, J = 8.80 Hz, 2 H).
Example 11. 6-Methyloxop-tolyl(4-(4,4,4-trifluorobutoxy)phenyl)-N-(4-
(trifluoromethoxy)-phenyl)-1,2,5,6-tetrahydropyridinecarboxamide
O CF
Intermediate 11A. 1-Bromo(4,4,4-trifluorobutoxy)benzene
F C O
To a solution of 4-bromophenol (2.2 g, 12.7 mmol) and 4-bromo-1,1,1-
trifluorobutane (2.4 g, 12.7 mmol) in anhydrous DMF (15 mL) was added K CO (3.5 g,
.4 mmol). The mixture was stirred at rt overnight. The mixture was diluted with
EtOAc (120 mL) and the solids were removed by filtration. The filtrate was washed with
water and sat'd aq NaCl, dried over anhydrous MgSO , filtered and concentrated. The
residue was purified by silica gel chromatography (40 g silica gel, eluted with EtOAc in
hexanes) to provide Intermediate 11A (3.05 g, 85%) as a colorless oil.
Intermediate 11B. (E)-Ethyl 3-(4-(4,4,4-trifluorobutoxy)phenyl)butenoate
F C O
Intermediate 11A (2.81 g, 9.93 mmol), (E)-ethyl butenoate (1.25 g, 10.9
mmol), palladium(II) acetate (0.11 g, 0.5 mmol), tetraethylammonium chloride (1.65 g,
11841-PCT
9.9 mmol), N-cyclohexyl-N-methylcyclohexanamine (2.91 g, 14.9 mmol) and
dimethylacetamide (30 ml) were placed in a oven-dried vial and sparged with argon for 5
min. The vial was sealed and the reaction heated to 110 °C for 6 h. The reaction was
cooled to rt, diluted with EtOAc (75 mL), washed with water and sat'd aq NaCl, dried
over anhydrous MgSO , filtered and concentrated. The residue was purified by silica gel
chromatography eluting with EtOAc in hexanes to provide Intermediate 11B (1.81 g,
49%) as a colorless oil. LCMS Anal. Calc'd for C H F O 316.32, found [M+H] 317.2.
16 19 3 3
Intermediate 11C. (E)-N-Methoxy-N-methyl(4-(4,4,4-trifluorobutoxy)phenyl)but
enamide
N CH
F C O
A solution of Intermediate 11B (2.67 g, 8.44 mmol) and N,O-
dimethylhydroxylamine hydrochloride (1.65 g, 16.9 mmol) in anhydrous THF (35 mL)
was cooled to -61°C (CHCl /dry ice) under an atmosphere of Ar. To this solution was
added 0.5 M isopropylmagnesium chloride (16.9 mL, 33.8 mmol) in THF slowly via a
syringe. The reaction was stirred at -61 °C for 1.5 h, warmed to -20 °C (sat'd aq
NaCl/ice) and stirred for 40 min, then warmed to 0 °C and stirred for 20 min. The
reaction was poured into 10 mL of sat'd aq NH Cl and 12 mL of water, and then extracted
with EtOAc. The organic layer was washed with sat'd aq NaCl, dried over anhydrous
MgSO , filtered and concentrated. The residue was purified by silica gel chromatography
eluting with EtOAc in hexanes to provide Intermediate 11C (1.62 g, 58%) as a light
brown oil. LCMS Anal. Calc'd for C H F NO 331.33, found [M+H] 332.2.
16 20 3 3
Intermediate 11D. (E)p-Tolyl(4-(4,4,4-trifluorobutoxy)phenyl)butenone
O CF
11841-PCT
To a solution of Intermediate11C (1.62 g, 4.89 mmol) in anhydrous THF (25
mL) at -78 °C was added dropwise 0.5 M p-tolylmagnesium bromide in ether (25 mL,
12.5 mmol). The reaction was stirred at -78 °C for 40 min, then gradually warmed to rt.
The reaction was poured into 1:1 sat'd aq NH Cl and water (60 mL). The mixture was
extracted with EtOAc. The organic layer was washed with sat'd aq NaCl, dried over
MgSO , filtered and concentrated. The residue was purified by silica gel chromatography
(eluted with EtOAc in hexanes) to provide Intermediate 11D (1.34 g, 76%) as a light
brown solid. LCMS Anal. Calc'd for C H F O 362.39, found [M+H] 363.2. H NMR
21 21 3 2
(500 MHz, CDCl ) δ 2.01 - 2.11 (m, 2 H), 2.29 - 2.37 (m, 2 H), 2.42 (s, 3 H), 2.58 (s, 3
H), 4.07 (t, J = 6.05 Hz, 2 H), 6.92 (d, J = 8.80 Hz, 2 H), 7.14 (s, 1 H), 7.23 - 7.34 (m, J =
8.25 Hz, 2 H), 7.55 (d, J = 8.80 Hz, 2 H), 7.90 (d, J = 8.25 Hz, 2 H).
Intermediate 11E. 3-Aminop-tolyl(4-(4,4,4-trifluorobutoxy)phenyl)butanone
H C NH
H C O CF
[00309] Ammonia was bubble into a solution of Intermediate 11D (1.34 mg, 0.64
mmol) in EtOH (20 mL) and DMSO (12 mL) for 10 min at 0 °C. The reaction was stirred
at rt overnight in a sealed pressure vessel. Analytical HPLC showed reaction to have
progressed only ca. 10%. The mixture was cooled to -15 °C, then ammonia was bubbled
through for 7 min. The vessel was sealed and the reaction was stirred at rt overnight.
Analytical HPLC showed the reaction to be ca. 25-30% complete. The mixture was
diluted with EtOAc (75 mL), washed with water and sat'd aq NaCl, dried over anhydrous
MgSO , filtered and concentrated in vacuo. The residue was purified by silica gel
chromatography to provide Intermediate11E (281 mg, 20%) as a light brown oil. LCMS
Anal. Calc'd for C H F NO 379.42, found [M+H] 380.3.
21 24 3 2
Intermediate 11F. 3-Oxo(4-(trifluoromethoxy)phenylamino)propanoic acid
F C O O
N OH
11841-PCT
By sequential application of the procedures for Intermediates 6A and 6B, 4-
trifluoromethoxyaniline (2.3 g, 13 mmol) was converted to Intermediate 11F (2.8 g, 11
mmol), which was isolated as a white solid. LCMS Anal. Calc'd for C H F NO 263.17,
8 3 4
found [M+H] 264.1.
Intermediate 11G. N -(4-Oxop-tolyl(4-(4,4,4-trifluorobutoxy)phenyl)butanyl)-
N -(4-(trifluoromethoxy)-phenyl)malonamide
O CF
O CF
HN O
To a solution of Intermediate 11F (41.6 mg, 0.158 mmol) in anhydrous
CH Cl (0.6 mL) was added PPh (124 mg, 0.474 mmol) followed by dropwise addition
2 2 3
of trichloroacetonitrile (27.4 mg, 0.19 mmol). The reaction was stirred at rt for 3 h. To
the freshly prepared acid chloride was added a solution of Intermediate 11E (20 mg,
0.053 mmol) in anhydrous CH Cl (0.3 mL) followed by pyridine (19 μL, 0.237 mmol).
The mixture was stirred at rt overnight. The solvent was removed in vacuo. The product
was purified by preparative HPLC (MeOH/H O/TFA) to yield Intermediate 11G (11 mg,
33%) as a brown solid. LCMS Anal. Calc'd for C H F N O 624.57, found [M+H]
31 30 6 2 5
625.4.
Example 11
[00312] To a solution of Intermediate 11G (11 mg, 0.018 mmol) in MeOH (0.8 ml)
was added piperidine (15 μL). The reaction was stirred at 75 °C for 1.5 h. The product
was isolated by preparative HPLC (CH CN/H O/TFA) to provide Example 11 (5.2 mg,
44%) as a brown solid. LCMS Anal. Calc'd for C H F N O 606.56, found [M+H]
31 28 6 2 4
607.4. H NMR (500 MHz, CD OD) δ 1.68 (s, 3 H), 1.95 - 2.07 (m, 2 H), 2.27 (s, 3 H),
2.30 - 2.41 (m, 2 H), 3.11 - 3.26 (m, 2 H), 4.03 (t, J = 6.05 Hz, 2 H), 6.91 (d, J = 8.80 Hz,
11841-PCT
2 H), 7.08 - 7.18 (m, 4 H), 7.22 (d, J = 8.25 Hz, 2 H), 7.38 (d, J = 8.80 Hz, 2 H), 7.45 (d,
J = 8.80 Hz, 2 H).
Example 12. 3-(2H-Tetrazolyl)p-tolyl(trifluoromethyl)(1-(5,5,5-
trifluoropentyl)-1H-pyrazolyl)-5,6-dihydropyridin-2(1H)-one
Intermediate 12A. 4-Iodo(5,5,5-trifluoropentyl)-1H-pyrazole
[00313] To a stirred solution of 4-iodo-1H-pyrazole (337 mg, 1.737 mmol) in DMF
(10 mL) was added sodium hydride (104 mg, 2.61 mmol). After 30 min, 5-bromo-1,1,1-
trifluoropentane (427 mg, 2.085 mmol) was added. The reaction was stirred at rt for 2 h.
3:1 hexane:ether and water were added. The organic layer was washed with H2O, dried
over MgSO , filtered and concentrated in vacuo. The crude product was purified by
silica gel chromatography (24 g silica gel, eluted with 0-60% EtOAc in hexanes) to give
the desired product (460 mg, 83%) as clear oil. LCMS Anal. Calc’d for C H F IN
8 10 3 2
318.0, found [M+H] 319.0. H NMR (400 MHz, CDCl ) δ 7.49 (s, 1 H), 7.40 (s, 1 H),
4.12 (t, J = 6.9 Hz, 2 H), 2.00 - 2.15 (m, 2 H), 1.85 - 1.96 (m, 2 H), 1.47 - 1.61 (m, 2 H).
Intermediate 12B. 2,2,2-Trifluoro(1-(5,5,5-trifluoropentyl)-1H-pyrazolyl)ethanone
To a stirred solution of Intermediate 12A (460 mg, 1.446 mmol) in
tetrahydrofuran (5 mL) at 0 °C was added isopropylmagnesium chloride (0.795 mL,
1.591 mmol) quickly. After 30 min, additional 0.25 eq of iPrMgCl was added and after
11841-PCT
30min, the mixure was cooled to -78 °C. 2,2,2-Trifluoro(piperidinyl)ethanone (288
mg, 1.591 mmol) was added quickly and the reaction was warmed to rt and stirred for 3
h. The reaction was quenched with sat’d aq NH Cl and diluted with EtOAc. The organic
layer was washed with sat’d aq NH Cl, dried over MgSO , filtered and concentrated in
vacuo. The crude product was purified by silica gel chromatography (40 g silica gel,
eluted with 0-100% EtOAc in hexanes) to give the desired product (265 mg, 64%) as
clear oil. H NMR (500 MHz, CDCl ) δ 8.08 (s, 2 H), 4.22 (t, J = 7.0 Hz, 2 H), 2.07 -
2.20 (m, 2 H), 1.98 - 2.05 (m, 2 H), 1.55 - 1.65 (m, 2 H).
Example 12
Example 12 was prepared using a procedure analogous to Example 2 by
replacing Intermediate 2C with Intermediate 12B. LCMS Anal. Calc’d for C22H21F6N7O
513.2, found [M+H] 514.3. H NMR (500 MHz, CDCl ) δ 7.75 (s, 1 H), 7.63 (s, 1 H),
7.54 - 7.59 (m, 1 H), 7.06 (d, J = 8.0 Hz, 2 H), 6.88 (d, J = 8.0 Hz, 2 H), 4.16 (t, J = 7.0
Hz, 2 H), 3.58 (d, J = 18.2 Hz, 1 H), 3.39 (d, J = 17.9 Hz, 1 H), 2.28 (s, 3 H), 2.02 - 2.17
(m, 2 H), 1.93 (quin, J = 7.4 Hz, 2 H), 1.46 - 1.55 (m, 2 H).
Example 13. 3-Nitrop-tolyl(4-(4,4,4-trifluorobutoxy)phenyl)(trifluoromethyl)-
,6-dihydropyridin-2(1H)-one
Intermediate 13A. 2-Nitro-N-(1,1,1-trifluorooxop-tolyl(4-(4,4,4-
trifluorobutoxy)phenyl)butanyl)-acetamide
11841-PCT
O CF
To a solution of Intermediate 2F (130 mg, 0.3 mmol) in anhydrous THF (1
mL) at 0 °C was added DCC (204 mg, 0.99 mmol) followed by a solution of 2-nitroacetic
acid (104 mg, 0.99 mmol) in anhydrous THF (0.5 mL) dropwise. The reaction was
stirred at 0 °C for 1 h then at rt overnight. The reaction was heated to 70 °C for 4 h. The
reaction was cooled to rt and diluted with EtOAc (3 mL). The solids were filtered off and
the filtrate was concentrated in vacuo. The residue was purified by silica gel
chromatography (eluted with EtOAc in hexanes) to provide Intermediate 13A (129 mg,
83%) as a brown oil. LCMS Anal. Calc'd for C H F N O 520.42, found [M+H] 521.1.
23 22 6 2 5
Example 13
To a solution of Intermediate 13A (126 mg, 0.24 mmol) in MeOH (2 mL) was
added piperidine (35 µL). The reaction mixture was heated at 75 °C for 1.5 h. The
product was isolated by preparative HPLC (MeOH/H O/TFA) to provide Example 13 (21
mg, 17%) as a off-white solid. LCMS Anal. Calc'd for C H F N O 502.41, found
23 20 3 2 4
[M+H] 503.1. H NMR (500 MHz, CD OD) δ 1.98 - 2.08 (m, 2 H), 2.28 - 2.45 (m, 5 H),
3.58 (d, J = 17.60 Hz, 1 H), 3.76 (d, J = 17.60 Hz, 1 H), 4.08 (t, J = 6.05 Hz, 2 H), 7.02
(d, J = 8.80 Hz, 2 H), 7.12 - 7.19 (m, 2 H), 7.22 - 7.30 (m, 2 H), 7.53 (d, J = 8.80 Hz, 2
Example 14. 8-(4-Methoxyphenyl)oxo(4-(4,4,4-trifluorobutoxy)phenyl)
(trifluoro-methyl)azaspiro[2.5]octenecarbonitrile
11841-PCT
Intermediate 14A. Methyl 3-oxo(4-(4,4,4-trifluorobutoxy)phenyl)propanoate
[00318] To a solution of methyl 3-(4-hydroxyphenyl)oxopropanoate (7.8 g, 40.2
mmol) and 4,4,4-trifluorobutanol (5.15 g, 40.2 mmol) in CH Cl (201 mL) at 0 °C was
added triphenylphosphine (12.6 g, 48.2 mmol). The mixture was stirred for a few min,
and then DIAD (9.37 mL, 48.2 mmol) was added. The reaction was stirred at 0 °C for 30
min, then warmed to rt and stirred for 3 days. The reaction was loaded directly onto a
300 g silica gel column and eluted with EtOAc in hexanes. Fractions containing the
product were combined and concentrated to provide Intermediate 14A (9.9 g, 80%) as a
colorless solid. H NMR (500 MHz, CDCl ) δ 2.03 - 2.13 (m, 2 H), 2.26 - 2.39 (m, 2 H),
3.75 (s, 3 H), 3.96 (s, 2 H), 4.09 (t, J = 6.05 Hz, 2 H), 6.92 - 6.96 (m, 2 H), 7.86 - 7.97
(m, 2 H).
Intermediate 14B. Methyl 1-(4-(4,4,4-trifluorobutoxy)benzoyl)cyclopropanecarboxylate
To a solution of Intermediate 14A (6.0 g, 19.7 mmol) in DMF (197 mL) was
added K CO (8.18 g, 59.2 mmol) followed by 1,2-dibromoethane (2.6 mL, 30 mmol).
The reaction mixture was stirred at rt for 2 days. The reaction was reduced in volume in
vacuo, then diluted with EtOAc, washed with a 1:1 solution of sat'd aq NaCl and water,
11841-PCT
dried over anhydrous MgSO , filtered and concentrated. The product was isolated by
silica gel chromatography (220 g silica gel, eluted with EtOAc in hexanes) to provide
Intermediate 14B (4.2 g, 61%) as a colorless oil. H NMR (500 MHz, CDCl ) δ 1.45 -
1.49 (m, 2 H), 1.56 - 1.61 (m, 2 H), 2.03 - 2.14 (m, 2 H), 2.26 - 2.39 (m, 2 H), 3.60 (s, 3
H), 4.09 (t, J = 6.05 Hz, 2 H), 6.90 - 6.94 (m, 2 H), 7.86 - 7.93 (m, 2 H).
Intermediate 14C. Methyl 1-((benzylimino)(4-(4,4,4-
trifluorobutoxy)phenyl)methyl)cyclopropane carboxylate
[00320] To a solution of Intermediate 14B (4.2 g, 13 mmol) and benzylamine (5.5 mL,
50 mmol) in diethyl ether (63 mL) at 0 °C was added 1.0 M TiCl in CH Cl (7.6 mL, 7.5
4 2 2
mmol). The reaction was stirred at 0 °C for a few minutes, then warmed to rt and stirred
for 16 h. Celite was added to the reaction and the solids were removed by filtering
through a bed of Celite . The filtrate was concentrated and purified by silica gel
chromatography (120 g silica gel, eluted with EtOAc in hexanes) to provide Intermediate
14C (4.6 g, 83%) as a colorless oil. H NMR (500 MHz, CDCl ) δ 7.82 (d, J = 8.8 Hz,
2H), 7.42 - 7.38 (m, 2H), 7.34 (t, J = 7.7 Hz, 2H), 7.27 - 7.24 (m, 1H), 6.87 (d, J = 8.8
Hz, 2H), 4.90 (s, 2H), 4.04 (t, J = 6.0 Hz, 2H), 3.69 (s, 3H), 2.39 - 2.26 (m, 2H), 2.11 -
2.02 (m, 2H), 1.78 - 1.72 (m, 2H), 1.11 (d, J = 3.3 Hz, 2H).
Intermediate 14D. Methyl 1-(1-(benzylamino)-2,2,2-trifluoro(4-(4,4,4-
trifluorobutoxy)phenyl)ethyl)-cyclopropane carboxylate
11841-PCT
HN CF
To a solution of Intermediate 14C (4.6 g, 11 mmol) in acetonitrile (22 mL)
and DMF (2.6 mL, 33 mmol) at 0 °C was added neat TFA (1.1 mL, 13.7 mmol) followed
by potassium hydrogen fluoride (0.64 g, 8.2 mmol). The reaction was stirred for ca. 5
min, then trimethyl(trifluoromethyl)silane (2.4 mL, 16.4 mmol) was added and the
reaction was warmed to rt and stirred for 16 h. Sat'd aqueous NaHCO was added to the
reaction and the mixture was extracted with EtOAc. The combined organic extracts were
washed with sat'd aq NaCl, dried over Na SO , filtered and concentrated. The residue
was purified by silica gel chromatography (220 g silica gel, eluted with EtOAc in
hexanes) to provide Intermediate 14D (1.8 g, 31%) as an oil. LCMS Anal. Calc'd for
C H F NO 489.45, found [M+H] 490.1.
24 25 6 3
Intermediate 14E. 1-(1-(Benzylamino)-2,2,2-trifluoro(4-(4,4,4-
trifluorobutoxy)phenyl)ethyl)-cyclopropane carboxylic acid
HN CF
To a solution Intermediate 14D (558 mg, 1.140 mmol) in pyridine (5.7 mL)
was added lithium iodide (1.53 g, 11.4 mmol). The reaction was heated to reflux
overnight. The reaction was cooled to rt and diluted with water and EtOAc. The aqueous
layer was made acidic with 1 N HCl and the layers were separated. The organic layer
was washed with sat'd aq NaCl, dried over MgSO , filtered and concentrated to provide
Intermediate 14E (506 mg, 84%) which was used in the next step without further
purification. LCMS Anal. Calc'd for C23H23F6NO3 475.42, found [M+H] 476.2.
11841-PCT
Intermediate 14F. 5-Benzyl(4-(4,4,4-trifluorobutoxy)phenyl)(trifluoromethyl)
azaspiro[2.3]-hexanone
[00323] To a solution of Intermediate 14E (506 mg, 1.1 mmol) in CH Cl (11 mL) was
added oxalyl chloride (0.12 mL, 2.2 mmol) followed by several drops of DMF. The
reaction was stirred at rt for 16 h. The solvent was removed in vacuo and the residue was
purified by silica gel chromatography (24 g silica gel, eluted with EtOAc in hexanes) to
provide Intermediate 14F (389 mg, 72%) as a yellow oil. LCMS Anal. Calc'd for
C H F NO 457.41, found [M+H] 458.2.
23 21 6 2
Intermediate 14G. (1-(1-(Benzylamino)-2,2,2-trifluoro(4-(4,4,4-
trifluorobutoxy)phenyl)ethyl)-cyclopropyl)-(4-methoxyphenyl)methanone
HN CF
F CH
[00324] Magnesium turnings (130 mg, 5.4 mmol) were suspended in anhydrous THF
(13 mL). 4-Bromoanisole (1 g, 670 μL, 5.4 mmol) was added followed by a few drops of
1,2-dibromoethane. The reaction mixture was stirred at rt for 1.5 h after which most of
the magnesium had dissolved. The reaction was warmed to 50 °C for 30 min, then cooled
to rt. Final concentration of the Grignard reagent was 0.4 M assuming complete
conversion. To a cold solution (-40 °C) of Intermediate 14F (200 mg, 0.44 mmol) in
THF (4.4 mL) was added the freshly prepared Grignard reagent. The reaction was
warmed from -40 °C to rt, then heated to reflux overnight. The reaction was cooled to
room temperature and quenched with sat'd aq NH Cl. The layers were separated and the
aqueous layer was extracted with EtOAc. The combined organic extracts were washed
with sat'd aq NaCl, dried over MgSO , filtered and concentrated. The product was
11841-PCT
isolated using preparative HPLC (MeOH/H O/TFA). Fractions containing the product
were combined and reduced in volume in vacuo. The resulting aqueous solution was
made basic with sat'd aq NaHCO and extracted with EtOAc. The combined organic
extracts were washed with sat'd aq NaCl, dried over Na SO , filtered and concentrated to
provide Intermediate 14G (6.1 mg, 2.5%). LCMS Anal. Calc'd for C H F NO 565.55,
29 6 3
found [M+H] 566.3.
Intermediate 14H. (1-(1-Amino-2,2,2-trifluoro(4-(4,4,4-
trifluorobutoxy)phenyl)ethyl)cyclopropyl)(4-methoxy-phenyl)methanone
H N CF
F CH
To a solution of Intermediate 14G (6 mg, 10.6 µmol) in MeOH (1 mL)
containing 4.4% formic acid was added 10% palladium on carbon (2 mg, 2 µmol). The
reaction was stirred at rt overnight. The reaction was filtered through Celite . The
filtrate was made basic with sat'd aq NaHCO , and then evaporated to remove MeOH.
The aqueous residue was diluted with sat'd aq NaCl and extracted with EtOAc. The
combined organic extracts were washed with sat'd aq NaCl, dried over Na SO , filtered
and concentrated to provide Intermediate 14H (4 mg, 71%) as a tan glass. LCMS Anal.
Calc'd for C H F NO 475.42, found [M+H] 476.2.
23 23 6 3
Intermediate 14I. 2-Cyano-N-(2,2,2-trifluoro(1-(4-methoxybenzoyl)cyclopropyl)
(4-(4,4,4-trifluorobutoxy)-phenyl)ethyl)acetamide
HN CF
F CH
To a solution of 2-cyanoacetic acid (320 mg, 3.8 mmol) in CH2Cl2 (9.1 mL)
was added oxalyl chloride (523 mg, 360 μL, 4.1 mmol) followed by a few drops of DMF.
The reaction was stirred at rt for 1 h. Final concentration of 2-cyanoacetyl chloride was
11841-PCT
0.4 M assuming complete conversion. To a solution of Intermediate 14H (4 mg, 8.4
µmol) and pyridine (2.0 µL, 0.025 mmol) in CH Cl (100 µL) at 0 °C was added the
freshly prepared 0.4 M 2-cyanoacetyl chloride in CH Cl (0.032 mL, 0.013 mmol). The
reaction was warmed to rt and stirred for 16 h. The reaction was quenched with one drop
of MeOH, diluted with EtOAc and washed with 1:1 sat'd aq NaCl and water, dried over
MgSO , filtered and concentrated to provide Intermediate 14I (7 mg, 153%), which was
used in the next step without further purification. LCMS Anal. Calc'd for C H F N O
26 24 6 2 4
542.47, found [M+H] 543.3.
Example 14
To a solution of Intermediate 14I (7 mg, 0.013 mmol) in EtOH (2 mL) was
added 25% w/w sodium methoxide (0.015 mL, 0.065 mmol). The reaction was stirred at
rt for 1.5 h. The reaction was made acidic with a few drops of 1 N aqueous HCl and then
concentrated. The product was isolated by preparative HPLC (MeOH/H OTFA). The
fraction containing the product was reduced in volume in vacuo, made basic with sat'd aq
NaHCO and extracted with EtOAc. The combined organic extracts were washed with
sat'd aq NaCl, dried over MgSO , filtered and concentrated to provide Example 14 (2.9
mg, 42%). LCMS Anal. Calc'd for C H F N O 524.46, found [M+H] 525.2. H NMR
26 22 6 2 3
(500 MHz, CD OD) δ 0.65 (t, J = 8.80 Hz, 2 H), 1.18 - 1.25 (m, 2 H), 1.99 - 2.08 (m, 2
H), 2.31 - 2.43 (m, 2 H), 3.85 (s, 3 H), 4.09 (t, J = 6.05 Hz, 2 H), 7.03 (d, J = 8.80 Hz, 2
H), 7.06 (br. s., 2 H), 7.23 (br. s., 2 H), 7.58 (d, J = 9.35 Hz, 2 H).
Examples 15-1 and Example 15-2. 3-Fluoro(4-methoxyphenyl)oxo(4-(4,4,4-
trifluorobutoxy)phenyl)(trifluoromethyl)-1,2,3,6-tetrahydropyridinecarbonitrile
To a solution of the Example 77 (70 mg, 0.140 mmol) in DMF (1.4 mL) was
added Na CO (30 mg, 0.28 mmol) followed by 1-fluorohydroxy-1,4-
11841-PCT
diazoniabicyclo[2,2,2]octane-bis-(tetrafluoroborate) (196 mg, 0.28 mmol). The reaction
was heated to 80 °C overnight. The reaction was cooled to rt and diluted with EtOAc and
water. The layers were separated and the aqueous layer was extracted with EtOAc. The
combined organic layers were washed with sat'd aq NaCl, dried over MgSO , filtered and
concentrated in vacuo. The residue was purified by preparative HPLC (MeOH/H OTFA)
to yield the product (44 mg, 61%) as a mixture of two diastereoisomers. The two
diastereoisomers were separated by preparative chiral SFC method B to provide Example
-1 (14.6 mg, 20%) and Example 15-2 (17.2 mg, 23%). Data for Example 15-1: LCMS
Anal. Calc'd for C H F N O 516.41, found [M+H] 517.2. H NMR (500 MHz,
24 19 7 2 3
CD OD) δ 2.00 - 2.08 (m, 2 H), 2.32 - 2.44 (m, 2 H), 3.85 (s, 3 H), 4.10 (t, J = 6.05 Hz, 2
H), 6.92 (d, J = 1.10 Hz, 1 H), 7.02 (d, J = 8.80 Hz, 2 H), 7.07 (d, J = 9.35 Hz, 2 H), 7.50
(d, J = 8.25 Hz, 2 H), 7.57 (d, J = 8.80 Hz, 2 H). Analytical chiral HPLC method B: RT
= 3.23 min, 99% ee. Data for Example 15-2: LCMS Anal. Calc'd for C H F N O
24 19 7 2 3
516.41, found [M+H] 517.2. H NMR (500 MHz, CD OD) δ 2.00 - 2.08 (m, 2 H), 2.32 -
2.44 (m, 2 H), 3.85 (s, 3 H), 4.10 (t, J = 6.05 Hz, 2 H), 6.92 (d, J = 1.10 Hz, 1 H), 7.02 (d,
J = 8.80 Hz, 2 H), 7.07 (d, J = 9.35 Hz, 2 H), 7.50 (d, J = 8.25 Hz, 2 H), 7.57 (d, J = 8.80
Hz, 2 H). Analytical chiral HPLC method B: RT = 4.84 min, 99% ee.
Examples 15-3 and Example 15-4. 3-Fluoro(4-methoxyphenyl)oxo(4-(4,4,4-
trifluorobutoxy)phenyl)(trifluoromethyl)-1,2,3,6-tetrahydropyridinecarbonitrile
Application of the method described for Example 15-1 and Example 15-2
provided Example 15-3 (4.6 mg, 43%) and Example 15-4 (4.6 mg, 43%) from the R-
isomer of Example 65 (10 mg, 0.02 mmol). Data for Example 15-3: LCMS Anal. Calc'd
for C H F N O 516.41, found [M+H] 517.1. H NMR (500 MHz, CD OD) δ 2.00 -
24 19 7 2 3 3
2.08 (m, 2 H) 2.31 - 2.44 (m, 2 H) 3.85 (s, 3 H) 4.10 (t, J = 6.05 Hz, 2 H) 6.92 (d, J =
1.65 Hz, 1 H) 7.02 (d, J = 8.80 Hz, 2 H) 7.07 (d, J = 8.80 Hz, 2 H) 7.50 (d, J = 8.25 Hz,
11841-PCT
2 H) 7.57 (d, J = 8.80 Hz, 2 H). Analytical chiral HPLC method B: RT = 5.13 min, 99%
ee. Data for Example 15-4: LCMS Anal. Calc'd for C H F N O 516.41, found [M+H]
24 19 7 2 3
517.1. H NMR (500 MHz, CD OD) δ 1.99 - 2.07 (m, 2 H) 2.30 - 2.43 (m, 2 H) 3.84 (s,
3 H) 4.09 (t, J = 6.05 Hz, 2 H) 6.78 (s, 1 H) 7.02 (d, J = 8.80 Hz, 2 H) 7.05 (d, J = 9.35
Hz, 2 H) 7.54 (dd, J = 8.25, 4.95 Hz, 4 H). Analytical chiral HPLC method B: RT = 5.13
min, 99% ee.
Example 16-1 and Example 16-2. N-(4-Methoxyphenyl)oxop-tolyl(4-(4,4,4-
trifluorobutoxy)phenyl)(trifluoromethyl)piperidinecarboxamide
O CH
F C H
To a solution of Example 6-2 (90 mg, 0.15 mol) in MeOH (2 mL) was added
% palladium on carbon (5 mg). The mixture was stirred under hydrogen (50 psi)
overnight. Additional palladium on carbon (5 mg) was added and the reaction was stirred
under hydrogen (50 psi) for an additional 1 h. The catalyst was removed by filtration
through a pad of Celite and the solution was concentrated in vacuo. The products were
partly separated by preparative HPLC (CH CN/H O/TFA). Fractions containing the two
products were combined and separated by chiral HPLC method D to provide Example
16-1 and Example 16-2. Data for Example 16-1: LCMS Anal. Calc'd for C H F N O
31 30 6 2 4
608.57, found [M+H] 609.2. H NMR (400 MHz, CD OD) δ 1.97 - 2.14 (m, 2 H), 2.25
(s, 3 H), 2.32 - 2.46 (m, 2 H), 2.54 - 2.69 (m, 2 H), 3.17 (td, J = 11.82, 3.85 Hz, 1 H),
3.60 (d, J = 11.54 Hz, 1 H), 3.71 (s, 3 H), 4.10 (t, J = 6.05 Hz, 2 H), 6.76 (d, J = 8.79 Hz,
2 H), 6.99 - 7.12 (m, 6 H), 7.13 - 7.23 (m, 2 H), 7.55 (d, J = 8.79 Hz, 2 H). Analytical
chiral HPLC method D RT = 6.75 min, 99% ee. Data for Example 16-2: LCMS Anal.
Calc'd for C31H30F6N2O4 608.57, found [M+H] 609.2. H NMR (400 MHz, CD3OD) δ
7.52 (d, J = 8.8 Hz, 2H), 7.25 - 7.20 (m, 2H), 7.19 - 7.15 (m, 2H), 7.14 - 7.10 (m, 2H),
7.02 - 6.97 (m, 2H), 6.81 - 6.75 (m, 2H), 4.07 (t, J = 6.0 Hz, 2H), 3.94 - 3.84 (m, 1H),
3.73 (s, 3H), 3.60 (d, J = 12.1 Hz, 1H), 2.90 (dd, J = 14.8, 3.3 Hz, 1H), 2.45 - 2.32 (m,
11841-PCT
2H), 2.31 (dd, 1H, overlaps with peak at δ 2.27), 2.27 (s, 3H), 2.08 - 1.98 (m, 2H).
Preparative chiral HPLC method D: RT = 10.9 min, 99% ee.
Examples 17-101 expressed by Formula (IIa), unless noted in the table, may
be made by one skilled in the art by appropriate application of the procedures described
11 15
for Examples 1-16. R to R are hydrogen, unless noted in the table.
11841-PCT
INFORMAL
Table 2
12 14
11 15
(IIa)
1 2 6 11 15
Example [M+H] HNMR (400 MHz, MeOD)
R R R R -R
17 CH CN 459.2*
R = morpholine
18 CH CN 345.1*
R = CH
R = CH
19 CH CN 377.2*
R = OCH CH
11841-PCT
INFORMAL
1 2 6 11 15
Example [M+H] HNMR (400 MHz, MeOD)
R R R R -R
CH CN 401.2*
R = t-Bu
N 13
21 CH 360.2
N R = CH
22 CF CN 371.2
R = CH
23 CH CN 331.3
R = CH
24 CF CN 391.1
R = CH
CF CN 375.2
R = CH
26 CF CN 393.2
R = CH
11841-PCT
INFORMAL
1 2 6 11 15
Example [M+H] HNMR (400 MHz, MeOD)
R R R R -R
27 CF CN 375.2
R = CH
28 CF CN 413.3
R = CH
29 CF CN 387.2
R = CH
CF CN 387.2
R = CH
31 CF CN 400.2
R = CH
32 CF CN 435.2
R = CH
11841-PCT
INFORMAL
1 2 6 11 15
Example [M+H] HNMR (400 MHz, MeOD)
R R R R -R
33 CF CN 483.3 2.03 - 2.12 (m, 2 H) 2.25 -
R = CH
Rac 2.36 (m, 2 H) 2.42 (s, 3 H)
F C O
3.51 - 3.68 (m, 2 H) 4.04 (t, J
= 5.50 Hz, 2 H) 6.94 (d, J =
8.80 Hz, 2 H) 7.31 (d, J =
7.70 Hz, 2 H) 7.40 (d, J =
8.80 Hz, 2 H) 7.47 (d, J =
7.70 Hz, 2 H) 7.64 (br. s., 1
34 CF CN 471.4
R = CH
Rac [M-H]-
CF CN 491.3 2.06 - 2.18 (m, 2 H) 2.41 (s, 3
R = CH
Rac H) 2.81 (t, J = 7.70 Hz, 2 H)
3.45 - 3.68 (m, 2 H) 3.97 (t, J
= 6.32 Hz, 2 H) 6.55 (s, 1 H)
6.93 (d, J = 8.80 Hz, 2 H)
7.21 (d, J = 7.15 Hz, 3 H)
11841-PCT
INFORMAL
1 2 6 11 15
Example [M+H] HNMR (400 MHz, MeOD)
R R R R -R
7.25 - 7.31 (m, 4 H) 7.37 (d, J
= 8.25 Hz, 2 H) 7.45 (d, J =
8.25 Hz, 2 H).
36 CF CN 469.3 1.16 (dd, J = 12.10, 8.25 Hz,
R = CH
Rac 2 H) 1.54 (dd, J = 7.42, 4.67
Hz, 2 H) 1.60 - 1.70 (m, 2 H)
1.81 (q, J = 6.60 Hz, 4 H)
1.96 (m, J = 7.70 Hz, 1 H)
2.41 (s, 3 H) 3.45 - 3.64 (m, 2
H) 3.98 (t, J = 6.60 Hz, 2 H)
6.50 (s, 1 H) 6.94 (d, J = 9.35
Hz, 2 H) 7.23 - 7.32 (m, 2 H)
7.37 (d, J = 8.80 Hz, 2 H)
7.44 (d, J = 8.25 Hz, 2 H).
37 CF CN 443.3
R = CH
11841-PCT
INFORMAL
1 2 6 11 15
Example [M+H] HNMR (400 MHz, MeOD)
R R R R -R
38 CF 430.1
R = CH
39 CF CN 387.2
R = CH
S-isomer
40 CF CN 463.2
R = CH
F 13
41 CF 499.2
R = CH
42 CF CN 427.4 0.85 - 0.96 (m, 3 H) 1.33 (d, J
R = CH
Rac = 2.75 Hz, 4 H) 1.47 - 1.69
(m, 4 H) 2.41 (s, 3 H) 2.56 -
2.67 (m, 2 H) 3.45 - 3.66 (m,
2 H) 6.46 (br. s., 1 H) 7.20 -
7.31 (m, 4 H) 7.37 (d, J =
7.15 Hz, 2 H) 7.45 (d, J =
11841-PCT
INFORMAL
1 2 6 11 15
Example [M+H] HNMR (400 MHz, MeOD)
R R R R -R
6.60 Hz, 2 H).
43 CF CN 434.3
R = CH
44 CF CN 450.3
R = CH
45 CF CN 449.3
R = CH
46 CF CN 451.3
R = CH
47 CF CN 463.3
R = CH
F 13
48 CF 561.4 2.36 (s, 3 H) 3.40 - 3.59 (m, 2
R = CH
Rac H) 6.82 (s, 1 H) 6.93 (t, J =
8.79 Hz, 2 H) 7.01 - 7.13 (m,
11841-PCT
INFORMAL
1 2 6 11 15
Example [M+H] HNMR (400 MHz, MeOD)
R R R R -R
H) 7.15 - 7.20 (m, 3 H)
7.34 - 7.45 (m, 4 H) 7.48 (d, J
= 8.79 Hz, 2 H) 9.86 (s, 1 H).
F 13
49 CF 547.4 2.30 (s, 3 H) 3.57 - 3.81 (m, 2
R = CH
Rac H) 6.96 (t, J = 8.79 Hz, 2 H)
7.17 (d, J = 7.70 Hz, 2 H)
7.27 - 7.38 (m, 4 H) 7.83 (m,
4 H) 9.11 (s, 2 H) 9.16 (s, 1
F 13
50 CF 547.4
R = CH
51 CF 539.5 0.90 (t, J = 6.87 Hz, 3 H)
R = CH
Rac 1.28 - 1.40 (m, 4 H) 1.58 -
1.71 (m, 2 H) 2.35 (s, 3 H)
2.55 - 2.71 (m, 2 H) 3.30 -
3.60 (m, 2 H) 6.63 (s, 1 H)
6.92 (t, J = 8.52 Hz, 2 H)
11841-PCT
INFORMAL
1 2 6 11 15
Example [M+H] HNMR (400 MHz, MeOD)
R R R R -R
7.05 - 7.12 (m, 2 H) 7.14 -
7.20 (m, 2 H) 7.22 - 7.31 (m,
2 H) 7.37 - 7.49 (m, 4 H)
9.94 (s, 1 H).
F 13
52 CF 563.4
R = CH
53 CF CN 483.2 1.93 - 2.09 (m, 2 H) 2.27 -
R = CH
S-isomer 2.38 (m, 2 H) 2.40 (s, 3 H)
F C O
3.62 - 3.78 (m, 2 H) 4.06 (t, J
= 6.05 Hz, 2 H) 7.00 (d, J =
8.80 Hz, 2 H) 7.33 (d, J =
7.70 Hz, 2 H) 7.44 - 7.58 (m,
4 H).
F 13
54 CF 575.3
R = CH
11841-PCT
INFORMAL
1 2 6 11 15
Example [M+H] HNMR (400 MHz, MeOD)
R R R R -R
55 CF 571.4
O R = CH
F C O
56 CF O 591.3
R = CH
Rac N
F C O
57 CF 605.4 2.02 (dd, J = 9.90, 6.05 Hz, 2
R = CH
Rac H) 2.28 - 2.40 (m, 5 H) 2.45 -
F C O
2.58 (m, 2 H) 3.12 - 3.35 (m,
2 H) 3.37 - 3.60 (m, 2 H)
4.05 (t, J = 6.05 Hz, 2 H)
6.91 - 7.01 (m, 4 H) 7.09 -
7.20 (m, 5 H) 7.21 - 7.26 (m,
2 H) 7.50 (d, J = 8.80 Hz, 2
58 CF 607.3 1.96 - 2.07 (m, 2 H) 2.26 -
R = CH
Rac CH 2.32 (m, 3 H) 2.32 - 2.42 (m,
F C O
2 H) 3.45 - 3.67 (m, 2 H)
4.06 (t, J = 6.05 Hz, 2 H)
11841-PCT
INFORMAL
1 2 6 11 15
Example [M+H] HNMR (400 MHz, MeOD)
R R R R -R
6.61 (dd, J = 8.25, 2.20 Hz, 1
H) 6.83 (d, J = 8.25 Hz, 1 H)
6.98 (d, J = 8.80 Hz, 2 H)
7.03 (s, 1 H) 7.09 (t, J = 8.25
Hz, 1 H) 7.16 (d, J = 8.25
Hz, 2 H) 7.28 (d, J = 8.25
Hz, 2 H) 7.52 (d, J = 8.80
Hz, 2 H).
59 CF 577.3 1.95 - 2.08 (m, 2 H) 2.28 (s, 3
R = CH
Rac H) 2.32 - 2.42 (m, 2 H) 3.42 -
F C O
3.70 (m, 2 H) 4.05 (t, J =
6.05 Hz, 2 H) 6.97 (d, J =
8.80 Hz, 2 H) 7.00 - 7.06 (m,
1 H) 7.15 (d, J = 8.25 Hz, 2
H) 7.20 (t, J = 7.97 Hz, 2 H)
7.30 (dd, J = 16.77, 7.97 Hz,
4 H) 7.52 (d, J = 8.80 Hz, 2
11841-PCT
INFORMAL
1 2 6 11 15
Example [M+H] HNMR (400 MHz, MeOD)
R R R R -R
60 CF 611.3
R = CH
F C O
61 CF 611.3
R = CH
N Cl
F C O
62 CF Cl 611.3
R = CH
F C O
63 CF CN 469.1 2.40 (s, 3 H) 2.63 - 2.75 (m, 2
R = CH
Rac H) 3.65 - 3.77 (m, 2 H) 4.24
(t, J = 6.05 Hz, 2 H) 7.01 (d,
J = 9.35 Hz, 2 H) 7.33 (d, J
= 7.70 Hz, 2 H) 7.50 (d, J =
8.25 Hz, 2 H) 7.54 (d, J =
8.80 Hz, 2 H).
64 CF CN 499.2
R = OCH
F C O
11841-PCT
INFORMAL
1 2 6 11 15
Example [M+H] HNMR (400 MHz, MeOD)
R R R R -R
65 CF CN 499.2 1.95 - 2.07 (m, 2 H) 2.29 -
R = OCH
Rac 2.43 (m, 2 H) 3.88 (s, 3 H)
F C O
3.92 (d, J = 16.51 Hz, 1 H)
4.06 (t, J = 6.05 Hz, 2 H)
4.55 (d, J = 16.23 Hz, 1 H)
6.96 (d, J = 9.08 Hz, 2 H)
7.01 (d, J = 8.80 Hz, 2 H)
7.52 (d, J = 9.08 Hz, 2 H)
7.97 (d, J = 9.08 Hz, 2 H)
66 CF CN 494.2
R = CN
F C O
67 CF CN 487.2
R = F
F C O
68 CF CN 503.2
R = Cl
F C O
11841-PCT
INFORMAL
1 2 6 11 15
Example [M+H] HNMR (400 MHz, MeOD)
R R R R -R
69 CF CN 494.2
R = CN
F C O
70 CF H 458.2
R = CH
F C O
71 CF CN all H 469.2
F C O
72 CF CN 503.1
R = Cl
F C O
12 13
73 CF CN 519.2 8.15 (d, J = 1.7 Hz, 1H), 8.01
R and R
Rac - 7.95 (m, 2H), 7.92 (d, J =
F C O
8.0 Hz, 1H), 7.65 - 7.55 (m,
5H), 7.05 - 7.00 (m, 2H),
4.07 (t, J = 6.1 Hz, 2H), 3.85
(ABq, J = 18.1 Hz, 2H), 2.42
- 2.29 (m, 2H), 2.06 - 1.98
11841-PCT
INFORMAL
1 2 6 11 15
Example [M+H] HNMR (400 MHz, MeOD)
R R R R -R
(m, 2H)
74 CF CN 487.2
R = F
F C O
75 CF CN 537.2
R = CF
F C O
76 CF CN 483.2
R = CH
F C O
77 CF CN 499.2 1.97 - 2.06 (m, 2 H) 2.27 -
R = OCH
S-isomer 2.42 (m, 2 H) 3.66 (d, J =
F C O
17.90 Hz, 1 H) 3.75 (d, J =
17.90 Hz, 1 H) 3.87 (s, 3 H)
4.06 (t, J = 6.05 Hz, 2 H)
6.96 - 7.02 (m, 2 H) 7.03 -
7.08 (m, 2 H) 7.52 (d, J =
8.80 Hz, 2 H) 7.61 - 7.68 (m,
2 H)
11841-PCT
INFORMAL
1 2 6 11 15
Example [M+H] HNMR (400 MHz, MeOD)
R R R R -R
78 CF CN 535.1 7.69 - 7.63 (m, 2H), 7.54 (d, J
R = OCHF
Rac = 9.1 Hz, 2H), 7.31 - 7.25
F C O
(m, 2H), 7.01 (m, 2H), 6.96
(t, J = 73.5 Hz, 1 H), 4.07 (t,
J = 6.1 Hz, 2H), 3.78 - 3.67
(m, 2H), 2.44 - 2.30 (m, 2H),
2.07 - 1.97 (m, 2H)
79 CF CN 553.1
R = OCF
F C O
80 CF CN 513.2
R = OCH CH
F C O
81 CF CN R = F 517.2 7.51 (d, J = 9.1 Hz, 2H), 7.36
3 11
Rac 13 (t, J = 8.8 Hz, 1H), 7.04 -
R = OCH
F C O
6.97 (m, 2H), 6.91 - 6.83 (m,
2H), 4.08 (t, J = 6.1 Hz, 2H),
3.87 (s, 3H), 3.65 (s, 2H),
2.46 - 2.29 (m, 2H), 2.08 -
11841-PCT
INFORMAL
1 2 6 11 15
Example [M+H] HNMR (400 MHz, MeOD)
R R R R -R
1.98 (m, 2H)
82 CF 591.2 7.52 (d, J = 8.8 Hz, 2H), 7.28
R = CH
Rac (d, J = 8.2 Hz, 2H), 7.15 (d, J
F C O
= 7.7 Hz, 2H), 7.19 (d, J =
8.8 Hz, 2H), 7.02 (d, J = 8.2
Hz, 2H), 6.98 (d, J = 7.7 Hz,
2H), 4.06 (t, J = 6.0 Hz, 2H),
3.64 (d, J = 17.0 Hz, 1H),
3.48 (d, J = 17.0 Hz, 1H),
2.39 - 2.32 (m, 2H), 2.29 (s,
3H), 2.24 (s, 3H), 2.06 - 1.98
(m, 2H).
83 CF O 661.2 7.53 (d, J = 8.8 Hz, 2H), 7.46
R = CH
O CF
Rac - 7.41 (m, 2H), 7.31 - 7.24
F C O
(m, J = 8.2 Hz, 2H), 7.13 (d,
J = 8.8 Hz, 2H), 7.17 (d, J =
7.7 Hz, 2H), 7.01 - 6.96 (m,
2H), 4.07 (t, J = 6.0 Hz, 2H),
11841-PCT
INFORMAL
1 2 6 11 15
Example [M+H] HNMR (400 MHz, MeOD)
R R R R -R
3.65 (d, J = 17.0 Hz, 1H),
3.50 (d, J = 17.0 Hz, 1H),
2.43 - 2.33 (m, 2H), 2.30 (s,
3H), 2.07 - 1.99 (m, 2H).
84 CF O 625.2 7.52 (d, J = 8.8 Hz, 2H), 7.30
R = CH
O CH
Rac - 7.24 (m, 3H), 7.17 (d, J =
F C O
7.7 Hz, 2H), 7.01 - 6.90 (m,
4H), 4.06 (t, J = 6.0 Hz, 2H),
3.82 - 3.77 (s, 3H), 3.64 (d, J
= 17.0 Hz, 1H), 3.49 (d, J =
17.0 Hz, 1H), 2.42 - 2.33 (m,
2H), 2.30 (s, 3H), 2.08 - 1.96
(m, 2H).
85 CF 609.2 7.56 - 7.50 (ab quartet, J =
R = CH
Rac 9.3 Hz, 2H), 7.30 - 7.20 (m,
F C O
3H), 7.16 (d, J = 8.2 Hz, 2H),
7.05 (t, J = 8.2 Hz, 1H), 7.01
- 6.95 (m, J = 8.8 Hz, 2H),
11841-PCT
INFORMAL
1 2 6 11 15
Example [M+H] HNMR (400 MHz, MeOD)
R R R R -R
6.91 (dd, J = 8.2, 1.6 Hz,
1H), 4.07 (t, J = 6.0 Hz, 2H),
3.64 (d, J = 17.6 Hz, 1H),
3.49 (d, J = 17.0 Hz, 1H),
2.43 - 2.32 (m, 2H), 2.30 (s,
3H), 2.16 (s, 3H), 2.08 - 1.97
(m, 2H).
86 CF CF 645.2 7.58 - 7.48 (m, 6H), 7.27 (d, J
R = CH
Rac = 8.2 Hz, 2H), 7.15 (d, J =
F C O
8.2 Hz, 2H), 7.00 - 6.95 (m,
2H), 4.06 (t, J = 6.0 Hz, 2H),
3.65 (d, J = 17.6 Hz, 1H),
3.50 (d, J = 17.0 Hz, 1H),
2.43 - 2.31 (m, 2H), 2.28 (s,
3H), 2.09 - 1.95 (m, 2H).
87 CF 538.2
R = CH
F C O
S-isomer
11841-PCT
INFORMAL
1 2 6 11 15
Example [M+H] HNMR (400 MHz, MeOD)
R R R R -R
88 CF O 579.2 2.31 (s, 3 H) 3.45 - 3.69 (m, 2
R = CH
O CH
Rac H) 3.70 - 3.76 (s, 3 H) 4.56
F C O
(q, J = 8.25 Hz, 2 H) 6.78 (d,
J = 9.35 Hz, 2 H) 7.07 (d, J =
9.35 Hz, 2 H) 7.13 - 7.22 (m,
4 H) 7.29 (d, J = 8.25 Hz, 2
H) 7.59 (d, J = 8.80 Hz, 2 H).
89 CF CN 455.1
R = CH
F C O
90 CF H 498.1 2.28 (s, 3 H) 3.63 - 3.82 (m, 2
R = CH
Rac H) 4.58 (q, J = 8.61 Hz, 2 H)
F C O
6.88 (d, J = 8.25 Hz, 2 H)
7.10 (dd, J = 12.65, 8.80 Hz,
4 H) 7.65 (d, J = 8.80 Hz, 2
91 CF CN R = F 517.2 7.51 (d, J = 9.1 Hz, 2H), 7.36
3 11
S-isomer 13 (t, J = 8.8 Hz, 1H), 7.03 -
R = OCH
F C O
6.99 (m, 2H), 6.90 - 6.84 (m,
11841-PCT
INFORMAL
1 2 6 11 15
Example [M+H] HNMR (400 MHz, MeOD)
R R R R -R
2H), 5.49 (s, 1H), 4.08 (t, J =
6.1 Hz, 2H), 3.87 (s, 3H),
3.65 (s, 2H), 2.46 - 2.28 (m,
2H), 2.10 - 1.97 (m, 2H)
92 CF H 556.3 1.34 (t, J = 6.87 Hz, 3 H)
R = OCH CH
Rac 1.96 - 2.09 (m, 2 H) 2.26 -
F C O
2.43 (m, 2 H) 3.70 (s, 2 H)
3.98 (q, J = 6.78 Hz, 2 H)
4.06 (t, J = 6.05 Hz, 2 H)
6.78 (d, J = 8.80 Hz, 2 H)
6.92 (d, J = 8.80 Hz, 2 H)
7.01 (d, J = 8.80 Hz, 2 H)
7.58 (d, J = 8.80 Hz, 2 H).
93 CF H 578.3 1.96 - 2.12 (m, 2 H) 2.28 -
R = OCHF
Rac 2.45 (m, 2 H) 3.63 - 3.85 (m,
F C O
2 H) 4.07 (t, J = 6.05 Hz, 2
H) 6.95 - 7.08 (m, 7 H) 7.59
(d, J = 8.80 Hz, 2 H).
11841-PCT
INFORMAL
1 2 6 11 15
Example [M+H] HNMR (400 MHz, MeOD)
R R R R -R
94 CF O 661.3 1.97 - 2.08 (m, 2 H) 2.29 (s, 3
R = CH
O CF
S-isomer H) 2.32 - 2.40 (m, 2 H) 3.50
F C O
(d, J = 17.05 Hz, 1 H) 3.65
(d, J = 17.60 Hz, 1 H) 4.06 (t,
J = 6.05 Hz, 2 H) 6.98 (d, J =
8.80 Hz, 2 H) 7.14 (dd, J =
16.77, 8.52 Hz, 4 H) 7.28 (d,
J = 8.25 Hz, 2 H) 7.43 (d, J =
9.35 Hz, 2 H) 7.52 (d, J =
8.80 Hz, 2 H).
95 CF H 560.3 1.95 - 2.08 (m, 2 H) 2.28 -
R = F
S-isomer 13 2.42 (m, 2 H) 3.58 - 3.71 (m,
R = OCH
F C O
2 H) 3.76 (s, 3 H) 4.06 (t, J =
6.05 Hz, 2 H) 6.59 (dd, J =
12.92, 2.47 Hz, 1 H) 6.69
(dd, J = 8.80, 2.75 Hz, 1 H)
6.91 - 6.96 (m, 1 H) 7.00 (d, J
= 8.80 Hz, 2 H) 7.57 (d, J =
11841-PCT
INFORMAL
1 2 6 11 15
Example [M+H] HNMR (400 MHz, MeOD)
R R R R -R
8.80 Hz, 2 H).
96 CF H 526.3
R = CH
F C O
97 CF H All H 512.2
F C O
98 CF H 580.3 7.60 (t, J = 8.2 Hz, 4H), 7.18
R = CF
Rac (d, J = 8.2 Hz, 2H), 7.03 (d, J
F C O
= 8.8 Hz, 2H), 4.08 (t, J =
6.0 Hz, 2H), 3.80 (d, J = 18.1
Hz, 1H), 3.69 (d, J = 18.1
Hz, 1H), 2.45 - 2.31 (m, 2H),
2.11 - 1.93 (m, 2H).
99 CF H 546.2
R = Cl
F C O
11841-PCT
INFORMAL
1 2 6 11 15
Example [M+H] HNMR (400 MHz, MeOD)
R R R R -R
100 CF H 542.3
R = OCH
F C O
101 CF H 546.2
R = Cl
F C O
*Data reported as molecular weight of compound based on electrospray mass spec results
11841-PCT
Example 102. N -(4-Methoxyphenyl)methyloxop-tolyl-N -(4,4,4-trifluorobutyl)-
1,2,3,6-tetrahydropyridine-2,5-dicarboxamide
Intermediate 102A. (E)-Ethyl 2-methyloxop-tolylbutenoate
A solution of Intermediate 2D (3.02 g, 7.65 mmol) and ethyl 2-oxopropanoate
(0.74 g, 6.37 mmol) in THF (12 mL) in a 5 mL microwave vial equipped with a magnetic
stirrer was heated at 150 °C under microwave conditions for 20 min. The solvent was
removed under vacuum and the residue was purified by silica gel chromatography (80 g
silica gel, eluted with EtOAc in hexanes) to provide the desired product (1.067 g, 72%) as
a yellow oil. LCMS Anal. Calc’d for C H O 232.11, found [M+H] 233.1. H NMR
14 16 3
(500 MHz, CDCl ) δ ppm 7.87 (d, J = 8.25 Hz, 2 H), 7.69 (q, J = 1.56 Hz, 1 H), 7.28 (d,
J = 7.98 Hz, 2 H), 4.30 (q, J = 7.15 Hz, 2 H), 2.42 (s, 3 H), 2.16 (d, J = 1.38 Hz, 3 H),
1.36 (t, J = 7.02 Hz, 3 H).
Intermediate 102B. Ethyl 2-aminomethyloxop-tolylbutanoate
To a solution of Intermediate 102A (1.067 g, 4.59 mmol) in DMSO (20 mL)
under argon was added NH OH (18.04 mL, 271 mmol) and the reaction mixture was
stirred at rt overnight. The reaction mixture was diluted with EtOAc (75 mL) and washed
sequentially with water (40 mL) and brine (20 mL). The organic phase was dried over
MgSO and concentrated in vacuo to give a yellow oil. The oil was purified by silica gel
11841-PCT
chromatography (120 g silica gel) to provide the desired product (0.632 g, 55%) as a clear
oil. LCMS Anal. Calc’d for C H NO 249.14, found [M+H] 250.1. H NMR (500
14 19 3
MHz, CDCl ) δ 7.83 (d, J = 8.25 Hz, 2 H), 7.24 (d, J = 7.98 Hz, 2 H), 4.14 (dd, J = 7.15,
2.75 Hz, 2 H), 3.65 (d, J = 17.61 Hz, 1 H), 3.20 (d, J = 17.61 Hz, 1 H), 2.40 (s, 3 H),
2.18 - 2.27 (m, 2 H), 1.39 (s, 3 H), 1.19 (t, J = 7.01 Hz, 3 H).
Intermediate 102C. Ethyl 2-(3-(4-methoxyphenylamino)oxopropanamido)methyl-
4-oxop-tolylbutanoate
[00334] To a solution of Intermediate 6B (0.388 g, 1.855 mmol) in DCM (10 mL)
under argon was added 1-chloro-N,N,2-trimethylpropenamine (0.293 g, 2.192
mmol) and the reaction mixtrue was stirred at rt for 20 min. A solution of Intermediate
102B (0.4204 g, 1.686 mmol) in DCM (1.000 mL) followed by pyridine (0.409 mL, 5.06
mmol) were added and the reaction mixture was stirred at rt for 2.5 h. The reaction
mixture was concentrated to give a dark oil which was dissolved in EtOAc (15 mL) and
washed with water (5 mL). The organic phase was dried over MgSO4, filtered, and
concentrated. The residue was purified by silica gel chromatography (80 g silica gel) to
provide the desired product (0.650 g, 88%) as an orange oil. LCMS Anal. Calc’d for
C24H28N2O6 440.19, found [M+H] 441.2. H NMR (500 MHz, CDCl3) δ 7.83 (d, J =
8.25 Hz, 2 H), 7.24 (d, J = 7.98 Hz, 2 H), 4.14 (dd, J = 7.15, 2.75 Hz, 2 H), 3.65 (d, J =
17.61 Hz, 1 H), 3.20 (d, J = 17.61 Hz, 1 H), 2.40 (s, 3 H), 2.18 - 2.27 (m, 2 H), 1.39 (s, 3
H), 1.19 (t, J = 7.01 Hz, 3 H).
Intermediate 102D. 5-(4-Methoxyphenylcarbamoyl)methyloxop-tolyl-1,2,3,6-
tetrahydropyridinecarboxylic acid
11841-PCT
To a solution of Intermediate 102C (0.033 g, 0.075 mmol) in THF (8 mL) and
water (1.600 mL) was added lithium hydroxide monohydrate (3.77 mg, 0.090 mmol) and
the reaction mixture was stirred at rt for 1 h. The reaction mixture was acidified with
AcOH (5 drops) and diluted with EtOAc (10 mL) and water (3 mL). The phases were
separated and the aqueous phase was extracted with EtOAc (10 mL). The organic phases
were combined and dried over MgSO , filtered, and concentrated in vacuo to give the
desired product (0.0213 g, 72%) as a white solid. LCMS Anal. Calc’d for C H N O
22 22 2 5
394.15, found [M+H] 395.0.
Example 102
To a solution of Intermediate 102D (0.0213 g, 0.054 mmol) in DCM (2 mL)
under argon was added EDC (0.014 g, 0.076 mmol), HOBT (9.92 mg, 0.065 mmol),
4,4,4-trifluorobutanamine (8.24 mg, 0.065 mmol), and DIEA (0.019 mL, 0.108 mmol).
The reaction mixture was stirred at rt for 3 days. The reaction mixture was diluted with
EtOAc (5 mL) and the solution was washed with water (2 mL) and brine (2 mL). The
organic phase was dried over MgSO , filtered, and concentrated in vacuo to give an
orange solid which was purified by preparative HPLC (ACN/H O/TFA) to afford the
desired product (4.6 mg, 15%) as a pale yellow solid. LCMS Anal. Calc’d for
C H F N O 503.2, found [M+H] 504.1. H NMR (500 MHz, CDCl ) δ 8.46 (br. s., 1
26 28 3 3 4 3
H), 7.61 (br. s., 1 H), 7.24 - 7.32 (m, 4 H), 7.16 (d, J = 7.83 Hz, 2 H), 6.79 (d, J = 8.84
Hz, 2 H), 3.75 (s, 3 H), 3.56 (d, J = 17.18 Hz, 1 H), 3.22 - 3.37 (m, 2 H), 3.14 (br. s., 1
H), 2.73 (d, J = 17.18 Hz, 1 H), 2.34 (s, 3 H), 2.00 - 2.15 (m, 2 H), 1.70 - 1.80 (m, 2 H),
1.54 (s, 3 H).
Example 103. N-(4-Cyanophenyl)-5,5-difluorooxop-tolyl(4-(4,4,4-
trifluorobutoxy)phenyl)(trifluoromethyl)-1,2,5,6-tetrahydropyridinecarboxamide
11841-PCT
Intermediate 103A. Methyl 2,2-difluorooxo(4-(4,4,4-
trifluorobutoxy)phenyl)propanoate
F C O
To a solution of Intermediate 14A (3 g, 9.86 mmol) and selectFluor (10.48 g,
29.6 mmol) in acetonitrile (10 mL) was added 1 M methanolic tetrabutylammonium
hydroxide (19.72 mL, 19.72 mmol). The reaction mixture was heated to 82 °C for 10
min under microwave conditions. The reaction was diluted with 1:1 ACN and MeOH
and filtered rinsing with 1:1 ACN in MeOH (50 mL). The filtrate was evaporated to
dryness and the crude product was purified by silica gel chromatography (80 g silica gel,
elute with EtOAc in hexanes) to yield the desired product (2.34 g, 69%) as a clear,
colorless oil. H NMR (500 MHz, CDCl ) δ 8.08 (d, J = 9.08 Hz, 2 H), 6.98 (d, J = 9.08
Hz, 2 H), 4.13 (t, J = 6.05 Hz, 2 H), 3.93 (s, 3 H), 2.27 - 2.39 (m, 2 H), 2.07 - 2.15 (m, 2
H).
Intermediate 103B. 2,2-Difluoro(piperidinyl)(4-(4,4,4-
trifluorobutoxy)phenyl)propane-1,3-dione
F C O
[00338] Piperidine (175 µL, 1.763 mmol) was slowly added to Intermediate 103A (500
mg, 1.470 mmol) at rt. The reaction was stirred at rt for 3 h. The reaction was diluted
with CH Cl , loaded onto a 12 g SiO column and eluted with EtOAc in hexanes.
2 2 2
Fractions containing the product were combined and evaporated to dryness to provide the
11841-PCT
product (520 mg, 81%) as a clear oil. LCMS Anal. Calc’d for C H F NO 393.14,
18 20 5 3
found [M+H] 394.2. H NMR (500 MHz, CDCl ) δ 8.10 (d, J = 9.1 Hz, 2 H), 6.98 -
6.91 (m, 2 H), 4.10 (t, J = 5.9 Hz, 2 H), 3.61 - 3.56 (m, 2 H), 3.54 - 3.50 (m, 2 H), 2.39 -
2.26 (m, 2 H), 2.14 - 2.05 (m, 2 H), 1.69 - 1.61 (m, 2 H), 1.60 - 1.51 (m, 4 H).
Intermediate 103C. N-(2,2-Difluorooxo(piperidinyl)(4-(4,4,4-
trifluorobutoxy)phenyl)propylidene)methylpropanesulfinamide
F C O
To a solution of Intermediate 103B (1.97 g, 5.01 mmol) and 2-methylpropane-
2-sulfinamide (1.821 g, 15.02 mmol) in anhydrous THF (25.04 mL) was added Ti(OEt)
(5.19 mL, 25.04 mmol). The reaction was heated at refluxed temperature overnight. The
reaction was cooled to rt, poured into brine, diluted with EtOAc, and stirred for 30 min.
The titanium oxide was removed by filtering through a plug of Celite®. The filtrate
layers were separated and the organic layer was washed with brine, dried over Na SO ,
filtered, and concentrated. The residue was purified by silica gel chromatography (80 g
silica gel, eluted with EtOAc in hexanes to yield the desired product (1.62 g, 59%) as a
yellow oil. H NMR (500 MHz, CDCl3) δ 7.56 (d, J = 8.80 Hz, 2 H), 6.95 (d, J = 9.08
Hz, 2 H), 4.07 (t, J = 6.05 Hz, 2 H), 3.62 - 3.69 (m, 1 H), 3.52 - 3.58 (m, 1 H), 3.39 (t, J
= 5.09 Hz, 2 H), 2.26 - 2.37 (m, 2 H), 2.05 - 2.11 (m, 2 H), 1.53 - 1.70 (m, 7 H), 1.25 (s,
9 H).
Intermediate 103D. 2-Methyl-N-(1,1,1,3,3-pentafluorooxo(piperidinyl)(4-
(4,4,4-trifluorobutoxy)phenyl)butanyl)propanesulfinamide
F C NH
F C O
11841-PCT
To a solution of TBAT (3.43 g, 6.36 mmol) in DMF (5.89 mL) was added a
solution of Intermediate 103C (1.17 g, 2.356 mmol) in THF (5.89 mL). The solution was
cooled to 0 °C, and then 2 M TMSCF (3.53 mL, 7.07 mmol) in THF was added
dropwise. The reaction was stirred at 0 °C for 1 h, and then quenched with brine (20 mL)
at 0 °C. The mixture was warmed to rt and diluted with water and EtOAc. The layers
were separated. The aqueous layer was washed with EtOAc. The combined organic
layers were washed with brine, dried over Na SO , filtered and concentrated. The residue
was purified by silica gel chromatography (80 g silica gel, eluted with EtOAc in hexanes)
to afford the desired product (773 mg, 58%) as a yellow gum. LCMS Anal. Calc’d for
C H F N O S 566.18, found [M+H] 567.1. H NMR (500 MHz, CD OD) δ 7.69 (d, J
23 30 8 2 3 3
= 8.53 Hz, 2 H), 6.91 (d, J = 9.08 Hz, 2 H), 4.03 (t, J = 5.91 Hz, 2 H), 3.50 - 3.62 (m, 2
H), 3.34 - 3.45 (m, 2 H), 2.23 - 2.35 (m, 2 H), 1.98 - 2.07 (m, 2 H), 1.48 - 1.69 (m, 6 H),
1.26 (s, 9 H).
Intermediate 103E. N-Benzylmethyl-N-(1,1,1,3,3-pentafluorooxo(piperidin
yl)(4-(4,4,4-trifluorobutoxy)phenyl)butanyl)propanesulfinamide
F C N
F C O
A solution of Intermediate 103D (461 mg, 0.814 mmol) in anhydrous DMF
(0.5 mL) was added to a suspension of NaH (65 mg, 1.627 mmol) (60% in mineral oil) at
0 °C. After stirring for 5 min, BnBr (0.484 mL, 4.07 mmol) was added. The reaction
mixture was warmed to rt and stirred for 1 h. The reaction was diluted with EtOAc,
washed with brine, dried over Na2SO4, filtered and concentrated. The residue was
purified by silica gel chromatography (4 g silica gel, eluted with EtOAc in hexanes) to
yield the desired product (260 mg, 44%) as a yellow gum. H NMR (500 MHz, CDCl ) δ
7.75 (d, J = 8.5 Hz, 2 H), 7.33 - 7.27 (m, 3 H), 7.14 (dd, J = 7.3, 2.1 Hz, 2 H), 6.80 (d, J
= 9.1 Hz, 2 H), 4.46 - 4.38 (m, 2 H), 4.00 - 3.95 (m, 2 H), 3.72 (br. s., 1 H), 3.51 (br. s., 1
H), 3.35 - 3.10 (m, 2 H), 2.37 - 2.25 (m, 2 H), 2.09 - 1.99 (m, 2 H), 1.70 - 1.39 (m, 6 H),
1.34 - 1.29 (m, 9 H).
11841-PCT
Intermediate 103F. 2-Methyl-N-(1,1,1,3,3-pentafluorooxop-tolyl(4-(4,4,4-
trifluorobutoxy)phenyl)butanyl)propanesulfinamide
F C NH
F C O
[00342] Mg turnings were suspended in 0.1 N aq HCl for a few minutes, rinsed with
water, MeOH and dried under vacuum. A flame dried flask equipped with a stir bar was
charged with Mg turnings (0.243 g, 10 mmol), anhydrous THF (4.4 mL) and 4-
bromotoluene (1.71 g, 10 mmol) in anhydrous THF (4.4 mL) followed by several drops
of 1,2-dibromoethane. The reaction initiated in a few minutes and the mixture became
warm. The approximate concentration of the Grignard reagent is 1 M. The mixture was
diluted with 10 mL anhydrous THF to produce a clear solution of p-tolylmagnesium
bromide (~0.5 M). To a solution of Intermediate 103E (260 mg, 0.396 mmol) in THF
(3959 µL) at 0 °C was added the freshly prepared p-tolylmagnesium bromide (3959 µL,
1.980 mmol). The reaction was warmed to rt, concentrated to half of the original volume,
and stirred for 3 h. The reaction was cooled to 0 °C, quenched with sat'd aq NH Cl, and
then diluted with EtOAc. The layers were separated and the organic layer was washed
with brine, dried over MgSO , filtered and concentrated. The residue was purified by
silica gel chromatography (24 g silica gel, eluted with EtOAc in hexanes) to afford the
desired product (60 mg, 24%) as a yellow gum. H NMR (500 MHz, CDCl ) δ 7.73 (d, J
= 8.0 Hz, 2H), 7.55 (d, J = 8.5 Hz, 2H), 7.19 (d, J = 8.0 Hz, 2H), 6.83 (d, J = 8.8 Hz,
2H), 4.19 (s, 1H), 4.01 (br. s., 2H), 2.40 (s, 3H), 2.31 (dd, J = 16.2, 10.2 Hz, 2H), 2.10 -
1.99 (m, 2H), 1.25 (s, 9H).
Intermediate 103G. 3-Amino-2,2,4,4,4-pentafluorop-tolyl(4-(4,4,4-
trifluorobutoxy)phenyl)butanone, HCl
F C NH
F C O
11841-PCT
To a solution of Intermediate 103F (30 mg, 0.052 mmol) in MeOH (0.5 mL)
was added 4.0 M HCl (0.026 mL, 0.105 mmol) in dioxane. The reaction was stirred at rt
for 1 h. The reaction was concentrated and the crude product was used in the next step
without further purification. LCMS Anal. Calc’d for C H F NO 469.13, found [M+H]
21 19 8 2
470.1.
Intermediate 103H. Ethyl 5,5-difluorooxop-tolyl(4-(4,4,4-
trifluorobutoxy)phenyl)(trifluoromethyl)-1,2,5,6-tetrahydropyridinecarboxylate
[00344] Intermediate 103G (268 mg, 0.530 mmol) was dissolved in MeOH and then
passed through NaHCO resin (500 mg; 0.9 mmol). The solution was concentrated to
yield the free base (230 mg). The free base was dissolved in 9:1 CH Cl /pyridine (3 mL)
added ethyl 3-chlorooxopropanoate (160 mg, 1.060 mmol). The resulting mixture was
stirred at rt for 24 h and then concentrated. The residue was taken up with EtOH (1 mL)
and treated with piperidine (20 uL). The resulting mixture was stirred at 65 °C for 24 h
and then concentrated. The residue was purified by preparative HPLC
(MeOH/H O/TFA) to yield the desired product (100 mg, 33%) as a foam. LCMS Anal.
Calc’d for C H F NO 565.15, found [M+H] 566.1.
26 23 8 4
Intermediate 103I. 5,5-Difluorooxop-tolyl(4-(4,4,4-trifluorobutoxy)phenyl)
(trifluoromethyl)-1,2,5,6-tetrahydropyridinecarboxylic acid
F OH
11841-PCT
To a solution of Intermediate 103H (100 mg, 0.177 mmol) in MeOH (2 mL)
was added 2 M LiOH (0.4 mL, 0.800 mmol). The resulting mixture was stirred at 100 °C
for 15 min. LC-MS indicated the product to be the major component along with a trace
amount of SM and 14% of the corresponding methyl ester. 2 M LiOH (100 uL) was then
added and the reaction was stirred at 100 °C for an additional 15 min. The reaction was
concentrated, acidified with 1 N HCl, and extracted with EtOAc. The organic layer was
washed with brine, dried over MgSO , filtered and concentrated to yield the desired
product (75 mg, 78%) as a solid. LCMS Anal. Calc’d for C H F NO 537.12, found
24 19 8 4
[M+H] 537.9.
Example 103
To a solution of Intermediate 103I (20 mg, 0.037 mmol) in MeCN (1 mL) was
added 3H-[1,2,3]triazolo[4,5-b]pyridinol (7.60 mg, 0.056 mmol), 4-aminobenzonitrile
(6.59 mg, 0.056 mmol), and EDC (10.70 mg, 0.056 mmol). The resulting mixture was
stirred at rt overnight. The reaction mixture was diluted with MeCN and purified by
preparative HPLC (MeCN/H O/TFA) to yield the desired product (11 mg, 46%) as a
solid. LCMS Anal. Calc’d for C H F N O 637.16, found [M+H] 637.9. H NMR (500
31 23 8 3 3
MHz, CD OD) δ 7.67 (d, J = 9.08 Hz, 2 H), 7.56 - 7.63 (m, 4 H), 7.22 - 7.26 (m, 2 H),
7.15 - 7.20 (m, 2 H), 7.04 - 7.09 (m, 2 H), 4.12 (t, J = 6.05 Hz, 2 H), 2.33 - 2.44 (m, 2 H),
2.30 (s, 3 H), 2.02 - 2.09 (m, 2 H).
Example 104. (S)Aminop-tolyl(4-(4,4,4-trifluorobutoxy)phenyl)
(trifluoromethyl)-5,6-dihydropyridin-2(1H)-one
Intermediate 104A. (S)(1,3-Dioxoisoindolinyl)-N-(1,1,1-trifluorooxop-tolyl-
2-(4-(4,4,4-trifluorobutoxy)phenyl)butanyl)acetamide
11841-PCT
O CF
To a solution of 2-(1,3-dioxoisoindolinyl)acetic acid (592 mg, 2.88 mmol)
in dry DCM (10 mL) was added PPh (2269 mg, 8.65 mmol) fairy rapidly, and then
CCl CN (500 mg, 3.46 mmol) was added dropwise. The mixture was stirred at rt for 3 h
and a solution of Intermediate 2F, isomer 2 (500 mg, 1.15 mmol) in dry DCM (3 mL),
followed by pyridine (0.3 mL) were added. The mixture was stirred at rt overnight. The
mixture was diluted with DCM (10 mL) and washed with sat’d NaHCO (2 × 8 mL). The
organic layer was dried over anhydrous MgSO , filtered and concentrated. The residue
was purified by silica gel chromatography to yield the desired product (620 mg, 87%).
LCMS Anal. Calc’d for C H F N O 620.17, found [M+H] 621.3.
31 26 6 2 5
Intermediate 104B. (S)(2-Oxop-tolyl(4-(4,4,4-trifluorobutoxy)phenyl)
(trifluoromethyl)-1,2,5,6-tetrahydropyridinyl)isoindoline-1,3-dione
Intermediate 104A (145 mg, 0.234 mmol) was dissolved in MeOH (2.2 mL)
and then 1 N NaOH (0.2 mL) was added. The mixture was stirred at 69 °C for 45 min
and added another 0.2 mL of 1 N NaOH. The reaction was heated at 130 °C under
microwave conditions for 10 min. The mixture was neutralized with 1 N HCl and then
concentrated. The residue was purified by silica gel chromatography (12 g silica gel,
11841-PCT
eluted with EtOAc in hexanes) to yield the desired product (80 mg, 57%). LCMS Anal.
Calc’d for C H F N O 602.16, found [M+H] 603.3.
31 24 6 2 4
Example 104
[00349] To a solution of Intermediate 104B (80 mg, 0.133 mmol) in 1 mL of EtOH
was added 1 mL of 2 N MeNH in MeOH. The mixture was stirred at 67 °C for 24 h.
The solvent was removed in vacuo and the crude product was purified by silica gel
chromatography (4 g silics gel, eluted with EtOAc in hexanes) to yield the desired
product (32.3 mg, 52%) as a light brown solid. LCMS Anal. Calc’d for C H F N O
23 22 6 2 2
472.16, found [M+H] 473.2. H NMR (500 MHz, CD OD) δ 7.49 (d, J = 8.8 Hz, 2 H),
7.31 - 7.17 (m, 4 H), 7.04 - 6.92 (m, 2 H), 4.08 (s, 2 H), 3.46 (d, J = 16.2 Hz, 1 H), 3.21
(d, J = 16.2 Hz, 1 H), 2.44 - 2.30 (m, 5 H), 2.09 - 1.99 (m, 2 H).
Example 105. (S)Methyl-N-(2-oxop-tolyl(4-(4,4,4-trifluorobutoxy)phenyl)
(trifluoromethyl)-1,2,5,6-tetrahydropyridinyl)benzamide
To a solution of 104 (15 mg, 0.032 mmol) in dry DCM (0.5 mL) was added 2-
methylbenzoyl chloride (5.4 mg, 0.035 mmol) and pyridine (2.8 μL, 0.035 mmol). The
mixture was stirred at rt for 2 h and then concentrated. The residue was purified by
preparative HPLC (MeCN/H O/TFA) to yield the desired product. LCMS Anal. Calc’d
for C31H28F6N2O3 590.20, found [M+H] 591.3. H NMR (500 MHz, CD3OD) δ 7.56 (d,
J = 8.80 Hz, 2 H), 7.11 - 7.29 (m, 8 H), 6.98 (d, J = 9.08 Hz, 2 H), 4.06 (t, J = 6.05 Hz, 2
H), 3.73 (d, J = 17.06 Hz, 1 H), 3.46 (d, J = 16.78 Hz, 1 H), 2.33 (s, 3 H), 2.30 - 2.42 (m,
2 H), 2.22 (s, 3 H), 1.98 - 2.06 (m, 2 H).
Example 106. (S)Phenoxyp-tolyl(4-(4,4,4-trifluorobutoxy)phenyl)
(trifluoromethyl)-5,6-dihydropyridin-2(1H)-one
11841-PCT
Intermediate 106A. (S)Phenoxy-N-(1,1,1-trifluorooxop-tolyl(4-(4,4,4-
trifluorobutoxy)phenyl)butanyl)acetamide
O CF
To a mixture of triphenylphosphine (138 mg, 0.318 mmol) in dry DCM (0.8
mL) was added 2-phenoxyacetic acid (26 mg, 0.173 mmol), followed by
trichloroacetonitrile (30 mg, 0.208 mmol). The mixture was stirred at rt for 2.5 h. To the
mixture was added a solution of Intermediate 2F, isomer 2 (30 mg, 0.069 mmol) in dry
DCM (0.5 mL) followed by pyridine (17 μL, 0.208 mmol). The reaction was stirred at rt
overnight. The mixture was concentrated and purified by preparative HPLC
(MeOH/H O/TFA) to yield the desired product (27 mg, 69%) as a brown oil. LCMS
Anal. Calc’d for C H F NO 567.18, found [M+H] 568.3.
29 27 6 4
Example 106
To a solution of Intermediate 106A (26 mg, 0.046 mmol) in MeOH (0.5 mL)
was added 1 N NaOH (60 μL). The mixture was heated at 130 °C under microwave
conditions for 10 min. The mixture was neutralized with 1 N HCl and concentrated. The
residue was purified by preparative HPLC (MeCN/H O/TFA) to yield the desired product
(1.5 mg, 6%) as a light brown oil. LCMS Anal. Calc’d for C H F NO 549.17, found
29 25 6 3
11841-PCT
[M+H] 550.3. H NMR (500 MHz, CD OD) δ 7.59 (d, J = 8.80 Hz, 2 H), 7.33 (d, J =
8.25 Hz, 2 H), 7.13 (d, J = 8.25 Hz, 2 H), 7.01 - 7.08 (m, 4 H), 6.85 - 6.90 (m, 1 H), 6.38
(dd, J = 8.67, 0.96 Hz, 2 H), 4.10 - 4.15 (m, 2 H), 3.71 - 3.76 (m, 1 H), 3.61 - 3.67 (m, 1
H), 2.34 - 2.45 (m, 2 H), 2.30 (s, 3 H), 2.02 - 2.11 (m, 2 H).
Example 107. 6-(4-Butoxyphenyl)methyloxop-tolyl-1,2,5,6-tetrahydropyridine-
3-carbonitrile
Intermediate 107A. (Z)-N-(1-(4-Butoxyphenyl)ethylidene)methylpropane
sulfinamide
To a stirred solution of 1-(4-butoxyphenyl)ethanone (3 g, 15.60 mmol) and 2-
methylpropanesulfinamide (2.84 g, 23.41 mmol) in THF (50 mL) was added
tetraethoxytitanium (8.90 g, 39.0 mmol). The reaction was heated to 70 °C for 3 d. Cold
water was added and the reaction was stirred vigorously for 20 min. The mixture was
filtered through Celite® and the filtrated was diluted with EtOAc. The organic solution
was washed with H O, brine, dried over MgSO , filtered and concentrated. The crude
product was by silica gel chromatography (220 g silica gel, eluted with EtOAc in
hexanes) to yield the desired product (4 g, 87%) as a yellow oil. H NMR (500 MHz,
CDCl ) δ 7.88 (d, J = 8.80 Hz, 2 H), 6.91 (d, J = 8.80 Hz, 2 H), 4.02 (t, J = 6.46 Hz, 2
H), 2.73 (s, 3 H), 1.75 - 1.83 (m, 2 H), 1.46 - 1.56 (m, 2 H), 1.32 (s, 9 H), 0.99 (t, J =
7.43 Hz, 3 H).
11841-PCT
Intermediate 107B. Methyl 3-(4-butoxyphenyl)(1,1-
dimethylethylsulfinamido)butanoate
O HN
To a stirred solution of diisopropylamine (3.86 mL, 27.1 mmol) in THF (40
mL) at -78 °C was added n-butyllithium (22.57 mL, 27.1 mmol) dropwise. The reaction
was slowly warmed up to -20 °C and stirred for 45 min. The reaction was cooled to -78
°C and methyl acetate (2.006 g, 27.1 mmol) was added dropwise. After 30 min,
chlorotitanium triisopropoxide (8.09 mL, 33.8 mmol) in THF (40 mL) was added
dropwise. The reaction was stirred at -78 °C for 1 h. Intermediate 107A (4 g, 13.54
mmol) in THF (15 mL) was added dropwise and the reaction was stirred at -78 °C for 2 h.
The reaction was quenched by addition of sat’d NH Cl solution and stirred vigorously
while warmed to rt. The mixture was filtered through Celite® and washed with EtOAc.
The filtrate was washed with H O, brine, dried over MgSO , filtered and concentrated.
The crude product was purified by silica gel chromatography (220 g silica gel, eluted
with EtOAc in hexanes) to yield the desired product (4.33 g, 87%) as a light yellow oil.
LCMS Anal. Calc’d for C H NO S 369.20, found [M+H] 370.2. H NMR (500 MHz,
19 31 4
CDCl ) δ 7.31 (d, J = 8.80 Hz, 2 H), 6.85 (d, J = 8.80 Hz, 2 H), 3.95 (t, J = 6.46 Hz, 2
H), 3.62 (s, 3 H), 2.05 (s, 2 H), 1.74 - 1.80 (m, 2 H), 1.74 (s, 3 H), 1.44 - 1.54 (m, 2 H),
1.29 (s, 9 H), 0.98 (t, J = 7.43 Hz, 3 H).
Intermediate 107C. Methyl 3-amino(4-butoxyphenyl)butanoate
O NH
To a stirred solution of Intermediate 107B (1 g, 2.71 mmol) in MeOH (6 mL)
was added 4 N HCl (3.38 mL, 13.53 mmol). The reaction was stirred at rt for 4 h. The
reaction mixture was concentrated in vacuo and diluted with EtOAc. The organic layer
was washed with saturated NaHCO , dried over MgSO , filtered and concentrated to
H NMR (500 MHz, CDCl ) δ
yield the desired product (700 mg, 97%) as a yellow oil. 3
11841-PCT
7.38 (d, J = 8.80 Hz, 2 H), 6.86 (d, J = 8.80 Hz, 2 H), 3.95 (t, J = 6.46 Hz, 2 H), 3.59 (s,
3 H), 1.73 - 1.80 (m, 2 H), 1.53 (s, 2 H), 1.45 - 1.52 (m, 2 H), 1.19 (s, 3 H), 0.98 (t, J =
7.29 Hz, 3 H).
Intermediate 107D. Methyl 3-(4-butoxyphenyl)(2-cyanoacetamido)butanoate
O HN O
To a stirred solution of 2-cyanoacetic acid (128 mg, 1.507 mmol) in CH Cl (5
mL) was added oxalyl chloride (0.754 mL, 1.507 mmol) and 1 drop of DMF. The
reaction was stirred at rt for 1 h and then concentrated. The resulting acid chloride was
dissolved in CH Cl (1 mL) and was then added to Intermediate 107C (200 mg, 0.754
mmol) and pyridine (0.183 mL, 2.261 mmol)in CH Cl (5 mL). The reaction was stirred
at rt for 5 h. The reaction mixture was concentrated and the residue was diluted with
EtOAc. The organic layer was washed with saturated NH Cl, dried over MgSO , filtered
and concentrated. The crude product was purified by silica gel chromatography (24 g
silica gel, eluted with EtOAc in hexanes) to yield the desired product (218 mg, 87%) as a
clear oil. H NMR (500 MHz, CDCl ) δ 7.22 (d, J = 8.80 Hz, 2 H), 6.85 (d, J = 8.80 Hz,
2 H), 3.94 (t, J = 6.46 Hz, 2 H), 3.65 (s, 3 H), 3.30 (s, 2 H), 3.03 (d, J = 15.13 Hz, 1 H),
2.85 (d, J = 15.13 Hz, 1 H), 1.80 (s, 3 H), 1.71 - 1.78 (m, 2 H), 1.44 - 1.53 (m, 2 H), 0.97
(t, J = 7.29 Hz, 3 H).
Intermediate 107E. 6-(4-Butoxyphenyl)hydroxymethyloxo-1,2,5,6-
tetrahydropyridinecarbonitrile
To a stirred solution of Intermediate 107D (218 mg, 0.656 mmol) in MeOH (5
mL) was added 4.37 M NaOMe (0.750 mL, 3.28 mmol) in methanol solution. The
reaction was heated to 55 °C for 5 h. The reaction mixture was concentrated and the
11841-PCT
residue was diluted with EtOAc. The organic layer was washed with 1 M HCl, dried over
MgSO , filtered and concentrated to yield the desired product (200 mg, 102%) as a light
yellow solid. LCMS Anal. Calc’d for C H N O 300.15, found [M+H] 301.1.
17 20 2 3
Intermediate 107F. 6-(4-Butoxyphenyl)chloromethyloxo-1,2,5,6-
tetrahydropyridinecarbonitrile
To a stirred solution of Intermediate 107E (130 mg, 0.433 mmol) in
ClCH CH Cl (3 mL) was added POCl (0.056 mL, 0.606 mmol) and Hunig's base (0.113
2 2 3
mL, 0.649 mmol). The reaction was stirred at rt for 30 min and then heated to 85 °C for 3
h. The reaction mixture was concentrated and the residue was diluted with EtOAc. The
organic layer was washed with saturated NH Cl, dried over MgSO , filtered and
concentrated. The crude product was purified by silica gel chromatography (24 g silica
gel, eluted with EtOAc in hexanes) to yiled the desired product (102 mg, 74%) as a white
solid. LCMS Anal. Calc’d for C H ClN O 318.11, found [M+H] 319.2. H NMR
17 19 2 2
(500 MHz, CDCl ) δ 7.23 (d, J = 8.80 Hz, 2 H), 6.90 (d, J = 8.80 Hz, 2 H), 3.97 (t, J =
6.60 Hz, 2 H), 2.05 (s, 2 H), 1.74 - 1.82 (m, 2 H), 1.69 (s, 3 H), 1.46 - 1.55 (m, 2 H), 0.99
(t, J = 7.43 Hz, 3 H).
Example 107
To a stirred solution of Intermediate 107F (11 mg, 0.035 mmol), p-
tolylboronic acid (5.63 mg, 0.041 mmol), and 1,1'-bis(di-tert-butylphosphino)ferrocene
palladium dichloride (2.270 mg, 3.45 µmol) in dioxane (1 mL) was added CsF (10.48 mg,
0.069 mmol). The reaction was degassed for 10 min and heated to 80 °C for 2 h. The
reaction mixture was concentrated. The residue was diluted with EtOAc, washed with
H O, brine, dried over MgSO , filtered and concentrated. The crude material was
purified by preparative HPLC (MeOH/H O/TFA) to yield the desired product (5.7 mg,
44%) as a brown solid. LCMS Anal. Calc’d for C H N O 374.20, found [M+H] 375.2.
24 26 2 2
H NMR (400 MHz, CD OD) δ 7.41 (d, J = 8.14 Hz, 2 H), 7.32 (d, J = 8.80 Hz, 2 H),
11841-PCT
7.28 (d, J = 8.14 Hz, 2 H), 6.89 (d, J = 8.80 Hz, 2 H), 3.96 (t, J = 6.38 Hz, 2 H), 3.46 (d,
J = 18.05 Hz, 1 H), 3.24 (d, J = 17.83 Hz, 1 H), 2.38 (s, 3 H), 1.69 - 1.78 (m, 2 H), 1.65
(s, 3 H), 1.43 - 1.55 (m, 2 H), 0.97 (t, J = 7.48 Hz, 3 H).
Example 108. 6-(5-Hexyloxazolyl)methyloxop-tolyl-1,2,5,6-
tetrahydropyridinecarbonitrile
Intermediate 108A. Ethyl 2-(2-cyanoacetamido)methyloxop-tolylbutanoate
To a solution of Intermediate 3C (2.192 g, 21.18 mmol) in DCM (30 mL)
under argon was added Intermediate 102C (1.2 g, 4.81 mmol), pyridine (0.779 mL, 9.63
mmol) and DMAP (0.059 g, 0.481 mmol). The reaction mixture was stirred at rt for 1 h.
The reaction mixture was loaded onto silica gel (25 g) and washed with EtOAc (4 × 50
mL). The filtrate was concentrated in vacuo to a dark red oil. The oil was dissolved in
EtOAc (100 mL) and washed with water (2 × 50 mL). The organic phase was dried over
MgSO and concentrated in vacuo. The residue was purified by silica gel
chromatography (80 g silica gel, eluted with EtOAc in hexanes) to afford the desired
product (1.28 g, 84%) as yellow oil. LCMS Anal. Calc’d for C H N O 316.1, found
17 20 2 4
[M+H] 317.1. H NMR (500 MHz, CDCl ) δ 7.82 (d, J = 8.0 Hz, 2 H), 7.39 (s, 1 H),
7.24 - 7.29 (m, 2 H), 4.45 (d, J = 18.2 Hz, 1 H), 4.22 - 4.31 (m, 2 H), 3.47 (d, J = 18.2
Hz, 1 H), 3.28 - 3.38 (m, 2 H), 2.42 (s, 3 H), 1.74 (s, 3 H), 1.24 (t, J = 7.0 Hz, 3 H).
11841-PCT
Intermediate 108B. Ethyl 5-cyanomethyloxop-tolyl-1,2,3,6-tetrahydropyridine-
2-carboxylate
Intermediate 108A (1.2837 g, 4.06 mmol) was dissolved in a mixture of THF
(15 mL) and water (3.00 mL) in a 25 mL 1 neck pear shaped flask that was equipped with
a magnetic stirrer. Lithium hydroxide monohydrate (0.204 g, 4.87 mmol) was added and
the reaxction mixture was stirred at rt for 1 h. The reaction mixture was acidified to pH 4
with AcOH, diluted with EtOAc (50 mL) and the solution was washed with water (20
mL). The organic phase was dried over MgSO and concentrated in vacuo to give the
desired product (1.40 g, 115%) as yellow oil. LCMS Anal. Calc’d for C H N O 298.1,
17 18 2 3
found [M+H] 299.1.
Intermediate 108C. 5-Cyanomethyloxop-tolyl-1,2,3,6-tetrahydropyridine
carboxylic acid
Intermediate 108B (1.211 g, 4.06 mmol) was dissolved in acetic acid (95 mL)
in a 250 mL 1 neck pear shaped flask that was equipped with a magnetic stirrer. HCl
(11.67 mL, 142 mmol) was added and the reaction mixture was stirred at 60 °C overnight.
The reaction mixture was concentrated in vacuo to give the desired product as a pale
yellow solid. LCMS Anal. Calc’d for C H N O 270.1, found [M+H] 271.0. H NMR
14 2 3
(500 MHz, CDCl ) δ 7.48 (d, J = 8.3 Hz, 2 H), 7.23 (d, J = 7.7 Hz, 2 H), 3.39 (d, J =
18.2 Hz, 1 H), 2.83 (d, J = 18.2 Hz, 1 H), 2.35 (s, 3 H), 1.54 (s, 3 H).
11841-PCT
Intermediate 108D. Ethyl 5-hexyloxazolecarboxylate
Ethyl 2-isocyanoacetate (1.0 g, 8.84 mmol) was dissolved in DMF (5 mL) in a 25 mL 1
neck pear shaped flask that was equipped with a magnetic stirrer and an Ar inlet. DBU
(1.999 mL, 13.26 mmol) and heptanoyl chloride (1.770 mL, 11.49 mmol) were added and
the reaction mixture was stirred at 80 °C for 6 h. The reaction mixture was poured into
water(50 mL) and extracted with EtOAc (3 × 30 mL). The phases were seperated and the
organic phase was dried over MgSO and concentrated in vacuo to a a dark oil. The
desired product was isolated by distillattion at 90-95°C at 0.3 mmHg as a clear oil (0.89
g, 45%). LCMS Anal. Calc’d for C H NO 225.1, found [M+H] 226.1. H NMR (500
12 19 3
MHz, CDCl ) δ 7.76 (s, 1H), 4.37 (q, J = 7.2 Hz, 2H), 3.03 (t, J = 7.6 Hz, 2H), 1.71 -
1.64 (m, 2H), 1.38 (t, J = 7.2 Hz, 3H), 1.35 - 1.26 (m, 6H), 0.86 (t, J = 6.3 Hz, 3H).
Intermediate 108E. 1-Aminooctanone, HCl salt
Intermediate 108D (0.8889 g, 3.95 mmol) was stirred in HCl (16.44 mL, 99
mmol) in a 100 mL 1 neck pear shaped flask that was equipped with a magnetic stirrer.
The reaction mixture was heated to 100 °C and stirred for 6 h. The reaction mixture was
concentrated in vacuo to a tan solid that was triturated in ether (15 mL). The slurry was
filtered and was washed with ether (3 mL). The filter cake was dried under vacuum to
give the desired product (0.57 g, 80%) as an off-white solid. H NMR (500 MHz,
MeOD) δ 3.97 (s, 2 H), 2.56 (t, J = 7.4 Hz, 2 H), 1.62 (quin, J = 7.4 Hz, 2 H), 1.26 - 1.40
(m, 6 H), 0.88 - 0.93 (m, 3 H).
Intermediate 108F. 5-Cyanomethyloxo-N-(2-oxooctyl)p-tolyl-1,2,3,6-
tetrahydropyridinecarboxamide
11841-PCT
Intermediate 108C (0.1 g, 0.370 mmol) was dissolved in DCM (4 mL) in a 10
mL 1 neck pear shaped flask that was equipped with a magnetic stirrer and an Ar inlet.
EDC (0.099 g, 0.518 mmol), HOBT (0.068 g, 0.444 mmol), Intermediate 108E (0.080 g,
0.444 mmol) and DIEA (0.194 mL, 1.110 mmol) were added and the reaction mixture
was stirred at rt overnight. The reaction mixture was concentrated in vacuo to an orange
oil that was purified by silica gel chromatography (40 g silica gel, eluted with 0-100%
EtOAc in hexanes) to give the desired product (0.09 g, 61%) as yellow oil.
Example 108
Intermediate 108F (0.045 g, 0.114 mmol) was dissolved in 1,2-dichloroethane
(2 mL) in a 10 mL 1 neck pear shaped flask that was equipped with a magnetic stirrer and
an Ar inlet. POCl (0.042 mL, 0.455 mmol) and DIEA (0.089 mL, 0.512 mmol) were
added and the reaction mixture was stirred at 85 °C overnight. The reaction mixture was
cooled in an ice/water bath and was quenched with water (3 mL). The mixture was
extracted with EtOAc (2 × 5 mL) and the organic phases were combined, dried over
MgSO and concentrated in vacuo to a brown oil. The crude product was purified by
preparative HPLC (MeOH/H O/TFA) to yield the desired product (3.5 mg, 8%) as a
yellow solid. LCMS Anal. Calc’d for C H N O 377.2, found [M+H] 378.2. H NMR
23 27 3 2
(500 MHz, CDCl ) δ 7.60 (d, J = 8.0 Hz, 2 H), 7.31 (d, J = 8.0 Hz, 2 H), 6.81 (br. s., 1
H), 3.65 (d, J = 17.9 Hz, 1 H), 3.09 (d, J = 17.9 Hz, 1 H), 2.63 (t, J = 7.4 Hz, 2 H), 2.43
(s, 3 H), 1.76 (s, 3 H), 1.57 - 1.67 (m, 2 H), 1.23 - 1.42 (m, 6 H), 0.89 (t, J = 6.7 Hz, 3 H).
Example 109. 6-(1-Heptyl-1H-pyrazolyl)methyloxop-tolyl-1,2,5,6-
tetrahydropyridinecarbonitrile
11841-PCT
Intermediate 109A. 5-Cyano-N-methoxy-N,2-dimethyloxop-tolyl-1,2,3,6-
tetrahydropyridinecarboxamide
Intermediate 108C (0.25 g, 0.925 mmol) was dissolved in DCM (15 mL) in a
mL 1 neck rb flask that was equipped with a magnetic stirrer and an Ar inlet. N,O-
Dimethylhydroxylamine (0.062 g, 1.017 mmol), EDC (0.195 g, 1.017 mmol) and N-
methylmorpholine (0.112 mL, 1.017 mmol) were added and the reaction mixture was
stirred at rt overnight. The reaction solvent was removed under vacuum. The residue
was dissolved in EtOAc (10 mL) and washed with water (5 mL). The organic phaase was
dried over MgSO and concentrated in vacuo to a dark solid. The crude product was
purified by silica gel chromatography (40 g silica gel, eluted with 0-100% EtOAc in
hexanes) to give the desired product (0089 g, 31%) as a white solid. LCMS Anal. Calc’d
for C H N O 313.3, found [M+H] 314.1. H NMR (500 MHz, CDCl ) δ 7.67 (d, J =
17 19 3 3 3
8.3 Hz, 2 H), 7.30 (d, J = 8.0 Hz, 2 H), 3.81 (s, 3 H), 3.69 - 3.75 (m, 1 H), 3.22 (s, 3 H),
2.72 (d, J = 17.6 Hz, 1 H), 2.42 (s, 3 H), 1.63 (s, 3 H).
Intermediate 109B. 6-Methyloxopropioloylp-tolyl-1,2,5,6-tetrahydropyridine
carbonitrile
11841-PCT
Intermediate 109A (0.0887 g, 0.283 mmol) was dissolved in tetrahydrofuran
(1 mL) in a 25 mL 1 neck pear shaped flask that was equipped with a magnetic stirrer and
an Ar inlet. Ethynylmagnesium bromide (5.66 mL, 2.83 mmol) was added dropwise and
the reaction mixture was stirred at 35 °C for 4 h. The reaction mixture was cooled to rt,
quenched with sat’d. aq NH Cl (5 mL) and extracted with EtOAc (2 × 10 mL). The
organic phases were combined and concentrated in vacuo. The residue was purified by
silica gel chromatography (24 g silica gel, eluted with 0-100% EtOAc in hexanes) to give
the desired product (0.06 g, 78%) as an orange solid. LCMS Anal. Calc’d for
C H N O 278.1, found [M+H] 279.0.
17 14 2 2
Example 109
Intermediate 109B (0.0613 g, 0.220 mmol) was dissolved in ethanol (3 mL) in
a 25 mL 1 neck pear shaped flask that was equipped with a magnetic stirrer.
Heptylhydrazine, HCl (0.073 g, 0.441 mmol) and TEA (0.061 mL, 0.441 mmol) were
added and the reaction mixture was stirred at rt overnight. The reaction mixture was
concentrated and purified by preparative HPLC (MeOH/H O/TFA) to yield the desired
product (3.2 mg, 4%) as a white solid. LCMS Anal. Calc’d for C H N O 390.2, found
24 30 4
[M+H] 391.2. H NMR (500 MHz, CDCl ) δ 7.55 (d, J = 8.3 Hz, 2 H), 7.25 - 7.30 (m, 2
H), 6.35 (s, 1 H), 6.15 (d, J = 1.7 Hz, 1 H), 3.98 - 4.08 (m, 2 H), 3.57 (d, J = 17.9 Hz, 1
H), 3.01 (d, J = 17.9 Hz, 1 H), 2.41 (s, 3 H), 1.81 (quin, J = 7.3 Hz, 2 H), 1.70 - 1.77 (m,
2 H), 1.68 (s, 3 H), 1.16 - 1.34 (m, 6 H), 0.87 (t, J = 7.0 Hz, 3 H).
Examples 110-273 expressed by Formula (II), unless noted in the table, may
be made by one skilled in the art by appropriate application of the procedures described
11 15
for Examples 1-16 and Examples 102-. R to R are hydrogen, unless noted in the
table.
11841-PCT
INFORMAL
12 14
11 15
(II)
3 4 1
1 2 6 11 15
Example R = R [M+H] HNMR (400 MHz, CDCl )
R R R R -R 3
N OMe
110 CF H 13 608.1 8.13 (d, J = 2.5 Hz, 1H),
3 R = CH
S-isomer 7.93 (dd, J = 9.1, 2.8 Hz,
F C O
1H), 7.46 (d, J = 9.1 Hz,
2H), 7.22 (s, 1H), 7.20 - 7.15
(m, 2H), 7.13 - 7.08 (m, 2H),
6.94 (d, J = 9.1 Hz, 2H),
6.67 (d, J = 9.1 Hz, 1H),
4.02 (t, J = 5.9 Hz, 2H), 3.90
(br. s., 3H), 3.56 - 3.38 (m,
2H), 2.39 - 2.25 (m, 5H),
2.10 - 2.01 (m, 2H).
11841-PCT
INFORMAL
3 4 1
1 2 6 11 15
Example R = R [M+H] HNMR (400 MHz, CDCl )
R R R R -R 3
111 CF H 13 645.2 7.88 (d, J = 8.5 Hz, 2H), 7.60
3 R = CH
S-isomer (d, J = 8.8 Hz, 2H), 7.54 (d, J
F C O
= 8.5 Hz, 2H), 7.29 (d, J =
8.0 Hz, 2H), 7.16 (d, J = 7.7
Hz, 2H), 7.00 (d, J = 8.8 Hz,
2H), 4.07 (t, J = 5.9 Hz, 2H),
3.75 - 3.46 (m, 2H), 2.43 -
2.32 (m, 2H), 2.29 (s, 3H),
2.11 - 1.97 (m, 2H).
112 CF H 13 480.0
3 R = CH
113 CF H 13 526.1 9.07 (d, J = 1.1 Hz, 1H),
3 R = CH
S-isomer 7.63 (d, J = 8.5 Hz, 2H),
F C O
7.16 - 7.09 (m, J = 8.0 Hz,
2H), 7.09 - 7.03 (m, 2H),
6.93 - 6.86 (d, J = 7.7 Hz,
2H), 4.12 (t, J = 6.1 Hz, 2H),
4.00 (s, 1H), 3.92 (d, J =
11841-PCT
INFORMAL
3 4 1
1 2 6 11 15
Example R = R [M+H] HNMR (400 MHz, CDCl )
R R R R -R 3
17.6 Hz, 1H), 3.77 (d, J =
17.6 Hz, 1H), 2.46 - 2.34 (m,
2H), 2.30 (s, 3H), 2.12 - 2.02
(m, 2H).
114 CF H 13 524.1
3 R = CH
S-isomer
F C O
115 CF H 577.2
R = CH
S-isomer
F C O
NH 13
116 CF H 554.2 7.42 (d, J = 8.5 Hz, 2H),
N R = CH
Rac 7.16 (d, J = 8.0 Hz, 2H),
F C O
7.10 (br. s., 1H), 6.95 (dd, J
= 15.0, 8.4 Hz, 4H), 3.97 (t,
J = 6.3 Hz, 2H), 3.59 (d, J =
.5 Hz, 2H), 2.36 (s, 3H),
2.16 - 2.04 (m, 2H), 1.86 -
1.77 (m, 2H), 1.69 - 1.59 (m,
2H), 1.59 - 1.50 (m, 2H),
11841-PCT
INFORMAL
3 4 1
1 2 6 11 15
Example R = R [M+H] HNMR (400 MHz, CDCl )
R R R R -R 3
0.93 - 0.79 (m, 3H)
NH 13
117 CF H 540.1 7.43 (d, J = 8.5 Hz, 2H),
N R = CH
Rac 7.17 (d, J = 7.7 Hz, 2H),
7.03 - 6.91 (m, 5H), 3.99 (t, J
= 5.9 Hz, 2H), 3.65 - 3.53
(m, 2H), 2.37 (s, 3H), 2.23 -
2.11 (m, 2H), 1.92 - 1.82 (m,
2H), 1.82 - 1.72 (m, 2H)
NH 13
118 CF H 576.1 7.44 (d, J = 8.5 Hz, 2H),
N R = CH
Rac 7.17 (d, J = 8.0 Hz, 2H),
6.96 (dd, J = 11.4, 8.7 Hz,
4H), 6.80 (br. s., 1H), 4.07 -
4.01 (m, 2H), 3.59 (d, J =
7.4 Hz, 2H), 2.37 (s, 3H),
2.33 - 2.19 (m, 2H), 2.10 (dd,
J = 9.5, 5.6 Hz, 2H)
119 CF H 541.2 7.44 (d, J = 8.3 Hz, 2H),
R = CH
S-isomer 7.21 - 7.16 (m, 2H), 7.14 -
F C O
11841-PCT
INFORMAL
3 4 1
1 2 6 11 15
Example R = R [M+H] HNMR (400 MHz, CDCl )
R R R R -R 3
7.09 (m, 2H), 6.96 (d, J =
8.8 Hz, 2H), 4.06 (t, J = 5.9
Hz, 3H), 3.58 - 3.27 (m, 2H),
2.48 - 2.27 (m, 5H), 2.09 (dd,
J = 9.5, 5.9 Hz, 2H), 0.97 -
0.80 (m, 2H), 0.75 - 0.61 (m,
2H), 0.38 (d, J = 3.6 Hz, 2H)
O 13
120 CF H 555.2 7.43 (d, J = 8.5 Hz, 2H),
R = CH
S-isomer 7.20 - 7.03 (m, 5H), 6.97 -
F C O
6.88 (m, 2H), 4.36 - 4.22 (m,
1H), 4.08 - 3.98 (m, 2H),
3.53 - 3.27 (m, 2H), 2.44 -
2.16 (m, 8H), 2.12 - 2.02 (m,
2H), 1.78 - 1.51 (m, 4H)
121 CF H 583.3 7.49 - 7.37 (m, 2H), 7.22 -
R = CH
S-isomer 7.07 (m, 4H), 6.97 - 6.84 (m,
F C O
3H), 6.74 (d, J = 8.0 Hz,
1H), 4.10 - 3.95 (m, 3H),
11841-PCT
INFORMAL
3 4 1
1 2 6 11 15
Example R = R [M+H] HNMR (400 MHz, CDCl )
R R R R -R 3
3.77 - 3.62 (m, 1H), 3.52 -
3.26 (m, 2H), 2.42 - 2.25 (m,
6H), 2.15 - 1.96 (m, 3H),
1.86 - 1.64 (m, 2H), 1.64 -
1.44 (m, 4H), 1.35 - 1.16 (m,
3H), 1.14 - 0.93 (m, 4H)
OH 13
122 CF H 593.3 7.55 (d, J = 8.5 Hz, 2H),
R = CH
S-isomer 7.32 (d, J = 8.3 Hz, 2H),
F C O
7.20 (d, J = 8.0 Hz, 2H),
7.14 - 7.09 (d, J = 8.8 Hz,
2H), 7.02 - 6.97 (d, J = 8.8
Hz, 2H), 6.68 - 6.62 (m, 2H),
4.08 (t, J = 6.1 Hz, 2H), 3.67
(d, J = 17.1 Hz, 1H), 3.51 (d,
J = 17.1 Hz, 1H), 2.45 - 2.35
(m, 2H), 2.34 (s, 3H), 2.09 -
2.00 (m, 2H).
11841-PCT
INFORMAL
3 4 1
1 2 6 11 15
Example R = R [M+H] HNMR (400 MHz, CDCl )
R R R R -R 3
123 CF H 515.2 7.57 - 7.50 (m, J = 8.8 Hz,
R = CH
S-isomer 2H), 7.27 - 7.23 (m, J = 8.3
F C O
Hz, 2H), 7.23 - 7.19 (m, J =
8.3 Hz, 2H), 7.02 - 6.97 (m,
J = 9.1 Hz, 2H), 4.08 (t, J =
6.1 Hz, 2H), 3.60 (d, J =
17.1 Hz, 1H), 3.46 (d, J =
17.1 Hz, 1H), 2.57 (s, 3H),
2.45 - 2.37 (m, 2H), 2.36 (s,
3H), 2.11 - 1.99 (m, 2H).
OMe 13
124 CF F 643.3 7.90 (s, 1H), 7.62 (d, J = 8.8
R = CH
Rac Hz, 2H), 7.25 - 7.17 (m, 6H),
F C O
6.98 (d, J = 8.8 Hz, 2H),
6.95 (br. s., 1H), 6.78 (d, J =
9.1 Hz, 2H), 4.05 (t, J = 5.9
Hz, 2H), 3.81 - 3.71 (m, 3H),
2.44 - 2.27 (m, 5H), 2.13 -
2.03 (m, 2H)
11841-PCT
INFORMAL
3 4 1
1 2 6 11 15
Example R = R [M+H] HNMR (400 MHz, CDCl )
R R R R -R 3
NH 13
125 CF H 512.1 7.45 (d, J = 8.5 Hz, 3H),
N R = CH
Rac 7.13 (d, J = 7.7 Hz, 2H),
6.93 (d, J = 7.7 Hz, 4H),
4.18 (t, J = 6.5 Hz, 2H), 3.68
- 3.52 (m, 2H), 2.67 - 2.56
(m, 2H)
NH 13
126 CF H 466.2
N R = CH
NH 13
127 CF H 480.1 7.50 - 7.40 (m, 4H), 7.16 (d,
N R = CH
Rac J = 7.7 Hz, 2H), 7.09 (br. s.,
1H), 6.98 (d, J = 7.7 Hz,
2H), 6.17 (br. s., 1H), 2.36
(s, 5H), 2.21 (d, J = 3.6 Hz,
2H), 1.82 - 1.74 (m, 2H),
1.70 - 1.62 (m, 2H)
128 CF H 591.3
R = CH
S-isomer
11841-PCT
INFORMAL
3 4 1
1 2 6 11 15
Example R = R [M+H] HNMR (400 MHz, CDCl )
R R R R -R 3
129 CF H 591.3
R = CH
S-isomer
130 CF H 568.2 8.47 (d, J = 1.9 Hz, 1H),
R = CH
S-isomer 7.61 - 7.54 (ab quartet, J =
8.8 Hz, 2H), 7.24 - 7.20 (ab
quartet, J = 8.3 Hz, 2H),
7.19 - 7.15 (ab quartet, J =
8.3 Hz, 2H), 7.04 - 6.98 (m,
2H), 6.93 - 6.87 (m, 1H),
4.09 (t, J = 6.1 Hz, 2H), 3.75
(d, J = 17.1 Hz, 1H), 3.51 (d,
J = 16.8 Hz, 1H), 2.46 - 2.34
(m, 2H), 2.32 (s, 3H), 2.12 -
2.01 (m, 3H).
131 CF H 581.3
R = CH
S-isomer
11841-PCT
INFORMAL
3 4 1
1 2 6 11 15
Example R = R [M+H] HNMR (400 MHz, CDCl )
R R R R -R 3
N 13
132 CF H 570.2
R = CH
S-isomer
OMe 13
133 CF F 643.1 8.07 (br. s., 1H), 7.63 (d, J =
R = CH
Rac 8.8 Hz, 2H), 7.24 - 7.15 (m,
6H), 6.96 (d, J = 9.1 Hz,
2H), 6.76 (d, J = 8.8 Hz,
2H), 4.09 - 3.97 (m, 2H),
3.75 (s, 3H), 2.39 - 2.25 (m,
5H), 2.12 - 2.02 (m, 2H)
134 CF F 680.9
R = CH
Rac N
135 CF F 626.9
R = CH
F C N
11841-PCT
INFORMAL
3 4 1
1 2 6 11 15
Example R = R [M+H] HNMR (400 MHz, CDCl )
R R R R -R 3
N 13
136 CF H 594.1
N R = CH
S-isomer
137 CF H 661.1
R = CH
S-isomer
O OCF
138 CF F CN 422.8
R = CH
N OMe 13
140 CF F 643.9
R = CH
F C O
141 CF F 604.9
R = CH
F C O
N 11
142 CF H 560.1 9.17 (s, 1H), 7.59 (d, J = 8.8
N R = F
S-isomer Hz, 2H), 7.07 - 7.00 (m, 2H),
R = OCH
F C O
6.95 (t, J = 8.5 Hz, 1H), 6.69
(dd, J = 8.8, 2.5 Hz, 1H),
6.63 (dd, J = 12.7, 2.5 Hz,
11841-PCT
INFORMAL
3 4 1
1 2 6 11 15
Example R = R [M+H] HNMR (400 MHz, CDCl )
R R R R -R 3
1H), 4.09 (t, J = 6.1 Hz, 2H),
3.90 - 3.81 (m, 1H), 3.76 (s,
3H), 3.74 - 3.66 (m, 1H),
2.47 - 2.30 (m, 2H), 2.12 -
1.94 (m, 2H).
N 13
143 CF H 542.1 9.05 (s, 1H), 7.60 (d, J = 8.8
N R = OCH
S-isomer Hz, 2H), 7.04 (d, J = 9.1 Hz,
F C O
2H), 6.97 - 6.88 (m, 1H),
6.86 - 6.76 (m, 1H), 4.09 (t, J
= 6.1 Hz, 2H), 3.92 - 3.70
(m, 2H), 3.75 (S, 3H), 2.45 -
2.29 (m, 2H), 2.10 - 1.94 (m,
2H).
144 CF H CN 535.1 7.65 (br. s., 2H), 7.53 (d, J =
R = OCHF
S-isomer 9.1 Hz, 2H), 7.32 - 7.24 (m,
F C O
2H), 7.05 - 6.98 (m, 2H),
6.96 (t, J = 75 Hz, 1H), 4.14
- 3.97 (m, 2H), 3.73 (d, J =
11841-PCT
INFORMAL
3 4 1
1 2 6 11 15
Example R = R [M+H] HNMR (400 MHz, CDCl )
R R R R -R 3
3.3 Hz, 2H), 2.42 - 2.27 (m,
2H), 2.09 - 1.96 (m, 2H).
145 CF H CN 513.1 7.64 (d, J = 9.1 Hz, 2H), 7.52
S-isomer (d, J = 9.1 Hz, 2H), 7.03 (d, J
OCH CH
F C O
= 9.1 Hz, 4H), 4.12 (d, J =
6.9 Hz, 2H), 4.08 - 4.03 (m,
2H), 3.82 - 3.58 (m, 2H),
2.45 - 2.26 (m, 2H), 2.08 -
1.95 (m, 2H), 1.41 (t, J = 6.9
Hz, 3H).
12 13
146 CF H CN 519.1 8.15 (d, J = 1.7 Hz, 1H), 8.01
R and R
S-isomer - 7.96 (m, 2H), 7.93 (d, J =
F C O
8.0 Hz, 1H), 7.67 - 7.54 (m,
5H), 7.06 - 7.00 (m, 2H),
4.08 (s, 2H), 3.93 - 3.77 (m,
2H), 2.48 - 2.25 (m, 2H),
2.13 - 1.92 (m, 2H).
11841-PCT
INFORMAL
3 4 1
1 2 6 11 15
Example R = R [M+H] HNMR (400 MHz, CDCl )
R R R R -R 3
147 CF H CN 469.1 7.55 (d, J = 8.8 Hz, 2H), 7.52
R = CH
S-isomer - 7.49 (m, 2H), 7.33 (d, J =
8.0 Hz, 2H), 7.04 - 6.99 (m,
2H), 4.24 (t, J = 6.1 Hz, 2H),
3.77 - 3.66 (m, 2H), 2.75 -
2.63 (m, 2H), 2.41 (s, 3H).
OMe 11
148 CF H 621.2 7.49 - 7.41 (m, 2H), 7.35 (d,
R = CH
S-isomer J = 8.0 Hz, 2H), 7.03 - 6.65
R = CH
F C O
(m, 7H), 4.07 - 3.99 (m, 2H),
3.71 (s, 3H), 3.51 - 3.42 (m,
1H), 3.28 – 3.14 (m, 1H),
2.38 - 2.21 (m, 8H), 2.11 -
1.99 (m, 2H).
N 13
149 CF H 578.1 9.09 (s, 1H), 7.61 (d, J =
R = OCHF
S-isomer 8.8 Hz, 2H), 7.08 - 7.03 (m,
F C O
6H), 6.97 – 6.68 (m, 1H),
4.09 (t, J = 6.1 Hz, 2H), 3.92
(d, J = 17.9 Hz, 1H), 3.77 (d,
11841-PCT
INFORMAL
3 4 1
1 2 6 11 15
Example R = R [M+H] HNMR (400 MHz, CDCl )
R R R R -R 3
J = 17.9 Hz, 1H), 2.43 - 2.31
(m, 2H), 2.10 - 1.98 (m, 2H).
N 13
150 CF F 582.2 7.54 (d, J = 8.8 Hz, 2H),
R = CH
S-isomer 7.23 - 7.11 (m, 4H), 7.03 -
F C O
6.94 (m, 2H), 6.71 (s, 1H),
4.06 (t, J = 6.1 Hz, 2H), 3.98
(s, 1H), 3.71 (d, J = 17.1 Hz,
1H), 3.47 (d, J = 16.8 Hz,
1H), 2.45 - 2.31 (m, 2H),
2.29 (d, J = 6.3 Hz, 6H),
2.12 - 1.96 (m, 2H).
N 13
151 CF H 568.2
R = CH
S-isomer
F C O
N 13
152 CF H 568.2
R = CH
S-isomer
F C O
11841-PCT
INFORMAL
3 4 1
1 2 6 11 15
Example R = R [M+H] HNMR (400 MHz, CDCl )
R R R R -R 3
N 13
153 CF H 579.2
R = CH
S-isomer N
F C O
N 13
154 CF H 583.1 7.58 - 7.49 (ab quartet, J =
N R = CH
S-isomer 8.8 Hz, 2H), 7.20 (d, J = 8.3
F C O
Hz, 2H), 7.15 (d, J = 8.3 Hz,
2H), 7.03 - 6.92 (m, 2H),
4.06 (t, J = 6.1 Hz, 2H), 3.72
(d, J = 17.3 Hz, 1H), 3.49 (d,
J = 17.1 Hz, 1H), 2.55 (s,
3H), 2.43 - 2.33 (m, 2H),
2.30 (s, 3H), 2.09 - 1.97 (m,
2H).
H OMe 13
155 CH H 478.4
R = CH
N 11
156 CF H 540.1
N R = CH
S-isomer
N 13
R = CH
F C O
11841-PCT
INFORMAL
3 4 1
1 2 6 11 15
Example R = R [M+H] HNMR (400 MHz, CDCl )
R R R R -R 3
157 CF H 582.2
R = CH
S-isomer
F C O
158 CF H 613.2
R = CH
S-isomer N N
F C O
N 13
159 CF F 562.2
R = CH
F C O
160 CF F CN 519.2
R = CH
F C O
OMe 13
161 CH H 464.3
R = CH
OMe 13
162 CF F 628.9
R = CH
Rac N
11841-PCT
INFORMAL
3 4 1
1 2 6 11 15
Example R = R [M+H] HNMR (400 MHz, CDCl )
R R R R -R 3
OMe 13
163 CF F 656.9 8.05 (s, 1H), 7.61 (d, J = 8.8
R = CH
Rac N Hz, 2H), 7.25 - 7.16 (m, 6H),
F C O
7.02 - 6.94 (m, 2H), 6.82 -
6.73 (m, 2H), 6.60 (br. s.,
1H), 4.01 (td, J = 6.1, 1.4
Hz, 2H), 3.75 (s, 3H), 2.35
(s, 3H), 2.24 - 2.10 (m, 2H),
1.93 - 1.85 (m, 2H), 1.83 -
1.74 (m, 2H), 1.67 (br. s.,
OMe 13
164 CF F 671.0
R = CH
Rac N
F 13
165 CF H 561.2 7.59 (d, J = 8.8 Hz, 2H),
R = CH
S-isomer 7.42 - 7.36 (m, 2H), 7.35 -
7.28 (m, 4H), 7.20 - 7.16 (m,
3H), 7.06 - 6.99 (m, 4H),
6.98 - 6.93 (m, 2H), 3.66 (d,
11841-PCT
INFORMAL
3 4 1
1 2 6 11 15
Example R = R [M+H] HNMR (400 MHz, CDCl )
R R R R -R 3
J = 17.3 Hz, 1H), 3.52 (d, J
= 17.3 Hz, 1H), 2.30 (s, 3H).
H OMe 13
166 CH H 492.2
R = CH
167 CF H 620.2 8.38 (d, J = 1.7 Hz, 1H),
R = OHCF
S-isomer 7.61 (s, 1H), 7.51 (d, J = 8.8
F C O
Hz, 2H), 7.34 - 7.24 (m, 2H),
7.13 - 7.04 (ab quartet, J =
8.8 Hz, 2H), 6.99 - 6.92 (m,
2H), 6.86 (s, 1H), 4.26 (br.
s., 1H), 4.05 (t, J = 5.9 Hz,
2H), 3.69 (d, J = 17.1 Hz,
1H), 3.42 (d, J = 17.1 Hz,
1H), 2.41 - 2.27 (m, 2H),
2.10 - 1.97 (m, 2H).
Cl 13
168 CF H 611.2
R = CH
S-isomer
F C O
11841-PCT
INFORMAL
3 4 1
1 2 6 11 15
Example R = R [M+H] HNMR (400 MHz, CDCl )
R R R R -R 3
169 CF H 611.2
R = CH
S-isomer
F C O
Cl F 13
170 CF H 629.2
R = CH
S-isomer N
F C O
171 CF H 629.3
R = CH
S-isomer N
F C O
172 CF H 584.2 8.37 (d, J = 1.7 Hz, 1H),
R = OCH
S-isomer 7.50 (d, J = 8.8 Hz, 2H),
F C O
7.28 - 7.17 (m, 2H), 6.99 -
6.91 (m, 2H), 6.89 - 6.82 (m,
3H), 4.05 (t, J = 6.1 Hz, 2H),
3.78 (s, 3H), 3.68 (d, J =
16.8 Hz, 1H), 3.42 (d, J =
17.1 Hz, 1H), 2.45 - 2.23 (m,
2H), 2.10 - 1.98 (m, 2H).
11841-PCT
INFORMAL
3 4 1
1 2 6 11 15
Example R = R [M+H] HNMR (400 MHz, CDCl )
R R R R -R 3
N OMe 13
173 CH H 618.4 7.34 (d, J = 8.0 Hz, 2H),
R = CH
Rac 7.26 (d, J = 9.1 Hz, 2H),
7.15 (d, J = 8.0 Hz, 2H),
6.79 (d, J = 9.1 Hz, 2H),
3.76 (s, 3H), 3.43 - 3.37 (d, J
= 17.5 Hz, 1H), 3.22 (t, J =
7.1 Hz, 2H), 2.86 - 2.80 (d, J
= 17.2 Hz, 1H), 2.32 (s, 3H),
1.53 (s, 3H), 1.31 - 1.21 (m,
28H), 0.88 (t, J = 7.1 Hz,
OMe 13
174 CH H 506.4
R = CH
OMe 13
175 CH H 512.4
R = CH
11841-PCT
INFORMAL
3 4 1
1 2 6 11 15
Example R = R [M+H] HNMR (400 MHz, CDCl )
R R R R -R 3
176 CF H 598.2 7.54 (d, J = 8.8 Hz, 2H),
R = OCH
S-isomer 7.32 - 7.23 (m, 2H), 6.97 (d,
F C O
J = 8.8 Hz, 2H), 6.88 (d, J =
8.8 Hz, 2H), 6.73 (s, 1H),
4.06 (t, J = 6.1 Hz, 2H), 3.76
(s, 3H), 3.71 (d, J = 17.1 Hz,
1H), 3.49 (d, J = 17.1 Hz,
1H), 2.45 - 2.32 (m, 2H),
2.31 - 2.26 (m, 3H), 2.08 -
1.97 (m, 2H).
H 13
177 CH H CN 382.3
R = CH
H OMe 13
178 CH H 526.4
R = CH
11841-PCT
INFORMAL
3 4 1
1 2 6 11 15
Example R = R [M+H] HNMR (400 MHz, CDCl )
R R R R -R 3
Br 13
179 CF H 648.2 7.54 (d, J = 8.8 Hz, 2H),
R = CH
S-isomer 7.23 - 7.11 (m, 4H), 7.03 -
F C O
6.93 (m, 3H), 4.06 (t, J = 6.1
Hz, 2H), 3.72 (d, J = 16.9
Hz, 1H), 3.48 (d, J = 17.2
Hz, 1H), 2.44 - 2.32 (m, 2H),
2.30 (s, 3H), 2.08 - 1.97 (m,
2H).
180 CF H 674.3
R = CH
S-isomer
F C O
OMe 13
181 CF F 547.0
R = CH
11841-PCT
INFORMAL
3 4 1
1 2 6 11 15
Example R = R [M+H] HNMR (400 MHz, CDCl )
R R R R -R 3
NH 13
182 CF H 510.3
R = CH
N 13
183 CF H 554.3 7.57 - 7.48 (m, 2H), 7.13 -
3 R = CH
Rac 7.05 (m, 2H), 7.02 - 6.94 (m,
F C O
S-isomer 2H), 6.88 - 6.77 (m, 2H),
4.07 - 3.99 (m, 2H), 2.29 (s,
3H), 2.19 - 2.07 (m, 2H),
1.89 - 1.78 (m, 2H), 1.69 -
1.55 (m, 4H)
184 CF H CN 511.1 7.46 (dd, J = 12.1, 8.5 Hz,
3 R = CH
S-isomer 4H), 7.31 (d, J = 8.3 Hz,
F C O
2H), 6.95 (d, J = 9.1 Hz,
2H), 4.32 - 4.22 (m, 1H),
4.00 (s, 2H), 3.67 - 3.55 (m,
1H), 2.41 (s, 3H), 2.23 - 1.99
(m, 2H), 1.88 - 1.76 (m, 2H),
1.70 - 1.50 (m, 5H)
11841-PCT
INFORMAL
3 4 1
1 2 6 11 15
Example R = R [M+H] HNMR (400 MHz, CDCl )
R R R R -R 3
185 CF H 678.3
3 R = CH
S-isomer
F C O
186 CF H 540.3
3 R = CH
S-isomer
F C O
187 CF H 598.3 7.57 - 7.50 (m, J = 8.8 Hz,
3 R = CH
S-isomer 2H), 7.21 - 7.12 (m, 4H),
F C O
7.01 - 6.94 (m, 2H), 6.48 (s,
O 1H), 4.06 (t, J = 6.1 Hz, 2H),
3.95 (s, 3H), 3.71 (d, J =
17.1 Hz, 1H), 3.47 (d, J =
17.1 Hz, 1H), 2.44 - 2.32 (m,
2H), 2.30 (s, 3H), 2.07 - 1.98
(m, 2H).
11841-PCT
INFORMAL
3 4 1
1 2 6 11 15
Example R = R [M+H] HNMR (400 MHz, CDCl )
R R R R -R 3
OMe 13
188 CH H 450.1
3 R = CH
Rac N
OMe 13
189 CH H 484.1
3 R = CH
Rac N
190 CF H 662.3
3 R = CH
S-isomer
F C O
O OMe 13
191 CH H 520.2
3 R = CH
Rac N
192 CF H 526.3
3 R = CH
S-isomer
F C O
11841-PCT
INFORMAL
3 4 1
1 2 6 11 15
Example R = R [M+H] HNMR (400 MHz, CDCl )
R R R R -R 3
193 CF H 542.1 H NMR (500 MHz, CDCl :
3 R = OCH 3
S-isomer MeOD (1:1)) δ 7.65 (s, 1H),
F C O
7.54 (d, J = 8.4 Hz, 2H), 6.98
(d, J = 8.6 Hz, 2H), 6.93 (d, J
= 8.4 Hz, 2H), 6.79 (d, J =
8.4 Hz, 2H), 4.07 (t, J = 6.0
Hz, 2H), 3.77 (s, 3H), 3.69
(d, J = 17.7 Hz, 1H), 3.60 (d,
J = 17.7 Hz, 1H), 2.41 - 2.28
(m, 2H), 2.06 (dq, J = 12.1,
6.3 Hz, 2H).
NH 13
194 CF H 432.3 7.21 (d, J = 7.9 Hz, 2H),
N R = CH
Rac 7.08 (d, J = 8.1 Hz, 2H),
6.25 (s, 1H), 3.39 (d, J =
18.5 Hz, 1H), 3.34 (d, J =
18.9 Hz, 1H), 2.39 (s, 3H),
2.23 (t, J = 7.2 Hz, 2H), 1.55
- 1.47 (m, 2H), 1.40 - 1.23
11841-PCT
INFORMAL
3 4 1
1 2 6 11 15
Example R = R [M+H] HNMR (400 MHz, CDCl )
R R R R -R 3
(m, 6H), 0.87 (t, J = 6.9 Hz,
3H).
195 CF H 460.4 7.21 (d, J = 7.9 Hz, 2H), 7.08
3 R = CH
Rac (d, J = 8.1 Hz, 2H), 6.32 (s,
1H), 3.37 (AB quartet, J =
18.7 Hz, 2H), 2.39 (s, 3H),
2.23 (t, J = 7.0 Hz, 2H), 1.51
(quin, J = 7.2 Hz, 2H), 1.39 -
1.20 (m, 10H), 0.91 - 0.84
(m, 3H).
196 CF H 460.4 7.17 (d, J = 7.9 Hz, 2H),
3 R = CH
R-isomer 7.04 (d, J = 8.1 Hz, 2H),
6.74 (s, 1H), 3.43 - 3.32 (m,
2H), 2.37 (s, 3H), 2.23 (t, J =
7.0 Hz, 2H), 1.55 - 1.47 (m,
2H), 1.37 - 1.22 (m, 10H).
197 CF H 388.3 7.20 (d, J = 7.9 Hz, 2H),
3 R = CH
S-isomer 7.07 (d, J = 8.1 Hz, 2H),
11841-PCT
INFORMAL
3 4 1
1 2 6 11 15
Example R = R [M+H] HNMR (400 MHz, CDCl )
R R R R -R 3
6.34 (s, 1H), 3.38, 3.32
(ABq, J = 18.9 Hz, 2H), 2.39
(s, 3H), 1.28 (tt, J = 8.3, 5.0
Hz, 1H), 0.89 - 0.83 (m, 2H),
0.76 - 0.71 (m, 2H).
198 CF H 452.3 7.30 - 7.23 (m, 2H), 7.22 -
3 R = CH
S-isomer 7.13 (m, 5H), 6.99 (d, J =
8.1 Hz, 2H), 6.57 (s, 1H),
3.33 (d, J = 18.9 Hz, 1H),
3.26 (d, J = 18.9 Hz, 1H),
2.85 - 2.80 (m, 2H), 2.57 -
2.53 (m, 2H), 2.38 (s, 3H)
NH 13
199 CF H 418.3 7.19 (d, J = 7.9 Hz, 2H),
3 R = CH
S-isomer 7.06 (d, J = 8.1 Hz, 2H),
6.68 (s, 1H), 3.38, 3.35
(ABq, J = 18.9 Hz, 2H), 2.37
(s, 3H), 2.24 (t, J = 7.4 Hz,
2H), 1.63 (dquin, J = 13.4,
11841-PCT
INFORMAL
3 4 1
1 2 6 11 15
Example R = R [M+H] HNMR (400 MHz, CDCl )
R R R R -R 3
6.7 Hz, 1H), 1.41 (q, J = 7.3
Hz, 2H), 0.88 (d, J = 6.6 Hz,
OCF 13
200 CF H 3 663.2 9.63 (s, 1H), 7.62 (s, 1H),
3 R = CH
Rac 7.54 (s, 1H), 7.50 (d, J = 8.9
Hz, 2H), 7.22 (d, J = 8.1 Hz,
2H), 7.18 (d, J = 8.1 Hz,
2H), 7.13 (d, J = 8.5 Hz,
2H), 6.87 (s, 1H), 4.13 (t, J =
7.2 Hz, 2H), 3.48 (d, J =
18.4 Hz, 1H), 3.25 (d, J =
18.4 Hz, 1H), 2.42 - 2.31 (m,
3H), 2.08 - 2.03 (m, 2H),
1.96 - 1.85 (m, 2H), 1.62 -
1.53 (m, 2H), 1.41 - 1.31 (m,
11841-PCT
INFORMAL
3 4 1
1 2 6 11 15
Example R = R [M+H] HNMR (400 MHz, CDCl )
R R R R -R 3
OHCF 13
201 CF H 2 645.3 10.16 (s, 1H), 9.00 (s, 1H),
3 R = CH
Rac N 7.99 (s, 1H), 7.70 (s, 1H),
7.51 (d, J = 8.8 Hz, 2H),
7.39 (d, J = 8.0 Hz, 2H),
7.19 (d, J = 8.3 Hz, 2H),
7.12 (t, J = 74.3 Hz, 1H),
7.09 (d, J = 8.8 Hz, 2H),
4.11 (t, J = 6.9 Hz, 2H),
3.41-3.37 (d, J = 17.4 Hz,
1H), 3.35 - 3.31 (d, J = 17.4
Hz, 1H), 2.28 (s, 3H), 2.23 -
2.17 (m, 2H), 1.85 - 1.75 (m,
2H), 1.52 - 1.44 (m, 2H),
1.31 - 1.22 (m, 2H).
NH 13
202 CF3 H 556.3 HNMR (500 MHz, DMSO-
N R =
S-isomer d ) δ 9.57 (s, 1H), 7.64 (d, J
CH OCH 6
F C O
= 8.8 Hz, 2H), 7.20 (d, J =
8.1 Hz, 2H), 7.04 (d, J = 8.8
11841-PCT
INFORMAL
3 4 1
1 2 6 11 15
Example R = R [M+H] HNMR (400 MHz, CDCl )
R R R R -R 3
Hz, 2H), 6.99 (d, J = 7.9 Hz,
2H), 4.36 (s, 2H), 4.09 (t, J =
6.1 Hz, 2H), 3.75 (d, J =
17.5 Hz, 1H), 3.69 (d, J =
17.5 Hz, 1H), 3.27 (s, 3H),
2.48 - 2.37 (m, 2H), 2.01 -
1.89 (m, 2H)
203 CF H R = F 574.3
S-isomer
F C O
OCH CH
204 CF H 512.1 H NMR (500 MHz,
3 R = CH
S-isomer MeOD:CDCl (1:1)) δ 7.61
(s, 2H), 7.55 (d, J = 8.6 Hz,
2H), 6.97 (dd, J = 10.4, 8.3
Hz, 4H), 6.84 (d, J = 8.1 Hz,
2H), 4.24 (t, J = 6.4 Hz, 2H),
3.71 (d, J = 17.2 Hz, 1H),
3.50 (d, J = 17.2 Hz, 1H),
11841-PCT
INFORMAL
3 4 1
1 2 6 11 15
Example R = R [M+H] HNMR (400 MHz, CDCl )
R R R R -R 3
3.08 - 3.03 (m, 4H), 2.67 (qt,
J = 10.8, 6.3 Hz, 2H), 1.78
(dq, J = 11.3, 5.5 Hz, 4H),
1.69 (q, J = 5.9 Hz, 2H).
NH 13
205 CF3 H 578.1 H NMR (500 MHz, CDCl3:
N R = OCHF
S-isomer MeOD (1:1)) δ 7.61 (s, 2H),
F C O
7.54 (d, J = 8.6 Hz, 2H), 7.05
- 6.96 (m, 5H), 6.66 (t, J =
73.4 Hz, 1H), 4.07 (t, J = 6.0
Hz, 2H), 3.70 (d, J = 17.9
Hz, 1H), 3.57 (d, J = 17.8
Hz, 1H), 2.41 - 2.28 (m, 2H),
2.11 - 2.02 (m, 2H).
NH 13
206 CF H 498.1 H NMR (500 MHz, MeOD-
N R = CH
S-isomer CDCl (1:1)) δ 7.60 - 7.57
F C O
(m, 2H), 7.07 (d, J = 8.6 Hz,
2H), 6.86 (d, J = 8.0 Hz,
1H), 4.48 (q, J = 8.2 Hz,
11841-PCT
INFORMAL
3 4 1
1 2 6 11 15
Example R = R [M+H] HNMR (400 MHz, CDCl )
R R R R -R 3
1H), 3.70 (d, J = 17.8 Hz,
1H), 3.58 (d, J = 17.8 Hz,
1H), 2.30 (s, 1H).
207 CF H 562.1 H NMR (500 MHz, CDCl :
3 R R = 3
S-isomer MeOD (1:1)) δ 7.81 - 7.73
F C O
(m, 2H), 7.72 (d, J = 8.6 Hz,
1H), 7.61 (s, 1H), 7.60 - 7.55
(m, 3H), 7.53 - 7.46 (m, 2H),
7.01 (d, J = 8.8 Hz, 2H), 6.98
(dd, J = 8.5, 1.8 Hz, 1H),
4.08 (t, J = 6.0 Hz, 2H), 3.83
(d, J = 17.8 Hz, 1H), 3.70 (d,
J = 17.8 Hz, 1H), 2.41 - 2.28
(m, 2H), 2.11 - 2.01 (m, 2H).
208 CF H 556.1 H NMR (500 MHz, CDCl3:
3 R =
S-isomer MeOD (1:1)) δ 7.62 (s, 1H),
OCH CH
F C O
7.54 (d, J = 8.5 Hz, 2H), 6.98
(d, J = 8.9 Hz, 2H), 6.91 (d, J
11841-PCT
INFORMAL
3 4 1
1 2 6 11 15
Example R = R [M+H] HNMR (400 MHz, CDCl )
R R R R -R 3
= 8.7 Hz, 2H), 6.77 (d, J =
8.8 Hz, 2H), 4.07 (t, J = 6.0
Hz, 2H), 4.00 (q, J = 7.0 Hz,
2H), 3.68 (d, J = 17.8 Hz,
1H), 3.59 (d, J = 17.7 Hz,
1H), 2.40 - 2.28 (m, 2H),
2.10 - 2.01 (m, 2H), 1.38 (t, J
= 7.0 Hz, 3H).
209 CF H 570.2 H NMR (500 MHz, DMSO-
3 R R =
S-isomer d ) δ 9.51 (s, 1H), 7.61 (d, J
F C O
= 8.4 Hz, 2H), 7.01 (d, J =
8.8 Hz, 2H), 6.70 (d, J = 8.4
Hz, 1H), 6.57 (d, J = 2.2 Hz,
1H), 6.41 (dd, J = 8.5, 2.2
Hz, 1H), 4.25 - 4.14 (m, 4H),
4.06 (t, J = 6.2 Hz, 2H), 3.68
(d, J = 18.2 Hz, 1H), 3.63 (d,
J = 18.5 Hz, 1H), 2.42 (ddd,
11841-PCT
INFORMAL
3 4 1
1 2 6 11 15
Example R = R [M+H] HNMR (400 MHz, CDCl )
R R R R -R 3
J = 16.4, 8.0, 5.1 Hz, 2H),
1.93 (dq, J = 12.3, 6.4 Hz,
2H).
210 CF H 566.1 H NMR (500 MHz, DMSO-
3 R R =
S-isomer d6) δ 9.42 (s, 1H), 7.60 (d, J
F C O
= 8.5 Hz, 2H), 7.01 (d, J =
8.6 Hz, 2H), 6.84 (d, J = 8.0
Hz, 1H), 6.80 (s, 1H), 6.56
(d, J = 7.7 Hz, 1H), 4.06 (t, J
= 6.1 Hz, 2H), 3.67 (d, J =
17.8 Hz, 1H), 3.60 (d, J =
17.9 Hz, 1H), 2.61 (s, 2H),
2.56 (s, 2H), 2.42 (ddd, J =
11.4, 8.3, 5.2 Hz, 2H), 1.98 -
1.88 (m, 2H), 1.65 (p, J = 2.8
Hz, 4H).
211 CF H 556.2 H NMR (500 MHz, DMSO-
3 R R =
S-isomer d ) δ 9.37 (s, 1H), 7.60 (d, J
F C O
11841-PCT
INFORMAL
3 4 1
1 2 6 11 15
Example R = R [M+H] HNMR (400 MHz, CDCl )
R R R R -R 3
O = 8.5 Hz, 2H), 7.01 (d, J =
8.6 Hz, 2H), 6.75 (d, J = 8.2
Hz, 1H), 6.57 (s, 1H), 6.48
(d, J = 8.1 Hz, 1H), 5.97 (d, J
= 3.1 Hz, 2H), 4.06 (t, J =
6.1 Hz, 2H), 3.65 (d, J = 17.6
Hz, 1H), 3.58 (d, J = 17.7
Hz, 1H), 2.46 - 2.35 (m, 2H),
1.93 (dd, J = 9.9, 5.4 Hz,
2H).
NH 12
212 CF H 582.3 H NMR (500 MHz, DMSO-
3 R R =
S-isomer d ) δ 9.30 (s, 1H), 7.56 (d, J
F C O
= 8.4 Hz, 2H), 6.99 (d, J =
8.7 Hz, 2H), 6.71 (d, J = 8.2
R = OCH
Hz, 1H), 6.62 (d, J = 8.4 Hz,
1H), 4.12 - 4.01 (m, 2H),
3.70 (s, 3H), 3.67 (m, 1H),
3.60 (d, J = 17.4 Hz, 1H),
11841-PCT
INFORMAL
3 4 1
1 2 6 11 15
Example R = R [M+H] HNMR (400 MHz, CDCl )
R R R R -R 3
2.67 - 2.55 (m, 2H), 2.46 -
2.35 (m, 2H), 2.31 - 2.07 (m,
2H), 1.97 - 1.91 (m, 2H),
1.81 - 1.69 (m, 2H).
NH 13
213 CHF2 H 508.3 H NMR (500 MHz, DMSO-
N R = CH
S-isomer d ) δ 9.10 (s, 1H), 7.52 (d, J
F C O
= 8.5 Hz, 2H), 7.07 (d, J =
7.8 Hz, 2H), 7.02 (d, J = 9.0
Hz, 2H), 6.88 (d, J = 7.9 Hz,
2H), 6.33 (t, J = 55.0 Hz,
1H), 4.07 (t, J = 6.2 Hz, 2H),
3.57 (d, J = 17.9 Hz, 1H),
3.41 (d, J = 18.2 Hz, 1H),
2.44 (ddd, J = 11.4, 8.1, 5.2
Hz, 2H), 1.99 - 1.91 (m, 2H).
OMe 13
214 H H 539.4 H NMR (500 MHz, DMSO-
R = CH
R-isomer N d ) δ 9.97 (s, 1H), 8.06 (s,
F C O
1H), 7.42 (d, J = 8.6 Hz,
11841-PCT
INFORMAL
3 4 1
1 2 6 11 15
Example R = R [M+H] HNMR (400 MHz, CDCl )
R R R R -R 3
2H), 7.36 (dd, J = 10.3, 8.2
Hz, 4H), 7.13 (d, J = 7.9 Hz,
2H), 6.96 (d, J = 8.5 Hz,
2H), 6.85 (d, J = 9.0 Hz,
2H), 4.82 - 4.73 (m, 1H),
4.05 (t, J = 6.2 Hz, 2H), 3.83
- 3.72 (m, 1H), 3.71 (s, 3H),
2.88 (qd, J = 17.0, 7.6 Hz,
1H), 2.48 - 2.35 (m, 2H),
2.25 (s, 3H), 1.94 (dq, J =
12.5, 6.4 Hz, 2H).
215 CF H CN 513.1 H NMR (500 MHz, MeOD)
R = CH
S-isomer δ 7.61 (s, 1H), 7.58 (s, 1H),
R = OCH
F C O
7.54 - 7.41 (m, 1H), 7.30 (dd,
J = 8.4, 2.0 Hz, 1H), 7.22 (s,
1H), 7.03 (d, J = 9.4 Hz, 1H),
6.96 (d, J = 8.9 Hz, 1H), 6.89
(d, J = 8.4 Hz, 1H), 4.32 (s,
11841-PCT
INFORMAL
3 4 1
1 2 6 11 15
Example R = R [M+H] HNMR (400 MHz, CDCl )
R R R R -R 3
2H), 4.10 - 4.03 (m, 2H),
3.86 (s, 2H), 3.67 - 3.55 (m,
1H), 2.40 - 2.27 (m, 2H),
2.27 - 2.23 (m, 1H), 2.22 (s,
2H), 2.10 - 2.00 (m, 2H)
216 CF H CN 529.1
3 R = OCH
S-isomer
R = OCH
F C O
217 CF H CN 497.1 H NMR (500 MHz, MeOD)
3 R = CH
S-isomer δ 7.61 (s, 1H), 7.49 - 7.43
R = CH
F C O
(m, 2H), 7.35 - 7.23 (m, 3H),
6.99 - 6.94 (m, 2H), 4.32 (s,
2H), 4.06 (t, J = 5.9 Hz, 2H),
3.61 (s, 2H), 2.38 - 2.33 (m,
2H), 2.31 - 2.28 (m, 1H),
2.09 - 2.01 (m, 2H)
218 CF H CN 517.1 H NMR (500 MHz, MeOD)
3 R = F
S-isomer δ 7.49 - 7.43 (m, 3H), 7.40
R = OCH
F C O
(dd, J = 11.9, 2.0 Hz, 1H),
11841-PCT
INFORMAL
3 4 1
1 2 6 11 15
Example R = R [M+H] HNMR (400 MHz, CDCl )
R R R R -R 3
7.14 (t, J = 8.4 Hz, 1H), 7.00
- 6.93 (m, 2H), 4.32 (s, 2H),
4.05 (t, J = 5.9 Hz, 2H), 3.96
(s, 3H), 3.61 (d, J = 3.0 Hz,
2H), 2.39 - 2.27 (m, 2H),
2.09 - 2.01 (m, 2H)
219 CF H CN 501.1 H NMR (500 MHz, MeOD)
3 R = F
S-isomer δ 7.49 - 7.43 (m, 2H), 7.39 -
R = CH
F C O
7.32 (m, 1H), 7.30 - 7.21 (m,
2H), 7.00 - 6.93 (m, 2H),
4.29 (s, 1H), 4.08 - 4.04 (m,
2H), 3.60 (d, J = 2.0 Hz, 2H),
2.35 (d, J = 5.4 Hz, 1H), 2.32
- 2.28 (m, 1H), 2.09 - 2.00
(m, 2H)
220 CF H CN 521.0 H NMR (500 MHz, MeOD)
3 R = F
S-isomer 13 δ 7.48 - 7.43 (m, 2H), 7.36 -
R = Cl
F C O
7.28 (m, 3H), 7.00 - 6.95 (m,
11841-PCT
INFORMAL
3 4 1
1 2 6 11 15
Example R = R [M+H] HNMR (400 MHz, CDCl )
R R R R -R 3
2H), 4.07 (t, J = 5.9 Hz, 2H),
3.59 (q, J = 1.0 Hz, 2H), 2.40
- 2.28 (m, 2H), 2.10 - 2.02
(m, 2H)
221 CF3 H CN 517.1 H NMR (500 MHz, MeOD)
R = CH
S-isomer δ 7.61 (s, 1H), 7.58 (s, 1H),
R = Cl
F C O
7.54 - 7.41 (m, 1H), 7.30 (dd,
J = 8.4, 2.0 Hz, 1H), 7.22 (s,
1H), 7.03 (d, J = 9.4 Hz, 1H),
6.96 (d, J = 8.9 Hz, 1H), 6.89
(d, J = 8.4 Hz, 1H), 4.32 (s,
2H), 4.10 - 4.03 (m, 2H),
3.86 (s, 2H), 3.67 - 3.55 (m,
1H), 2.40 - 2.27 (m, 2H),
2.27 - 2.23 (m, 1H), 2.22 (s,
2H), 2.10 - 2.00 (m, 2H)
222 CF H CN 539.0
3 R = Cl
S-isomer
R = Cl
F C O
11841-PCT
INFORMAL
3 4 1
1 2 6 11 15
Example R = R [M+H] HNMR (400 MHz, CDCl )
R R R R -R 3
223 CF H CN 532.8
3 R = Cl
S-isomer
R = OCH
F C O
224 CF H CN 493.9
3 R = CN
S-isomer
F C O
225 CF H CN 562.1
3 R =
S-isomer
NHSO CH
F C O
226 CF H CN 547.1 H NMR (500 MHz, MeOD)
3 R = Cl
S-isomer 13 δ 7.61 - 7.58 (m, 1H), 7.44
F C O
(d, J = 8.4 Hz, 2H), 7.06 -
OCH CH
7.00 (m, 2H), 7.00 - 6.95 (m,
2H), 6.89 (dd, J = 8.4, 2.5
Hz, 1H), 4.11 - 4.04 (m, 4H),
3.66 (d, J = 18.3 Hz, 1H),
3.43 (d, J = 18.3 Hz, 1H),
2.40 - 2.28 (m, 2H), 2.10 -
2.02 (m, 2H), 1.45 - 1.39 (m,
11841-PCT
INFORMAL
3 4 1
1 2 6 11 15
Example R = R [M+H] HNMR (400 MHz, CDCl )
R R R R -R 3
227 CF H CN 471.2
3 R = CH
OMe 13
228 CF H 609.2 7.86 (s, 1H), 7.66 (s, 1H),
3 R = CH
Rac 7.37 (d, J = 8.25 Hz, 2H),
7.26 (d, J = 9.08 Hz, 2H),
7.21 (d, J = 7.98 Hz, 2H),
6.82 (d, J = 9.08 Hz, 2H),
4.18 (t, J = 6.88 Hz, 2H),
3.76 (s, 3H), 3.58 (d, J =
17.33 Hz, 1H), 3.35 (d, J =
17.33 Hz, 1H), 2.34 (s, 3H),
2.13 (m, 2H), 1.89 (m, 2H),
1.57 (m, 2H), 1.35 (m, 2H).
11841-PCT
INFORMAL
3 4 1
1 2 6 11 15
Example R = R [M+H] HNMR (400 MHz, CDCl )
R R R R -R 3
OMe 13
229 CF H 595.2
3 R = CH
Rac N
230 CF H CN 434.0
3 R = CH
231 CF H 581.4 H NMR (500 MHz, DMSO-
3 R = CH
S-isomer d ) δ 10.43 (s, 1H), 9.23 (s,
F C O
1H), 7.54 (d, J = 8.80 Hz,
2H), 7.48 (d, J = 1.65 Hz,
1H), 7.29 (d, J = 7.98 Hz,
2H), 7.15 (d, J = 7.98 Hz,
2H), 7.00 (d, J = 8.80 Hz,
2H), 6.34 (d, J = 1.93 Hz,
1H), 4.07 (t, J = 6.05 Hz,
2H), 3.67 (s, 3H), 3.48 (d, J
11841-PCT
INFORMAL
3 4 1
1 2 6 11 15
Example R = R [M+H] HNMR (400 MHz, CDCl )
R R R R -R 3
= 17.06 Hz, 1H), 3.39 (d, J =
17.06 Hz, 1H), 2.43 (m, 2H),
2.27 (s, 3H), 1.95 (m, 2H).
OMe 13
232 CF H 609.1 8.13 (d, J = 9.63 Hz, 1H),
3 R = CH
S-isomer N N 7.54 (d, J = 8.80 Hz, 2H),
F C O
7.26 (d, J = 8.25 Hz, 2H),
7.23 (d, J = 9.63 Hz, 1H),
7.17 (d, J = 7.99 Hz, 2H),
6.99 (d, J = 9.08 Hz, 2H),
4.07 (t, J = 6.05 Hz, 2H),
4.01 (s, 3H), 3.67 (d, J =
17.33 Hz, 1H), 3.53 (d, J =
17.06 Hz, 1H), 2.37 (m, 2H),
2.29 (s, 3H), 2.03 (m, 2H).
233 CF H R = CH 479.8
S-isomer
11841-PCT
INFORMAL
3 4 1
1 2 6 11 15
Example R = R [M+H] HNMR (400 MHz, CDCl )
R R R R -R 3
234 CF H 589.9 7.54 (d, J = 8.3 Hz, 2H), 7.43
3 R = Br
S-isomer (d, J = 8.5 Hz, 2H), 6.97 (dd,
F C O
J = 8.7, 2.3 Hz, 4H), 6.85
(br. s., 1H), 4.04 (t, J = 5.8
Hz, 2H), 3.69 - 3.59 (m, 1H),
3.56 - 3.46 (m, 1H), 2.40 -
2.26 (m, 2H), 2.08 (dd, J =
9.4, 6.1 Hz, 2H).
235 CF H H NMR (500 MHz, DMSO)
S-isomer
δ 9.55 (br. s., 1H), 7.62 (d, J
F C O
= 8.8 Hz, 2H), 7.02 (d, J =
8.8 Hz, 2H), 6.98 - 6.92 (m,
2H), 6.87 (d, J = 8.3 Hz,
2H), 4.07 (t, J = 6.1 Hz, 2H),
3.80 - 3.61 (m, 2H), 2.46 -
2.29 (m, 2H), 2.00 - 1.90 (m,
2H), 1.89 - 1.79 (m, 1H),
1.00 - 0.88 (m, 2H), 0.69 -
11841-PCT
INFORMAL
3 4 1
1 2 6 11 15
Example R = R [M+H] HNMR (400 MHz, CDCl )
R R R R -R 3
0.54 (m, 2H).
236 CF H 578.0 H NMR (500MHz, DMSO)
S-isomer
δ 9.42 (br. s., 1H), 8.47 (d, J
F C O
= 2.5 Hz, 1H), 7.73 (d, J =
1.1 Hz, 1H), 7.69 (d, J = 8.8
Hz, 2H), 7.64 (d, J = 8.5 Hz,
2H), 7.12 (d, J = 8.5 Hz,
2H), 7.03 (d, J = 8.8 Hz,
2H), 6.53 (d, J = 1.9 Hz,
1H), 4.08 (t, J = 6.2 Hz, 2H),
3.78 - 3.63 (m, 2H), 2.46 -
2.34 (m, 2H), 2.02 - 1.86 (m,
2H).
NH 13
237 CF H 554.0 H NMR (500MHz, DMSO)
3 R R =
S-isomer O
δ 9.42 (br. s., 1H), 7.62 (d, J
F C O
= 8.5 Hz, 2H), 7.02 (d, J =
8.8 Hz, 2H), 6.97 (s, 1H),
6.68 (d, J = 8.5 Hz, 1H), 6.59
11841-PCT
INFORMAL
3 4 1
1 2 6 11 15
Example R = R [M+H] HNMR (400 MHz, CDCl )
R R R R -R 3
(d, J = 8.3 Hz, 1H), 4.50 (t, J
= 8.7 Hz, 2H), 4.07 (t, J =
6.2 Hz, 2H), 3.65 (br. s., 2H),
3.06 (t, J = 8.7 Hz, 2H), 2.47
- 2.34 (m, 2H), 2.00 - 1.89
(m, 2H).
238 CF H 555.1 H NMR (500 MHz, DMSO)
S-isomer R = δ 9.41 (br. s., 1H), 7.61 (d, J
F C O
= 8.3 Hz, 2H), 7.01 (d, J =
8.5 Hz, 2H), 6.84 (d, J = 8.5
Hz, 2H), 6.52 (d, J = 8.8 Hz,
2H), 4.06 (t, J = 5.9 Hz, 2H),
3.75 - 3.55 (m, 2H), 2.89 (s,
6H), 2.42 (dd, J = 16.5, 11.0
Hz, 2H), 2.02 - 1.84 (m, 2H).
H 13
239 CF H 593.3 H NMR (400 MHz, MeOD)
3 R = CH
S-isomer
δ 7.52 (d, J = 8.8 Hz, 2H),
F C O
7.24 - 7.15 (m, 4H), 6.96 (d,
11841-PCT
INFORMAL
3 4 1
1 2 6 11 15
Example R = R [M+H] HNMR (400 MHz, CDCl )
R R R R -R 3
J = 8.8 Hz, 2H), 4.06 (t, J =
6.1 Hz, 2H), 3.97 (s, 2H),
3.67 (d, J = 16.9 Hz, 1H),
3.43 (d, J = 16.9 Hz, 1H),
2.93 (s, 3H), 2.44 - 2.28 (m,
5H), 2.09 - 1.96 (m, 2H).
240 CF H 514.3 H NMR (400 MHz, MeOD)
3 R = OCH
S-isomer δ 7.65 (d, J = 9.0 Hz, 2H),
F C O
7.13 - 7.08 (m, 2H), 6.97 -
6.93 (m, 2H), 6.84 - 6.78 (m,
2H), 4.57 (q, J = 8.4 Hz,
2H), 3.75 (s, 3H), 3.72 (d, J
= 2.4 Hz, 2H).
NH 13
241 CF H 528.3 H NMR (400 MHz, MeOD)
3 R = OCH
S-isomer
δ 7.61 (d, J = 8.8 Hz, 2H),
F C N
7.03 (d, J = 9.0 Hz, 2H),
6.95 (d, J = 8.8 Hz, 2H),
6.81 (d, J = 8.8 Hz, 2H),
11841-PCT
INFORMAL
3 4 1
1 2 6 11 15
Example R = R [M+H] HNMR (400 MHz, CDCl )
R R R R -R 3
4.25 (t, J = 6.1 Hz, 2H), 3.76
(s, 3H), 3.71 (d, J = 1.5 Hz,
2H), 2.77 - 2.63 (m, 2H).
242 CF H 582.2 H NMR (400 MHz, MeOD)
3 R = OCF
S-isomer δ 7.62 (d, J = 8.8 Hz, 2H),
F C N
7.23 - 7.17 (m, 2H), 7.14 -
7.09 (m, 2H), 7.08 - 7.02 (m,
2H), 4.26 (t, J = 6.2 Hz, 2H),
3.83 - 3.66 (m, 2H), 2.77 -
2.63 (m, 2H).
NH 13
243 CF3 H 596.3 H NMR (400 MHz, MeOD)
N R = OCF
S-isomer
δ 7.61 (d, J = 8.8 Hz, 2H),
F C O
7.22 - 7.17 (m, 2H), 7.15 -
7.09 (m, 2H), 7.06 - 7.00 (m,
2H), 4.08 (t, J = 6.1 Hz, 2H),
3.82 - 3.65 (m, 2H), 2.44 -
2.30 (m, 2H), 2.09 - 1.99 (m,
2H).
11841-PCT
INFORMAL
3 4 1
1 2 6 11 15
Example R = R [M+H] HNMR (400 MHz, CDCl )
R R R R -R 3
244 CF H 556.3 H NMR (400 MHz, MeOD)
3 R = OCH
S-isomer
δ 7.58 (d, J = 8.8 Hz, 2H),
F C O
7.00 (d, J = 9.0 Hz, 2H),
6.95 (d, J = 9.0 Hz, 2H),
6.81 (d, J = 8.8 Hz, 2H),
4.04 (t, J = 6.1 Hz, 2H), 3.76
(s, 3H), 3.70 (d, J = 1.3 Hz,
2H), 2.31 - 2.17 (m, 2H),
1.92 - 1.83 (m, 2H), 1.80 -
1.70 (m, 2H).
245 CF H 592.1 H NMR (400 MHz, MeOD)
3 R =
S-isomer
OCHCF δ 7.59 (d, J = 8.6 Hz, 2H),
F C O
7.05 (s, 4H), 7.02 (d, J = 9.0
Hz, 2H), 6.87 (t, J = 74.6
Hz, 1H), 4.04 (t, J = 6.1 Hz,
2H), 3.74, 3.70 (ABq, J =
18.0 Hz, 2H), 2.31 - 2.17 (m,
2H), 1.92 - 1.84 (m, 2H),
11841-PCT
INFORMAL
3 4 1
1 2 6 11 15
Example R = R [M+H] HNMR (400 MHz, CDCl )
R R R R -R 3
1.80 - 1.70 (m, 2H)
246 CF H 582.3 H NMR (400 MHz, MeOD)
R = CH
S-isomer
N δ 8.18 (s, 1H), 7.56 (d, J =
F C O N
8.8 Hz, 2H), 7.25 - 7.19 (m,
2H), 7.11 (d, J = 7.9 Hz,
2H), 6.98 (d, J = 9.0 Hz,
2H), 4.09 (s, 3H), 4.07 - 4.03
(m, 2H), 3.71 (d, J = 16.9
Hz, 1H), 3.48 (d, J = 16.9
Hz, 1H), 2.44 - 2.31 (m, 2H),
2.28 (s, 3H), 2.08 - 1.98 (m,
2H).
247 CF H 570.1 H NMR (400 MHz, MeOD)
3 R = OCH
S-isomer
δ 7.57 (d, J = 8.8 Hz, 2H),
F C O
7.03 - 6.92 (m, 4H), 6.84 -
6.79 (m, 2H), 4.02 (t, J = 6.3
Hz, 2H), 3.76 (s, 3H), 3.70
(d, J = 1.5 Hz, 2H), 2.25 -
11841-PCT
INFORMAL
3 4 1
1 2 6 11 15
Example R = R [M+H] HNMR (400 MHz, CDCl )
R R R R -R 3
2.11 (m, 2H), 1.87 - 1.77 (m,
2H), 1.69 - 1.53 (m, 4H).
248 CF H 606.3 H NMR (400 MHz, MeOD)
3 R =
S-isomer
OCHCF δ 7.61 (d, J = 8.8 Hz, 2H),
F C O
7.08 (s, 4H), 7.05 - 7.01 (m,
J = 9.0 Hz, 2H), 6.90 (t, J =
73.7 Hz, 1H), 4.05 (t, J = 6.2
Hz, 2H), 3.76, 3.73 (ABq, J
= 18.5 Hz, 2H), 2.28 - 2.14
(m, 2H), 1.89 - 1.81 (m, 2H),
1.72 - 1.56 (m, 4H)
F 13
249 CF H 595.3 H NMR (400 MHz, MeOD)
3 R = CH
S-isomer N
δ 7.62 - 7.53 (m, 3H), 7.51 -
F C O
O 7.45 (m, 1H), 7.27 - 7.09 (m,
6H), 7.01 - 6.95 (m, 2H),
4.07 (t, J = 6.1 Hz, 2H), 3.71
(d, J = 16.9 Hz, 1H), 3.48 (d,
J = 16.9 Hz, 1H), 2.43 - 2.29
11841-PCT
INFORMAL
3 4 1
1 2 6 11 15
Example R = R [M+H] HNMR (400 MHz, CDCl )
R R R R -R 3
(m, 5H), 2.08 - 1.98 (m, 2H).
O 13
250 CF H 543.4 8.35 (br. s., 1H), 7.44 (d, J =
R = CH
S-isomer 8.8 Hz, 2H), 7.18 - 7.13 (m,
F C O
2H), 7.11 - 7.06 (m, 2H),
6.96 - 6.90 (m, 2H), 6.30 (s,
1H), 4.03 (t, J = 5.9 Hz, 2H),
3.61 (d, J = 17.2 Hz, 1H),
3.38 (d, J = 17.4 Hz, 1H),
2.41 - 2.25 (m, 8H), 2.11 -
2.02 (m, 2H).
H 13
251 CF H 645.4 H NMR (400 MHz, MeOD)
3 R =
S-isomer
OCHCF δ 7.52 (d, J = 8.8 Hz, 2H),
F C O
7.35 (d, J = 8.8 Hz, 2H),
7.12 (d, J = 8.8 Hz, 2H),
6.97 (d, J = 9.0 Hz, 2H),
7.04 - 6.63 (m, 1H), 4.06 (t, J
= 6.1 Hz, 2H), 3.98 (s, 2H),
3.69 (d, J = 16.9 Hz, 1H),
11841-PCT
INFORMAL
3 4 1
1 2 6 11 15
Example R = R [M+H] HNMR (400 MHz, CDCl )
R R R R -R 3
3.45 (d, J = 16.9 Hz, 1H),
2.93 (s, 3H), 2.44 - 2.29 (m,
2H), 2.09 - 1.98 (m, 2H).
H 13
252 CF H 623.3 H NMR (400 MHz, MeOD)
3 R = OCH
S-isomer δ 7.51 (d, J = 8.8 Hz, 2H),
F C O
7.30 (d, J = 9.0 Hz, 2H),
6.98 - 6.88 (m, 4H), 4.02 (t, J
= 6.1 Hz, 2H), 3.99 (s, 2H),
3.79 (s, 3H), 3.66 (d, J =
16.9 Hz, 1H), 3.44 (d, J =
16.7 Hz, 1H), 2.97 (s, 3H),
2.30 - 2.16 (m, 2H), 1.90 -
1.81 (m, 2H), 1.79 - 1.69 (m,
2H).
253 CF H 545.4 H NMR (400 MHz, MeOD)
3 R = CH
S-isomer
δ 7.56 (d, J = 8.8 Hz, 2H),
F C O
7.22 - 7.17 (m, 4H), 7.03 -
6.96 (m, 2H), 4.09 (t, J = 6.1
11841-PCT
INFORMAL
3 4 1
1 2 6 11 15
Example R = R [M+H] HNMR (400 MHz, CDCl )
R R R R -R 3
Hz, 2H), 4.02 (q, J = 6.8 Hz,
1H), 3.66 (d, J = 17.2 Hz,
1H), 3.47 (d, J = 16.9 Hz,
1H), 2.46 - 2.32 (m, 5H),
2.10 - 2.00 (m, 2H), 1.19 (d,
J = 6.8 Hz, 3H).
H H 13
254 CF H 596.2 H NMR (400 MHz, MeOD)
3 R =
S-isomer δ 7.53 (d, J = 8.8 Hz, 2H),
OCHCF
F C O
7.39 - 7.33 (m, 2H), 7.11 (d,
J = 8.6 Hz, 2H), 7.00 - 6.95
(m, 2H), 7.02 - 6.63 (m, 1H),
4.06 (t, J = 6.1 Hz, 2H), 3.65
(d, J = 16.9 Hz, 1H), 3.42 (d,
J = 16.7 Hz, 1H), 2.96 (q, J
= 7.3 Hz, 2H), 2.43 - 2.28
(m, 2H), 2.07 - 1.97 (m, 2H),
0.92 (t, J = 7.3 Hz, 3H).
11841-PCT
INFORMAL
3 4 1
1 2 6 11 15
Example R = R [M+H] HNMR (400 MHz, CDCl )
R R R R -R 3
H 13
255 CF H 545.3 H NMR (400 MHz, MeOD)
3 R = CH
S-isomer
δ 7.53 (d, J = 8.8 Hz, 2H),
F C O
7.29 - 7.22 (m, 2H), 7.21 -
7.14 (m, 2H), 6.97 (d, J =
9.0 Hz, 2H), 4.06 (t, J = 6.2
Hz, 2H), 3.66 (d, J = 16.9
Hz, 1H), 3.45 (d, J = 16.7
Hz, 1H), 3.07 (q, J = 7.2 Hz,
2H), 2.45 - 2.29 (m, 5H),
2.02 (dd, J = 10.2, 5.8 Hz,
2H), 1.06 (t, J = 7.2 Hz, 3H).
256 CF H CN 501.1 H NMR (400 MHz, MeOD)
3 R = F
S-isomer 13
δ 1.96 - 2.13 (m, 2 H) 2.24 -
R = CH
F C O
2.39 (m, 2 H) 2.41 (s, 3 H)
3.49 - 3.68 (m, 2 H) 3.75 (s,
1 H) 4.06 (t, J = 5.95 Hz, 2
H) 4.33 (s, 1 H) 6.97 (d, J =
1.00 Hz, 2 H) 7.00 - 7.14 (m,
11841-PCT
INFORMAL
3 4 1
1 2 6 11 15
Example R = R [M+H] HNMR (400 MHz, CDCl )
R R R R -R 3
2 H) 7.24 (t, J = 7.68 Hz, 1
H) 7.45 (d, J = 1.00 Hz, 2 H)
7.61 (s, 1 H)
257 CF H CN R = 541.5
S-isomer NHCO2Me
F C O
258 CF H CN R = Cl 533.1
S-isomer R = OCH
F C O
12 1
259 CF H CN R = Cl [M-H] H NMR (500 MHz, MeOD)
S-isomer R = CH 515.0
3 δ 2.05 (m, J = 9.90, 5.90
F C O
Hz, 2 H) 2.22 - 2.41 (m, 2 H)
2.24 - 2.42 (m, 2 H) 2.43 (s,
2 H) 3.62 (br. s., 1 H) 4.06 (t,
J = 5.95 Hz, 2 H) 4.29 - 4.48
(m, 2 H) 6.98 (d, J = 8.92
Hz, 1 H) 7.40 (br. s., 1 H)
7.47 (d, J = 8.42 Hz, 1 H)
7.54 (s, 1 H) 7.63 (br. s., 1
11841-PCT
INFORMAL
3 4 1
1 2 6 11 15
Example R = R [M+H] HNMR (400 MHz, CDCl )
R R R R -R 3
13 1
260 CF H CN R = 513.1 H NMR (500 MHz, MeOD)
S-isomer CH OCH
2 3 δ 1.97 - 2.11 (m, 2 H) 2.33
F C O
(m, J = 5.40 Hz, 2 H) 3.43
(s, 3 H) 3.63 (s, 2 H) 4.06 (t,
J = 5.95 Hz, 2 H) 4.53 (s, 2
H) 6.97 (d, J = 1.00 Hz, 2 H)
7.47 (d, J = 8.42 Hz, 4 H)
7.55 (d, J = 7.93 Hz, 2 H)
7.60 (s, 1 H)
261 CF3 H CN R = F 571.1
S-isomer R = OCF
F C O
12 1
262 CF H CN R = OCH 513.1 H NMR (500 MHz, MeOD)
S-isomer R = CH
3 δ 1.95 - 2.12 (m, 2 H) 2.25
F C O
(s, 3 H) 2.27 - 2.44 (m, 2 H)
3.63 (d, J = 2.48 Hz, 2 H)
3.87 (s, 3 H) 4.05 (t, J = 5.95
Hz, 2 H) 6.97 (m, J = 8.92
11841-PCT
INFORMAL
3 4 1
1 2 6 11 15
Example R = R [M+H] HNMR (400 MHz, CDCl )
R R R R -R 3
Hz, 2 H) 7.08 (d, J = 1.49
Hz, 1 H) 7.24 (s, 1 H) 7.47
(m, J = 8.92 Hz, 2 H) 7.60
(s, 1 H)
12 1
263 CF3 H CN R = Cl 547.1 H NMR (500 MHz, MeOD)
S-isomer R =
δ 1.49 (t, J = 6.94 Hz, 3 H)
F C O
OCH CH
2 3 1.95 - 2.12 (m, 2 H) 2.23 -
2.41 (m, 2 H) 3.60 (s, 2 H)
4.05 (t, J = 5.95 Hz, 2 H)
4.19 (q, J = 6.90 Hz, 2 H)
6.96 (d, J = 9.41 Hz, 2 H)
Ĉ栕栕{栖Ӊ7栗栗*䡣桤뎑䝃ęĈ
䠄栅뎑䝃栕栕{栖栗*ēĈ䠄栅
뎑䝃栖紫* ㍨笽 쥨㜄 ㍨笽
ᔌ ᘀ ᔔ
쥨㜄㜄 䔀煮⋿ 55 (dd, J =
1.00 Hz, 1 H) 7.60 (s, 1 H)
12 1
264 CF H CN R = F [M-H] H NMR (500 MHz, MeOD)
S-isomer R = 529.1
δ 1.47 (t, J = 7.18 Hz, 3 H)
F C O
11841-PCT
INFORMAL
3 4 1
1 2 6 11 15
Example R = R [M+H] HNMR (400 MHz, CDCl )
R R R R -R 3
OCH CH 1.95 - 2.12 (m, 2 H) 2.33 (s,
2 H) 4.06 (t, J = 5.95 Hz, 2
H) 4.19 (q, J = 6.90 Hz, 2 H)
6.97 (d, J = 8.92 Hz, 2 H)
7.12 (t, J = 1.00 Hz, 1 H)
7.37 - 7.53 (m, 4 H) 7.62 (s,
1 H)
13 1
265 CF H R = CH 607.1 H NMR (500 MHz, MeOD)
S-isomer
δ 7.88 (dd, J = 8.0, 1.4 Hz,
F C O H
1H), 7.55 (d, J = 8.8 Hz,
2H), 7.25 (d, J = 8.0 Hz,
2H), 7.16 (d, J = 8.0 Hz,
2H), 7.05 - 6.97 (m, 3H),
6.89 (d, J = 7.4 Hz, 1H),
6.85 - 6.80 (m, 1H), 4.07 (t, J
= 6.1 Hz, 2H), 3.68 (s, 3H),
3.63 (d, J = 17.3 Hz, 1H),
3.51 (d, J = 17.3 Hz, 1H),
11841-PCT
INFORMAL
3 4 1
1 2 6 11 15
Example R = R [M+H] HNMR (400 MHz, CDCl )
R R R R -R 3
2.43 - 2.32 (m, 2H), 2.31 (s,
3 H), 2.07 - 1.98 (m, 2H).
13 1
266 CF H R = CH 544.1 H NMR (500 MHz, MeOD)
S-isomer δ 7.50 (dd, J = 12.7, 2.5 Hz,
F C O
1H), 7.45 - 7.38 (m, 1H),
7.18 (t, J = 8.7 Hz, 1H), 7.12
- 7.06 (m, 2H), 6.89 (d, J =
8.2 Hz, 2H), 4.16 (t, J = 6.1
Hz, 2H), 3.74 (d, J = 17.8
Hz, 1H), 3.68 (d, J = 17.8
Hz, 1H), , 2.52 - 2.32 (m,
2H), 2.29 (s, 3H), 2.13 - 1.98
(m, 2H).
267 CF H R = CH 526.2
F C O
S-isomer
13 1
F NH
268 CF H R = CH 544.2 HNMR (500 MHz, DMSO-
S-isomer d ) δ 9.58 (s, 1H), 7.59 (t, J =
9.2 Hz, 1H), 7.09 (d, J = 8.0
F C O
11841-PCT
INFORMAL
3 4 1
1 2 6 11 15
Example R = R [M+H] HNMR (400 MHz, CDCl )
R R R R -R 3
Hz, 2H), 6.99 – 6.92 (m,
2H), 6.89 (d, J = 8.1 Hz,
2H), 4.11 (t, J = 6.1 Hz, 2H),
3.81 (d, J = 17.7 Hz, 1H),
3.73 (d, J = 17.8 Hz, 1H),
2.49 – 2.30 (m, 2H), 2.25 (s,
3H), 2.03 – 1.78 (m, 2H).
13 1
269 CF H CN R = CH 483.2 HNMR (400 MHz, MeOD)
F C O
S-isomer
δ 8.18 (s, 1H), 7.56 (d, J =
8.8 Hz, 2H), 7.25 - 7.19 (m,
2H), 7.11 (d, J = 7.9 Hz,
2H), 6.98 (d, J = 9.0 Hz,
2H), 4.09 (s, 3H), 4.07 - 4.03
(m, 2H), 3.71 (d, J = 16.9
Hz, 1H), 3.48 (d, J = 16.9
Hz, 1H), 2.44 - 2.31 (m, 2H),
2.28 (s, 3H), 2.08 - 1.98 (m,
2H).
11841-PCT
INFORMAL
3 4 1
1 2 6 11 15
Example R = R [M+H] HNMR (400 MHz, CDCl )
R R R R -R 3
13 1
270 CF H R = CH 554.1 H NMR (400 MHz, MeOD)
R-isomer
δ 7.51 (d, J = 8.8 Hz, 2H),
F C O
7.30 (d, J = 9.0 Hz, 2H),
6.98 - 6.88 (m, 4H), 4.02 (t, J
= 6.1 Hz, 2H), 3.99 (s, 2H),
3.79 (s, 3H), 3.66 (d, J =
16.9 Hz, 1H), 3.44 (d, J =
16.7 Hz, 1H), 2.97 (s, 3H),
2.30 - 2.16 (m, 2H), 1.90 -
1.81 (m, 2H), 1.79 - 1.69 (m,
2H).
13 1
271 CF H R = CH CF 594.1 H NMR (500 MHz, 1:1
3 2 3
S-isomer
MeOD/CDCl ) δ 7.52 (d, J =
F C O
8.8 Hz, 2H), 7.20 (d, J = 8.0
Hz, 2H), 6.96 (dd, J = 8.4,
2.1 Hz, 4H), 4.04 (t, J = 6.1
Hz, 2H), 3.73 - 3.64 (m, 1H),
3.60 - 3.49 (m, 1H), 3.35 (d,
11841-PCT
INFORMAL
3 4 1
1 2 6 11 15
Example R = R [M+H] HNMR (400 MHz, CDCl )
R R R R -R 3
J = 10.7 Hz, 2H), 2.39 - 2.23
(m, 2H), 2.13 - 1.91 (m, 2H).
272 CF H R = CH 540.3
S-isomer
N OMe
273 CF H R = CH 608.2 1.98 – 2.11 (m, 2H), 2.29 (s,
S-isomer 3H), 2.33 - 2.49 (m, 2H),
3.71 - 3.47 (m, 2H), 3.91 (s,
3H), 4.20 - 4.02 (m, 2H),
6.95 – 7.03 (m, 2H), 7.15 (d,
J = 8.3 Hz, 2H), 7.26 (d, J =
8.0 Hz, 2H), 7.53 (d, J = 8.8
Hz, 2H), 7.86 (d, J = 1.4 Hz,
1H), 8.76 (d, J = 1.4 Hz, 1H).
13 1
274 CF H R = OCHF 624.1 H NMR (500 MHz, DMSO-
S-isomer d ) δ 9.63 (s, 1H), 7.58 (t, J
F C O
= 9.3 Hz, 1H), 7.43 – 6.98
(m, 5H), 6.92 (d, J = 12.1
11841-PCT
INFORMAL
3 4 1
1 2 6 11 15
Example R = R [M+H] HNMR (400 MHz, CDCl )
R R R R -R 3
Hz, 2H), 4.03 (t, J = 6.4 Hz,
2H), 3.80 (d, J = 17.8 Hz,
1H), 3.76 (d, J = 17.9 Hz,
1H), 2.37 – 2.14 (m, 2H),
1.83 – 1.66 (m, 2H), 1.63 –
1.32 (m, 4H).
13 1
275 CF H R = OCHF 630.2 H NMR (400 MHz, MeOD)
S-isomer δ 8.75 (br. s., 2H), 7.87 (br.
F C O
s., 2H), 7.57 (d, J = 8.6 Hz,
2H), 7.36 (d, J = 8.6 Hz,
2H), 7.12 (d, J = 8.6 Hz,
2H), 7.04 - 6.62 (m, 3H),
4.08 (t, J = 5.8 Hz, 2H), 3.75
(br. s., 1H), 3.52 (d, J = 16.9
Hz, 1H), 2.45 - 2.29 (m, 2H),
2.09 - 1.99 (m, 2H).
12 13 1
276 CF H R R = 608.2 H NMR (500 MHz, MeOD)
S-isomer δ 7.83 – 7.66 (m, 3H), 7.61
F C O
11841-PCT
INFORMAL
3 4 1
1 2 6 11 15
Example R = R [M+H] HNMR (400 MHz, CDCl )
R R R R -R 3
(s, 2H), 7.56 – 7.43 (m, 3H),
7.01 (d, J = 8.6 Hz, 1H), 6.85
– 6.67 (m, 2H), 4.05 (d, J =
18.0 Hz, 1H), 4.01 (t, J = 6.4
Hz, 2H), 3.76 (d, J = 17.9
Hz, 1H), 2.05-2.20 (m, 2H),
1.91 – 1.72 (m, 2H), 1.74 –
1.45 (m, 4H).
277 CF H 567.1 H NMR (500 MHz, 1:1
S-isomer
CDCl :MeOD) δ 7.54 (d, J =
F C O
8.4 Hz, 2H), 7.16 (d, J = 7.9
Hz, 2H), 6.99 (d, J = 8.9 Hz,
2H), 6.90 (d, J = 8.4 Hz, 2H),
4.07 (t, J = 5.9 Hz, 2H), 3.79
- 3.66 (m, 1H), 3.63 - 3.50
(m, 1H), 2.49 (d, J = 6.9 Hz,
2H), 2.40 - 2.25 (m, 2H),
2.13 - 1.97 (m, 2H), 0.97 -
11841-PCT
INFORMAL
3 4 1
1 2 6 11 15
Example R = R [M+H] HNMR (400 MHz, CDCl )
R R R R -R 3
0.82 (m, 1H), 0.58 - 0.45 (m,
2H), 0.16 (q, J = 5.0 Hz, 2H).
13 1
278 CF H R = CH 558.2 H NMR (500 MHz, 1:1
S-isomer
CDCl :MeOD) δ 7.43 (t, J =
9.17 Hz, 1H), 7.02 (d, J =
7.93 Hz, 2H), 6.87 (d, J =
7.93 Hz, 2H), 6.75 (dd, J =
2.48, 8.92 Hz, 1H), 6.71 (dd,
J = 2.23, 14.61 Hz, 1H), 3.99
(t, J = 5.95 Hz, 2H), 3.87 (d,
J = 17.83 Hz, 1H), 3.61 (d, J
= 17.83 Hz, 1H), 2.26 (s,
3H), 2.11-2.21 (m, 2H),
1.80-1.89 (m, 2H), 1.69-1.78
(m, 2H).
279 CF H R = CH 573.2 7.79 (br. s., 1H), 7.46 - 7.38
S-isomer (m, 7H), 7.22 - 7.17 (m, 2H),
7.15 - 7.10 (m, 2H), 7.02 (d,
11841-PCT
INFORMAL
3 4 1
1 2 6 11 15
Example R = R [M+H] HNMR (400 MHz, CDCl )
R R R R -R 3
J = 9.0 Hz, 2H), 6.69 (br. s.,
1H), 5.07 (s, 2H), 3.82 (br.
s., 2H), 3.63 (d, J = 17.2 Hz,
1H), 3.37 (d, J = 17.2 Hz,
1H), 2.95 (s, 3H), 2.36 (s,
3H).
280 CF H R = OCHF 630.2
S-isomer
F C O
13 1
281 CF H R = CH 582.2 H NMR (500MHz, MeOD)
S-isomer
δ 7.56 (d, J = 8.92 Hz, 2H),
F C O
H 7.30 (d, J = 8.42 Hz, 2H),
7.10 (d, J = 7.93 Hz, 2H),
6.97 (d, J = 8.92 Hz, 2H),
6.37 (s, 1H), 4.06 (m, 2H),
3.59 (d, J = 17.83 Hz, 1H),
3.43 (d, J = 17.34 Hz, 1H),
2.32 (m, 2H), 2.30 (s, 3H),
2.22 (s, 3H), 2.06 (m, 2H).
11841-PCT
INFORMAL
3 4 1
1 2 6 11 15
Example R = R [M+H] HNMR (400 MHz, CDCl )
R R R R -R 3
13 1
282 CF H R = CH 651.2 H NMR (500MHz, MeOD)
S-isomer O
δ 7.61 (s, 1H), 7.47 (d, J =
F C O
8.4 Hz, 2H), 7.15 (d, J = 5.9
Hz, 4H), 6.93 (d, J = 8.9 Hz,
2H), 4.33 (br. s., 1H), 4.07 -
4.02 (m, 2H), 4.02 - 3.94 (m,
4H), 3.67 - 3.56 (m, 1H),
3.37 - 3.34 (m, 1H), 2.94 -
2.78 (m, 2H), 2.33 (s, 5H),
2.09 - 2.00 (m, 2H), 1.22 (d,
J = 1.5 Hz, 6H).
13 1
283 CF H R = 602.2 H NMR (500 MHz, DMSO-
S-isomer OCH CH d ) δ 9.39 (s, 1H), 7.56 (t, J =
2 3 6
F C O
9.3 Hz, 1H), 6.92 (t, J = 8.6
Hz, 4H), 6.81 (d, J = 8.8 Hz,
2H), 4.03 (t, J = 6.4 Hz, 2H),
3.99 (q, J = 6.9 Hz , 2H),
3.82 (d, J = 17.3 Hz, 1H),
11841-PCT
INFORMAL
3 4 1
1 2 6 11 15
Example R = R [M+H] HNMR (400 MHz, CDCl )
R R R R -R 3
3.69 (d, J = 17.7 Hz, 1H),
2.34 – 2.15 (m, 2H), 1.85 –
1.70 (m, 2H), 1.65 – 1.42 (m,
4H), 1.29 (t, J = 6.9 Hz, 3H).
13 1
284 CF3 H R = CH2CF3 640.1 H NMR (500 MHz, DMSO-
S-isomer
d ) δ 9.36 (w, 1H), 7.59 (t, J
F C O
= 9.3 Hz, 1H), 7.20 (d, J =
7.9 Hz, 2H), 7.07 – 6.74 (m,
4H), 4.03 (t, J = 6.4 Hz, 2H),
3.76 (d, J = 17.4 Hz, 1H),
3.70 (d, J = 17.7 Hz, 1H),
3.58 (dd, J = 23.3, 11.7 Hz,
2H), 2.33 – 2.16 (m, 2H),
1.86 – 1.68 (m, 2H), 1.545-
1.60 (m, 4H).
13 1
285 CF H R = CH 484.1 H NMR (500 MHz, DMSO-
S-isomer
d ) δ 9.58 - 9.48 (m, 1H),
7.65 - 7.55 (m, 2H), 7.07 (d,
11841-PCT
INFORMAL
3 4 1
1 2 6 11 15
Example R = R [M+H] HNMR (400 MHz, CDCl )
R R R R -R 3
J = 8.0 Hz, 2H), 7.04 - 6.97
(m, 2H), 6.94 - 6.85 (m, 2H),
4.06 (s, 2H), 3.69 (s, 2H),
2.24 (s, 3H), 1.63 (q, J = 6.6
Hz, 2H), 1.35 - 1.08 (m, 1H),
0.94 - 0.77 (m, 1H), 0.51 -
0.38 (m, 2H), 0.16 - 0.06 (m,
11 1
286 CF H R = F 544.2 H NMR (500 MHz, DMSO-
S-isomer R = CH
3 d ) δ 7.62 (d, J = 8.80 Hz,
F C O
2H), 7.02 (d, J = 8.80 Hz,
2H), 7.01 (m, 1H), 6.98 (t, J
= 7.98 Hz, 1H), 6.93 (d, J =
11.55 Hz, 1H), 4.08 (t, J =
6.93 Hz, 2H), 3.68 (d, J =
18.16 Hz, 1H), 3.62 (d, J =
17.88 Hz, 1H), 2.42 (m, 2H),
2.28 (s, 3H), 1.95 (m, 2H).
11841-PCT
INFORMAL
3 4 1
1 2 6 11 15
Example R = R [M+H] HNMR (400 MHz, CDCl )
R R R R -R 3
13 1
287 CF H R = CH 568.2 H NMR (500 MHz, DMSO-
S-isomer
d ) δ 9.47 (s, 1H), 7.49 (s,
F C O
1H), 7.45 (d, J = 8.80 Hz,
1H), 7.07 (d, J = 7.98 Hz,
2H), 6.98 (d, J = 8.80 Hz,
1H), 6.89 (d, J = 8.25 Hz,
2H), 4.00 (t, J = 6.19 Hz,
2H), 3.66 (s, 2H), 2.24 (s,
3H), 2.20-2.32 (m, 2H), 2.17
(s, 3H), 1.71-1.80 (m, 2H),
1.47-1.61 (m, 4H).
13 1
288 CF H R = CH 520.0 H NMR (500 MHz, DMSO-
S-isomer
d ) δ 9.67 (s, 1H), 8.15 (d, J
= 4.1 Hz, 1H), 7.55 (d, J =
8.8 Hz, 2H), 7.05 (d, J = 4.1
Hz, 1H), 6.98 (d, J = 8.8 Hz,
2H), 4.03 (t, J = 6.2 Hz, 2H),
3.98 (d, J = 17.6 Hz, 1H),
11841-PCT
INFORMAL
3 4 1
1 2 6 11 15
Example R = R [M+H] HNMR (400 MHz, CDCl )
R R R R -R 3
3.62 (d, J = 17.3 Hz, 1H),
2.45 - 2.33 (m, 2H), 2.31 -
2.23 (m, 1H), 1.94 - 1.79 (m,
2H), 1.23 - 1.11 (m, 2H),
0.87 - 0.77 (m, 2H).
289 CF H R = CH 444.1 7.17 (d, J = 7.9 Hz, 2H),
S-isomer 7.05 (d, J = 8.4 Hz, 2H),
6.84 (s, 1H), 3.39 (AB
quartet, J = 18.7 Hz, 2H),
2.36 (s, 3H), 2.13 (d, J = 6.6
Hz, 2H), 1.77 - 1.60 (m, 5H),
1.55 - 1.42 (m, 1H), 1.29 -
0.88 (m, 5H).
290 CF H R = CH 468.1 7.36 - 7.27 (m, 5H), 7.18 (s,
S-isomer 1H), 7.13 (d, J = 7.9 Hz,
2H), 7.01 (d, J = 8.1 Hz,
2H), 4.57 (AB quartet, J =
11.7 Hz, 2H), 4.22 (s, 2H),
11841-PCT
INFORMAL
3 4 1
1 2 6 11 15
Example R = R [M+H] HNMR (400 MHz, CDCl )
R R R R -R 3
3.39 (AB quartet, J = 18.9
Hz, 2H), 2.34 (s, 3H).
291 CF H R = CH 430.1 7.19 (d, J = 7.9 Hz, 2H),
S-isomer 7.06 (d, J = 8.1 Hz, 2H),
6.59 (s, 1H), 3.38 (AB
quartet, J = 18.9 Hz, 2H),
2.49 - 2.41 (m, 1H), 2.38 (s,
3H), 1.81 - 1.72 (m, 2H),
1.65 (dd, J = 5.9, 2.4 Hz,
2H), 1.54 - 1.40 (m, J =
12.5, 8.9, 8.9, 8.9 Hz, 3H),
1.38 - 1.28 (m, 3H).
292 CF H R = CH 394.5
11841-PCT
INFORMAL
3 4 1
1 2 6 11 15
Example R = R [M+H] HNMR (400 MHz, CDCl )
R R R R -R 3
293 CF H R = CH 432.1 7.19 (d, J = 7.9 Hz, 2H),
S-isomer 7.06 (d, J = 8.1 Hz, 2H),
6.67 (s, 1H), 3.38 (AB
quartet, J = 18.9 Hz, 2H),
2.37 (s, 3H), 2.23 (t, J = 7.0
Hz, 2H), 1.51 (quin, J = 7.3
Hz, 2H), 1.40 - 1.22 (m, 6H),
0.87 (t, J = 6.8 Hz, 3H).
294 CF H R = OCH 468.1 1H NMR (500 MHz, MeOD)
S-isomer
δ 7.31 - 7.15 (m, 5H), 6.96
(d, J = 8.9 Hz, 2H), 6.81 (d, J
= 8.9 Hz, 2H), 3.79 (s, 3H),
3.34 (AB quartet, J = 18.3
Hz, 2H, partially overlapping
with solvent), 2.85 (t, J = 7.2
Hz, 2H), 2.58 (t, J = 7.4 Hz,
2H).
11841-PCT
INFORMAL
3 4 1
1 2 6 11 15
Example R = R [M+H] HNMR (400 MHz, CDCl )
R R R R -R 3
295 CF H R = OCH 434.1 1H NMR (500 MHz, MeOD)
S-isomer
δ 7.01 (d, J = 8.9 Hz, 2H),
6.78 (d, J = 8.9 Hz, 2H), 3.77
(s, 3H), 3.40 (s, 2H), 2.29 (t,
J = 7.4 Hz, 2H), 1.69 (dt, J =
13.5, 6.9 Hz, 1H), 1.45 (q, J
= 7.4 Hz, 2H), 0.91 (dd, J =
6.9, 2.0 Hz, 6H).
11 1
296 CF H R = F 625.2 H NMR (500 MHz, DMSO-
S-isomer R = CH
3 d ) δ 7.55 (d, J = 8.80 Hz,
F C O
2H), 7.31 (d, J = 9.08 Hz,
2H), 7.13 (m, 1H), 7.06 (d, J
= 11.83 Hz, 1H), 7.00 (d, J =
8.8 Hz, 2H), 6.94 (d, J = 7.70
Hz, 1H), 6.80 (d, J = 9.08
Hz, 2H), 4.08 (m, 2H), 3.70
(m, 2H), 3.68 (s, 3H), 2.43
(m, 2H), 2.27 (s, 3H), 1.95
11841-PCT
INFORMAL
3 4 1
1 2 6 11 15
Example R = R [M+H] HNMR (400 MHz, CDCl )
R R R R -R 3
(m, 2H).
297 CF H O R = CH 608.1 7.43 (d, J = 8.6 Hz, 2H),
S-isomer 7.20 - 7.16 (m, 2H), 7.15 -
F C O O
7.10 (m, 2H), 6.93 (d, J =
8.8 Hz, 2H), 6.57 (s, 1H),
.10 (br. s., 1H), 4.03 (t, J =
.9 Hz, 2H), 3.72 (br. s., 2H),
3.62 (d, J = 17.6 Hz, 1H),
3.38 (d, J = 17.8 Hz, 1H),
2.80 - 2.74 (m, 3H), 2.40 -
2.24 (m, 5H), 2.12 - 2.02 (m,
298 CF H R = CH 499.1 7.74 (br. s., 1H), 7.26 - 7.20
S-isomer (m, 4H), 5.88 (s, 1H), 3.84
(s, 2H), 3.29 (ABq, J = 17.6
Hz, 2H), 2.95 (s, 3H), 2.37
(s, 3H), 2.23 (t, J = 7.0 Hz,
2H), 1.57 - 1.48 (m, 2H),
11841-PCT
INFORMAL
3 4 1
1 2 6 11 15
Example R = R [M+H] HNMR (400 MHz, CDCl )
R R R R -R 3
1.41 - 1.25 (m, 6H), 0.89 (t, J
= 6.8 Hz, 3H)
299 CF H R = CH 578.1 9.08 (br. s., 1H), 8.77 (d, J =
S-isomer 4.2 Hz, 1H), 8.37 (br. s., 1H),
F C O
8.25 (br. s., 1H), 7.65 (br. s.,
1H), 7.46 (d, J = 8.8 Hz,
2H), 7.19 - 7.11 (m, 4H),
6.95 (d, J = 9.0 Hz, 2H),
6.88 (s, 1H), 4.04 (t, J = 5.9
Hz, 2H), 3.66 (d, J = 17.6
Hz, 1H), 3.43 (d, J = 17.4
Hz, 1H), 2.40 - 2.25 (m, 5H),
2.12 - 2.03 (m, 2H).
13 1
300 CF H R = CH 484.2 H NMR (400 MHz, MeOD)
S-isomer
δ 9.00 (br. s., 1H), 8.79 (dd,
J = 5.3, 1.3 Hz, 1H), 8.46 (d,
J = 7.3 Hz, 1H), 7.78 (dd, J
= 8.0, 5.4 Hz, 1H), 7.33 (d, J
11841-PCT
INFORMAL
3 4 1
1 2 6 11 15
Example R = R [M+H] HNMR (400 MHz, CDCl )
R R R R -R 3
= 8.1 Hz, 2H), 7.21 (d, J =
7.9 Hz, 2H), 3.38 (s, 2H),
2.35 - 2.27 (m, 5H), 1.60 -
1.50 (m, 2H), 1.48 - 1.38 (m,
2H), 1.35 - 1.27 (m, 4H),
0.93 - 0.87 (m, 3H).
13 1
301 CF H R = OCHF 624.2 H NMR (500 MHz, DMSO-
F 3 2
S-isomer d ) δ 9.53 (s, 1H), 7.65 (dd, J
F C O
= 13.0, 2.0 Hz, 1H), 7.49 (d,
J = 7.4 Hz, 1H), 7.46 – 6.88
(m, 6H), 4.11 (t, J = 6.3 Hz,
2H), 3.77 (d, J = 17.9 Hz,
1H), 3.72 (d, J = 17.9 Hz,
1H), 2.36 – 2.08 (m, 2H),
1.88 – 1.71 (m, 2H), 1.67 –
1.34 (m, 4H).
13 1
302 CF H R = CH 525.0 HNMR (400 MHz, MeOD)
S-isomer
δ 7.50 (d, J = 8.8 Hz, 2H),
11841-PCT
INFORMAL
3 4 1
1 2 6 11 15
Example R = R [M+H] HNMR (400 MHz, CDCl )
R R R R -R 3
7.23 - 7.15 (m, 4H), 6.93 (d,
J = 9.0 Hz, 2H), 4.00 - 3.92
(m, 4H), 3.66 (d, J = 17.2
Hz, 1H), 3.43 (d, J = 16.9
Hz, 1H), 2.93 (s, 3H), 2.32
(s, 3H), 1.79 (sxt, J = 7.0 Hz,
2H), 1.04 (t, J = 7.4 Hz, 3H).
303 CF H R = CH 572.3
F 3 N 3
S-isomer
F C O
12 1
304 CF H R R13 = 608.3 HNMR (500 MHz, DMSO-
S-isomer
d ) δ 9.57 (br. s., 1H), 7.84
F C O
(dd, J = 7.84, 13.34 Hz, 2H),
7.71-7.77 (m, 2H), 7.67 (d, J
= 12.93 Hz, 1H), 7.47-7.57
(m, 3H), 7.26 (t, J = 8.94 Hz,
1H), 6.93 (d, J = 8.80 Hz,
1H), 5.56 (d, J = 7.70 Hz,
11841-PCT
INFORMAL
3 4 1
1 2 6 11 15
Example R = R [M+H] HNMR (400 MHz, CDCl )
R R R R -R 3
1H), 4.10 (t, J = 6.19 Hz,
2H), 3.79-3.92 (m, 2H),
2.20-2.33 (m, 2H), 1.68-1.83
(m, 2H), 1.45-1.65 (m, 4H).
13 1
305 F CF3 H R = 602.3 HNMR (500 MHz, DMSO-
S-isomer OCH CH
2 3 d ) δ 9.38-9.54 (m, 1H), 7.63
F C O
(d, J = 13.20 Hz, 1H), 7.46
(d, J = 8.80 Hz, 1H), 7.24 (t,
J = 8.80 Hz, 1H), 6.96 (d, J
= 8.53 Hz, 2H), 6.79 (d, J =
8.53 Hz, 2H), 4.09 (t, J =
6.33 Hz, 2H), 3.98 (q, J =
6.88 Hz, 2H), 2.20-2.34 (m,
2H), 1.77 (quin, J = 6.81 Hz,
2H), 1.46-1.61 (m, 4H), 1.28
(t, J = 7.02 Hz, 3H).
13 1
306 CF H R = CH CF 640.2 HNMR (500 MHz, DMSO-
F 3 2 3
S-isomer
d ) δ 9.56 (br. s., 1H), 7.65
F C O
11841-PCT
INFORMAL
3 4 1
1 2 6 11 15
Example R = R [M+H] HNMR (400 MHz, CDCl )
R R R R -R 3
(d, J = 12.93 Hz, 1H), 7.49
(d, J = 8.80 Hz, 1H), 7.20-
7.28 (m, 3H), 7.03 (d, J =
7.98 Hz, 2H), 4.10 (t, J =
6.33 Hz, 2H), 3.71-3.81 (m,
2H), 3.61 (q, J = 11.55 Hz,
2H), 2.20-2.33 (m, 2H), 1.78
(quin, J = 6.74 Hz, 2H),
1.44-1.61 (m, 4H)
307 CF H R = OCHF 484.1 7.19 (d, J = 8.8 Hz, 2H),
S-isomer 7.12 (d, J = 8.6 Hz, 2H),
6.78 (br. s., 1H), 6.56 (t, J =
73.1 Hz, 1H), 3.37 (AB
quartet, J = 18.9 Hz, 2H),
2.24 (t, J = 7.0 Hz, 2H), 1.52
(quin, J = 7.3 Hz, 2H), 1.41 -
1.21 (m, 6H), 0.87 (t, J = 6.8
Hz, 3H).
11841-PCT
INFORMAL
3 4 1
1 2 6 11 15
Example R = R [M+H] HNMR (400 MHz, CDCl )
R R R R -R 3
308 CF H R = 462.1 7.10 (d, J = 9.0 Hz, 2H),
S-isomer OCH CH 6.85 (d, J = 8.8 Hz, 2H),
6.72 (s, 1H), 4.04 (q, J = 7.0
Hz, 2H), 3.37 (AB quartet, J
= 18.9 Hz, 2H), 2.22 (t, J =
7.2 Hz, 2H), 1.51 (quin, J =
7.3 Hz, 2H), 1.42 (t, J = 7.0
Hz, 3H), 1.39 - 1.22 (m, 6H),
0.87 (t, J = 6.6 Hz, 3H).
12 1
309 CF H R R13 = 612.1 HNMR (500 MHz, DMSO-
S-isomer
d ) δ 9.52 (br. s., 1H), 7.63
F C O
(d, J = 13.20 Hz, 1H), 7.46
(d, J = 8.53 Hz, 1H), 7.25 (t,
J = 8.94 Hz, 1H), 6.88 (d, J
= 7.98 Hz, 1H), 6.83 (s, 1H),
6.58 (d, J = 7.98 Hz, 1H),
4.09 (t, J = 6.19 Hz, 2H),
3.64-3.75 (m, 2H), 2.54-2.67
11841-PCT
INFORMAL
3 4 1
1 2 6 11 15
Example R = R [M+H] HNMR (400 MHz, CDCl )
R R R R -R 3
(m, 4H), 2.20-2.34 (m, 2H),
1.77 (quin, J = 6.74 Hz, 2H),
1.67 (br. s., 4H), 1.44-1.61
(m, 4H).
13 1
310 CF3 H R = CH3 569.0 HNMR (400 MHz, MeOD)
S-isomer
δ 7.56 (d, J = 8.8 Hz, 2H),
F C O
7.26 - 7.21 (m, 2H), 7.18 -
7.12 (m, 2H), 6.99 (d, J =
9.0 Hz, 2H), 4.07 (t, J = 6.2
Hz, 2H), 3.73 (d, J = 17.2
Hz, 1H), 3.51 (d, J = 16.9
Hz, 1H), 2.43 - 2.32 (m, 2H),
2.29 (s, 3H), 2.08 - 1.98 (m,
2H).
13 1
311 CF H R = CH 475.1 HNMR (400 MHz, MeOD)
S-isomer
δ 7.34 (d, J = 8.1 Hz, 2H),
7.19 (d, J = 7.9 Hz, 2H),
3.37 (s, 2H), 2.34 - 2.26 (m,
11841-PCT
INFORMAL
3 4 1
1 2 6 11 15
Example R = R [M+H] HNMR (400 MHz, CDCl )
R R R R -R 3
5H), 1.53 (d, J = 7.3 Hz,
2H), 1.42 (br. s., 2H), 1.34 -
1.25 (m, 4H), 0.92 - 0.86 (m,
3H).
312 CF3 H R = 529.4 7.73 (br. s., 1H), 7.31 (d, J =
S-isomer OCH CH 8.6 Hz, 2H), 6.92 (d, J = 8.8
Hz, 2H), 5.91 (s, 1H), 4.06
(q, J = 7.0 Hz, 2H), 3.86 (s,
2H), 3.30, 3.28 (ABq, J =
18.3 Hz, 2H), 2.99 (s, 3H),
2.23 (t, J = 7.0 Hz, 2H), 1.52
(quin, J = 7.3 Hz, 2H), 1.43
(t, J = 6.9 Hz, 3H), 1.41 -
1.22 (m, 7H), 0.89 (t, J = 6.9
Hz, 2H).
313 CF H R = OCHF 551.0 7.85 (br. s., 1H), 7.38 (d, J =
S-isomer 8.6 Hz, 2H), 7.17 (d, J = 8.6
Hz, 2H), 6.55 (t, J = 72.4
11841-PCT
INFORMAL
3 4 1
1 2 6 11 15
Example R = R [M+H] HNMR (400 MHz, CDCl )
R R R R -R 3
Hz, 1H), 5.97 (s, 1H), 3.84
(s, 2H), 3.30, 3.28 (ABq, J =
17.8 Hz, 2H), 2.89 (s, 3H),
2.24 (t, J = 7.0 Hz, 2H), 1.52
(dt, J = 14.6, 7.2 Hz, 2H),
1.43 - 1.23 (m, 6H), 0.89 (t, J
= 6.8 Hz, 3H).
314 CF H R = CH 540.3
3 N 3
S-isomer
F C O
11841-PCT
The term 'comprising' as used in this specification and claims means
'consisting at least in part of'. When interpreting statements in this specification and
claims which include 'comprising'; other features besides the features prefaced by this
term in each statement can also be present. Related terms such as 'comprise' and
'comprised' are to be interpreted in a similar manner.
11841-PCT
Claims (44)
1. A compound of Formula (I): 12 14 5 or a stereoisomer, a tautomer, a pharmaceutically acceptable salt, or a solvate thereof, wherein: designates a single or double bond; x and y can be both a single bond; when x is a double bond, then y is a single 4 16 5 bond and R and R are absent; when y is a double bond, then x is a single bond and R 10 and R are absent; R is independently selected from the group consisting of: -CONH(C alkyl), 4-18 -CONHC haloalkyl, -CONH(CH ) Ph, -CONHCH COC alkyl, 2-8 2 1-8 2 2-8 -(CH ) -(C carbocycle substituted with 0-2 R and 0-2 R ), -(CH ) -(5- to 2 m 3-10 2 m 6-membered heteroaryl comprising: carbon atoms and 1-4 heteroatoms selected from N, e b g 15 NR , O and S; wherein said heteroaryl is substituted with 0-1 R and 0-2 R ), and a C hydrocarbon chain substituted with 0-3 R ; wherein said hydrocarbon chain may be 1-12 straight or branched, saturated or unsaturated; R is independently selected from the group consisting of: C alkyl, C cycloalkyl, and C haloalkyl; 3-4 1-4 20 R is independently selected from the group consisting of: H, F, Cl, C alkyl and R and R are independently selected from the group consisting of: H, F, Cl, and C alkyl; when x is a single bond, R and R may be combined with the carbon atom to 25 which they are attached to form a 3- to 6-membered carbocycle; 11841-PCT R is independently selected from the group consisting of: H, halo, C alkyl, NO , R , -(CH ) -(X) -(CH ) R , NH , -CONH(C alkyl), -NHCOX SO R , 2 2 n t 2 m 2 1-6 1 2 j j j -NHCOCH PO(OEt) , -NHCOCOR , -NHCOCH(OH)R , -NHCOCH COR , 2 2 2 j f j -NHCONHR , and -OCONR R ; 5 X is independently selected from the group consisting of: O, S, NH, CONH, and NHCO; X is independently C hydrocarbon chain optionally substituted with C alkyl 1 1-4 1-4 or C cycloalkyl; when y is a single bond, R and R may be combined with the carbon atom to 10 which they are attached to form a 3- to 6-membered carbocycle; 11 12 13 14 15 R , R , R , R and R are independently selected from the group consisting of: H, halo, C alkyl substituted with 0-2 R , C alkoxy, C haloalkyl, 1-4 1-4 1-4 f j j j C haloalkoxy, -(CH ) -C cycloalkyl, CN, NR R , OR , SR , NHCO (C alkyl), 1-4 2 m 3-6 2 1-4 NHSO (C alkyl), and a 4- to 6-membered heterocycle comprising: carbon atoms and 2 1-4 15 1-4 heteroatoms selected from N, NR , O, and S; 11 12 alternatively, R and R , together with the carbon atoms to which they are attached, combine to form a 5- to 6-membered carbocyclic ring or a 5- to 6-membered heterocyclic ring comprising: carbon atoms and 1-3 heteroatoms selected from N, NR , O, and S; 12 13 20 alternatively, R and R , together with the carbon atoms to which they are attached, combine to form a 5- to 6-membered carbocyclic ring or a 5- to 6-membered heterocyclic ring comprising: carbon atoms and 1-3 heteroatoms selected from N, NR , O, and S; R is independently selected from the group consisting of: H and C alkyl; 25 R is, at each occurrence, independently selected from the group consisting of: halo, OH, C alkoxy, C haloalkyl, C haloalkoxy, N(C alkyl) , 1-6 1-6 1-6 1-4 2 -(CH ) -(X) -(CH ) R , and -(CH ) -(CH O) -(CH ) R ; 2 n t 2 m 2 n 2 m 2 n R is, at each occurrence, independently selected from the group consisting of: halo, OH, C alkyl, C alkoxy, C haloalkyl, C haloalkoxy, C alkylthio, 1-10 1-10 1-10 1-10 1-10 11841-PCT C haloalkylthio, N(C alkyl) , -CONH(CH ) H, -O(CH ) O(C alkyl), R , 1-10 1-4 2 2 4-20 2 s 1-6 -(CH ) -(X) -(CH ) R , and -(CH ) -(CH O) -(CH ) R ; 2 n t 2 m 2 n 2 m 2 n R is, at each occurrence, independently selected from the group consisting of: C cycloalkyl substituted with 0-2 R , C cycloalkenyl substituted with 0-2 R , 3-6 3-6 5 -(CH ) -(phenyl substituted with 0-3 R ), and a 5- to 6-membered heterocycle comprising: carbon atoms and 1-4 heteroatoms selected from N, NR , O, and S; wherein said heterocycle is substituted with 0-2 R ; R is, at each occurrence, independently selected from the group consisting of: halo, OH, CN, NO , C alkyl, C alkoxy, C haloalkyl, C haloalkoxy, tetrazolyl, 2 1-4 1-4 1-4 1-4 10 OBn and phenyl substituted with 0-2 R ; R is, at each occurrence, independently selected from the group consisting of: H, C alkyl, C haloalkyl, benzyl optionally substituted with C alkoxy, CO(C alkyl) 1-8 1-8 1-4 1-4 and COBn; R is, at each occurrence, independently selected from the group consisting of: H 15 and C alkyl; g h i R , R and R are, at each occurrence, independently selected from the group consisting of: halo, C alkyl, C alkoxy, C haloalkyl, and C haloalkoxy; 1-4 1-4 1-4 1-4 R is, at each occurrence, independently selected from the group consisting of: 20 C alkyl, C cycloalkyl and phenyl; n, at each occurrence, is independently 0 or 1; m, at each occurrence, is independently 0, 1, 2, 3, or 4 s, at each occurrence, is independently 1, 2, or 3; and 25 t, at each occurrence, is independently 0 or 1; provided that the following compound is excluded: Me H
2. A compound according to claim 1, wherein: 11841-PCT R is independently selected from the group consisting of: -CONHC alkyl, 4-18 -CONH(CH ) Ph, C alkyl substituted with 0-2 R , C alkenyl substituted with 2 1-8 1-12 1-12 a a b 0-2 R , C alkynyl substituted with 0-2 R , -(CH ) -(phenyl substituted with 0-1 R 1-12 2 m and 0-2 R ), -(CH ) -(C cycloalkyl substituted with 0-1 R ), and -(CH ) -(5- to 2 m 3-6 2 m 5 6-membered heteroaryl substituted with 0-1 R and 0-2 R ), wherein said heteroaryl is selected from: pyridyl, oxazolyl, thiazolyl and .
3. A compound according to claim 1 or claim 2, wherein: 11 15 R and R are independently selected from the group consisting of: H, C 10 alkyl and halo; 12 14 R and R are independently selected from the group consisting of: H, halo, C alkyl and C alkoxy; and 1-4 1-4 R is independently selected from the group consisting of: H, halo, C alkyl substituted with 0-1 R , C alkoxy, C haloalkyl, C haloalkoxy, -(CH ) -C 1-4 1-4 1-4 2 m 3-4 f j j 15 cycloalkyl, CN, NR R , SR , NHCO (C alkyl), NHSO (C alkyl), and a 4- to 2 1-4 2 1-4 6-membered heterocycle comprising: carbon atoms and 1-4 heteroatoms selected from N, NR , O, and S.
4. A compound according to any one of claims 1 to 3, wherein the compound is of 20 Formula (II): (II) or a stereoisomer, a tautomer, a pharmaceutically acceptable salt, or a solvate thereof.
5. A compound according to any one of claims 1 to 4, wherein: 11841-PCT R is independently selected from the group consisting of: C alkyl, C cycloalkyl, -CONHC alkyl, -CONHC haloalkyl, -CONH(CH ) Ph, 3-6 4-18 2-8 2 1-8 -(CH ) -(phenyl substituted with 1 R and 0-2 R ), and a 5- to 6-membered heteroaryl substituted with 0-1 R and 0-2 R , wherein said heteroaryl is selected from: pyridyl, 5 oxazolyl, thiazolyl and ; R is independently selected from the group consisting of: C alkyl and C haloalkyl; R is independently selected from the group consisting of: H and F; R is independently selected from the group consisting of: H and F; 10 R is independently selected from the group consisting of: NH , -CONH(C alkyl), R , -(CH ) -(X) -(CH ) R , -NHCO(CH )SO (C alkyl), 1-6 2 n t 2 m 2 2 1-4 -NHCOCH PO(OEt) , -NHCOCO(C alkyl), -NHCOCH(OH)(C alkyl), 2 2 1-4 1-4 -NHCOCH CO(C alkyl), -NHCONH(C alkyl), and -OCONH(C alkyl); 2 1-4 1-4 1-4 11 15 R and R are independently selected from the group consisting of: H, C 15 alkyl and halo; 12 14 R and R are independently selected from the group consisting of: H, halo, C alkyl and C alkoxy; 1-4 1-4 R is independently selected from the group consisting of: H, halo, C alkyl substituted with 0-1 C alkoxy, C alkoxy, C haloalkyl, C haloalkoxy, 1-4 1-4 1-4 1-4 20 -(CH ) -C cycloalkyl, CN, N(C alkyl) , NHCO (C alkyl), NHSO (C alkyl), 2 m 3-4 1-4 2 2 1-4 2 1-4 pyrazolyl, and morpholinyl; 12 13 alternatively, R and R , together with the carbon atoms to which they are attached, combine to form a 5- to 6-membered carbocyclic ring or a 5- to 6-membered heterocyclic ring comprising: carbon atoms and 1-3 heteroatoms selected from N, NR , 25 O, and S; R is, at each occurrence, independently selected from the group consisting of: halo, OH, C alkyl, C alkoxy, C haloalkyl, C haloalkoxy, -O(CH ) O(C 1-8 1-8 1-8 1-10 2 s 1-6 alkyl), 11841-PCT N(C alkyl) , -CONH(CH ) H, -(CH ) (C cycloalkyl), -(CH ) (C 1-4 2 2 6-20 2 m 3-6 2 m 4-6 cycloalkenyl), -O(CH ) (C cycloalkyl), 4-C alkoxy-Ph, -O(CH ) Ph, morpholinyl, 2 m 3-6 1-4 2 m pyridyl, 2-C alkoxy-pyridinyl, pyrimidinyl, pyrazinyl, and -O-pyrimidinyl; R is, at each occurrence, independently selected from the group consisting of: 5 halo, C alkyl, C alkoxy, C haloalkyl, and C haloalkoxy; 1-4 1-4 1-4 1-4 m, at each occurrence, is independently 0, 1, 2 or 3; and s, at each occurrence, is independently 1, 2, or 3. 10
6. A compound according to any one of claims 1 to 5, wherein: R is independently selected from the group consisting of: C alkyl, -CONHC alkyl, -CONH(CH ) Ph, and ; 4-18 2 1-8 R is independently selected from the group consisting of: NH , -CONH(C alkyl), 2 1-6 c c c -NHCOCH PO(OEt) , -NHCO(CH )SO (C alkyl), R , OR , -CONHR , and 2 2 2 2 1-4 15 -NHCOR ; R is independently selected from the group consisting of: H, halo, C alkyl and C alkoxy; R is independently selected from the group consisting of: H, halo, C alkyl substituted with 0-1 C alkoxy, C alkoxy, C haloalkyl, C haloalkoxy, 1-4 1-4 1-4 1-4 20 -(CH ) -C cycloalkyl, CN, N(C alkyl) , NHCO (C alkyl), NHSO (C alkyl), 2 m 3-4 1-4 2 2 1-4 2 1-4 pyrazolyl, and morpholinyl; 12 13 alternatively, R and R , together with the carbon atoms to which they are attached, combine to form a 5- to 6-membered carbocyclic ring or a 5- to 6-membered saturated heterocyclic ring comprising: carbon atoms and 1-2 oxygen atoms; 25 R is independently selected from the group consisting of: H and C alkoxy; R is, at each occurrence, independently selected from the group consisting of: halo, C alkyl, C alkoxy, C haloalkyl, C haloalkoxy, -O(CH ) O(C alkyl), 1-6 1-6 1-6 1-10 2 s 1-6 -CONH(CH ) H, -(CH ) (C cycloalkyl), -(CH ) (C cycloalkenyl), 2 6-20 2 m 3-6 2 m 4-6 11841-PCT -O(CH ) (C cycloalkyl), phenoxy, benzoxy, morpholinyl, 2-C alkoxy-pyridinyl, 2 m 3-6 1-4 pyrimidinyl, pyrazinyl and -O-pyrimidinyl; and R is, at each occurrence, independently selected from the group consisting of: C cycloalkyl substituted with 0-2 R , -(CH ) -(phenyl substituted with 0-3 R ), and a 3-6 2 m 5 heteroaryl selected from: oxazolyl, isoxazolyl, thiazolyl, pyrazolyl, imidazolyl, oxadiazolyl, triazolyl, tetrazolyl, pyridyl, and pyrazinyl; wherein said heteroaryl is substituted with 0-2 R .
7. A compound according to any one of claims 1 to 6, wherein: 10 R is independently selected from the group consisting of: CF and Me; R is independently selected from the group consisting of: H and F; R is independently selected from the group consisting of: H and F; R is independently selected from the group consisting of: NH , -CONHMe, OPh, -CONH(cyclopropyl), -CONH(cyclobutyl), -CONH(cyclopentyl), -CONH(cyclohexyl), 15 -CONHPh, -CONH(4-F-Ph), -CONH(2-Cl-Ph), -CONH(4-Cl-Ph), -CONH(4-Me-Ph), -CONH(4-OH-Ph), -CONH(3-OMe-Ph), -CONH(4-OMe-Ph), -CONH(4-CF -Ph), -CONH(4-OCF -Ph), -CONH(1-Me-pyrazolyl), -CONH(4-(1H-tetrazolyl)-Ph), -CONH(4-(2H-tetrazolyl)-Ph), -CONH(3-FMe-Ph), -CONH(3-FOMe-Ph), -CONH(CH ) Ph, -CONH(5-OMe-pyridyl), -CONH(6-OMe-pyridyl), 20 -CONH(5-OMe-pyrazinyl), -CONH(6-OMe-pyridazinyl), -NHCO(CH )SO Me, -NHCOPh, -NHCO(2-Me-Ph), -NHCO(3-Me-Ph), -NHCO(4-Me-Ph), -NHCO(2-Cl-Ph), -NHCO(3-Cl-Ph), -NHCO(2-ClF-Ph), -NHCO(2-ClF-Ph), -NHCO(isoxazolyl), -NHCO(3-Me-isoxazolyl), -NHCO(4-Me-isoxazolyl), -NHCO(3-OMe-isoxazolyl), -NHCO(3-Br-isoxazolyl), 25 -NHCO(3-(2-Cl-Ph)-isoxazolyl), -NHCO(3-(3-F-Ph)-isoxazolyl), -NHCO(3-OBn-isoxazolyl), 1H-imidazolyl, -NHCO(5-Me-1,3,4-oxadiazolyl), -NHCO(1-Me-1,2,3-triazolyl), -NHCO(6-OMe-pyridyl), -NHCO(6-Cl-pyridazinyl), 5-CF -1,3,4-oxadiazolyl, 1H-tetrazolyl, 1H-tetrazolyl, and 2H-tetrazolyl; 11841-PCT 11 15 R and R are independently selected from the group consisting of: H, Me, F, and Cl; R is independently selected from the group consisting of: H, F, Cl, Me and OMe; 5 R is independently selected from the group consisting of: H, F, Cl, Br, Me, OMe, OEt, CH OMe, CF , CH CF , OCHF , OCF , CN, N(Me) , cyclopropyl and 2 3 2 3 2 3 2 cyclopropylmethyl; 12 13 alternatively, R and R , together with the carbon atoms to which they are attached, combine to form a 5- to 6-membered carbocyclic ring or a 5- to 6-membered 10 saturated heterocyclic ring comprising: carbon atoms and 1-2 oxygen atoms; R is H; R is, at each occurrence, independently selected from the group consisting of: n-pentyl, methoxy, n-butoxy, i-butoxy, i-pentoxy, -O(CH ) CF , -O(CH ) CF CF , 2 1-6 3 2 1-4 2 3 -CONH(CH ) H, cyclopropyl, cyclopentenyl, cyclohexenyl, 2 6-20 15 -O(CH ) (cyclopentyl), phenoxy, benzoxy, pyrimidinyl, pyrazinyl and -O-pyrimidinyl; and R is F.
8. A compound according to Claim 4 or Claim 5, wherein: 20 R is ; R is independently selected from CF and CH ; 6 c c c R is independently selected from: R , -CONHR , -NHCOR , and -NHCOCH SO (C alkyl); 2 2 1-4 R is independently selected from: -O(CH ) CF , -O(CH ) CF CF , 2 1-6 3 2 1-4 2 3 25 -CONH(CH ) H, cyclopentenyl, cyclohexenyl, -O(CH ) (cyclopentyl), 2 6-20 2 2 phenoxy, benzoxy, pyrimidinyl, pyrazinyl and -O-pyrimidinyl; R is, at each occurrence, independently selected from the group consisting of: -(CH ) -(phenyl substituted with 0-3 R ), and a heteroaryl selected from: oxazolyl, 11841-PCT isoxazolyl, pyrazolyl, imidazolyl, oxadiazolyl, triazolyl, tetrazolyl, pyridyl, and pyrazinyl; wherein said heteroaryl is substituted with 0-2 R ; and R is, at each occurrence, independently selected from the group consisting of: halo, OH, CN, C alkyl, C alkoxy, C haloalkyl, C haloalkoxy, tetrazolyl and 1-4 1-4 1-4 1-4 5 OBn.
9. A compound according to any one of claims 1 to 6, or 8, wherein: R is independently selected from the group consisting of: H, halo, C alkyl substituted with 0-1 C alkoxy, C alkoxy, C haloalkyl, C haloalkoxy, CN or 1-4 1-4 1-4 1-4 10 C cycloalkyl.
10. A compound according to any one of claims 1 to 5, 8, or 9, wherein: R is independently . 15
11. A compound according to any one of claims 1 to 10, wherein: R is independently selected from: -O(CH ) CF , and -O(CH ) CF CF . 2 1-6 3 2 1-4 2 3
12. A compound according to any one of claims 1 to 5, wherein: R is independently 5-membered nitrogen heteroaryl.
13. A compound according to any one of claims 1 to 12, wherein: R is independently: 1H-imidazolyl, 1H-tetrazolyl, 1H-tetrazolyl, or 2H-tetrazolyl. 25
14. A compound according to claim 1, wherein the compound is selected from: 3-(1H-Tetrazolyl)p-tolyl(4-(4,4,4-trifluorobutoxy)phenyl)(trifluoromethyl)- 5,6-dihydropyridin-2(1H)-one; (S)(1H-Tetrazolyl)p-tolyl(4-(4,4,4-trifluorobutoxy)phenyl) (trifluoromethyl)-5,6-dihydropyridin-2(1H)-one; 11841-PCT (R)(1H-Tetrazolyl)p-tolyl(4-(4,4,4-trifluorobutoxy)phenyl) (trifluoromethyl)-5,6-dihydropyridin-2(1H)-one; N-(4-Methoxyphenyl)oxop-tolyl(4-(4,4,4-trifluorobutoxy)phenyl)(trifluoro- methyl)-1,2,5,6-tetrahydropyridinecarboxamide; 5 (R)-N-(4-Methoxyphenyl)oxop-tolyl(4-(4,4,4-trifluorobutoxy)phenyl) (trifluoro-methyl)-1,2,5,6-tetrahydropyridinecarboxamide; (S)-N-(4-Methoxyphenyl)oxop-tolyl(4-(4,4,4-trifluorobutoxy)phenyl) (trifluoro-methyl)-1,2,5,6-tetrahydropyridinecarboxamide; (S)(2H-Tetrazolyl)p-tolyl(4-(6,6,6-trifluorohexyloxy)phenyl) 10 (trifluoromethyl)-5,6-dihydropyridin-2(1H)-one; 3-(2-Ethyl-2H-tetrazolyl)p-tolyl(4-(4,4,4-trifluorobutoxy)phenyl) (trifluoromethyl)-5,6-dihydropyridin-2(1H)-one; 4-p-Tolyl(4-(4,4,4-trifluorobutoxy)phenyl)(trifluoromethyl)(5-(trifluoromethyl)- 1,3,4-oxadiazolyl)-5,6-dihydropyridin-2(1H)-one; 15 6-Methyloxop-tolyl(4-(4,4,4-trifluorobutoxy)phenyl)-N-(4-(trifluoromethoxy)- phenyl)-1,2,5,6-tetrahydropyridinecarboxamide; 3-(2H-Tetrazolyl)p-tolyl(trifluoromethyl)(1-(5,5,5-trifluoropentyl)-1H- pyrazolyl)-5,6-dihydropyridin-2(1H)-one; 3-Nitrop-tolyl(4-(4,4,4-trifluorobutoxy)phenyl)(trifluoromethyl)-5,6- 20 dihydropyridin-2(1H)-one; N-(4-Methoxyphenyl)oxop-tolyl(4-(4,4,4-trifluorobutoxy)phenyl) (trifluoromethyl)piperidinecarboxamide; compounds of formula (IIa) 12 14 11 15 (IIa) 1 2 6 wherein R , R and R are the substituents set out in the table below, and 11 15 wherein R to R are hydrogen, unless otherwise noted in the table below: 1 2 6 11 15 R R R R -R Rac CH R = CH N 13 Rac CF R = CH F 13 Rac CF R = CH F 13 Rac CF R = CH F 13 Rac CF R = CH F 13 Rac CF R = CH Rac CF R = CH F 13 Rac CF R = CH N O H F 13 Rac CF R = CH Rac CF R = CH F C O 1 2 6 11 15 R R R R -R Rac CF O R = CH F C O Rac CF R = CH F C O Rac CF R = CH F C O Rac CF R = CH F C O Rac CF R = CH F C O H Rac CF R = CH N Cl F C O Rac CF Cl R = CH F C O Rac CF H R = CH F C O Rac CF CH R = CH F C O Rac CF R = CH O CF F C O 1 2 6 11 15 R R R R -R Rac CF O R = CH O CH F C O Rac CF CH R = CH F C O Rac CF CF R = CH F C O Rac CF R = CH S-isomer F C O Rac CF O R = CH O CH F C O Rac CF H R = CH F C O Rac CF H OCH CH F C O Rac CF H OCHF F C O S-isomer CF O R = CH O CF F C O S-isomer CF H R = F R = OCH F C O 1 2 6 11 15 R R R R -R Rac CF H R = CH F C O Rac CF H All H F C O Rac CF H R = CF F C O Rac CF H R = Cl F C O Rac CF H R = OCH F C O Rac CF H R = Cl F C O N -(4-Methoxyphenyl)methyloxop-tolyl-N -(4,4,4-trifluorobutyl)-1,2,3,6- tetrahydropyridine-2,5-dicarboxamide; N-(4-Cyanophenyl)-5,5-difluorooxop-tolyl(4-(4,4,4-trifluorobutoxy)phenyl) 5 (trifluoromethyl)-1,2,5,6-tetrahydropyridinecarboxamide; (S)Aminop-tolyl(4-(4,4,4-trifluorobutoxy)phenyl)(trifluoromethyl)-5,6- dihydropyridin-2(1H)-one; (S)Methyl-N-(2-oxop-tolyl(4-(4,4,4-trifluorobutoxy)phenyl)(trifluoromethyl)- 1,2,5,6-tetrahydropyridinyl)benzamide; 10 (S)Phenoxyp-tolyl(4-(4,4,4-trifluorobutoxy)phenyl)(trifluoromethyl)-5,6- dihydropyridin-2(1H)-one; and compounds of formula (II) 12 14 11 15 (II) 1 2 3 4 6 wherein R , R , R , R and R are the substituents set out in the table below, and 1 15 wherein R to R are hydrogen, unless otherwise noted in the table below: 1 2 6 11 15 R = R R R R R -R N OMe S-isomer CF H 13 3 R = CH F C O S-isomer CF H 13 3 R = CH F C O Rac CF H 13 3 R = CH S-isomer CF H 13 3 R = CH F C O S-isomer CF H 13 3 R = CH F C O S-isomer CF H R = CH F C O NH 13 Rac CF H N R = CH F C O 1 2 6 11 15 R = R R R R R -R NH 13 Rac CF H R = CH NH 13 Rac CF H N R = CH O 13 S-isomer CF H R = CH F C O O 13 S-isomer CF H R = CH F C O S-isomer CF H R = CH F C O H OH 13 S-isomer CF H R = CH F C O H O 13 S-isomer CF H R = CH F C O Rac CF F R = CH F C O NH 13 Rac CF H N R = CH NH 13 Rac CF H N R = CH 1 2 6 11 15 R = R R R R R -R NH 13 Rac CF H R = CH S-isomer CF H R = CH S-isomer CF H R = CH S-isomer CF H R = CH S-isomer CF H R = CH N 13 S-isomer CF H R = CH OMe 13 Rac CF F R = CH Rac CF F R = CH Rac CF F R = CH F C N N 13 S-isomer CF H N R = CH 1 2 6 11 15 R = R R R R R -R S-isomer CF H R = CH O OCF N OMe 13 Rac CF F R = CH F C O Rac CF F R = CH F C O N 11 S-isomer CF H N R = F F C O N 13 S-isomer CF H N R = F C O OMe 11 S-isomer CF H R = CH R = CH F C O N 13 S-isomer CF H N R = OCHF F C O N 13 S-isomer CF F O R = CH F C O N 13 S-isomer CF H R = CH F C O N 13 S-isomer CF H R = CH F C O N 13 S-isomer CF H R = CH F C O 1 2 6 11 15 R = R R R R R -R S-isomer CF H R = CH F C O H OMe 13 Rac CH H R = CH N 11 S-isomer CF H R = CH R = CH F C O S-isomer CF H R = CH F C O Cl 13 S-isomer CF H R = CH F C O N 13 Rac CF F R = CH F C O H OMe 13 Rac CH H R = CH OMe 13 Rac CF F R = CH OMe 13 Rac CF F R = CH F C O OMe 13 Rac CF F R = CH 1 2 6 11 15 R = R R R R R -R F 13 S-isomer CF H R = CH H OMe 13 Rac CH H R = CH S-isomer CF H OHCF F C O Cl 13 S-isomer CF H R = CH F C O S-isomer CF H R = CH F C O Cl F 13 S-isomer CF H R = CH F C O Cl 13 S-isomer CF H R = CH F C O S-isomer CF H F C O N OMe 13 Rac CH H R = CH H OMe 13 Rac CH H R = CH 1 2 6 11 15 R = R R R R R -R OMe 13 Rac CH H R = CH S-isomer CF H N OCH F C O H OMe 13 Rac CH H R = CH Br 13 S-isomer CF H R = CH F C O S-isomer CF H R = CH F C O OMe 13 Rac CF F R = CH NH 13 Rac CF H N R = CH N 13 Rac CF H 3 R = CH S-isomer F C O 1 2 6 11 15 R = R R R R R -R S-isomer CF H 3 R = CH F C O S-isomer CF H N R = CH F C O S-isomer CF H 3 R = CH F C O H OMe 13 Rac CH H 3 R = CH OMe 13 Rac CH H 3 R = CH S-isomer CF H 3 R = CH F C O O OMe 13 Rac CH H 3 R = CH N 13 S-isomer CF H N R = CH F C O 1 2 6 11 15 R = R R R R R -R S-isomer CF H 3 R = F C O Rac CF H 3 R = CH Rac CF H 3 R = CH NH 13 R-isomer CF H 3 R = CH NH 13 S-isomer CF H N R = CH S-isomer CF H 3 R = CH S-isomer CF H 3 R = CH OCF 13 Rac CF H 3 3 R = CH OHCF 13 Rac CF H 2 3 R = CH NH 13 S-isomer CF H 3 R = CH2OCH F C O 1 2 6 11 15 R = R R R R R -R S-isomer CF H R = F F C O OCH CH NH 13 S-isomer CF3 H R = CH F C N S-isomer CF H 3 R = OCHF F C O S-isomer CF H 3 R = CH F C O NH 13 S-isomer CF3 H R R = F C O S-isomer CF H 3 R = OCH CH F C O NH 13 S-isomer CF3 H R R = F C O S-isomer CF H 3 R R = F C O S-isomer CF H 3 R R = F C O S-isomer CF H 3 R R = F C O 1 2 6 11 15 R = R R R R R -R R = OCH NH 13 S-isomer CHF2 H R = CH F C O OMe 13 R-isomer H H R = CH F C O OMe 13 Rac CF H 3 R = CH OMe 13 Rac CF3 H R = CH S-isomer CF H 3 R = CH F C O OMe 13 S-isomer CF H 3 R = CH F C O S-isomer CF H R = CH S-isomer CF H 3 R = Br F C O S-isomer CF H N 13 F C O 1 2 6 11 15 R = R R R R R -R S-isomer CF H 3 R = F C O N S-isomer CF H 3 R R = F C O NH 13 S-isomer CF3 H F C O H 13 S-isomer CF H 3 R = CH F C O S-isomer CF H 3 R = F C O S-isomer CF H 3 R = F C N S-isomer CF H 3 R = OCF NH 13 S-isomer CF3 H R = OCF F C O S-isomer CF H 3 R = F C O S-isomer CF H 3 R = OCHCF F C O 1 2 6 11 15 R = R R R R R -R S-isomer CF H 3 R = CH F C O S-isomer CF H 3 R = F C O S-isomer CF H 3 R = OCHCF F C O F 13 S-isomer CF H 3 R = CH F C O S-isomer CF H 3 R = CH F C O H 13 S-isomer CF H 3 R = OCHCF F C O H 13 S-isomer CF H 3 R = F C O S-isomer CF H 3 R = CH F C O H H 13 S-isomer CF H OCHCF F C O H 13 S-isomer CF H 3 R = CH F C O S-isomer CF H R = CH F C O 1 2 6 11 15 R = R R R R R -R S-isomer CF H R = CH F C O S-isomer CF H R = CH F C O N S-isomer CF H R = CH F C O R-isomer CF H R = CH F C O S-isomer CF H R = CH CF F C O S-isomer CF H R = CH N OMe S-isomer CF H R = CH S-isomer CF H R = OCHF F C O S-isomer CF H R = OCHF F C O 12 13 S-isomer CF H R R = F C O 1 2 6 11 15 R = R R R R R -R S-isomer CF H R = F C O S-isomer CF H R = CH S-isomer CF H R = CH S-isomer CF3 H R = OCHF F C O S-isomer CF H R = CH F C O S-isomer CF H R = CH F C O S-isomer CF3 H R = OCH CH F C O S-isomer CF H R = CH CF F C O S-isomer CF H R = CH S-isomer CF H R = F R = CH F C O 1 2 6 11 15 R = R R R R R -R S-isomer CF H R = CH F C O S-isomer CF H R = CH S-isomer CF H R = CH S-isomer CF H R = CH S-isomer CF H R = CH Rac CF H R = CH S-isomer CF H R = CH S-isomer CF H R = OCH S-isomer CF H R = OCH S-isomer CF H R = F R = CH F C O 1 2 6 11 15 R = R R R R R -R S-isomer CF H O R = CH F C O S-isomer CF H R = CH S-isomer CF H R = CH F C O S-isomer CF H R = CH S-isomer CF H R = OCHF F C O S-isomer CF H R = CH S-isomer CF H R = CH F 3 3 F C O S-isomer CF H R R13 = F C O S-isomer CF H R = OCH CH F C O S-isomer CF H R = CH CF F C O S-isomer CF H R = OCHF 1 2 6 11 15 R = R R R R R -R S-isomer CF H R = OCH CH S-isomer CF H R R13 = F C O S-isomer CF H R = CH F C O S-isomer CF3 H R = CH3 S-isomer CF H R = OCH CH S-isomer CF H R = OCHF S-isomer CF H R = CH F C O or a stereoisomer, a tautomer, a pharmaceutically acceptable salt, or a solvate thereof.
15. A compound according to claim 1, wherein the compound has the following 5 formula: or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt thereof.
16. A compound according to claim 15, wherein the compound has the following formula: 5 or a tautomer, or a pharmaceutically acceptable salt thereof.
17. A compound according to claim 15, wherein the compound is:
18. A pharmaceutically acceptable salt of the compound according to claim 15 or claim 16.
19. A compound according to claim 1, wherein the compound has the following 15 formula: or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt thereof.
20. A compound according to claim 19, wherein the compound has the following 5 formula: or a tautomer, or a pharmaceutically acceptable salt thereof.
21. A compound according to claim 19, wherein the compound is: 10 .
22. A compound according to claim 1, wherein the compound has the following formula: 15 or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt thereof.
23. A compound according to claim 22, wherein the compound has the following formula: or a tautomer, or a pharmaceutically acceptable salt thereof.
24. A compound according to claim 22, wherein the compound is:
25. A compound according to claim 1, wherein the compound has the following 10 formula: or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt thereof.
26. A compound according to claim 25, wherein the compound has the following 15 formula: or a tautomer, or a pharmaceutically acceptable salt thereof.
27. A compound according to claim 25, wherein the compound is:
28. A compound according to claim 1, wherein the compound has the following formula: 10 or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt thereof.
29. A compound according to claim 28, wherein the compound has the following formula: or a tautomer, or a pharmaceutically acceptable salt thereof.
30. A compound according to claim 28, wherein the compound is:
31. A pharmaceutical composition, comprising: a pharmaceutically acceptable carrier and a compound of any one of claims 1 to 30, a stereoisomer, a tautomer, a pharmaceutically acceptable salt or a solvate thereof, optionally in combination 10 simultaneously, separately or sequentially with one or more additional therapeutic agents.
32. The pharmaceutical composition according to claim 31, further comprising one or more additional therapeutic agents selected from: anti-diabetic agents, anti-hyperglycemic agents, anti-hyperinsulinemic agents, anti-retinopathic agents, 15 anti-neuropathic agents, anti-nephropathic agents, anti-atherosclerotic agents, anti-ischemic agents, anti-hypertensive agents, anti-obesity agents, anti-dyslipidemic agents, anti-hyperlipidemic agents, anti-hypertriglyceridemic agents, anti-hypercholesterolemic agents, anti-restenotic agents, lipid lowering agents, anorectic agents, and appetite suppressants.
33. The pharmaceutical composition according to claim 31, further comprising one or more other suitable therapeutic agents selected from: a dipeptidyl peptidase-IV inhibitor, a sodium-glucose transporter-2 inhibitor and a 11b-HSD-1 inhibitor. 5
34. A compound of any one of claims 1 to 30, or a stereoisomer, a tautomer, a pharmaceutically acceptable salt or a solvate thereof, for use in therapy.
35. A compound of any one of claims 1 to 30, or a stereoisomer, a tautomer, a pharmaceutically acceptable salt or a solvate thereof, for use in preventing, modulating or 10 treating diabetes, hyperglycemia, impaired glucose tolerance, gestational diabetes, insulin resistance, hyperinsulinemia, nonalcoholic fatty liver disease (NAFLD), retinopathy, neuropathy, nephropathy, delayed wound healing, atherosclerosis and its sequelae, abnormal heart function, myocardial ischemia, stroke, Metabolic Syndrome, hypertension, obesity, dyslipidemia, hyperlipidemia, hypertriglyceridemia, 15 hypercholesterolemia, low high-density lipoprotein (HDL), high low-density lipoprotein (LDL), non-cardiac ischemia, lipid disorders, or glaucoma.
36. A compound for use according to claim 35, wherein the NAFLD is nonalcoholic steatohepatitis (NASH).
37. A compound for use according to any one of claims 34 to 36, wherein the compound is for use simultaneously, separately or sequentially with one or more additional therapeutic agents. 25
38. Use of a compound of any one of claims 1 to 30, or a stereoisomer, a tautomer, a pharmaceutically acceptable salt or a solvate thereof, for the manufacture of a medicament for preventing, modulating or treating diabetes, hyperglycemia, impaired glucose tolerance, gestational diabetes, insulin resistance, hyperinsulinemia, nonalcoholic fatty liver disease (NAFLD), retinopathy, neuropathy, nephropathy, delayed wound 30 healing, atherosclerosis and its sequelae, abnormal heart function, myocardial ischemia, stroke, Metabolic Syndrome, hypertension, obesity, dyslipidemia, hyperlipidemia, hypertriglyceridemia, hypercholesterolemia, low high-density lipoprotein (HDL), high low-density lipoprotein (LDL), non-cardiac ischemia, lipid disorders, or glaucoma.
39. Use according to claim 38, wherein the NAFLD is nonalcoholic steatohepatitis 5 (NASH).
40. Use according to claim 38 or 39, wherein the medicament is for use simultaneously, separately or sequentially with one or more additional therapeutic agents. 10
41. A compound of any one of claims 1 to 30 substantially as herein described with reference to any example thereof.
42. A pharmaceutical composition of any one of claims 31 to 33 substantially as herein described with reference to any example thereof.
43. A compound of any one of claims 1 to 30 for use according to any one of claims 34 to 37 substantially as herein described with reference to any example thereof.
44. Use of any one of claims 38 to 40 substantially as herein described with reference 20 to any example thereof.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161566039P | 2011-12-02 | 2011-12-02 | |
US61/566,039 | 2011-12-02 | ||
US13/688,584 | 2012-11-29 | ||
US13/688,584 US8791091B2 (en) | 2011-12-02 | 2012-11-29 | Aryl dihydropyridinone and piperidinone MGAT2 inhibitors |
PCT/US2012/067173 WO2013082345A1 (en) | 2011-12-02 | 2012-11-30 | Aryl dihydropyridinone and piperidinone as mgat2 inhibitors |
Publications (2)
Publication Number | Publication Date |
---|---|
NZ626751A NZ626751A (en) | 2016-07-29 |
NZ626751B2 true NZ626751B2 (en) | 2016-11-01 |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10966967B2 (en) | Aryl dihydropyridinones and piperidinone MGAT2 inhibitors | |
EP3114121B1 (en) | Dihydropyridinone mgat2 inhibitors for use in the treatment of metabolic disorders | |
US9822074B2 (en) | Dihydropyridinone MGAT2 inhibitors | |
CA2941951C (en) | Tetrazolone-substituted dihydropyridinone mgat2 inhibitors | |
NZ626751B2 (en) | Aryl dihydropyridinones and piperidinones as mgat2 inhibitors |